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Chapter 1 - Photocatalytic Difunctionalisation of Vinyl Ureas by Radical-Polar Crossover 
 
The -tertiary amine is a functional group that is commonly found in natural and synthetic 
compounds for medicinal and agrochemical applications. For example, -tertiary amine-
based compounds feature as anti-obesity agents, herbicides, fungicides, and anti-
depressants. As such, methodologies for the preparation of -tertiary amines is a topic of 
continual interest within the synthetic community. In the past, the Clayden group have been 
able to prepare -tertiary amines by overcoming the poor reactivity between carbanions and 
C-(sp2) ‘electrophiles’ by tethering the two coupling components through a urea linkage. 
This thesis details the development and scope of conditions for the photoredox catalysed 
alkyl-arylation and aryl-phosphorylation of vinyl ureas, by use of alkyl sodium sulfinate and 
diarylphosphine oxide radical precursors. This alkene difunctionalisation process makes use 
of an organophotocatalyst, allowing the reaction to be driven by visible light. The afforded -
tertiary urea products can be simply converted into their respective -tertiary amines by 
solvolysis. 
 
This difunctionalisation process has been probed mechanistically using a suite of methods, 
which together imply the presence of a reductive quenching photoredox cycle and the 
formation of -metallated urea intermediate that undergoes N to C intramolecular arylation 








Chapter 2 - Aryl Diazonium Salt-Promoted Azo-Cycloamination of Allyl Ureas and 
Carbamates  
 
Vicinal triamines and 1,2,3-diamino alcohols are structural motifs that have captivated the 
attention of synthetic chemists for the past 50 years, due to their prevalence in natural 
products, antiviral agents and peptidomimetics. The diamination of allyl amines and allyl 
alcohols make for attractive routes to vicinal triamines and 1,2,3-diamino alcohols.  
This thesis explores an approach based on the aminative cyclisation of allyl ureas and allyl 
carbamates using photoredox catalysis to generate amidyl radicals by proton-coupled 
electron-transfer (PCET). However, instead it was discovered that the azo-cycloamination of 
allyl ureas and carbamates could be conducted in the absence of photocatalyst and light, by 
simple exposure of certain olefinic starting materials to aryl diazonium salt in the presence of 
phosphate base. The resulting azo compound products were amenable to deprotection steps, 
such as hydrogenation of the azo bond to a primary amine. 
 
Preliminary mechanistic investigation of this azo-cycloamination were conducted and 
comprised of radical trapping experiments and cyclic voltammetry analysis. These 
experiments imply the presence of a radical-chain process initiated by formation of aryl 
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Abbreviations   
 
3DPAIPN  2,4,6-tris(diphenylamino)-5-fluoroisophthalonitrile 
4CzIPN   1,2,3,5-tetrakis-(carbazol-yl)-4,6-dicyanobenzene 
BDE    Bond disassociation energy  
CCR1   C-C motif chemokine receptor 1 
CFL    Compact fluorescent lamp  
cSNAr   Concerted nucleophilic aromatic substitution 
CT    Charge transfer  
CV    Cyclic voltammetry  
D-A    Donor-acceptor 
DPA   9, 10- Diphenylanthracene  
ET    Electron transfer  
HAT    Hydrogen atom transfer  
IC    Internal conversion  
ISC    Inter-system crossing  
LED    Light-emitting diode 
Mbs   p-Methoxybenzenesulfonyl 
OLED   Organic light-emitting diode 
PC    Photocatalyst  
PCET    Proton-coupled electron-transfer  
PMP   p-Methoxyphenyl 
PRC    Photoredox catalysis   
SCE    Saturated calomel electrode  
SES   2-(Trimethylsilyl)ethanesulfonyl 
SET   Single electron transfer 
TADF   Thermally activated delayed fluorescence 
tRNA   Transfer ribonucleic acid 


































































1. Importance and Synthesis of -Tertiary Amines 
 
-Tertiary amines (1) are comprised of a carbon atom bonded to three other carbon atoms 
and one nitrogen atom through single bonds (Scheme 1-1). -Tertiary amines are commonly 
found throughout medically relevant molecules. As such, the discovery and development of 
methods for the synthesis of -tertiary amines has been and still is an area of interest to 
synthetic chemists for the past 50 years, resulting in an armamentarium of procedures being 
developed for their preparation (vide infra).  
 























1.1 Cyanate to Isocyanate [3,3]-Sigmatropic Rearrangements  
 
The transposition of allyl cyanates to allyl isocyanates was first reported by Holm and 
Christophersen in 1970,1 but due to allyl cyanates being rarely isolable use of this synthetic 
approach was initially ignored for 20 years.2 It was not until methods were established for the 
conversion of allyl alcohols (2) to allyl carbamates (3) then in situ formation of allyl cyanates 
(4) by dehydration, that brought this synthetic approach to the mainstream (Scheme 1-2).3 
The conversion of allyl cyanates (4) to allyl isocyanates (5) proceeds by a [3,3]-sigmatropic 
rearrangement, in which high fidelity of chirality transfer and good E stereoselectivity of the 
new alkene are explained by a chair-like transition state.2a,4 Naturally, the transposition of 
allyl cyanates to allyl isocyanates has been well utilised in the synthesis of allyl amines and -
tertiary amines.5 
 
Scheme 1-2. Generalised transformation of allyl alcohol (2) to an -tertiary isocyanate (5), by 
allyl cyanate (4) formation.  
In 1962, Calvin L. Stevens first synthesised the -tertiary amine ketamine (6, Scheme 1-3), 
while exploring thermal -hydroxyimine rearrangements.6   Ketamine (6) was branded as 
Ketalar and sold as a human and veterinary anaesthetic.7 The anaesthetic potency of the (S)-
enantiomer of ketamine (6) is 3-4 times stronger than the racemic form. Also, for ketamine 
(6) only the (R)-enantiomer is responsible for abhorrent side-effects, such as hallucination and 
agitation. 8  In addition to its anaesthetic applications, ketamine (6) has recently been 
approved by the US FDA as an antidepressant in the form of a nasal spray.9 Due to the 
medicinal properties ketamine (6) exhibits,  several of its racemic 10  and asymmetric 11 
syntheses have been published.   
 








Chen and Li reported a relatively short route to enantiopure (S)-ketamine (6), by use of the 
cyanate to isocyanate [3,3]-sigmatropic rearrangement (Scheme 1-4).12 Firstly, enantiopure 
allyl carbamate 7 was synthesised by an enantioselective ruthenium-catalysed transfer 
hydrogenation of the parent enone, followed by carbamate formation. Dehydration of 
carbamate 7 gives the intermediary cyanate 8, which spontaneously undergoes [3,3]-
sigmatropic rearrangement to give the -tertiary isocyanate 9 without erosion of 
enantiopurity. The -tertiary isocyanate 9 was reduced to the -tertiary methylamine 10, 
which then only requires acid-mediated hydrolysis of the enol ether to form (S)-ketamine (6).  
 
Scheme 1-4. The [3,3]-sigmatropic rearrangement of carbamate 7 to isocyanate 9 for the 




















1.2 Overman Rearrangement 
 
The Overman rearrangement, discovered by Larry Overman in 1974,13 entails the conversion 
of allylic alcohols (2) to allylic trichloro- or trifluoroacetimidates (11), followed by a thermally 
initiated or transition metal-catalysed [3,3]-sigmatropic rearrangement to yield allylic amides 
(12) (Scheme 1-5).14 The conversion of an imidate to an amide is exothermic by approximately 
15 kcal/mol and so is essentially irreversible.15 The Overman rearrangement proceeds in a 
suprafacial concerted manner by a six-membered chair transition state, resulting in excellent 
E selectivity in the newly formed alkene and transfer of chirality from the allylic 
trichloroacetimidate (11) to the allylic amide (12).16 Alternatively, enantio-induction of the 
Overman rearrangement can be communicated from a separate chiral centre in a 
diastereoselective fashion.17 The Overman rearrangement has been used for the formation 
of carbon-nitrogen bonds in the synthesis of nucleotides, amino acids, N-heterocycles, amino 
sugars, and of course -tertiary amine-containing molecules.14 
 
Scheme 1-5. Conversion of allyl alcohols (2) to allyl amides (12) by the Overman 
rearrangement.  
Tetrodotoxin (13, Scheme 1-6) is a key venomous component of puffer-fish poison. 18        
Tetrodotoxin (13) acts as a potent neurotoxin and performs as a sodium channel blocker to 
inhibit the stimulation of action potentials within neurons.19 Due to the pronounced affect 
tetrodotoxin (13) has upon neurological systems it has become a commonly used tool in 
neurophysiology.20 In addition to possessing potent biological activity, tetrodotoxin (13) is 
also made up of a unique chemical structure, which was elucidated in the 1960s by effort 
from several academic teams. 21  Tetrodotoxin (13) contains a variety of functionalities, 
including a cyclic guanidine unit, a polyhydroxylated dioxaadamantane containing an ortho 
ester, and an -tertiary amine ring junction.  
 






Unsurprisingly, the distinct structure of tetrodotoxin (13) has captivated the attention of 
synthetic chemists with several total syntheses being reported.22 For example, Isobe and co-
workers disclosed a concise asymmetric route to tetrodotoxin (13) and several of its 
derivatives.23 The -tertiary amine of tetrodotoxin (13) was constructed in the opening stages 
of Isobe’s synthesis using levoglucosenone derived allyl trichloroacetimidate 14               
(Scheme 1-7). Exposure of allyl trichloroacetimidate 14 to thermal Overman rearrangement 
conditions gives the -tertiary amide 15, with the stereochemistry of the resulting -tertiary 
amide being controlled by the adjacent stereocentre.  
 
Scheme 1-7. Thermal Overman rearrangement of allyl imidate 14 to allyl amide 15 for the 




















1.3 Curtius Rearrangement 
 
Julius Curtius reported in 1885 that carboxylic acids (16) can be converted into acyl azides 
(17), which undergo thermal decomposition to afford isocyanates (18) and molecular 
nitrogen, a process coined the Curtius rearrangement (Scheme 1-8).24 Isocyanates (18) are 
synthetically useful building blocks that can be converted into a variety of functionalities, 
including amines (19) by simple hydrolysis or reduction.5,25 The mechanism for the Curtius 
rearrangement of an acyl azide (17) to give isocyanate (18) can be thought of as two 
independent steps that occur in a concerted manner, which include loss of molecular nitrogen 
to form an acyl nitrene then migration of the adjacent group to the acyl.26 The curly arrow 
notation of acyl azide 17 to isocyanate 18 can be more clearly seen from the resonance 
structure 20. In the Curtius rearrangement the migration of the group adjacent to the acyl 
occurs with retention of stereochemistry,27 and so has found much application within the 
context of synthesis.28 
 
Scheme 1-8. The Curtius rearrangement to convert -quaternary carboxylic acid 16 to                














Rheumatoid arthritis is a frequently found affliction of the developed world, existing as a 
chronic inflammatory autoimmune disease resulting in pain, joint destruction, and 
disability.29 In the search for new treatments of rheumatoid arthritis, CCR1 antagonism has 
been postulated to reduce inflammation by diminution of macrophage infiltration of synovial 
tissue.30 As such, CCR1 antagonists have been sought after by several research organisations 
to combat the symptoms of rheumatoid arthritis. To this end, the -tertiary amine 21 has 
been identified as a promising CCR1 antagonist and is being developed as an oral treatment 
against rheumatoid arthritis (Scheme 1-9).31 
 
Scheme 1-9. -Tertiary amine 21 a CCR1 antagonist. 
To support the clinical trial investigation of -tertiary amine 21, a kilogram scale synthesis 
with emphasis placed on green chemistry was developed by Marsini and co-workers.32 The 
key transformation of Marsini’s route towards -tertiary amine 21 is a Curtius rearrangement 
of carboxylic acid 22, in which flow protocol was developed for the formation of acyl azide 23, 
which under the reaction conditions spontaneously decomposes to -tertiary isocyanate 24 
(Scheme 1-10). -Tertiary isocyanate 24 is then used in a decarboxylative coupling with 
fragment 25 to give CCR1 antagonist 21.  
 
Scheme 1-10. The Curtius rearrangement of carboxylic acid 22 to afford -tertiary isocyanate 





1.4 Stevens Rearrangement 
 
During their investigation of ammonium salts as amine protecting groups, Stevens and co-
workers serendipitously found that application of alkali solutions to benzylated ammonium 
salts (26) resulted in a [1,2]-migration of the benzyl group, a reaction later termed the [1,2]-
Stevens rearrangement (Scheme 1-11).33 The mechanism of the [1,2]-Stevens rearrangement 
has been a controversial subject since its discovery. 34  Originally, the [1,2]-Stevens 
rearrangement was thought to involve the heterolytic dissociation of an ylide (27), then 
reassociation of a close-contact zwitterionic pair (28) to afford an -benzylated amine 
product (29). The zwitterionic mechanism was reasoned as no crossover products were 
afforded in crossover experiments and that retention of stereochemistry was observed.35 The 
now more widely accepted mechanism of the [1,2]-Stevens rearrangement is by a homolytic 
cleavage manifold (30), which Stevens and Thomson hypothesised in 1932,35b but was not 
fully validated until 1970 with work from Lepley36 and Baldwin and co-workers.37  
 














In addition to the migration of benzyl groups, Stevens and co-workers also reported that allylic 
functionality undergoes migration from an ammonium centre to an adjacent carbon, later 
known as the [2,3]-Stevens rearrangement.35b Misleadingly, the [1,2]-Stevens rearrangement 
and the [2,3]-Stevens rearrangement do not share similarities in their mechanisms. The            
[1,2]-Stevens rearrangement proceeds by a radical manifold (Scheme 1-11), while the [2,3]-
Stevens rearrangement is a sigmatropic process.38 A synthetically useful attribute of the [2,3]-
Stevens rearrangement is that transfer of chirality is observed. For example, West and co-
workers reported the stereoinvertive -allylation of proline derivatives (31), by a 
diastereoselective N-quarternisation with prenyl bromide (32) to afford quaternary 
ammonium salts (33) (Scheme 1-12). 39  Base-mediated [2,3]-Stevens rearrangement of    
ammonium 33 yields the -tertiary amino acid 34. Over the past 90 years the [1,2]-Stevens 
rearrangement and [2,3]-Stevens rearrangement have both found significant application in 
amine synthesis.33,35a,40 
 
Scheme 1-12. Stereoinvertive [2,3]-Stevens rearrangement of proline derivative 31 to form 
the -tertiary amino acid (34).  
Amathaspiramide F (35, Scheme 1-13) is a member of a family of alkaloids isolated from 
marine bryozoan Amathia wilsoni in New Zealand. 41  It has been demonstrated that the 
amathaspiramide family display a myriad of affects upon biological systems, such as antiviral, 
cytotoxic, and antimicrobial activities,41 while also demonstrating promise as -turn mimics 
in proteomics.42 Members of the amathaspiramide family share a unique aza-spirobicyclic 
framework, which consists of three contiguous chiral centres, one of which is an -tertiary 
amine. 
 







Unsurprisingly, due to the novel structure and medicinal significance of the amathaspiramide 
family, amathaspiramide F (35) has been the subject of total syntheses where the 
construction of its -tertiary amine centre is of chief consideration.43 Tambar and Soheili 
disclosed a route to racemic Amathaspiramide F (35), in which a [2,3]-Stevens rearrangement 
was used to form the -tertiary amine intermediate 39 (Scheme 1-14). 44 Firstly, a palladium-
catalysed allylic N-quaternisation of proline derivative 36 with allylic carbonate 37 was 
performed to give the ylide 38, which spontaneously underwent [2,3]-Stevens 
rearrangement. The afforded -tertiary amine 39 was obtained with modest diastereocontrol 
as the exo product, which was favoured as to avoid steric clash between the ester and aryl 
groups. 
 
Scheme 1-14. Palladium-catalysed allylic N-quaternisation of allyl amine 36 with allyl 
















1.5 Ellman’s Auxiliary 
 
In 1997, the application of tert-butanesulfinamide (40, Scheme 1-15) as an auxiliary for the 
preparation of enantioenriched amines was reported by Ellman and co-workers.45 The use of 
Ellman’s auxiliary (40) in amine synthesis has impacted multiple chemical fields, including the 
development of agrochemicals, natural product synthesis, and the preparation of chemical 
tools for a wide range of biological investigations. 46  Use of sulfinamide 40 over other 
sulfinamide auxiliaries47 incurs superior stereoselectivity, reduction of nucleophilic additions 
at sulfur, and ease of synthesis and procurement of both enantiomers.48 Furthermore, the 
condensation of sulfinamide 40 with aldehydes is easily performed at ambient temperature 
with a catalytic amount of acid.49 For the condensation of sulfinamide 40 with ketones (41) to 
form ketimines (42) more forcing conditions are employed, with the addition of titanium(IV) 
ethoxide as a promoter (Scheme 1-15). Ketimine 42 can be used in a variety of synthetic 
transformations,50 the most common being the 1,2-addition of organometallic reagents to 
form -tertiary sulfinamides (43), which can be converted to -tertiary amines by acid 
mediated removal of the auxiliary.51 The diastereoselectivity observed in the transformation 
of ketimine 42 to -tertiary sulfinamide 43 depends on the coordinating strength of the 
solvent, the cation of the organometallic nucleophile and the chemical functionality present 
near the ketimine.45,49,50e, 52  These parameters will affect whether the addition of an 
organometallic reagent to ketimine 42 will occur by a closed six-membered transition state 
or via an open transition state. 
 
Scheme 1-15. Use of the (R) enantiomer of Ellman’s auxiliary (40) in the synthesis of 
enantioenriched -tertiary sulfinamide 43. 
Studies into the neurophysiological basis of cold thermoception and cold nociception using L-
menthol-induced cold hypersensitivity relies on direct sensitisation of TRPM8 on Aδ and           
C-fibres.53 Inhibitors of TRPM8 have been touted as potential remedies for migraines and 
neuropathic pain. 54  As a result, scientists from Amgen developed a series of chroman 
derivatives as inhibitors of TRPM8, with the lead candidate identified as -tertiary amine 44 
(Scheme 1-16).55 
 




The synthesis of TRPM8 inhibitor 44 begins with the preparation of benzophenone derivative 
45, in which Weinreb ketone synthesis was used (Scheme 1-17).55 The titanium(IV) ethoxide 
promoted condensation of benzophenone derivative 45 with the (R) enantiomer of Ellman’s 
auxiliary (40) yields the ketimine 46. Addition of the enolate of methyl acetate to ketimine 46 
affords the -tertiary sulfinamide 47. Later, the reduction of the ester of 47 to a primary 
alcohol is carried out and used in the formation of the chroman skeleton of TRPM8 inhibitor 
44, by an intramolecular SNAr of the chloro-aryl bond. 
 






















1.6 Modern Approaches towards -Tertiary Amines 
 
Considering the wide range of appearances -tertiary amines make throughout biologically 
potent structures, it is unsurprising that contemporary fields of synthetic chemistry have 
found application towards their construction. In 2004, Waser and Carreira reported a 
Markovnikov hydrohydrazination of 1,1-disubstituted alkenes (48) with DBAD (49) to form -
tertiary hydrazines (50) by using cobalt complex 51 (Scheme 1-18).56  The mechanism of 
Scheme 1-18 has been proposed to operate via a cobalt(III)-hydride complex, which performs 
hydrocobaltation of a double bond, forming a cobalt(III)-alkyl complex. The alkyl portion of 
the cobalt(III)-alkyl complex disassociates from the cobalt centre as a free radical and adds to 
DBAD (49) to give an amide-coordinated cobalt(III) complex, which undergoes proto-
demetallation to yield the desired -tertiary hydrazine (48). Waser and Carreira expanded 
this protocol to operate under manganese catalysis57  and encompass hydroazidations of 
olefins.58 Also Boger and co-workers showed that transformations are applicable under iron 
catalysis.59 -Tertiary hydrazines60 (50) and -tertiary azides61 can both be converted into 
their related -tertiary amines under reductive conditions. 
 















In 2010, Cramer and co-workers disclosed the rhodium-catalysed [3+2] cycloaddition of 
acetophenone and benzophenone derived primary ketimines (52) with allenes (53), to afford 
-tertiary amines (54) by using ligand 55 (Scheme 1-19).62 Scheme 1-19 proceeds by rhodium 
C-H insertion ortho to the imine of 52, followed by migratory insertion of the aryl into the 
central carbon of an allene (53), forming an allyl rhodium complex that participates in 
intramolecular nucleophilic allylation of the imine. This rhodium-catalysed [3+2] 
cycloaddition with primary ketimines has been further developed by Cramer and Zhao 
independently to also include alkynes as the unsaturated coupling partners 63  and 
enantioselective variants.64 
 
Scheme 1-19. Rhodium-catalysed [3+2] cycloaddition of primary ketimines (52) with allenes 



















In 2015, Deng and co-workers reported an enantioselective umpolung approach to the -
functionalisation of trifluoromethylketimines (56) with α,β-unsaturated carbonyls (57) by 
phase-transfer catalysis (Scheme 1-20).65 Scheme 1-20 operates within an organic-aqueous 
biphasic reaction medium, where the cinchonine derived phase-transfer catalyst 58 facilitates 
movement of hydroxide anions from the aqueous into the organic phase. In the organic 
phase, catalyst 58 associated hydroxide anion deprotonates the benzylic position of 
trifluoromethylketimines (56) forming chiral quaternary ammonium bound 2-azaallyl anions, 
which couple with acrolein (57) through the carbon  to the trifluoromethyl group to form 
enantio-enriched -tertiary secondary aldimine (59). The absolute stereochemistry of 59 was 
assigned by its transformation into the pyrrolidine 60, by acid mediated transimination then 
reduction of the cyclic secondary aldimine, followed by resolution of the crystal structure of 
the ammonium chloride salt. This approach was found to be applicable to alkyl 
trifluoromethylketimines and 1,2-disubstituted acroleins. 
 
Scheme 1-20. Enantioselective umpolung -functionalisation of trifluoromethylketimines 
(56) by phase-transfer-catalysis.  
Poly(ADP ribose) polymerase is an arbitrator of DNA damage repair within systems 
susceptible to breast cancer. Preclinical testing has shown that poly(ADP ribose) polymerase 
inhibitors increase the efficacy of chemotherapeutics and radiation therapy. 66  Veliparib            
(61, Scheme 1-21) has been touted as a poly(ADP ribose) polymerase inhibitor and is currently 
under investigation for the treatment of a variety of oncological afflictions.67    
 








The asymmetric synthesis of Veliparib (61) was carried out by Kolaczkowski and co-workers, 
where -tertiary amine 63 is a key intermediate of their route (Scheme 1-22). 68  The 
construction of -tertiary amine 63 was achieved by a cyclization upon alkyl chloride 62, 
which proceeds with memory of chirality.69 It was proposed that the stereoretentive nature 
of Scheme 1-22 originates from alkyl chloride 62 predominantly existing in two conformers 
64 and 65, both of which can thermodynamically be deprotonated by KHMDS. However, 
deprotonation of conformer 65 under the reaction conditions is disfavoured due to an 
unfavourable steric interaction between the Boc group and the incoming base, an interaction 
64 does not incur. Once enolates 66 and 67 are formed they could potentially interconvert 
with each other by rotation of the nitrogen enolate bond, however 66 and 67 were shown to 
be atropisomers with a barrier to rotation of 16 kcal/mol.70  
 
Scheme 1-22. Stereoretentive cyclisation of alkyl chloride 62 to give -tertiary amine 63 by 















In 2019, Dixon and co-workers looked for inspiration from copper amine oxidases for the 
development of a novel synthesis of -tertiary amines. Copper amine oxidases are a class of 
metalloenzymes that facilitate the oxidation of primary amines into aldehydes, by use of 
oxygen, a quinone-based co-factor and a copper(II) species. 71 Dixon and co-workers found 
that the condensation of primary amines (68) with quinone 69 formed N-aryl ketimines (70), 
by an in situ rearomative [1,5] H-shift of the Schiff base (Scheme 1-23).72  It was shown that 
the newly formed N-aryl ketimines (70) could be coupled with a variety of organometallic 
reagents and cyanide, and be a source of -amino radical by reductive electron transfer for 
coupling with electron deficient olefins by photoredox catalysis. The utility of this method was 
underscored by its use in the one-pot preparation of the anorectic drug phentermine (72),73 
where the primary amine 68 was condensed with quinone 69 to form N-aryl ketimine 70, 
which was then coupled with benzyl magnesium bromide to give the N-aryl -tertiary amine 
71. N-aryl bond cleavage of -tertiary amine 71 was achieved by hydrolysis under oxidative 
conditions to give the desired phentermine (72).  
 
Scheme 1-23. -C-H functionalisation of -secondary amines (68) by condensation and [1,5] 















In addition to new synthetic disconnections for -tertiary amine preparation, innovative 
enabling-technologies are now being used, of which electrochemistry is of particular note for 
achieving atom-efficient transformations. In 2020, Rovis and co-workers reported the 
electrochemical reductive coupling of iminium salts (73) with cyano functionalised aryl N-
heterocycles (74) to afford , -diaryl alkylamines (75) (Scheme 1-24).74 Multiple mechanistic 
pathways to exact Scheme 1-24 were probed computationally, leading to the proposition that 
first cathodic electron transfer to iminium salt (73) occurs affording -amino radical. 
Simultaneously, aryl N-heterocycle (74) undergoes reductive proton-coupled electron 
transfer from the cathode to form a 1,4-dihydropyridine-4-carbonitrile persistent radical, 
which engages in radical-radical coupling with -amino radical. Finally, rearomative 
elimination of hydrogen cyanide furnishes the desired -tertiary amine (75). 
 




















Soon after publishing conditions to exact the electrochemical reductive coupling of iminium 
salts with cyano functionalised aryl N-heterocycles (Scheme 1-24), Rovis and co-workers 
disclosed the reductive coupling of O-benzoyl oximes (76) with cyano functionalised aryl N-
heterocycles (74) by photocatalysis (Scheme 1-25).75 The mechanism of Scheme 1-25 was 
probed computationally, leading to the proposition that first photoexcited 77 acts as a triplet 
sensitizer and engages in Dexter energy-transfer with O-benzoyl oxime (76), homolysing the 
N-O bond to form iminyl radical and O-centred benzoyloxyl radical. The iminyl radical 
hydrogen atom abstracts from the tertiary C-H of DIPA forming imine. Newly formed imine is 
protonated by benzoic acid, then reduced either by DIPA radical or by photoexcited 77, 
forming -amino radical. Simultaneously, photoexcited 77 is reduced by oxidation of DIPA, 
then formally reduced 77 engages in reductive proton-coupled electron transfer to cyano 
functionalised aryl N-heterocycle 74, affording 1,4-dihydropyridine-4-carbonitrile persistent 
radical. Radical-radical coupling between -amino radical and 1,4-dihydropyridine-4-
carbonitrile radical occurs, followed by rearomative elimination of hydrogen cyanide yielding 
the desired -tertiary amine product (75). This methodology was also found to be compatible 
with iminium salts (73). 
 















2. Project Background 
2.1 Photoredox Catalysis 
 
For the last century, the development of photoredox catalysis (PRC) has allowed for the 
inception of a variety of new chemical technologies. For example, PRC has found application 
in carbon dioxide reduction,76 water splitting77 and solar cell materials.78 However, use of PRC 
for organic synthesis has only been truly recognised in the past decade.79 
The inaugural report of PRC for organic synthesis came from Kellogg in 1978. 80  Kellogg 
reported the photoinduced ruthenium complex 80-catalysed reduction of sulfonium ion 78 
to form acetophenone 81 and dimethyl sulfide, using Hantzsch ester derivative 79 as a 
terminal reductant (Scheme 2-1). Kellogg’s reduction protocol was further expanded to other 
organic functionalities by Pac,81 Tanaka and Fukuzumi.82 
 
Scheme 2-1. First report of photoredox catalysis for organic synthesis.  
Later, Cano-Yelo and Deronzier disclosed the first redox-neutral photoredox-catalysed 
transformation in 1984, in the form of a ruthenium complex 80-catalysed Pschorr reaction to 
quantitively convert aryl diazonium salt 82 into phenanthrene derivative 83 (Scheme 2-2).83 
In this seminal work it was noted that the reaction occurred with significantly lower quantum 
efficacy in the absence of photocatalyst 80. 
 
Scheme 2-2. First example of a redox-neutral photoredox-catalysed process. 
The time between Kellogg’s publication and 1991 denotes the first period of sparse academic 
interest in PRC for application in organic synthesis. During this period, PRC entered a state of 
dormancy regarding academic attention until the late 2000s. The advent of modern PRC for 







Firstly, Yoon and co-workers demonstrated the photoredox-catalysed intramolecular [2 + 2] 
enone cycloaddition of 84 to give the bicyclo[3.2.0]heptane 85, by use of photocatalyst 80 
(Scheme 2-3).84 It was found that the addition of LiBF4 was crucial for Scheme 2-3 to proceed, 
as it was rationalised that lithium coordination to the carbonyls of 84 activates the enone for 
reduction by photoexcited 80.  
 
Scheme 2-3. Ruthenium complex 80-catalysed [2+2] cycloaddition of enone (84). 
Soon after Yoon’s report, Macmillan and Nicewicz disclosed the enantioselective -alkylation 
of aldehydes. This was achieved by use of a dual catalytic system, consisting of chiral 
organocatalyst 88 and photocatalyst 80 (Scheme 2-4).85 This reaction is proposed to initiate 
by photoexcited 80 oxidising a catalytic quantity of enamine formed by condensation of 
aldehyde 86 with organocatalyst 88, yielding formally reduced ruthenium complex 80 and 
enamine radical cation. Resting state photocatalyst 80 is regenerated from formally reduced 
ruthenium complex 80 by performing single electron reduction on bromomalonate 87 to 
generate -malonyl radical, which adds to enamines (formed in the condensation of aldehyde 
86 with organocatalyst 88) to form -amino radical. Photoexcited 80 oxidises -amino radical 
intermediate, to give an iminium species that is hydrolysed resulting in the desired product 
89, release of the organocatalyst 88 and reforming of formally reduced ruthenium complex 
80 to continue the photocatalytic cycle. Since these initial reports from Yoon, and MacMillan 
and Nicewicz an array of PRC-enabled methodologies have been published.79,86  
 








In addition to the variety of products that are obtainable by PRC, academic attention has also 
been directed at mechanistic understanding of these processes. 87 PRC generally begins with 
excitation of the resting catalyst by absorption of a photon, which promotes an electron from 
the HOMO to a higher energy orbital by a spin-allowed transition. As the resting catalyst exists 
in a singlet state, the resulting excited catalyst must occupy a higher energy singlet state in 
accordance with selection rules of electronic transitions (Figure 2-1).  The excited catalyst will 
then relax to a lower energy singlet state by vibrational quenching, termed internal 
conversion (IC), where it may then return to its ground state by emission of a lower energy 
photon than the one it originally absorbed, a process called fluorescence. Alternatively, the 
lowest energy excited singlet state of the catalyst may undergo the non-radiative transition, 
intersystem crossing (ISC), and adopt the lowest energy triplet state through IC. Direct 
relaxation to the ground state from a triplet state requires simultaneous emission of a photon 
and spin inversion of the excited electron, a forbidden transition termed phosphorescence 
and so is slow. Therefore, the lowest energy triplet state of the photoredox catalyst is thought 
to be its long-lived excited state. However, the singlet lifetime of certain photoexcited species 
can be long enough to facilitate redox processes.86d 
 
Figure 2-1. Jablonski diagram illustrating the electronic transitions and states a photoredox 











If the lifetime of the excited state of the photocatalyst is longer than the timescale of 
diffusion, it can engage in redox chemistry with a substrate. The electronic structure of an 
excited photoredox catalyst contains two SOMOs of differing energy (Figure 2-2), so acts as 
more powerful reducing and oxidising agents compared to their ground state. When an 
excited photoredox catalyst engages in reduction of a substrate it is formally oxidised. The 
subsequent oxidation of a substrate by the oxidised photocatalyst to regenerate resting 
photocatalyst is more exergonic than from its ground or excited state, a process termed 
oxidative quenching. Conversely, reduction of a substrate by the reduced photocatalyst to 
regenerate resting photocatalyst is more exergonic than from its ground or excited state, a 
process termed reductive quenching. Despite the variety of chemical change photoredox 
catalysis can exact, most processes can be described using these four elementary steps of 
reduction then oxidation, or oxidation then reduction.86b 
 
Figure 2-2. Generalised photoredox catalytic cycle, highlighting the two non-radiative 
regenerative pathways of the ground-state photocatalyst (PC) from its photoexcited state. 















In recent years, the most commonly employed families of photoredox catalysts for synthesis 
have been the polypyridyl complexes of ruthenium and iridium (77, 80 and 90, Scheme 2-5). 
These complexes absorb visible light, possess long-lived photoexcited states that outcompete 
unproductive pathways and span a range of redox potentials to exact synthetically useful 
electron transfers.88 However, despite the undeniable influence the polypyridyl complexes of 
ruthenium and iridium have had in reigniting the field of synthetic photoredox catalysis, they 
do possess undesirable traits. For one, these complexes are precious metal-centred and so 
their precursors incur a substantial cost due to their low abundance.89 Additionally, multistep 
syntheses are required for the preparation of iridium and ruthenium photoredox catalysts 
and their respective bipyridyl ligands, which require the use of palladium precatalysts.90 
Consequently, academic effort has been directed at the development of new classes of 
photoredox catalysts that can be attained rapidly from abundant resources, while exhibiting 
synthetically serviceable redox potentials. For example, endeavours towards the 
development of earth-abundant metal-centred photoredox catalysts have been 
undertaken.91 Furthermore, organic dyes have now recently begun to receive interest as a 
low cost, high availability, and benign alternatives to precious metal photocatalysts.86d 
  
Scheme 2-5. Redox potentials of commonly used precious-metal containing visible light 












One family of organic photoredox catalysts that have gained particular popularity in recent 
times as metal-free alternatives to precious metal polypyridyl complexes, are the donor-
acceptor dyads of isophthalonitriles.92 The first and most widely used of this class is 4CzIPN 
(91), which was originally developed by Adachi and co-workers as a highly efficient, green 
TADF emitter for use as an OLED (Scheme 2-6).93 4CzIPN (91) possesses a variety of desirable 
photophysical properties to exact redox processes. Firstly, 4CzIPN (91) absorbs light in the 
visible blue region distinct from most organic substrates, allowing its photoexcitation to be 
achieved by simple household light sources without perturbation of reactants.94 Next, 4CzIPN 
(91) possesses a very small energy gap between its singlet state and triplet state (EST = 0.08 
eV), resulting in a near energetically lossless ISC and therefore maximal conversion of 
absorbed photonic energy to chemical energy. 95  Finally, 4CzIPN (91) demonstrates 
photoexcited lifetimes from the triplet state on par with that of commonly used iridium 
photocatalysts for synthesis.96 The donor-acceptor substitution pattern of 4CzIPN (91) allows 
for conceptual visualisation of the spatial separation of the HOMO-LUMO, which are situated 
on the carbazolyl donors and the cyanoarene acceptor core respectively. Furthermore, the 
dihedral angle of the carbazolyl donors to the cyanoarene core is typically about 60°, allowing 
for near independent tuning of the oxidation or reduction power by modifications to the 
acceptor or donor moieties, respectively.97 
 














The use of 4CzIPN (91) in a synthetic context was first investigated by Zhang and Luo, who 
disclosed the redox potentials of its ground and photoexcited  states (Scheme 2-7).94 
Inspection of the redox potentials of 4CzIPN (91) highlights its promise as an inexpensive 
metal-free iridium photoredox catalyst alternative, especially when compared to iridium 
complex 77 with respect to the potentials pertaining to a reductive quenching mechanism. 
Zhang and Luo synthesised a library of 4CzIPN (91) derivatives by altering the number of donor 
moieties and changing the substitution pattern. However, the obtained donor-substituted 
isophthalonitriles demonstrated only minor deviations in redox potentials from 4CzIPN (91), 
but significant diminution of stabilities in all cases apart with 4DPAIPN (92), a slightly more 
reducing derivative.  
 
Scheme 2-7. Redox potentials of donor-acceptor fluorophores 4CzIPN (91) and 4DPAIPN (92) 
versus SCE. Asterisk indicates photoexcited state. 
The method by which Zhang and Luo tested the stability of 4CzIPN (91) and 4DPAIPN (92) for 
synthetic purposes was by their application in the decarboxylative cross-coupling of carboxylic 
acid 93 with aryl iodide 94 to give cross-coupled product 95, where both catalysts were found 
to be effective (Scheme 2-8).94 Once Scheme 2-8 had reached completion, HPLC analysis of 
the reaction mixture showed that 58% and 78% of 4CzIPN (91) and 4DPAIPN (92) remained 
respectively, indicating these PCs are stable under synthetic reaction conditions and do not 
simply undergo photodegradation. 
 
Scheme 2-8. Photoredox/nickel-catalysed decarboxylative cross-coupling facilitated by 





It was proposed that Scheme 2-8 proceeds by initial deprotonation of carboxylic acid 93 to 
give the carboxylate 96 (Scheme 2-9). Carboxylate 96 has an oxidation potential of +0.95 V 
versus SCE so is oxidised by excited photocatalyst (97), resulting in its decarboxylation to -
amino radical 98 and reduced photocatalyst (99).98 Simultaneously, the nickel catalytic cycle 
begins with oxidative addition of nickel(0) complex (100) with aryl iodide 94 to give nickel(II) 
intermediate 101, which coordinates with free radical 98 to give nickel(III) intermediate 102. 
Nickel(III) intermediate 102 performs reductive elimination to yield the desired product 95 
and the nickel(I) complex 103, which is reduced to nickel(0) intermediate 100 by the formally 
reduced form of the photocatalyst (99), regenerating resting photocatalyst (104) and closing 
both catalytic cycles (Scheme 2-9).94,99 
 











Recently there has been disagreement in the literature over the structure of 4DPAIPN (92) 
(Scheme 2-10). 4DPAIPN (92)  was originally synthesised by Zhang and Luo, by fourfold-SNAr 
of aryl fluoride 105 with diphenylamine.94 However, Zeitler and co-workers have reported the 
attempted reproduction of Zhang’s synthesis of 4DPAIPN (92) and instead obtained 3DPAFIPN 
(106), the threefold-SNAr product between aryl fluoride 105 and diphenylamine.97a 4DPAIPN 
(92) and 3DPAFIPN (106) were found to possess very similar redox and UV-visible absorption 
properties, implying that the use of 4DPAIPN (92) in Scheme 2-8 may have mistakenly been 
3DPAFIPN (106).  
 























2.2 Photoredox-Catalysed Alkene Difunctionalisation by Radical-Polar 
Crossover  
 
The fundamental power of PRC is that a photoredox cycle consists of two successive opposing 
single electron redox processes that are mediated by a single entity, the photocatalyst. If a 
single-electron redox-neutral transformation was attempted on a substrate by two separate 
electron donor and acceptor entities each facilitating their own separate redox steps, 
unproductive redox processes between the electron donor and acceptor would be 
problematic. However, conceptually a photoredox catalyst is an infinite number of single 
electron donor and acceptor entities in one, by virtue of the photoredox catalytic cycle  
(Figure 2-2), making PRC effective in performing redox-neutral reactions. The revitalisation of 
PRC for organic synthesis has led to the discovery of a plethora of new transformations, by 
allowing for precise small-molecule activation in ways that were not previously possible. For 
example, PRC has been applied to dual photoredox/transition metal–catalysed cross–
coupling reactions, by the generation of mono-valent species to circumvent difficult oxidative 
addition, transmetalation and reductive elimination steps.100 Previously benign functional 
groups have found activation by PRC, such as the -functionalisation of tertiary aliphatic 
amines.101 Furthermore, highly impressive late-stage modifications of unactivated C-H bonds 
have been enabled by PRC, by activation of hydrogen atom transfer catalysts.102 Lastly, PRC 


















The difunctionalisation of an alkene by PRC will generally initiate by the generation of a radical 
species (107) by reduction or oxidation (Scheme 2-11). Depending on the reaction conditions 
radical 107 may add to a radical acceptor (108) forming new radical species 109. From here, 
several mechanistic pathways can occur to determine the fate of radical 109. 1) A second 
radical species is generated by the PC through the opposite redox process that formed radical 
107, allowing for transient-radical persistent-radical coupling of radical 109 with another 
radical to give product 110.103 2) The PC enables oxidative-termination radical-polar crossover 
by oxidising radical 109 to carbocation 111, if radical 107 was formed by reduction. The 
cationic species 111 can then couple with a nucleophile to give product 112. 3) Or finally, the 
PC can mediate a reductive-termination radical-polar crossover and reduce radical 109 to 
carbanion 113, if radical 107 was formed by oxidation. The carbanion 113 can then react with 
an electrophile to give product 114.  
 
Scheme 2-11. The three mechanistic pathways of PRC enable difunctionalisation of an alkene 
(108), by 1) radical-radical coupling, 2) oxidative-termination radical-polar crossover and 3) 













2.2.1 Alkene Difunctionalisation by Oxidative-Termination Radical-
Polar Crossover  
 
For the difunctionalisation of an alkene to occur by oxidative-termination radical-polar 
crossover the PC must engage in an oxidative quenching photoredox cycle, so that a 
carbocation is formed by oxidation of a radical in the final redox step of the photoredox cycle 
(Scheme 2-12). The restriction placed upon the PC, that it must first perform a reduction then 
an oxidation, means that careful consideration of radical precursors and PC selection must be 
taken. However, despite this mechanistic limitation a variety of PRC-mediated 
transformations proceed by oxidative-termination radical-polar crossover.104 
 
Scheme 2-12. General depiction of an alkene difunctionalisation by oxidative-termination 
radical-polar crossover. Astrisks denotes photoexcited state. 
In 2012, Akita and Koike reported conditions for the three-component 
oxytrifluoromethylation of alkenes (Scheme 2-13).105  This transformation was realised by 
using Umemoto reagent (115), a source of trifluoromethyl radical upon reduction by 
photoexcited 117. The resultant trifluoromethyl radical adds to an olefin such as styrene 
(116), resulting in a benzylic radical intermediate that is oxidised to a phenyl-stabilised 
carbocation by formally oxidised 117 (that was generated in trifluoromethyl radical 
generation). The benzylic carbocationic product of the oxidative quenching photoredox cycle 
couples with alcoholic solvent to give oxytrifluoromethylation product (118). 
 
Scheme 2-13. Oxytrifluoromethylation of styrene (116) with Umemoto reagent (115) in the 







Following on, Magnier and Masson developed a three-component azidotrifluoromethylation 
of alkenes (Scheme 2-14). 106  Again Umemoto reagent (115) is used as a source of 
trifluoromethyl radical upon reduction (from photoexcited 80), which adds to styrene (116). 
The resulting benzylic radical is oxidised to a carbenium intermediate by formally oxidised 80. 
The benzylic carbocationic intermediate then combines with azidotrimethylsilane to give 
azidotrifluoromethylation product (119). 
 
Scheme 2-14. Ruthenium complex 80 catalysed-aminotrifluoromethylation of styrene (116). 
Later, Masson and co-workers reported the three-component trifluoromethyl-arylation of 
alkenes (Scheme 2-15). 107  Using similar conditions to Magnier and Masson’s 
aminotrifluoromethylation (Scheme 2-14), the resulting aryl-stabilised carbenium 
intermediate, formed by trifluoromethyl radical addition to styrene (116) followed by 
oxidation, was used in a Friedel-Crafts-type alkylation with an electron-rich aryl (120) to yield 
the benzhydryl product (121). Furthermore, indoles were found to be amenable aryl coupling-
partners with the intermediary aryl-stabilised carbenium ions formed.  
 














In addition to new forms of reactivity being enabled by PRC, the field has also contributed to 
the improvement of previously well-studied synthetic protocols. In 2015, Konig and co-
workers reported a formyloxylation-arylation of styrenes by a photo-Meerwein arylation 
(Scheme 2-16).108 Aryl diazonium salts (122) possess very low reduction potentials, as such 
their reduction by photoexcited 80 is trivial, and yields oxidised 80 and aryl radical.109 The 
newly generated aryl radical adds to a styrene (116) to give a benzylic radical species that is 
oxidised to a carbenium ion intermediate by the oxidised form of ruthenium complex 80 (that 
was formed during aryl radical generation). The aryl-stabilised carbenium ion is quenched by 
the carbonyl of DMF to generate an iminium intermediate (124), which is hydrolysed to give 
the formyloxylation-arylation product (123). 
 
Scheme 2-16. Dormyloxylation-arylation of styrene (116) by photo-Meerwein arylation. 
Finally, in 2017 Aggarwal and co-workers developed protocol for a general method of forming 
two carbon-carbon single bonds across vinyl boronate esters (Scheme 2-17). 110  This 
methodology begins with the union of a lithiated hydrocarbon with a vinyl boronic ester (125) 
to form an intermediary boronate complex (126). A solvent switch is performed and boronate 
126 is exposed to photocatalyst 80 and an -bromo ketone (87). Scheme 2-17 proceeds by 
reduction of bromo malonate 87 by photoexcited 80 to yield electrophilic α-malonyl radicals, 
which add to the electron rich olefin of vinyl borate 126 forming a radical anion species (128). 
The oxidised form of the photocatalyst 80 (generated in α-malonyl radical formation) oxidises 
radical anion 128 to form an ylide that undergoes 1,2-metalate rearrangement to the desired 
difunctionalised product (127). In some cases, this protocol was found to occur by a radical 
chain mechanism, that initiates by photolysis of iodoacetophenones and is propagated by 
electron transfer from intermediary radical anion 128 to iodoacetophenones.111  
 








2.2.2 Alkene Difunctionalisation by Reductive-Termination Radical-
Polar Crossover 
 
For the functionalisation of an alkene to occur by reductive-termination radical-polar 
crossover, the PC must partake in a reductive quenching photoredox cycle. In this mechanism 
a carbanion is formed by reduction of a radical in the final redox process of the photoredox 
cycle (Scheme 2-18). Contrary to oxidative-termination radical-polar crossover, the 
requirement placed upon the PC is that it must first perform an oxidation followed by a 
reduction, hence judicious selection of radical precursors and PC must be undertaken (vide 
infra). 
 
Scheme 2-18. General mechanistic depiction of an alkene difunctionalisation by reductive-
termination radical-polar crossover. Asterisk indicates photoexcited state. 
In 2012, Nishibayashi and co-workers reported the -functionalisation of tertiary amines by 
PRC (Scheme 2-19).112  This approach proceeds by oxidation of a tertiary amine (129) by 
photoexcited iridium catalyst 131 yielding an N-centred radical cation. The N-centred radical 
cation greatly destabilises the carbon-hydrogen bond  to it, resulting in its  deprotonation 
by another separate tertiary amine (129) and concurrent 1,-2-electron transfer from the          
-carbanion to the nitrogen radical cation, yielding an α-aminoalkyl radical (133).113 -Amino 
radical 133 is nucleophilic in nature and adds to an electron-deficient radical acceptor, such 
as methylene malonate 130 to form -malonyl radical. The intermediary -malonyl radical is 
reduced to a carbanion (by formally reduced 131 that was generated in the oxidation of 
tertiary amine (129)), which closes the catalytic cycle. The enolate of 132 is protonated by 
diphenylmethylammonium formed during -amino radical 133 generation, yielding the 
intended product 132. 
 





A vast majority of reported accounts of alkene functionalisations by PRC mediated reductive-
termination radical-polar crossover start with formation of a nucleophilic radical, by oxidation 
of a radical precursor. The nucleophilic radical adds to an olefin substituted with an electron-
withdrawing group, such as acrylates, vinyl ketones, α,β-unsaturated malonates or 
acrylonitriles. This yields an intermediary radical adjacent to an electron-withdrawing 
stabilising group, which is reduced by the formally reduced form of the photocatalyst to a 
stabilised carbanion. At this point the enolate-type product of PRC is typically protonated, like 
in Scheme 2-19. Although a variety of fascinating synthetic methodologies have been built 
around this concept, it does only deliver a monofunctionalisation of an olefin,112,114 a fact that 
is emphasised when compared to the diversity of difunctionalisations of alkenes by oxidative-
termination radical-polar crossover. Therefore, recent academic attention has been directed 
at the difunctionalisation of olefins by reductive-termination radical-polar crossover, in which 
the carbanion product of PRC is not simply protonated but instead used in another carbon-
carbon bond-forming process (vide infra). 
The first reported difunctionalisation of an alkene by photoredox catalysis mediated 
reductive-termination radical-polar crossover was by Martin and co-workers in 2017, who 
disclosed the trifluoromethylation-carboxylation of styrenes (Scheme 2-20).115 Scheme 2-20 
proceeds by oxidation of Langlois reagent (134) by reduction of photoexcited iridium 
photocatalyst 131. Upon oxidation Langlois reagent (134) decomposes to sulfur dioxide and 
trifluoromethyl radical, which adds to alkene 135 yielding benzhydrylic-stabilised C-centred 
radical. The benzhydrylic-stabilised radical is reduced by reduced 131 (formed in the oxidation 
of Langlois reagent (134)), giving carbanion 137 as the product of the photoredox cycle. 
Carbanion 137 then attacks carbon dioxide present in solution to give the carboxylate of 136, 
which is protonated upon acidic work up. 
 











Molander and co-workers and Aggarwal and co-workers independently disclosed methods for 
the cyclopropanations of olefins by reductive-termination radical-polar crossover. Molander’s 
contribution was the development of a C1 delivering cyclopropanation reagent (138), which 
contains an alkyl iodide and oxidisable silicate functionality (Scheme 2-21).116  Scheme 2-21 
proceeds by oxidation of silicate 138 by photoexcited 4CzIPN (91), forming the radical anion 
of 4CzIPN (91) and C-centred iodomethyl radical, which adds to olefin 139 generating a benzyl 
radical. The intermediary benzyl radical is reduced to carbanion 141 by the radical anion of 
4CzIPN (91) formed in the oxidation of silicate 138. Carbanion 141 undergoes intramolecular 
attack of the pendent alkyl iodide to yield cyclopropane 140. 
 
Scheme 2-21. 4CzIPN (91)-catalysed formal [2+1]-type cycloaddition of olefin 139 with silicate 
138. 
Very soon after Molander’s report the Aggarwal group independently published their own 
PRC-mediated cyclopropanation protocol by reductive-termination radical-polar crossover 
(Scheme 2-22).117 Aggarwal’s protocol again uses 4CzIPN (91), but with more emphasis placed 
upon radical coupling then intramolecular alkylation, rather than [2+1]-type cycloaddition. 
Scheme 2-22 starts with deprotonation of carboxylic acid 93 by caesium carbonate to give the 
related caesium carboxylate, which undergoes radical decarboxylation upon oxidation by 
photoexcited 4CzIPN (91) yielding intermediary -amino radical. The C-centred radical 
formed is nucleophilic in nature and adds to an electron-deficient olefin (142) forming a new 
C-centred radical species, where the radical is stabilised by an adjacent EWG. This EWG-
stabilised C-centred radical is reduced by the radical anion of 4CzIPN (91) (formed during the 
oxidation of deprotonated 93, generating carbanion 144 that performs intramolecular 
alkylation to yield the cyclopropane 143. Later, Aggarwal and co-workers developed protocol 
for the cyclobutanation of olefins by a similar approach to Scheme 2-22 by homologating the 
tether between the alkyl chloride and alkene.118 
 
Scheme 2-22. 4CzIPN (91)-catalysed decarboxylative radical-addition with subsequent 





Lastly, Zuo and co-workers reported a [5+2] cycloaddition by dual catalysis (Scheme 2-23).119 
The mechanism of Scheme 2-23 deviates from the one depicted in Scheme 2-18 as an 
oxidative quenching photoredox cycle occurs. Firstly, photoexcited DPA reduces radical 
acceptor 146 to form DPA radical cation and the radical anion of 146. DPA radical cation 
oxidises cerium(III) chloride to a cerium(IV) species, which complexes to alcohol 145 through 
its hydroxyl. Cerium(IV) complexed 145 undergoes photolytic Ce-O cleavage forming the O-
centred radical of 145 and cerium(III). The O-centred radical of 145 undergoes -scission to 
form an aldehyde-containing benzyl radical, which adds to radical acceptor 146 forming            
-malonyl radical. The -malonyl radical is reduced by photoexcited DPA to give enolate 148 
and DPA radical cation, which oxidises cerium(III) chloride back to a cerium(IV) species closing 
both catalytic cycles. Enolate 148 performs an intramolecular aldol reaction forming the 
related cycloheptanol structure, which is converted to lactone 147 upon addition of acid. 
 
Scheme 2-23. DPA and cerium(III)-catalysed synthesis of lactone 147 by [5+2] cycloaddition. 
These seminal reports of photoredox-mediated difunctionalisations of alkenes by reductive-
termination radical-polar crossover from Martin, Molander, Aggarwal and Zuo, demonstrate 
that the carbanion product of the reductive quenching photoredox cycle can couple with 

















2.3 Concerted Nucleophilic Aromatic Substitutions 
 
The nucleophilic substitution of aromatic rings (SNAr) represents a long-studied class of 
reactions, which have been used in a variety of synthetic contexts.120 The mechanism of SNAr 
has long been accepted to occur in a two-step process (Scheme 2-24).121 Firstly, a nucleophile 
adds to an aromatic ring (149) substituted with one or more EWGs. The EWGs are positioned 
ortho or para to the site of ipso substitution to provide resonance stabilisation of the anionic 
charge introduced by the nucleophile. The anionic dearomatised adduct 150 is commonly 
termed the Meisenheimer intermediate, as Jakob Meisenheimer in 1901 isolated such species 
(152) when studying the SNAr of 1,2,3-trinitrobenzenes. 122  Once the Meisenheimer 
intermediate (150) is formed the second step of the SNAr mechanism proceeds by ejection of 
an inductively electron-withdrawing leaving group, with concurrent rearomatisation to give 
the substituted aromatic ring (151). The generation and isolation of a Meisenheimer 
intermediate will depend on the ability of the aromatic ring’s substituents to stabilise anionic 
charge, the nucleophilicity of the incoming nucleophile, and the nucleofugality of the leaving 
group. 
 
Scheme 2-24. Generalised mechanism of a two-step SNAr. Common EWGs – -NO2, -CN, -C(O)R, 
-CF3. Common X – F, Cl, Br, -OR.  
The mechanism of two-step SNAr reactions has been investigated through Hammett analysis 
by elucidation of the  values of such processes. Two-step SNAr reactions are generally 
characterised by large and positive  values, indicating substantial build-up of negative charge 
over the rate-determining step and formation of a Meisenheimer intermediate. For example, 
the  value Miller and co-workers obtained in the conversion of para-functionalised aryl 
chlorides (153) to para-functionalised methoxybenzene by two-step SNAr was + 8.47 (Scheme 
2-25).123 
 







Despite the general acceptance of the two-step SNAr mechanism, anomalous examples 
appeared to not need the perceived requirements for aryl rings to be substituted with EWGs 
or halide leaving groups.124 A very early example of these supposed abnormal SNAr processes 
were from Pierre and co-workers in 1980, who disclosed the dehalogenation of simple 
electron-neutral aryl halides (155) with potassium hydride (Scheme 2-26).125 By performing 
Scheme 2-26 in THF-d8 and observing no deuterium incorporation into the resulting biphenyl 
product (156) a benzyne intermediate was discounted and instead SNAr was proposed. 
Furthermore, the authors found that the reactivity order followed: ArI > ArBr > ArCl > ArF, 
opposite to what is observed in a two-step SNAr process. To explain a SNAr mechanism in the 
absence of substituents that could stabilise a Meisenheimer intermediate, Pierre and co-
workers proposed a concerted process by a four-centred transition state (157). However, due 
to lack of computational chemistry the preceding proposition was made without any 
evidence. Instead Tuttle, Murphy and co-workers later validated Pierre and co-workers’ claim 
that Scheme 2-26 proceeds by a concerted SNAr (cSNAr) through DFT computation.126 
 
Scheme 2-26. Proto-dehalogenation of aryl chloride 155 by a cSNAr mechanism. 
In 1993 and 1995, Williams and co-workers reported a variety of SNAr reactions of 1,3,5-
triazines (158), which involved the exchange of 4-nitrophenol with various phenolate ions 
(159) to form new 1,3,5-triazines (160) (Scheme 2-27).127 It was found that when the pKArOH 
of the substituting phenolate ions (159) were incorporated into a Brønsted plot a linear 
relationship was observed, which suggests no change in mechanism across the phenolate ions 
used and is consistent with a concerted mechanism. Williams and co-workers also performed 
Hammett analysis of the SNAr of 1,3,5-triazine cores substituted with pyridine and aryloxy 
leaving groups in aminolysis reactions, obtaining  values of + 1.65 and + 0.82 when 
morpholine and N,N-dimethylaminopyridine were used respectively as the substituting 
nucleophiles. These  values are considerably less positive than values related to typical two-
step SNAr processes (Scheme 2-25). 
 







A series of seminal modern acknowledgements and investigations of cSNAr were carried out 
by Ritter and co-workers.128 Who in 2016 developed a two-step fluorodeoxygenation protocol 
of phenols by cSNAr (Scheme 2-28) to chemically install fluorine-18 for application in positron 
emission tomography.129 Scheme 2-28 proceeds by phenol 161 activation from NHC 162 to 
form the adduct 163, which is substituted with fluoride to give the aryl fluoride 164 and the 
urea 165. Hammett analysis was performed on para-substituted phenols for the second step 
of Scheme 2-28 at 110 °C yielding a  value of +1.79, suggesting that a carbanion does not 
fully develop at the transition state. It was proposed that with Scheme 2-28 proceeding by 
cSNAr this would avoid the formation of high energy intermediates on route to a 
Meisenheimer intermediate, allowing more general reactivity with respect to the electronics 
of the phenol undergoing substitution compared to if a two-step SNAr was in operation. 
 
Scheme 2-28. cSNAr fluorodeoxygenation sequence of phenol 161 by activation from NHC 
162.  
Although historically Hammett analysis and  value elucidation has been a popular approach 
to ascertaining whether a SNAr reaction proceeds in a two-step or concerted fashion, this 
method can be misleading. Firstly, there are no well-established reference  values for cSNAr 
reactions. Also, the Hammett slope is temperature-dependent and so comparison of  values 
from different systems conducted at different temperatures is incorrect. Furthermore, during 
Hammett analysis a transition from a stepwise mechanism to a concerted mechanism may 
occur over a range of substituents, which have similar  values and so hide the transition. 
These shortcomings were highlighted by Rohrbach, Murphy and Tuttle, who in response 
developed a computational model to identify changes in mechanism of a SNAr reaction of aryl 
fluorides over a range of substituents, by using the electron affinity of the aryl undergoing 









The precedent established for the existence of cSNAr-centred transformations by Pierre,125 
Williams127 and others,131 followed by Ritter’s reintroduction of cSNAr to the modern synthetic 
community,128,129 led to a seminal investigation by Jacobsen and co-workers.132 The aim of 
the investigation was to uncover the degree of contribution SNAr reactions operate in a 
stepwise or concerted manner, by probing three SNAr reactions (Scheme 2-29). 1) The 
methoxylation of nitro-substituted aryl fluoride 166 to give aryl methoxy 167. 2) The 
fluorination of bromopyridine 168 to give fluoropyridine 169. 3) The fluorination of nitro-
substituted aryl chloride 170 to give aryl fluoride 171. These three SNAr examples were 
selected, as case 1 represents a SNAr reaction that goes by the classic two-step mechanism. 
Case 2 exemplifies a SNAr reaction that proceeds by a concerted process. Finally, case 3 is an 
example that is in between the classic two-step and concerted mechanisms for SNAr, as the 
nitro substituents of 170 provide anion stabilisation, but the chloride leaving group kinetically 
destabilises formation of a Meisenheimer intermediate. 
 
Scheme 2-29. The three SNAr scenarios studied by Jacobsen and co-workers, representing 










The experimental method Jacobsen and co-workers used to probe the three scenarios of 
scheme 2-29 was by indirect measurement of the 13C/12C kinetic isotope effect (KIE) in the 
breaking or forming of carbon fluorine bonds, by quantification of the 13C–19F satellites to the 
12C–19F peak. The maximum KIE observed for any reaction is when the bonds to both the 
nucleophile and electrophile are weakest in the transition state. Therefore, comparison of 
experimental KIE measurements against computed maximum KIE values indicates whether a 
stepwise or concerted SNAr manifold is present. A two-step mechanism where each bond is 
altered in succession leads to a small KIE, while a concerted mechanism in which both bonds 
change simultaneously gives rise to a large KIE. This method demonstrates good agreement 
with the three cases of Scheme 2-29, with case 1 giving an experimental KIE 47% of the 
maximum theoretical KIE indicating a two-step mechanism. Case 2 yielded a KIE value that 
was 87% of the maximum theoretical KIE pointing to a concerted mechanism. Finally, case 3 
proceeds by a mechanism in between the extremes of the two-step and concerted 
mechanisms, with a KIE measurement that is 73% of the maximum theoretical KIE. The most 
striking finding of Jacobsen and co-workers’ investigation was that when their study was 
extended to 120 other SNAr reactions, their experimentally determined and computationally 
obtained KIE values indicated that 99 of the examples proceeded by a concerted mechanism. 
This seminal result took cSNAr from being a mechanistic rarity into general acceptance by the 
synthetic community, allowing the discovery of new methodologies and further 


















2.4 The Truce-Smiles Rearrangement of -Metalated Ureas 
 
The first documented report of the Smiles rearrangement was carried out by Henriques in 
1894,134 with follow up reports by Hinsberg.135 However, it was not until the 1930’s where  
the synthetic utility of the Smiles rearrangement was realised by Smiles. 136  The Smiles 
rearrangement represents an intramolecular SNAr between two heteroatoms (alkoxyl aryl 172 
to alkyl aniline 173). Like the classic two-step SNAr mechanism (Scheme 2-24) the Smiles 
rearrangement typically requires the migrating aryl group to be furnished with EWGs to lower 
the activation energy barrier towards accessing the Meisenheimer intermediate (174) 
(Scheme 2-30). In the Smiles rearrangement the collapse of the Meisenheimer intermediate 
(174) is thought to be the rate-determining step of this transformation.137 The kinetics of the 
Smiles rearrangement are dependent on the nucleophilicity of the incoming heteroatom, the 
nucleofugality of the leaving heteroatom, the degree of activation of the aryl ring undergoing 
ipso substitution, the length of the tether connecting the two hetero-atoms and if substitution 
on the tether incurs the Thorpe-Ingold effect.138  
 
Scheme 2-30. The Smiles rearrangement.  
Later, Truce found that carbanions (177) were sufficiently nucleophilic to lift the requirement 
for EWGs on the aryl ring experiencing ipso substitution (sulfonyldiaryl 175 to sulfinate 176) 
(Scheme 2-31).139 The application of a Smiles rearrangement involving the use of a carbanion 
is termed the Truce-Smiles rearrangement. The Smiles rearrangement and the Truce-Smiles 
rearrangement have both enjoyed much application over the past 50 years in a variety of 
synthetic scenarios, in the form of polar, 140  radical 141  and transition-metal-catalysed 
processes.142 
 






In 2007, while exploring the lithiation of N-aryl ureas, Clayden and co-workers uncovered a 
unique class of intramolecular aryl migrations.143 These processes were originally performed 
by  C-H bond lithiation of N-benzyl ureas (178), by exposure to an alkyllithium base and 
lithium coordinator DMPU. The -lithiated N-benzyl urea (180) undergoes Truce-Smiles aryl 
migration to give -tertiary ureas (179) (Scheme 2-32). A remarkable trait of this 1,5-aryl shift 
of -lithiated N-benzyl ureas (180) was that even though this transformation proceeds by an 
SNAr mechanism, the usual requirement for EWGs to be present on the aryl ring undergoing 
ipso substitution was not necessary, instead EDGs were very well tolerated. Furthermore, 
enantioenriched -lithiated N-benzyl ureas were configurationally stable on the timescale of 
the reaction, as such their aryl migration proceeded in a stereoretentive manner, allowing for 
the synthesis of enantioenriched -tertiary amines upon solvolysis of the -tertiary urea 
products (179).144 
 
Scheme 2-32. N to C intramolecular electrophilic arylation of -metalated urea 180.  
In Clayden and co-workers initial report of the Truce-Smiles rearrangement of -lithiated 
ureas, it was not completely understood why the excellent variety of electronics for the 
translocating aryl ring is observed.143 The presence of a Meisenheimer intermediate was 
predicated on the isolation of enone 183, by performing the Truce-Smiles rearrangement of 
urea 181 under aerobic conditions. It is presumed that enone 183 is formed by oxidation of 
the Meisenheimer intermediate 182. However, as this study was performed a decade earlier 
than Jacobsen and co-workers’ seminal investigation into cSNAr,132 such a manifold was not 
suggested for the N to C aryl migration of -lithiated ureas. 
 
Scheme 2-33. Evidence for a Meisenheimer intermediate during the Truce-Smiles 






In 2015 a more in-depth mechanistic study of the Truce-Smiles rearrangement of -lithiated 
ureas was carried out by Clayden and co-workers using DFT computation.145 It was found that 
N-aryl ureas exhibit a strong conformational bias for the aryl to be positioned anti to the urea 
carbonyl, to avoid an unfavourable stereo-electronic clash between the aryl -system and 
lone pairs of the urea carbonyl, a concept observed in other studies.146 Next, it was suggested 
that after  C-H lithiation, the -lithiated urea adopts the conformation 184, orienting the 
benzyllithium s-cis to the ureido carbonyl to offer a stabilising interdipolar interaction, which 
presumably attenuates racemisation of the benzylic position (Scheme 2-34). For aryl 
translocation to occur the urea carbonyl dipole interaction with the benzyllithium must break, 
allowing the benzylic group to occupy an anti-conformation to the urea carbonyl (185). When 
the -lithiated urea adopts the conformation 185 both the N-aryl and benzyllithium are anti 
to the urea carbonyl, and so are in very close proximity to each other. This is likely the origin 
of the rate acceleration of the anionic arylation, compared to if such reactions were 
attempted in an intermolecular fashion. Finally, Truce-Smiles rearrangement of intermediate 
185 proceeds to give -tertiary urea 186.  
 
















The degree of stepwise or concerted contribution in the Truce-Smiles rearrangement of           
-metalated ureas was first acknowledged and investigated by Clayden and co-workers in 
2018,147 soon after Jacobsen and co-workers study of the cSNAr mechanism.132 In this report 
Clayden and co-workers disclosed a method for the preparation of enantiopure quaternary 
amino acids by N to C aryl migration of ureas (Scheme 2-35). This protocol relied on Seebach’s 
concept of Self-Regeneration of Stereocentres,148 where enantiopure amino acids (187) were 
used to form imidazolidin-4-ones (188) that contain a new aminal stereocentre defined by 
the chirality of the amino acid starting material. Formation of enolate 190 destroys the 
original source of chirality of the amino acid starting material, however the aminal 
stereocentre is preserved and controls the stereochemistry of the proceeding Truce-Smiles 
rearrangement. Like benzylic carbanions, enolates had been previously shown to be viable 
nucleophiles in the N to C aryl migration of ureas.149 As such, enolate 190 converts to -
tertiary urea 189 by anti-arylation to the aminal stereocentre. Through methylation then 
hydrolysis of -tertiary urea 189 the free quaternary amino acid (191) is yielded. A  value of 
+ 4.5 was obtained at a reaction temperature of ‒20 °C by Hammett analysis of the Truce-
Smiles rearrangement of enolate 190, indicating a significant build-up of charge occurring at 
the transition state, but not full development of a Meisenheimer intermediate. 
 
Scheme 2-35. Preparation of enantiopure quaternary amino acids (191) by merging the Truce-












In addition to initiating the N to C aryl migration of -metallated ureas by deprotonation, 
Clayden and co-workers also reported the carbolithiation of vinyl ureas (192) as a second 
method.150 Remarkably, it was found that vinyl ureas (192) engage in umpolung chemistry, 
where organolithiums add to the more nucleophilic -carbon yielding -lithiated N-benzyl 
ureas (194) that undergo 1,5-aryl shift to give -alkylated--arylated -tertiary ureas (193). 
Due to carbolithiation proceeding syn, concurrently yielding configurationally stable -
lithiated N-benzyl urea (194), the products of this alkyl-arylation difunctionalisation are 
obtained as a single diastereomer.  Later, asymmetric variants of the carbolithiation of vinyl 
ureas (192) were developed by use of (‒)-sparteine or (+)-sparteine surrogate to generate 
enantioenriched -lithiated N-benzyl ureas.151  
 
Scheme 2-36. N to C intramolecular electrophilic arylation of metalated urea 194 by 

















3. Results and Discussion 
3.1 Project Aims 
 
It was intended to develop protocol for the addition of radicals (195), generated by reduction 
of an excited photocatalyst (196), to vinyl urea (197) (Scheme 3-1). The preceding process 
would yield intermediary ureido benzyl radical (198) that could be reduced by the radical 
anion of the photocatalyst (199), to give -metalated urea (200) that undergoes N to C 
intramolecular arylation across the urea, yielding -tertiary urea (201). If Scheme 3-1 came 
to fruition this would represent the first example of a photoredox-catalysed reductive-
termination radical polar crossover where the intermediary carbanion product engages in 
carbon-aryl bond formation. Furthermore, a photoredox mediated intramolecular 
electrophilic arylation of -metalated ureas could provide a useful method for the 
construction of -tertiary amines. Furthermore, it was intended that to make the 
transformation of vinyl urea 197 to -tertiary urea 201 as procedurally simple as possible, 
cheap and easily accessible photocatalysts 4CzIPN (91) and 3DPAFIPN (106) would be 
investigated. 
 
Scheme 3-1. A design plan to perform the intramolecular electrophilic arylation of vinyl urea 









3.2 Reaction Discovery and Optimisation 
 
Firstly, work was undertaken to reproduce the results of Zhang and Luo for the preparation 
of PCs 4CzIPN (91) and 4DPAIPN (92). 4CzIPN (91) was successfully synthesised by fourfold-
SNAr upon tetrafluoroisophthalonitrile (105) with carbazole (202) by following literature 
protocol (Scheme 3-2).94 It is noteworthy that the reported cost to synthesise 4CzIPN (91) is 
~£5/g and no chromatography was required, highlighting its accessibility over the polypyridyl 
complexes of ruthenium and iridium.94 
 
Scheme 3-2. Synthesis of 4CzIPN (91). 
Attempted synthesis of 4DPAIPN (92) by fourfold-SNAr upon tetrafluoroisophthalonitrile (105) 
with diphenylamine did not give the intended product, but instead photocatalyst 3DPAFIPN 
(106) by threefold-SNAr (Scheme 3-3). The formation of 3DPAFIPN (106) over 4DPAIPN (92), 
even under extended reaction times and elevated temperatures compared to Zhang and Luo’s 
procedure,94 gives further support to Zeitler and co-workers claim that 3DPAFIPN (106) has 
been mis-assigned as 4DPAIPN (92) (Scheme 2-10).97a  However, the use of 3DPAFIPN (106) 
over 4DPAIPN (91) is inconsequential to this project, as their redox potentials from the ground 
state and photoexcited state are similar. 
 







With photocatalysts 4CzIPN (91) and 3DPAFIPN (106) in hand, work was directed towards the 
synthesis of vinyl urea 205, which was selected as a model substrate for initial optimisation 
studies. Vinyl urea 205 was synthesised by imine condensation between acetophenone (81) 
and methylamine to give imine 203 (Scheme 3-4). Imine 203 was used crude and coupled with 
phenyl isocyanate (204); subsequent one-pot methylation at the carbamoyl nitrogen with 
methyl iodide gave the desired vinyl urea 205.152 
 
Scheme 3-4. Synthesis of vinyl urea 205. 
Initial forays to achieve a photoredox-mediated intramolecular electrophilic arylation of vinyl 
urea 205 were performed using photocatalysts 4CzIPN (91) and 3DPAFIPN (106). Langlois 
reagent (134) was selected as a commercially available radical precursor that upon SET 
oxidation decomposes to yield sulfur dioxide and trifluoromethyl radical.153 Trifluoromethyl 
radical is well documented in adding to electron-rich olefins such as enamides, giving 
confidence that it would engage in addition to a vinyl urea.154 Furthermore,    Langlois reagent 
(134) possesses an oxidation potential (E1/2 = 1.05 V vs SCE)155 of smaller magnitude than that 
of photoexcited photocatalysts 4CzIPN (91) (E1/2 (P*/P‒) = 1.35 V vs SCE) and 3DPAFIPN (106) 

















Unexpectedly, initial attempts at the photoredox-mediated intramolecular electrophilic 
arylation of vinyl urea 205 yielded the 3,4-dihydroquinazolinone 206 and not the intended   
-tertiary urea 207 (Table 3-1). Use of 4CzIPN (91) (Table 3-1, entries 1-3) over 3DPAFIPN 
(106) (Table 3-1, entries 4 and 5) gave greater productivity for the formation of 3,4-
dihydroquinazolinone 206, which may imply 3DPAFIPN  (106) is too slow to oxidise Langlois 
reagent (134) under the reaction conditions. With 4CzIPN (91) superior yields were observed 
when DMF was used as solvent over DMSO and THF in the conversion of vinyl urea 205 to       
3,4-dihydroquinazolinone 206.  
 
Entry Photocatalyst Solvent 206/ %[a] 
1 4CzIPN (91) DMF 58[b] 
2 4CzIPN (91) THF 12 
3 4CzIPN (91) DMSO 49 
4 3DPAFIPN (106) DMF 2 
5 3DPAFIPN (106) THF 9 
Table 3-1. Initial attempts at the photoredox mediated intramolecular electrophilic arylation 
of vinyl urea 205. [a] Yields obtained by 19F NMR and compared with benzotrifluoride internal 
standard. [b] Isolated yield.  
The formation of 3,4-dihydroquinazolinone 206 (Table 3-1), although not the intended 
product (207), does impart some key information. Firstly, under certain conditions 4CzIPN 
(91) can oxidise Langlois reagent (134) for trifluoromethyl radical generation. Secondly, the 
trifluoromethyl radicals formed in situ can add to the olefin of a vinyl urea. It should be 
highlighted that formation of 3,4-dihydroquinazolinone 206 from vinyl urea 205 is a net-
oxidative process, so an unintentional oxidant must be present. As stringent exclusion of 
oxygen was performed, sulfur dioxide was implicated as a non-innocent by-product of 
trifluoromethyl radical formation, as it demonstrates a reduction potential (E1/2 = ‒0.7 V vs 









Condensation of 4'-chloroacetophenone (208) with methylamine forms imine 209, which was 
subjected to isocyanate 210 and then methylated to give vinyl urea 211 (Scheme 3-5). Vinyl 
urea 211 was synthesised as the N-aryl bears a para-chloro substituent. Whether this para-
chloro relationship is maintained in the 4CzIPN (91)-catalysed net-oxidative trifluoromethyl-
arylation of vinyl urea 211 would give insight into how this reaction proceeds.  
 
Scheme 3-5. Synthesis of vinyl urea 211. 
Irradiation of 4CzIPN (91) in the presence of vinyl urea 211 and Langlois reagent (134) in DMF 
gave predominantly the N-aryl urea 212 and a complex mixture of unidentifiable fluorinated 
products observable by 19F NMR (Scheme 3-6). Attempts at separation of products other than 
N-aryl urea 212 failed, even by preparative TLC.  
 
Scheme 3-6. Subjection of vinyl urea 211 and Langlois reagent (134) to 4CzIPN (91)-catalysed 













The significant production of N-aryl urea 212 in Scheme 3-6 presumably originates from the 
hydrolytic cleavage of a uronium species, generated by either PRC-enabled trifluoromethyl 
radical addition (213) then oxidation (214), or by acid-catalysed tautomerisation (215)                          
(Scheme 3-7).152 It was hypothesised that the addition of a base to the reaction mixture of 
Scheme 3-6 would sequester acid by-product generated in net-oxidative processes, 
potentially limiting the formation of 212 by acid-catalysed tautomerisation of vinyl urea 211. 
 


















Exposure of vinyl urea 211 and Langlois reagent (134) to 4CzIPN (91) under blue LED 
irradiation, with the addition of caesium carbonate as a base was performed (Table 3-2). 
Remarkably, neither N-aryl urea 212 nor vinyl urea 217 were observed as products of Table 
3-2, instead the originally sought -tertiary urea 216 was isolated in moderate yield. The 
presence of caesium carbonate clearly has a pronounced effect on moving the mechanism of 
the reaction away from a net-oxidative manifold to a redox-neutral one. Reports exist of 
caesium carbonate displaying a direct reaction with sulfur dioxide generating caesium sulfite 
and carbon dioxide, however this appears to only take place at elevated temperatures (>100 
°C). 157  Instead, under ambient conditions physisorption of sulfur dioxide onto caesium 
carbonate is observed. Thus, the effect of caesium carbonate to change the afforded product 
from N-aryl urea 212 to -tertiary urea 216 may-be by in situ sequestering of sulfur dioxide, 
which allows 4CzIPN (91) radical anion to reduce benzyl radical, formed after trifluoromethyl 
radical addition to vinyl urea 211, generating key -metalated urea intermediate (200) for 
intramolecular electrophilic arylation. 
 
Entry 134/ eq. Cs2CO3/ eq. 216/ %[a] 
1 3.0 1.5 66 (53)[b] 
2 2.0 1.5 58 
3 1.0 1.0 44 
Table 3-2. Discovery of the 4CzIPN (91)-catalysed trifluoromethylation followed by 
intramolecular electrophilic arylation of vinyl urea 211. [a] Yields obtained by 19F NMR and 













With caesium carbonate identified as a key additive to exact the photoredox-mediated 
intramolecular electrophilic arylation of a vinyl urea, the reliability of this discovery was 
validated with vinyl urea 205 before optimisation studies were carried out. Gratifyingly, when 
vinyl urea 205 and Langlois reagent (134) were exposed to 4CzIPN (91) under blue LED 
irradiation, with the addition of caesium carbonate, the desired -tertiary urea 207 was 
isolated in good yield. Also, no production of the previously afforded                                                         
3,4-dihydroquinazolinone 206 was founded (Scheme 3-8). 
 
Scheme 3-8. The 4CzIPN (91) mediated trifluoromethyl-arylation of vinyl urea 205.  
Optimisation studies were performed using vinyl urea 211 as a model substrate. A solvent 
screen was carried out, where vinyl urea 211 and Langlois reagent (134) were exposed to 
4CzIPN (91) in a reaction mixture containing caesium carbonate (Table 3-3). Use of DMSO as 
the solvent gave poor productivity for -tertiary urea 216 (Table 3-3, entry 1), while use of 
acetone or acetonitrile gave excellent levels of product formation (Table 3-3, entries 2 and 3).  
Use of benzotrifluoride, dichloromethane or 1,2-dicholorethane as solvent proved 
detrimental to -tertiary urea 216 generation (Table 3-3, entries 4-6). Guided by the results 
of Table 3-3, acetonitrile and acetone were selected as optimum solvents. 
 
Entry Solvent 216/ %[a] 
1 DMSO 36 
2 MeCN 94 
3 Acetone 94 
4 PhCF3 Trace 
5 DCM Trace 
6 DCE 4 
Table 3-3. Solvent screen for the 4CzIPN (91)-catalysed trifluoromethylation intramolecular 
electrophilic arylation of vinyl urea 211. [a] Yields obtained by 19F NMR and compared with 





Attention was next directed at whether the cation of the carbonate used in the photoredox 
mediated formation of -tertiary urea 216 had any impact upon the reaction (Table 3-4). A 
trend of increasing yield for -tertiary urea 216 was observed when going down the rows of 
group one cationic carbonates. 
 
Entry M 216/ %[a] 
1 Cs 93 
2 K 79 
3 Na 20 
4 Li 7 
Table 3-4. Carbonate screen for the 4CzIPN (91)-catalysed trifluoromethylation then 
intramolecular electrophilic arylation of vinyl urea 211. [a] Yields obtained by 19F NMR and 



















Next, an investigation into the optimal stoichiometries of Langlois reagent (134) and caesium 
carbonate were performed. Firstly, productivity for -tertiary urea 216 decreased upon 
lowering the stoichiometry of caesium carbonate from 1.5 to 1.0 equivalent (Table 3-5, 
entries 1, 3 vs 2, 4). Formation of -tertiary urea 216 was not perturbed by lowering of the 
stoichiometry of Langlois reagent (134) from 3.0 to 1.5 equivalents (Table 3-5, entries 1, 3, 5). 
As such, 1.5 equivalents of Langlois reagent (134) and caesium carbonate were selected as 
optimum stoichiometries for the transformation of vinyl urea 211 to -tertiary urea 216. 
Finally, an isolated yield for -tertiary urea 216 was recorded using the optimised conditions 
outlined in Table 3-5 entry 5, which proved to be in good agreement with the spectroscopic 
yield obtained. 
 
Entry 134/ eq. Cs2CO3/ eq. 216/ %[a] 
1 3.0 1.5 79 
2 3.0 1.0 40 
3 2.0 1.5 83 
4 2.0 1.0 58 
5 1.5 1.5 89 (87)[b] 
Table 3-5. Langlois reagent (134) and caesium carbonate stoichiometry screen in the 
conversion of vinyl urea 211 to -tertiary urea 216. [a] Yields obtained by 19F NMR and 















Optimised conditions for the 4CzIPN (91)-catalysed trifluoromethylation with subsequent aryl 
migration of vinyl urea 211 (Table 3-5, entry 5) were also applicable when acetone was used 
as solvent (Table 3-6, entry 1).  As expected when considering Table 3-1, use of 3DPAFIPN 
(106) resulted in trace -tertiary urea 216 formation, the same being true when ruthenium 
photocatalyst 80 was used (Table 3-6, entries 2 and 3). Iridium photocatalyst 90 demonstrates 
activity in the formation of -tertiary urea 216 (Table 3-6, entry 4). Iridium photocatalyst 90 
displays an oxidation potential from the photoexcited state of (E1/2 (P*/P‒) = 1.21 V vs SCE),86b 
giving indication that the lack of activity observed with 3DPAFIPN (106) (E1/2 (P*/P‒) = 1.09 V 
vs SCE)97a and ruthenium photocatalyst 80 (E1/2 (P*/P‒) = 0.77 V vs SCE)86b may be due to 
insufficient oxidation power for trifluoromethyl radical generation from Langlois reagent 
(134) (E1/2 = 1.05 V vs SCE).155 
 
Entry PC 216/ %[a] 
1 4CzIPN (91) 86 
2 3DPAFIPN (106) 3 
3 [Ru(bpy)3]Cl2•6H2O (80) 2 
4 [Ir{dF(CF3)ppy}2(dtbpy)]PF6 (90) 70 
Table 3-6. Photocatalyst screen for the conversion of vinyl urea 211 to -tertiary urea 216. 















3.3 Scope of Aryl Migrating Groups 
 
With optimised conditions established for the 4CzIPN (91)-catalysed transformation of vinyl 
urea 211 to -tertiary urea 216, an investigation into the applicability of these conditions to 
other vinyl ureas was performed. To this end, acetophenone (81) and 4'-chloroacetophenone 
(208) were separately converted into their respective imines (203 and 209) by condensation 
with methylamine (Scheme 3-9). The crude imines obtained were coupled with a variety of 
different aryl isocyanates then methylated to give an assortment of vinyl ureas (218 to 228) 
all in serviceable yields, apart for vinyl ureas 229 and 230 which failed to give the desired 
product. 
 
Scheme 3-9. Synthesis of vinyl ureas 218 to 228. Yields given are over three steps. [a] 2.0 eq. 




The synthesised library of vinyl ureas (218 to 228), possessing a variety of functionality on the 
N-aryl urea, were tested in the 4CzIPN (91)-catalysed trifluoromethylation followed by Truce 
Smiles arylation with Langlois reagent (134). Pleasingly, vinyl ureas 218 to 226 gave their 
respective -tertiary urea products (231 to 239) in mostly good yields (Scheme 3-10). An array 
of para-substituents were found to be compatible under the conditions outlined in Table 3-5 
entry 5, including fluoro (231), bromo (234), trifluoromethyl (237) and ethyl ester (239). Good 
representation of successful meta-substituted N-aryl ureas was obtained, including fluoro 
(232), methoxy (235), methyl (236) and bis-trifluoromethyl (238). Finally, ortho-fluorinated N-
aryl vinyl urea (233) was observed to give desired product albeit in poor yield, under the 
conditions of Scheme 3-10. 
 
Scheme 3-10. 4CzIPN (91)-catalysed trifluoromethylation and subsequent intramolecular 





From Scheme 3-10, vinyl ureas 218 and 220 stood out as more difficult substrates and so were 
selected for re-optimisation. Gratifyingly, the formation of -tertiary ureas 231 and 233 could 
be enhanced by simply using acetone in place of acetonitrile and increasing the equivalents 
of Langlois reagent (134) used (Scheme 3-11). 
 
Scheme 3-11. 4CzIPN (91)-catalysed trifluoromethylation then subsequent intramolecular 
electrophilic arylation of vinyl ureas 218 and 220.  
Limitations were identified for the 4CzIPN (91)-catalysed trifluoromethyl-arylation of vinyl 
ureas (Scheme 3-12). Firstly, the attempted conversion of vinyl urea 227 to -tertiary ureas 
240 was unsuccessful, indicating that substitution at the ortho position of the migrating aryl 
ring is problematic. Also, efforts to form -tertiary urea 241 from vinyl urea 227 resulted only 
in re-isolation of starting material, suggesting that an electron rich p-methoxyphenyl may 
possess insufficient migratory aptitude for aryl translocation under these conditions. 
Interestingly, the aryl migration of a 1-naphthyl and p-methoxyphenyl have both successfully 
been achieved previously under base mediated benzylic lithiation conditions, underscoring 
an advantage of that approach over this newly developed photoredox method.143 
 
Scheme 3-12. Attempted 4CzIPN (91)-catalysed trifluoromethylation with subsequent 




3.4 Scope of Radical/Anion Stabilising Groups 
 
With the 4CzIPN (91)-catalysed trifluoromethylation followed by intramolecular electrophilic 
arylation of vinyl ureas successfully applied to a variety of migrating aromatic rings (Scheme 
3-10 and Scheme 3-11), attention was turned to what functionality could be tolerated on the 
aryl group attached to the vinyl urea. A selection of acetophenone derivatives were 
transformed into their respective imines by condensation with methylamine (Scheme 3-13). 
The crude imines obtained were coupled with either 4-chlorophenyl isocyanate (210) or 4-
bromophenyl isocyanate (242), then methylated to give vinyl ureas (243 to 251) in moderate 
to poor yield. 
 









It was found that certain vinyl ureas were unobtainable by standard imine-isocyanate 
coupling conditions (Scheme 3-14). Specifically, the imines required for the preparation of 
vinyl ureas 252 to 257 were accessible, but their subsequent coupling with aryl isocyanate 
and methylation proved fruitless. In the attempted synthesis of vinyl ureas 258 and 259, imine 
formation resulted in little consumption of starting acetophenone. 
 












With an ensemble of vinyl ureas synthesised collectively possessing functional diversity on 
the aromatic moiety bonded to the olefin (Scheme 3-13), a selection were tested in the 
4CzIPN (91)-catalysed trifluoromethylation with subsequent Truce-Smiles rearrangement. 
Vinyl ureas 243, 244 and 245 were found to be amenable substrates yielding the desired -
tertiary ureas 260, 261 and 262 in good yields (Scheme 3-15).  
 
Scheme 3-15. 4CzIPN (91)-catalysed trifluoromethylation then subsequent intramolecular 
electrophilic arylation of vinyl ureas 243, 244 and 245. 
Vinyl ureas 246 and 247 were found to not achieve full consumption of starting material when 
optimised conditions were used (Table 3-5, entry 5). To obtain complete conversion of vinyl 
ureas 246 and 247 the equivalents of Langlois reagent (134) used were increased from 1.5 to 
2.0, giving the desired -tertiary ureas 263 and 264 in moderate to good yield (Scheme 3-16). 
 
Scheme 3-16. 4CzIPN (91)-catalysed trifluoromethylation and subsequent intramolecular 




Vinyl ureas 248 to 251 were found to give full conversion when acetone and 2.0 equivalents 
of Langlois reagent (134) were used, to give -tertiary ureas 265 to 268 (Scheme 3-17). The 
successful formation of -tertiary ureas 265 and 266 demonstrates that phenyl rings  to the 
urea bearing meta- trifluoromethyl and para- iodo substituents partake in this 4CzIPN (91)-
catalysed Truce-Smiles rearrangement. Furthermore, the formation of -tertiary ureas 267 
and 268 shows that thiophene heterocycles also stabilise the intermediary ureido benzyl 
radical and -metalated urea. 
 
Scheme 3-17. 4CzIPN (91)-catalysed trifluoromethylation then subsequent intramolecular 















So far only 1,1’-disubstituted vinyl ureas have been used as starting material in this 4CzIPN 
(91)-catalysed trifluoromethyl-arylation of vinyl ureas. More structurally diverse -tertiary 
ureas would be accessible if trisubstituted vinyl ureas were also compatible. To this end, -
tetralone (269) and 1-benzosuberone (270) were used as starting materials in the synthesis 
of tri-substituted cyclic vinyl ureas 271 to 273 in moderate yield (Scheme 3-18). 
 
Scheme 3-18. Synthesis of tri-substituted cyclic vinyl ureas 271 to 273. 
For the preparation of the five-membered cyclic vinyl urea 277, it was postulated that the 
acidic proton of the indene ring would complicate the methylation step if standard conditions 
for vinyl urea synthesis were used (Scheme 3-18). An alternative sequence towards vinyl urea 
277 was employed, where successful imine condensation of 274 was realised, but subsequent 
deprotonation of imine 275 with KHMDS and coupling with carbamoyl chloride 276 was 
unsuccessful (Scheme 3-19).  
 










Cyclic vinyl urea 271 was exposed to 4CzIPN (91) and Langlois reagent (134) under blue LED 
irradiation with acetone used as solvent, to afford the -tertiary urea 278 in good yield and 
excellent diastereoselectivity (Scheme 3-20). NOESY NMR experiments were used to confirm 
the anti-relationship between the trifluoromethyl group and the para-chlorophenyl aryl 
group. 
 
Scheme 3-20. 4CzIPN (91)-catalysed trifluoromethyl-arylation of cyclic vinyl urea 271.  
The anti-diastereoselectivity observed in Scheme 3-20 presumably is derived from -
metalated urea anti-279 (where the trifluoromethyl group is directed away from the N-aryl), 
being lower in energy than conformation syn-279 (where the trifluoromethyl group is directed 
towards the N-aryl urea) (Scheme 3-21). 
 
Scheme 3-21. Skeletal and 3-D depiction of the intermediate -metalated urea in the 
synthesis of -tertiary urea 278, in its two reactive conformations to give anti and syn 











Unfortunately, when 7-membered cyclic vinyl ureas 272 and 273 were subjected to conditions 
for 4CzIPN (91)-catalysed trifluoromethyl-arylation conditions little consumption of starting 
material was observed (Scheme 3-22). To the best of this author’s knowledge, there are no 
reported successful attempts at the N to C aryl migration of benzosuberane related -
metalated ureas, potentially indicating that these structures may incur a conformation that is 
incompatible for Truce-Smiles rearrangement. 
 
Scheme 3-22. Attempted synthesis of cyclic -tertiary ureas 280 and 281.  
It was wondered if amino acid derived vinyl ureas would be compatible in this photocatalytic 
trifluoromethyation followed by Truce-Smiles rearrangement. Towards this end, vinyl urea 
285 was selected for synthesis starting from the methyl ester of serine (282), which was 
coupled with carbamoyl chloride 276 to give urea 283 (Scheme 3-23). The hydroxyl of urea 
283 underwent 1,2-elimination upon tosylation to give vinyl urea 284, which was methylated 
to give the desired vinyl urea 285. 
 






Methyl ester-containing vinyl urea 285 was subjected to conditions for 4CzIPN (91)-catalysed 
trifluoromethylation with ensuing N to C aryl migration, of which the intended product was 
hydantoin 286, resulting from urea cyclisation (Scheme 3-24). However, instead only the 
hydrotrifluoromethylation product 287 was isolated, presumably due to the reduced 
nucleophilicity of the resulting enolate in comparison to a benzylic anion. 
 























3.5 Radical Precursor Scope 
 
With a variety of aromatic functionality found to be compatible in the 4CzIPN (91)-catalysed 
trifluoromethylation with subsequent intramolecular electrophilic arylation of vinyl ureas, 
effort was directed to what radical precursors other than Langlois reagent (91) could be used. 
Synthesis of sodium sulfinate radical precursors were carried out by sulfinate-deiodination of 
perfluoroalkyl halides (Scheme 3-25). Synthesis of perfluorobutyl- and perfluorohexyl- 
containing sodium sulfinates 288 and 289 was realised,158 but preparation of the ethyl ester 
and ethyl phosphonate containing sodium sulfinates 290 and 291 was unsuccessful. 
 
Scheme 3-25. Successful synthesis of perfluoroalkyl sodium sulfinates 288 and 289, and the 



















Radical precursors 288 and 289, along with a variety of other commercially available sodium 
sulfinates,159 were successfully used in the alkylation-arylation of vinyl ureas 221 and 245 
(Scheme 3-26). Specifically, it was found that difluoromethyl (292) and 1,1-difluoroethyl (293) 
could be incorporated into -tertiary urea products. Formation of -tertiary urea 293 gave 
confidence that other 1,1-difluoroalkyl sodium sulfinates would be amenable in this 
methodology, leading to the successful inclusion of chloride (294) and azide (295) containing 
1,1-difluoroheptyl chains. In addition, (2,2-difluoroethyl)benzenes furnished with a bromide 
at the para- (296), meta- (297) and ortho- (298) positions were respectively realised. Finally, 
use of sodium sulfinates 288 and 289 smoothly gave -tertiary ureas 299 and 300. 
 





With a variety of 1,1-difluoroalkyl sodium sulfinate radical precursors found to be effective in 
achieving the alkyl-arylation of vinyl urea (Scheme 3-26), it was wondered if the geminal 
difluoro  to the alkyl sodium sulfinates is necessary for reaction. The attempted 4CzIPN          
(91)-catalysed butylation with subsequent intramolecular electrophilic arylation of vinyl urea 
221 with sodium butyl sulfinate (301) resulted in no formation of -tertiary urea (302) 
(Scheme 3-27). Scheme 3-27 suggests that the butyl radical, generated upon oxidative 
decomposition of sodium butyl sulfinate, is maybe too nucleophilic for addition into the 
electron rich olefin of vinyl urea 221. The substitution of hydrogen atoms for fluorine 
increases the electrophilic character of the C-centred radical formed, aiding polarity-matching 
for the addition to vinyl urea.160 
 
Scheme 3-27. Attempted 4CzIPN (91)-catalysed butyl-arylation of vinyl urea 221. 
Effort towards the identification of radical precursors distinct from alkyl sodium sulfinates 
was undertaken. Yu and co-workers reported the 4CzIPN (91)-catalysed 
phosphonocarboxylation of enamides, with diphenylphosphine oxide and carbon dioxide 
(Scheme 3-28). 161  Scheme 3-28 has been proposed to proceed by oxidation and 
deprotonation of diphenylphosphine oxide (304) by photoexcited 4CzIPN (91) and caesium 
carbonate to yield P-centred radical. Diphenylphosphinoxyl radical adds to enamide (303) 
forming a radical at the benzylic position, which undergoes reductive-termination radical-
polar crossover with the radical anion of 4CzIPN (91) giving a benzylic anion and closing the 
photoredox cycle. The generated benzylic anion attacks carbon dioxide forming -tertiary 
amide 305 upon acidic work up.  
 
Scheme 3-28. 4CzIPN (91)-catalysed phosphonocarboxylation of enamide 303 to give -







While considering work from Yu and co-workers (Scheme 3-28), it was wondered whether a 
4CzIPN (91)-mediated diphenylphosphine oxide addition to vinyl urea could be realised to 
achieve an non-annulative arylphosphonylation of an alkene, a rare class of reaction.162 To 
this end, Yu and co-workers’ conditions for phosphonocarboxylation of enamides were 
applied to the attempted arylphosphonylations of vinyl urea 249 (Table 3-7). It was found that 
the desired diphenylphosphine oxide-containing -tertiary urea 306 was only observed in 
trace amounts when DMF and acetone were used as solvent (Table 3-7, entries 1 and 2), but 
when acetonitrile was used significant levels of product were discerned by 1H and 31P NMR 
(Table 3-7, entry 3).   
 
Entry Solvent 306/ %[a] 
1 DMF Trace 
2 Acetone Trace 
3 MeCN 72 
Table 3-7. Solvent screen for the 4CzIPN (91)-catalysed phosphonocarboxylation of vinyl urea 
249. [a] Yields obtained by 31P NMR and compared with dibutyl phosphate internal standard.  
The spectroscopic yield for the 4CzIPN (91)-mediated arylphosphonylation of vinyl urea 249 
with diphenylphosphine oxide (304) gave confidence that other diarylphosphine oxides would 
perform well in this reaction (Table 3-7, entry 3). Diphenylphosphine oxide derivatives were 
prepared by conversion of aryl bromides 307 and 308 to aryl magnesium bromides 309 and 
310, which were reacted with diethyl phosphonate (311) to afford diarylphosphine oxides 312 
and 313 in poor but serviceable yields (Scheme 3-29). 
 




A scope of diarylphosphine oxides was constructed for the arylphosphonylation of vinyl urea 
252. Diarylphosphine oxide containing -tertiary ureas 306, 314, 315 and 316, bearing phenyl, 
meta-xylene, 2-naphthyl and para-chlorophenyl were successfully yielded (Scheme 3-30). The 
attempted formation of -quaternary urea 317 gave low levels of productivity, while -
quaternary urea 318 was found to decompose upon purification attempts. No consumption 
of starting vinyl urea 252 was observed in the attempted synthesis of 319. 
 

















A range of other oxidisable radical precursors were tested in the addition to vinyl ureas               
221 and 243 to initiate N to C aryl migration (Scheme 3-31). Unfortunately, attempts at 
oxidation and addition of potassium phthalimide (320), potassium thioacetate (321) and 
sodium ethanethiol (322) to vinyl urea 243 proved unsuccessful. Presumably due to their 
respective radical precursors being insufficiently oxidisable by photoexcited 4CzIPN (91), or 
upon -metalated urea formation anionic 1,2-elimination of the radical adduct occurs over  
N to C aryl migration. The attempted arylazidination of vinyl urea 221 with sodium azide to 
form -tertiary urea 323 was found to be fruitless. Sodium azide should be oxidisable (E1/2 = 
0.9 V vs SCE)163 by photoexcited 4CzIPN (91), but the resulting azide radical is most likely 
nucleophilic in nature. Also, if azide radical addition did occur anionic 1,2-elimination from 
the -metalated urea could be envisaged. The photoredox mediated addition of benzyl 
radical and aryl sulfonyl radical to electron deficient olefins has been documented. 164 
However, the attempted phenyl sulfonylation (324) and benzylation (325) of vinyl ureas  243 
and 221 with sodium benzenesulfinate and potassium benzyltrifluoroborate respectively only 
returned starting material, presumably due to the nucleophilic character of the radicals 
formed.160 
 














3.6 Solvolysis of -Tertiary Ureas 
 
With an assortment of -tertiary ureas synthesised by the 4CzIPN (91)-catalysed radical 
addition with following N to C aryl migration of vinyl ureas, the validity of this methodology 
for -tertiary amine synthesis was investigated. Attention was directed towards the removal 
of the urea of -tertiary urea 262. First, hydrolytic conditions were employed in the 
attempted conversion of -tertiary urea 262 to -tertiary amine 329,165 however this resulted 
in starting material decomposition with no discernible indication of -tertiary amine 329 
formation (Scheme 3-32).  
 
Scheme 3-32. Attempted hydrolysis of -tertiary urea 262.  
Gratifyingly, the ureas of 261, 262, 265 and 266 were removed in refluxing butanol,144 to yield 
their corresponding -tertiary amines 326 to 329, validating the 4CzIPN (91)-catalysed radical 
addition with subsequent N to C aryl migration as a method for -tertiary amine synthesis 
(Scheme 3-33).  
 







3.7 Mechanistic Investigation 
 
With the synthetic utility for the 4CzIPN (91)-catalysed trifluoromethylation followed by 
Truce-Smiles rearrangement of vinyl ureas firmly established, attention was directed at 
understanding of the mechanism. A proposed mechanism started with resting state 4CzIPN 
(91) reaching its photoexcited state (330) by absorption of a photon (Scheme 3-34). 
Photoexcited 4CzIPN (330, E1/2 (PC*/PC‒) = 1.35 V vs SCE)94 oxidises Langlois reagent (134) 
(E1/2 = 1.05 V vs SCE)155 resulting in its decomposition to sulfur dioxide and trifluoromethyl 
radical (331), concurrently forming 4CzIPN radical anion (332). Trifluoromethyl radical (331) 
adds to a vinyl urea (333) forming ureido benzyl radical (334) that is reduced by 4CzIPN radical 
anion (332), closing the photoredox cycle and simultaneously generating -metalated urea 
(335) that undergoes N to C intramolecular arylation, to give an -tertiary urea (336). 
 
Scheme 3-34. Proposed mechanism for the 4CzIPN (91)-catalysed trifluoromethylation 
followed by intramolecular electrophilic arylation of vinyl ureas. Asterisk denotes 












Work was undertaken to test the validity of the proposed mechanism outlined in              
Scheme 3-34. Firstly, control experiments were performed, with vinyl urea 211 and Langlois 
reagent (134) being exposed to each other under optimised conditions, but in the absence of 
photocatalyst 4CzIPN (91) (Scheme 3-35). No consumption of the starting vinyl urea 211 was 
observed, suggesting 4CzIPN (91) plays a key role in -tertiary urea 216 formation. 
 
Scheme 3-35. Attempted trifluoromethyl-arylation of vinyl urea 211, in the absence of 
photocatalyst 4CzIPN (91).  
A second control experiment was performed in which vinyl urea 211 was subjected to 
optimised conditions for trifluoromethylation with subsequent Truce-Smiles rearrangement, 
but with the omission of any light source (Scheme 3-36). Again, no conversion of vinyl urea 
211 was observed, indicating that light is a key component for -tertiary urea 216 formation. 
 
Scheme 3-36. Attempted trifluoromethylation with subsequent intramolecular electrophilic 













Vinyl urea 221 was subjected to optimised conditions for trifluoromethyl-arylation in the 
presence of persistent radical TEMPO, which resulted in complete inhibition of -tertiary urea 
234 formation (Scheme 3-37). No obvious TEMPO adducts (337) could be discerned from the 
reaction mixture of Scheme 3-37, implicating the oxidation of TEMPO (E1/2 = 0.62 V vs SCE)166 
by 4CzIPN (91) as its mode of reaction inhibition. 
 
Scheme 3-37. Attempted trifluoromethylation with subsequent intramolecular electrophilic 
arylation of vinyl urea 221, in the presence of TEMPO.  
A second radical probe experiment was performed, using 1,1-diphenylethylene (135)167 as a 
radical trap that would not be oxidised or reduced by photoexcited 4CzIPN (91). Subjection of 
vinyl urea 221 to optimised conditions for trifluoromethyl-arylation in the presence of 1,1-
diphenylethylene (135) drastically attenuated formation of -tertiary urea 234 (Scheme           
3-38). Also, the hydrotrifluoromethylation product 338 was observed confirming the 
formation of trifluoromethyl radical and highlighting its importance in -tertiary urea 234 
production. 
 
Scheme 3-38. Attenuated trifluoromethylation with subsequent intramolecular electrophilic 
arylation of vinyl urea 221 in the presence of radical acceptor 135. Yields obtained by 19F NMR 










Scheme 3-38 gives evidence that photoexcited 4CzIPN (91) oxidises Langlois reagent (134) 
over other species, however more evidence was sought to substantiate this claim. Stern-
Volmer quenching studies can be used to elucidate which substrates a photocatalyst transfers 
its photonic energy to. A photoexcited species will typically dissipate its absorbed photonic 
energy by fluorescence (Figure 2-1). However, in the presence of an appropriate substrate a 
photoexcited species can be quenched by single electron transfer or energy transfer, which 
reduces the radiative quantum yield of the fluorophore.86b,168 This reduction of fluorescence 
of a photoexcited species can be measured by fluorimetry and compared between quenchers. 
Emission quenching of 4CzIPN (91) with quenchers Langlois reagent (134) and vinyl urea 219 
were performed over a quencher concentration range close to the 4CzIPN (91):quencher ratio 
of a typical trifluoromethyl-arylation reaction (Figure 3-1). Figure 3-1 shows that photoexcited 
4CzIPN (91) is quenched to a greater degree by Langlois reagent (134) than vinyl urea 219, 
implying a greater rate of photonic energy transfer from 4CzIPN (91) to Langlois reagent (134) 
over vinyl urea 219. 
 
Figure 3-1. Stern-Volmer quenching plot of an 8.0 x 10-6 M solution of 4CzIPN (91) in 











Stern-Volmer quenching studies of 4CzIPN (91) with quenchers Langlois reagent (134) and 
vinyl urea 219 were repeated using a larger quencher concentration range. Like in Figure 3-1, 
it was observed in Figure 3-2 that photoexcited 4CzIPN (91) is quenched to a greater degree 
by Langlois reagent (134) over vinyl urea 219. 
 
Figure 3-2. Repeated Stern-Volmer quenching plot of a 9.9 x 10-6 M solution of 4CzIPN              
(91) in acetonitrile, over higher concentrations of quenchers Langlois reagent (134) (Blue line) 
and vinyl urea (219) (Orange line).  
Using the line gradients of Figure 3-2 and the Stern-Volmer equation (1), the quencher rate 
coefficient (𝐾𝑞, M
-1.s-1) can be calculated.169 In equation (1), 𝐼0 is the emission intensity of the 
fluorophore in the absence of quencher, 𝐼𝑛 is the emission intensity of a fluorophore in the 
presence of quencher, 𝜏0 is the fluorescence lifetime of the excited state of a fluorophore (s) 
(2.37 ns for 4CzIPN (91))170 and [Q] is the quencher concentration (M).   
                                               
𝐼0
𝐼𝑛
= 1 +  𝐾𝑞 ×  𝜏0 × [𝑄]     (1) 
The quencher rate coefficient between 4CzIPN (91) and quenchers Langlois reagent (134) and 









Stern-Volmer quenching studies indicate that quenching of photoexcited 4CzIPN (91) is 
observed by vinyl urea 219 (Figure 3-1 and Figure 3-2). To ascertain the cause of this 
observation, cyclic voltammetry analysis of vinyl urea 219 was performed (Figure 3-3). An 
irreversible oxidation wave was observed at a potential scan rate of 100 mV.s–1 and                   
500 mV.s–1. The half wave oxidation potential of vinyl urea 219 was found to be 0.96 V versus 
the ferrocenium couple and 1.33 V versus the SCE. This gives indication that 4CzIPN (91) from 
its photoexcited state (E1/2 (P*/P‒) = 1.35 V vs SCE) may be able to oxidise vinyl urea 219, 
possibly indicating how quenching is observed although an energy transfer pathway cannot 
be discounted.171 
 
Figure 3-3. Overlayed cyclic voltammogram of vinyl urea 219 at a scan rate of 500 mVs-1 
















To summarise, Scheme 3-38 gives indication that trifluoromethyl radical is generated in the 
4CzIPN (91)-catalysed trifluoromethyl-arylation of vinyl urea 221, as trifluoromethyl radical 
adduct 338 is observed. Next, Stern-Volmer quenching studies confirm that there is transfer 
of photonic energy between photoexcited 4CzIPN (91) and Langlois reagent (134)              
(Figure 3-1 and Figure 3-2). It is likely the quenching of photoexcited 4CzIPN (91) by  Langlois 
reagent (134) is derived from electron transfer when considering their respective oxidation 
potentials (Langlois reagent (134): E1/2 = 1.05 V vs SCE), (4CzIPN (91): E1/2 (P*/P‒) = 1.35 V vs 
SCE).94,155 Quenching of photoexcited 4CzIPN (91) by vinyl urea 219 is observed, the origin of 
which may be photoexcited 4CzIPN (91) oxidising vinyl urea 219 when comparing their 
oxidation potentials (Figure 3-3), or through energy transfer. However, quenching from vinyl 
urea 219 occurs to a lesser degree than quenching from Langlois reagent (134). Therefore, 
the results of Scheme 3-38, Figure 3-1, Figure 3-2 and Figure 3-3 together give evidence that 
photoexcited 4CzIPN (91) oxidises Langlois reagent (134) for trifluoromethyl radical 
generation, which then adds to vinyl urea (Scheme 3-34). 
Next, effort was made to confirm the reduction of the intermediary ureido benzyl radical 
(334) to an -metalated urea (335) (Scheme 3-34). To this end, vinyl urea 339, which does not 
bear a N-aryl so cannot undergo N to C aryl migration, was synthesised (Scheme 3-39).  
 















It was throught that the anion of an -metalated urea (335) could be intercepted by an 
electrophile, such as deuterium from deuterium oxide, which is relatively acidic (pKa = 15.9) 
but resistant to hydrogen atom transfer (BDE = 120.9 kcal.mol-1)172 . Vinyl urea 339 was 
subjected to conditions for trifluoromethyl-arylation, but with deuterium oxide present as an 
additive (Table 3-8). Conversion of vinyl urea 342 to the hydrotrifluoromethylation product 
340 was achieved, furthermore significant deuterium incorporation at the benzylic position 
was observed. Thus, Table 3-8 gives evidence that under the optimised conditions of this 
study the formation of -metalated urea (335) is feasible. 
 
Entry Solvent 340/ % D-incorporation/ % 
1 Acetone 89 76 
2 MeCN 77 83 
3 DMF 67 82 




















Although the results of Table 3-8 indicate the feasibility of -metalated urea (335) formation 
under conditions for 4CzIPN (91)-catalysed trifluoromethyl-arylation of vinyl urea, it does not 
distinguish whether the aryl migration occurs by a polar manifold, or by an unprecedented 
but still conceivable radical process. To answer this, the trifluoromethyl-arylation of vinyl urea 
223 was performed in acetone and acetonitrile (Table  3-9, entries 1 and 2), yielding -tertiary 
urea 236 and small amounts of the hydrotrifluoromethylation product 341, presumably due 
to adventitious traces of water present in Langlois reagent (134) and caesium carbonate. 
Next, the trifluoromethyl-arylation of vinyl urea 223 was repeated, but with the addition of 
deuterium oxide (Table 3-9, entries 3 and 4) resulting in -tertiary urea 236 being formed as 
the minor product and -secondary urea 341 as the major product. Furthermore, significant 
levels of deuterium incorporation were observed in -secondary urea 341. The results of 
Table 3-9 indicate that the addition of deuterium oxide interrupts the N to C aryl migration of 
vinyl urea 223 by protonation of an -metalated urea (335).  
 
Entry Solvent Additive 236 /% 341 /% 341 D-incorporation/ % 
1 Acetone None 70 6 - 
2 MeCN None 79 9 - 
3 Acetone D2O (10 eq.) 25 59 69 
4 MeCN D2O (10 eq.) 20 55 82 
Table 3-9. Isotope labelling studies in the 4CzIPN (90)-catalysed hydrotrifluoromethylation of 














In opposition to Table 3-9, the trifluoromethyl-arylation of vinyl urea 221 in the presence of 
deuterium oxide proceeded to give -tertiary urea 234, without the formation of 
hydrotrifluoromethylation product 342 (Scheme 3-40). An explanation may be that for vinyl 
urea 221 aryl migration is much faster than protonation of an -metalated urea, while the 
converse being true for vinyl urea 223. Especially when considering an electron deficient 
migrating aryl is used in Scheme 3-40 and an electron rich migrating aryl is used in Table 3-
9.173 However, it is still conceivable that the aryl migration for the formation of -tertiary urea 
234 could proceed by a ureido benzyl radical (334). 
 
Scheme 3-40. Trifluoromethyl-arylation of vinyl urea 221 in the presence of deuterium oxide.  
To ascertain more information of the species undergoing aryl migration under 4CzIPN (91)-
mediated conditions, vinyl urea 344 was synthesised in moderate yield (Scheme 3-41). 
 














The outcome of the 4CzIPN (91)-catalysed trifluoromethylation followed by Truce-Smiles 
rearrangement of vinyl urea 344 was dependent on the solvent used (Table 3-10, entries           
1-3). Firstly, the trifluoromethyl-arylation of vinyl urea 344 with DMF used as solvent 
predominantly yielded -tertiary urea 345 and a small amount of hydrotrifluoromethylation 
product 346 (Table 3-10, entry 1). Next, when acetonitrile was used as solvent the -tertiary 
urea 345 was formed as the minor product and -secondary urea 346 was received as the 
major product (Table 3-10, entry 2). Finally, when acetone was used as solvent the 
hydrotrifluoromethylation product 346 was exclusively observed (Table 3-10, entry 3). -
Secondary urea 346 is presumably formed by trifluoromethyl radical addition to vinyl urea 
344, resulting in an ureido benzyl radical (334) that either undergoes hydrogen atom 
abstraction with solvent or is reduced by 4CzIPN radical anion (332) to an -metalated urea 
(335) that is protonated.  
 





1 DMF 66 11 >35174 89.7,[a] 89.1[b]175 
2 MeCN 14 27 31.3176 93.1177 
3 Acetone 2 62 26.5178 93.7179 
Table 3-10. Solvent dependent 4CzIPN (91)-catalysed trifluoromethylation with subsequent 
intramolecular electrophilic arylation or protonation of vinyl urea 344. [a] BDE for 














To rationalise this solvent-dependent outcome of Table 3-10, the propensity for DMF, 
acetonitrile and acetone to be deprotonated and hydrogen atom abstracted were examined 
by inspection of their respective pKa and carbon-hydrogen bond dissociation energies. 
Acetone was found to have the lowest pKa followed by acetonitrile then DMF. Conversely, 
DMF demonstrates the lowest bond dissociation energy for its carbon-hydrogen bonds, 
followed by acetonitrile then acetone. Therefore, the results of Table 3-10 imply that 
hydrotrifluoromethylation product 346 is formed by protonation of an -metalated urea 
(335) and by not hydrogen atom abstraction from a ureido benzyl radical (334). As acetone, 
the solvent most prone to deprotonation with the strongest C-H bonds, leads to significant 
hydrotrifluoromethylation product 346 formation. While DMF, the solvent least prone to 
deprotonation with the weakest C-H bonds, does not yield substantial amounts of 
hydrotrifluoromethylation product 346. This interpretation of Table 3-10 relies on a 
thermodynamic explanation; however, a kinetic argument can also be made where the C-H 
bonds in DMF are viewed as hydric while the C-H bonds of acetone and acetonitrile are seen 
as electron deficient. So, hydrotrifluoromethylation product 346 may form by preferential 
HAT from acetone or acetonitrile to nucleophilic ureido benzyl radical (334), which occurs to 
a lesser degree with DMF. Also, the radicals of solvent that have been subjected to HAT can 
be reduced to their respective anions by the radical anion of 4CzIPN (332), a process that is 
conceivably more exergonic with acetone and acetonitrile over DMF. So, the solvent-
dependent outcome of Table 3-10 may be derived from a Curtin–Hammett principle scenario, 
where the radicals of acetone and acetonitrile formed by HAT to ureido benzyl radical (334) 


















An alternative mechanism to Scheme 3-34 for the 4CzIPN (91)-catalysed trifluoromethyl-
arylation of vinyl urea is depicted in Scheme 3-42. Wherein ground state 4CzIPN (91) is 
photoexcited (330) by absorption of a photon, then oxidises Langlois reagent (134) forming 
trifluoromethyl radical (331), sulfur dioxide and 4CzIPN radical anion (332). Trifluoromethyl 
radical (331) adds to vinyl urea (333) forming ureido benzyl radical 334, which is then not 
reduced by 4CzIPN radical anion (332). Instead, the photoredox cycle does not close and 
ureido benzyl radical 334 is directly reduced by Langlois reagent (134), forming -metalated 
urea 335, sulfur dioxide and trifluoromethyl radical (331). Newly generated trifluoromethyl 
radical (331) adds to vinyl urea (333) propagating the radical chain. -Metalated urea (335) 
performs N to C intramolecular arylation to give -tertiary urea (336). Thus, the proposed 
mechanism of Scheme 3-42 renders photocatalyst 4CzIPN (91) as an initiator rather than a 
mediator of a catalytic loop. 
 
Scheme 3-42. Proposed radical-chain mechanism for the 4CzIPN (91) initiated 
trifluoromethyl-arylation of vinyl ureas. Asterisks denotes photoexcited state.   
Quantum yield measurement of photochemical reactions is a useful method of determining 
the presence of radical chains. A photoredox catalytic cycle can only afford a maximum 
theoretical quantum yield of one, where every photon absorbed by the photocatalyst results 
in one molecule of product being produced. Any non-productive photochemical processes 
such as phosphorescence, internal conversion, or back electron transfer would only decrease 
the observed quantum yield. With regards to a radical chain mechanism, the quantum yield 







To gain insight into which mechanistic paradigm (Scheme 3-34 vs Scheme 3-42) is present for 
the trifluoromethyl-arylation of vinyl urea, a quantum yield (Ф) for such a reaction was 
sought. First the photon flux of a photoreactor set up was determined by ferrioxalate 
actinometry to be 1.33 x 10-9 Einsteins.s-1 (See Experimental for details).180,181 The light source 
of the photoreactor set up was a single 0.1 W blue LED, opposed to an array of 24 W blue 
LEDs used throughout this study. The change of light source to a weaker LED was to maximise 
the ratio of propagation events to initiation events in any possible radical chains. With the 
photon flux of a photoreactor set up determined it can be used calculate the quantum yield 
of a reaction, using equation (1). Where t is the duration of the reaction in seconds and f is 
the fraction of absorbed light at λ = 450 nm for a 5.0 × 10–3 M solution of 4CzIPN (91) in DMF 
measured to be 0.999 (derived from f = 1 – 10–A  where A is absorbance at 450 nm measured 
by UV-Vis spectroscopy). 
                                                  Ф =  
mol product
photon flux × t × f
                                                   (2) 
A requirement for good quantum yield elucidation is that the reaction mixture is 
homogeneous to allow for maximum light penetration into solvent and minimal light 
scattering off particulates. To meet this requirement in the context of the trifluoromethyl-
arylation of vinyl urea, which generally gives heterogeneous reaction mixtures in acetone and 
acetonitrile, DMF was used as solvent to improve reaction homogeneity. The 4CzIPN (91)-
catalysed trifluoromethylation with subsequent N to C aryl migration of vinyl urea 219 was 
still found to give good levels of -tertiary urea 232 productivity, despite the use of DMF as a 
subpar solvent according to optimisation studies (Scheme 3-43). 
 
Scheme 3-43. 4CzIPN (91)-catalysed trifluoromethyl-arylation of vinyl urea 219 with DMF 











Finally, the 4CzIPN (91)-catalysed trifluoromethyl-arylation of vinyl urea 219 was performed 
in the photoreactor of known photon flux for 4 hours and 24 hours independently, affording  
-tertiary urea 232 in a 1.3% and 13.1% yield respectively (Table 3-11). Using equation (1) the 
quantum yields of the two runs for the conversion of vinyl urea 219 to -tertiary urea 232 in 
DMF were calculated to be 0.13 and 0.23 giving an average value of 0.18. A quantum yield of 
0.18 substantiates the claim that 4CzIPN (91)-catalysis is in effect (Scheme 3-34), or any 
present radical chains are very short. 
 
Entry Time/ hrs Time/ s 232/ %[a] 
Moles of 
232/ x 10-5 
 
1 4 14400 1.2 5.0 0.13 
2 24 86400 13.1 26.2 0.23 
Table 3-11. Quantum yield elucidation for the trifluoromethyl-arylation of vinyl urea 219.                 




















A transition metal-free method for the alkyl-arylation of vinyl ureas has been developed, 
allowing the construction of two carbon-carbon bonds across an olefin in an operationally 
simple manner (Scheme 3-44). This methodology has been demonstrated through 31 
examples to be amenable to a variety of functionality on the migrating aryl group and the aryl 
group  to the urea tether. Furthermore, studies have shown this method not to be limited 
to only trifluoromethyl incorporation, but also 1,1-difluoroalkyl groups by use of sodium 
sulfinate radical precursors other than Langlois reagent. A representative selection of 
trifluoromethyl-containing -tertiary urea products have been converted to their respective 
-tertiary amines, by solvolysis of the urea. Additionally, preliminary work has been 
undertaken to demonstrate a photoredox approach for the addition of diarylphosphinoxyl 
radical to vinyl urea to initiate the N to C aryl migration.  
 
Scheme 3-44. Summarisation of the difunctionalisation protocol developed within this 
chapter.  
This alkyl-arylation approach is built around the use of a photoredox catalyst that is able to 
generate electrophilic 1,1-difluoroalkyl radical from commercially available sodium sulfinates, 
which subsequently add to a vinyl urea forming ureido benzyl radical, as shown through 
radical trapping studies, Stern-Volmer fluorescence quenching and cyclic voltammetry 
analysis. Direct reduction of the newly generated ureido benzyl radical by sodium sulfinate 
radical precursor has been shown to be unlikely as an average quantum yield of 0.18 was 
obtained for a representative example. The ureido benzyl radical is then reduced to -
metalated urea initiating the N to C intramolecular arylation across the urea tether to give an 
-tertiary urea, evidence for which is provided through deuterium incorporation studies and 
a solvent-selectivity study. Thus, this reaction is the first example of a photoredox-catalysed 
reductive-termination radical-polar crossover where the carbanion product of the 





































4. Vicinal Triamines, 1,2,3-Diamino Alcohols and 1,2,3-Amino Diols 
4.1 Importance and Synthesis of 1,2,3-Diamino Alcohols and 1,2,3-
Amino Diols 
 
1,2,3-Diamino alcohols and 1,2,3-amino diols (Scheme 4-1) are a commonly found scaffold in 
medicinally relevant synthetics and natural products, and thus have received the attention of 
synthetic chemists for the past 50 years.182 However, the construction of three contiguous 
carbons each bearing an alcohol or amine functional group is non-trivial. Synthetic challenges 
related to their construction include avoiding wasteful heteroatom protection and 
deprotection steps, induction of enantio- and diastereoselectivity, while averting competing 
substitutions between heteroatoms.  
 
Scheme 4-1. 1,2,3-Amino diols (Top) and 1,2,3-amino diols (Bottom). 
1,2,3-Amino diol-containing sphingoid-type bases play significant roles in the plasma 
membranes of nearly all eukaryotic cells. 183  Sphingoid-type bases are precursors to 
sphingolipids, which play significant roles in numerous biological processes184 and human 
diseases, including diabetes,185 cancer186 and various neurological afflictions.187 Furthermore, 
sphingoid-type bases themselves exhibit physiological activity, with both D-erythro-
sphingosine (347) and D-erythro-sphinganine (348) demonstrating inhibition of protein kinase 
C (Scheme 4-2).188 
 









Due to the difficult isolation of sphingolipids from natural sources, various total syntheses of 
D-erythro-sphingosine (347) and D-erythro-sphinganine (348) have been reported.189 In 2008 
Smith and co-workers disclosed a route towards triacylated D-erythro-sphingosine (347).190 A 
diastereoselective anti-aminohydroxylation of -unsaturated ester 349 was used for the 
construction of the 1,2,3-amino diol of 353 (Scheme 4-3). The aminohydroxylation proceeds 
by conjugate addition with enantiopure secondary lithium amide 350, followed by one-pot 
enolate oxidation with (+)-(camphorsulfonyl)oxaziridine (351) to give 1,2,3-amino diol 352 as 
a single diastereomer. 1,2,3-Amino diol 352 was then transformed into the triacylated natural 
product 353 by using the tert-butyl carboxylate as a synthetic handle. 
 


















Synthesis of D-erythro-sphinganine (348) was completed by Sutherland and co-workers,191 
with their 1,2,3-amino diol-forming sequence starting with the acetimidation of allyl alcohol 
354 to give trichloroacetimidate 355 (Scheme 4-4). Overman rearrangement of crude 
trichloroacetimidate 355 gave the 1,2-amino alcohol 356 in a diastereoselective fashion, the 
selectivity of which was proposed to originate from coordination of palladium(II) with the 
MOM ether. Next, one-pot ozonolysis and subsequent reduction of 1,2-amino alcohol 356 
forms the 1,2,3-amino diol 357, which upon acid-mediated global deprotection yields the 
target D-erythro-sphinganine (348). 
 
Scheme 4-4. Synthesis of D-erythro-sphinganine (348) by Overman rearrangement then 
ozonolysis. 
Recently, much academic and media attention has been focused on the very real threat of 
avian H5N1 influenza virus, which holds a mortality rate of over 50%. 192  (‒)-Oseltamivir 
phosphate (358•H3PO4, Scheme 4-5), marketed as Tamiflu is a neuraminidase inhibitor used 
in the treatment of both type A and type B human influenza,193 and represents a promising 
medicine for combating an H5N1 influenza virus pandemic. However, recent studies have cast 
a shadow of doubt over the actual effectiveness of (‒)-oseltamivir (358) in a genuine 
pandemic, bringing into question the billions of dollars’ worth of stockpiling that has been 
performed by western countries.194 
 





Several routes towards (‒)-oseltamivir (358) have been reported by research groups,195 with 
the shortest coming from Trost and co-workers (Scheme 4-6). 196  Their approach to the 
installation of the 1,2,3-diamino ether of (‒)-oseltamivir (358) relied on a regio- and 
diastereoselective rhodium-catalysed aziridination of diene 359 to give aziridine 360. Lewis 
acid-mediated opening of aziridine 360 gives the 1,2,3-diamino ether 361, which is then 
converted into desired (‒)-oseltamivir (358) in a few steps. 
 
Scheme 4-6. Synthesis of 1,2,3-diamino ether 361 by a rhodium-catalysed aziridination. 
In 1997, PM-94128 (362) was isolated from the culture broth of Bacillus sp. PhM-PHD-090, a 
bacterium growing in marine sediment. PM-94128 (362) demonstrates cytotoxic activity 
against several tumour cell lines, and is an inhibitor of protein and DNA synthesis.197 In Vallée 
and co-workers’ synthesis of PM-94128 (362), 1,2,3-amino diol fragment (363) was identified 
as a key intermediate for their route (Scheme 4-7).198 
 
Scheme 4-7. PM-94128 (362) and key fragment 363 required for its synthesis.  
Vallée and co-workers’ approach to the synthesis of 1,2,3-amino diol fragment 363 was by a 
ruthenium-catalysed dihydroxylation of 1,2-oxazone 364, which was prepared from (R)-
valinol (Scheme 4-8).198 Procedurally, the dihydroxylation of 1,2-oxazone 364 was performed 
by using Shing’s “flash dihydroxylation” conditions to give diol 365 with excellent 
diastereoselectivity.199 Subsequent ring-opening of oxazinanone 365 and amide coupling of 
the resulting carboxylic acid gives access to PM-94128 (362). 
 





Bathymodiolamide A (366), a natural product isolated from the deep-sea hydrothermal vent 
invertebrate mussel Bathymodiolus thermophilus, demonstrates growth inhibition of cervical 
and breast cancer cell lines.200 Structurally, bathymodiolamide A (366) contains an amino 
alcohol stereo quintad core (367), which was of chief consideration to Liu and co-workers in 
their synthesis (Scheme 4-9).201 
 
Scheme 4-9. Bathymodiolamide A (366) and its key 1,2,3-amino diol containing core (367). 
To construct the 1,2,3-amino diol of fragment 367, Liu and co-workers used a palladium-
catalysed aminohydroxylation of allyl alcohol 368, which was prepared from D-mannitol.202 
First, allyl alcohol 368 was converted to carbamate 369 by reaction with tosyl isocyanate. 
Palladium catalysed aminohydroxylation was then performed in aqueous hydrogen peroxide 
to access palladium(IV) species and form the 1,2,3-amino diol containing fragment 370 
(Scheme 4-10). Completing the amination intramolecularly ensured regioselectivity of the 
aminohydroxylation across the alkene.  
 















4.2 Importance and Synthesis of Vicinal Triamines  
 
Vicinal triamines, an array of three contiguous carbons each bearing an amine are a feature 
of numerous bioactive compounds (Scheme 4-11).203 However, similarly to 1,2,3-amino diols 
and 1,2,3-diamino alcohols, the construction of vicinal triamines is a challenge that 
continually requires new approaches to. As such, academic attention has been directed at the 
development of efficient methodologies for 1,2,3-triamine fragment and natural product 
preparation. 
 
Scheme 4-11. A generic vicinal triamine.  
The Agelastatins are a family of cytotoxic pyrrole-imidazole alkaloids, structurally 
characterised by their unique vicinal triamine containing tetracyclic framework. Agelastatin A 
(371, Scheme 4-12) was isolated in 1993 from the Coral Sea sponge Agelas dendromorpha 
and was found to show antineoplastic activity against multiple tumour cell lines.203b,204 Due 
to the prevalence of agelastatin A (371) as a pharmacophore, several syntheses have been 
explored.205 
 













In 2013, Movassaghi and co-workers reported a route towards racemic agelastatin A (371) 
and five other members of the agelastatin family (Scheme 4-13).206 The 1,2,3-triamine of 
agelastatin A (371) was constructed in the final step of the sequence using a bioinspired 
cyclisation. It was found that late-stage intermediate 372, derived from aspartic acid,207 
undergoes acid-mediated 5-exo-trig cyclisation to give agelastatin A (371) and its 
diastereomer 373. This cyclisation was proposed to initiate by formation of iminium 374 to 
give the kinetic product 373, which equilibrates to the thermodynamically favoured 
agelastatin A (371). 
 
Scheme 4-13. Synthesis of agelastatin A (371) and its diastereomer 373 by acid-mediated 
cyclisation. 
Cyanocycline A (375, Scheme 4-14) was first isolated in 1982 from the fermentation broth of 
Streptomyces flavogriseus and exhibits a variety of antimicrobial and antitumor activities.203c 
Cyanocycline A (375) contains a vicinal triamine that is a component of five of its six rings. The 
challenge of reproducing cyanocycline A (375) in total synthesis has been completed by 
several research groups,208 with the shortest route coming Garner and Ümit who completed 
the synthesis in an impressive 22 steps.209 
 











Garner and co-worker’s synthetic route targeted 376, a late-stage intermediate of 
Fukuyama’s synthesis of cyanocycline A (375) (Scheme 4-14).209 The key transformation of 
this synthesis was a silver catalysed three-component pyrrolidine formation, by mixing of 
serine derived aldehyde 377 with L-glycylsultam (378) in methyl acrylate to give a single regio- 
and diastereomer of vicinal triamine 380 (Scheme 4-15). The diastereoselectivity was 
rationalised to occur by endo-Si addition of 2-azaallyl anion 379 to methyl acrylate. 
 
Scheme 4-15. The three-component cyclisation of aldehyde 377 to form key intermediate 













Peptidomimetics are synthetic molecules able to mimic the  folding of peptides and protein 
fragments, they have widespread application within both chemical biology and medicinal 
chemistry for the selective perturbation of protein−protein interactions. 210  The most 
prevalent nonrepetitive motif of proteins is the four-residue β turn, in which proline and 
glycine are generally found at the i+1 and i+2 positions.211 Numerous synthetic scaffolds that 
attempt to mimic the β turn of natural peptides have been developed.212 In 2014, Pellegrino 
and co-workers contributed to this field by reporting the vicinal triamine scaffold 381 acts as 
a β turn nucleator (Scheme 4-16).213 
 
Scheme 4-16. The dipeptide mimic 381 a β turn nucleator. AA - amino acid. 
Synthesis of dipeptide mimic 381 is achieved by a three-component coupling between ketone 
382, proline methyl ester (383) and tosyl azide (Scheme 4-17).213 The formation of vicinal 
triamine diastereomers 385 and 386 was proposed to proceed by enamine formation 
between ketone 382 and proline methyl ester (383). The intermediary enamine then engages 
in [3+2] cycloaddition with tosyl azide, then subsequent concerted proline transposition and 
expulsion of molecular nitrogen to give imine 384. Imine 384 is then reduced to vicinal 
triamine diastereomers 385 and 386. It was noted that side product 387 is also formed in this 
reaction, by piperidone contraction instead of proline transposition. 
 






Due to the various appearances 1,2,3-triamines make in biologically relevant structures, 
methodologies have been developed for their specific preparation, away from the context of 
total synthesis. Trost and co-workers disclosed conditions for the intramolecular aziridination 
of allylic hydroxylamine-derived sulfamate esters (Scheme 4-18).214  This approach uses a 
rhodium pre-catalyst and hypervalent iodine oxidant to perform the oxidative cyclisation of 
hydroxylamine (388) to give aziridine (389). Aziridine (389) was then ring-opened with sodium 
azide to give the seven-membered heterocycle 390. Finally, one-pot reduction and 
deprotection of azide 390 yields the vicinal triamine 391 as an unnatural amino ester. 
 
















Finally, Jørgensen and co-workers disclosed conditions for the enantioselective synthesis of 
4-nitropyrazolidines as precursors to 1,2,3-triamines (Scheme 4-19).215 This was achieved by 
a 1,3-dipolar cycloaddition of hydrazones (392) with nitro-olefins (393), which were activated 
by hydrogen-bonding thiourea catalyst 394, allowing control of all three stereocentres of the 
4-nitropyrazolidine 395 product. 4-Nitropyrazolidine 395 could then be converted to its 
corresponding 1,2,3-triamine (396) by nitro reduction then N-N reductive cleavage. 
 














5. Project Background 
5.1 Photoredox Catalysis and Proton-Coupled Electron Transfer 
 
The term proton-coupled electron transfer (PCET) was first coined in 1981, to describe the 
elementary step of a simultaneous proton and electron transfer. PCET was originally used to 
define the comproportionation process between the ruthenium complexes 397 and 398 to 
give two equivalents of ruthenium complex 399, in which a proton and electron are 
synchronously transferred from RuII-OH22+ to RuIV=O2+ (Scheme 5-1).216 Further distinctions 
can be made within PCET; if an electron and proton both travel in an elementary step this is 
said to be a concerted PCET, such as the one depicted in Scheme 5-1. Furthermore, unlike 
hydrogen atom transfer (HAT), where a proton and electron travel as H•, in multisite PCET the 
proton and electron need not originate nor terminate from the same bond or even the same 
molecule.  
 
Scheme 5-1. Comproportionation of ruthenium complexes 397 and 398 by PCET. 
From its inception, PCET as a terminology has found applicability in various fields of chemistry, 
such as enzymatic C-H bond oxidation,217 biosynthesis of natural products218 and several small 
molecule activation techniques.219 Photosynthesis for example is a stunning success of PCET, 
with 12 electrons and protons being transferred upon photoexcitation from at least 24 
photons (Scheme 5-2).220 However, despite the frequent identification of PCET processes 
within biological systems, the use of PCET as an enabling mechanism for organic synthesis has 
only begun to be explored in recent years. 
 













Similarities can be drawn between multisite PCET and HAT, in that both processes involve the 
transfer of the constitutional parts of H• to provide a neutral free radical product. The 
thermodynamic driving force of HAT reactions is correlated to the net increase in bond energy 
of the bonds being broken and formed. Therefore, the homolytic cleavage of a strong bond 
between hydrogen and a donor requires the formation of an equally strong or stronger bond 
between hydrogen and an acceptor. This thermodynamic limitation creates a substantial 
challenge when developing methodologies by homolytic bond activation, as it typically 
restricts reactions entirely to exergonic processes (Scheme 5-3). 
 
Scheme 5-3. Examples of organic functionality that possess bonds with high BDEs.221222223224 
A variety of protic organic functionality display bond-disassociation energies (BDEs) greater 
than 100 kcal/mol (Scheme 5-3). Consequently, homolytic activation of common O-H and N-
H bonds even by the most powerful HAT mediators, such as organometallic tungsten 
complexes,225  are usually ineffective. It is also worth noting that typical alkyl C-H bonds 
possess lower BDEs than O-H and N-H bonds, resulting in unselective homolytic activation 


















The conventional method for defining covalent bond energies, popularised by Bordwell, is 
through observing the energy required for heterolytic bond cleavage, represented by pKa, 
summed together with the energies needed to oxidise the resulting anion and reduce the 
resulting proton to their respective neutral radicals.226 In 2010 Mayer brought to attention 
that the classical method of conceptualising BDEs draws thermodynamic parallels between 
HAT and multisite PCET, in that a hydrogen atom acceptor may be seen to be equivalent to a 
Brønsted base and a one-electron oxidant. Despite there being no formal homolytic bond 
cleavage in an oxidative multisite PCET, the capacity for a base and an oxidant to act as a 
hydrogen atom acceptor can be assessed by summing of the pKa and redox potential values 
to give the ‘effective’ BDE. This highlights an advantage of multisite PCET over HAT, in that 
the pKa and redox potential of the respective base and oxidant (or acid and reductant) can be 
independently tuned, which are inversely correlated properties and hard to adjust within a 
sole HAT mediator. This practically manifests as a tool to easily identify acid/reductant 
combinations and base/oxidant pairings with desirable BDEs (Scheme 5-4). 
 
Hydrogen Atom Acceptor Pair 
Oxidant Base Eo (V) pKa ‘BDE’/ kcal.mol-1 
FeIII(bpy)3 pyridine 0.70 12.5 87 
*RuII(bpy)3 acetate 0.39 23.5 96 
*RuII(bpz)3 lutidine 1.07 14.1 100 
IrIII(dF(CF3)ppy)2(bpy) DMAP 1.0 18.0 103 
 
Scheme 5-4. Square scheme of a generic multisite PCET manifold to give the ‘effective’ BDE 
in acetonitrile. Example bond strengths available by the joint action of a selection of 
base/oxidant pairs. Asterisks denotes ET from a photoexcited state.227 
Multisite PCET also allows for the selective homolytic activation of N-H and O-H bonds in the 
presence of C-H bonds. C-H bonds are typically poor hydrogen bond donors; therefore, a 
base/oxidant pair can engage in initial pre-association between a polar O-H or N-H bond and 
a base by hydrogen bonding. Hydrogen bonding of a base with a targeted bond confines the 
subsequent deprotonation and electron removal to the hydrogen bond donating substrate. 
Lastly, the formation of a hydrogen bond can be viewed as initial progression through the 
reaction coordinate of a PCET, allowing for the use of redox mediators that possess 





Use of PCET for enabling organic synthesis was popularised by Knowles through several 
seminal reports.102c,228 In 2013 Knowles and co-workers disclosed the catalytic generation of 
ketyl radicals by multisite PCET (Scheme 5-5). 229  The reduction potential of ketones is 
substantial (acetophenone: E1/2red = −2.48 V vs Fc/Fc+), 230  rendering them an inert 
functionality to all but the most reducing photocatalysts. In addition, ketones are weakly basic 
(acetophenone: pKa = −0.1), so only particularly strong acids are able to generate any practical 
quantities of the protonated carbonyl.231 However, Knowles and co-workers demonstrated 
that through reductive multisite PCET, photocatalyst 80 (RuI/RuII = −1.71 V vs Fc/Fc+) and 
diphenyl hydrogen phosphate (402) (pKa = 13) could be used for formal H• donation into 
ketones for ketyl radical generation, with dihydrobenzothiazole 401 used as a sacrificial 
electron donor.  Ketyl formation from ketone 400 results in a 5-exo-trig radical cyclisation to 
give bicyclic lactone 403 and ester 404. 
 



















The mechanism for Scheme 5-5 was proposed to initiate by photoexcitation of ruthenium 
complex 80 followed by subsequent reductive quenching with electron donor 401 to give the 
ruthenium complex 405 and persistent radical cation 406 (Scheme 5-6). Ruthenium complex 
405 and diphenyl hydrogen phosphate (403) facilitate reductive PCET of ketone 400 to give 
the ketyl radical 407, diphenyl phosphate (408) and regenerated photocatalyst 80. The 
nucleophilic ketyl radical 407 undergoes cyclisation with the pendent electrophilic olefin 
generating ester-stabilised radical 409, which abstracts a hydrogen atom from electron donor 
401 to yield the phenyl-stabilised radical 410 and the desired product 411.  To complete the 
catalytic cycle, ruthenium complex 80 undergoes photoexcitation then reductive quenching 
with phenyl-stabilised radical 410 to give iminium 412 and regenerate ruthenium complex 
405. Diphenyl phosphate (408) deprotonates iminium 412 producing thiazole by-product 413 
and reforming diphenyl hydrogen phosphate (403).229 
 




Later, in 2015 Knowles and co-workers reported the carboamination between anilides 
containing a pendant olefin with electrophilic radical acceptors, by the oxidative PCET of N-H 
bonds (Scheme 5-7).232 It was highlighted that the N-H bond of amide 414 possesses large pKa 
and oxidation potential values (pKa = 32; E1/2ox = 1.2 V vs Fc/Fc+). However, it was shown that 
by using iridium photocatalyst 77 (E1/2ox = 1.04 V vs Fc/Fc+, from an photoexcited state) and 
hydrogen-bond acceptor dibutyl phosphate (415) (pKa = 13), components that cannot perform 
an electron or proton transfer individually, amidyl radical formation is achieved. Once amidyl 
radical formation of amide 414 occurs, cycloamination followed by radical addition to methyl 
acrylate gives lactam 416. 
 





















The catalytic cycle of Scheme 5-7 starts with photoexcitation of iridium photocatalyst 77, 
which with dibutyl phosphate (415) mediates the oxidative PCET of amide 414 to give N-
centred radical 417, iridium complex 418 and dibutyl hydrogen phosphate (419). The N-
centred radical 417 undergoes cyclisation to give the nucleophilic C-centred radical 420, 
which adds to methyl acrylate generating intermediate ester-stabilised radical 421. Radical 
421 is reduced by iridium complex 418 to the carbanion 422, which is protonated by dibutyl 
hydrogen phosphate (419) and closes the catalytic cycle. 
 
Scheme 5-8. Catalytic cycle for the oxidative PCET-mediated carboamination of anilides 












5.2 Aryl Diazonium Salts as Amine Transfer Reagents 
 
Aryl diazonium salts (424) as a class of molecule were first reported in 1858 by Peter Griess, 
when he disclosed conditions for the diazotization of anilines (423) with nitrous acid and 
picramic acid.233 Since the discovery of aryl diazonium salts they have found application in 
surface chemistry,234 assembly of soluble carbon nanotubes,235 molecular optoelectronics236 
and silicon-molecule junctions.237 However, the field of synthetic chemistry is where aryl 
diazonium salts have found the most use.  Aryl diazonium salts are amenable substrates in a 
variety of synthetic transformations, such as palladium-catalysed cross-couplings, 238 
fluorination by the Balz-Schiemann reaction239 and aryl radical generation for Meerwein240 or 
Sandmeyer chemistry (Scheme 5-9).241 These transformations are only possible due to the 
diazonium functional group acting as a very efficient leaving group, by expulsion of molecular 
nitrogen.   
 
Scheme 5-9. Generalised synthesis of diazonium salts from anilines (423) and a selection of 










In addition to the reactivity depicted in Scheme 5-9, aryl diazonium salts (424) also possess 
an electrophilic site on the terminal nitrogen, which allows their azo-coupling with electron-
rich aryls or radical donors to yield azo compounds (425) that find common use as dyes.242 
However, azo compounds have recently become of more medicinal and synthetic importance. 
The azo functional group can be reductively cleaved to give the primary amines of the two 
constituent parts of the original azo compound. Therefore, the N-terminus of an aryl 
diazonium salt can be viewed as an amine transfer reagent. Furthermore, azo compounds 
have been investigated as potential prodrugs that adopt an inactive form until they reach the 
colon, where the therapeutically active amine is revealed upon site-specific reduction 
catalysed by bacterial extracellular azoreductase.243 Subsequently, academic attention has 
been directed at the installation and reductive cleavage of azo functionality (vide infra).  
In 2015 Heinrich and co-workers reported the Meerwein-type carboamination protocol of 
1,1-disubstituted alkenes (426) (Scheme 5-10).244 In this reaction aryldiazonium salts (122) 
are used to perform a dual function of being a source of aryl radical donor and electrophilic 
radical acceptor. The reaction is carried out by slow addition of aryl diazonium salts to a 
solution of olefin and potassium carbonate. It was proposed that Gomberg−Bachmann-type 
decomposition of aryl diazonium salt generates aryl radical, which attack 1,1-disubstituted 
alkene forming nucleophilic tertiary C-centred radical. The newly formed tertiary C-centred 
radical attacks the N-electrophilic site of an aryl diazonium salt, forming a N-centred radical 
cation that is claimed to be reduced by separate olefin starting material (426) to give the final 
azo product (427). One of the azo-compound products (427) of this Meerwein-type 
carboamination was submitted to conditions for reductive cleavage of the azo bond to give 
the primary amine (428).  
 










In 2017 Hao and co-workers disclosed protocol for the synthesis of azo compounds by silver 
nitrate-initiated benzo-1,3-diazolic difluoromethylenation of aryl diazonium salts (Scheme 5-
11). 245  The authors proposed that silver(I) acts as a single electron oxidant of sodium 
sulfinates (429), which results in the expulsion of sulfur dioxide and formation of benzo-1,3-
diazolic difluoromethylene radical. Intermediary benzo-1,3-diazolic difluoromethylene radical 
attacks aryl diazonium salt 430 forming a N-centred radical cation, which is reduced to the 
desired product 431 through oxidation of sodium sulfinate 429, propagating the radical chain. 
 
Scheme 5-11. Silver nitrate-initiated gem-difluoromethylenation of aryl diazonium salts.  
Aryl diazonium salts possess very low reduction potentials (E1/2red = ‒0.06 V vs SCE, for 
PhN2BF4),246 as such they can oxidise other reaction components in addition to reacting in 
their typical manner. This was used by Wu and co-workers in the in situ oxidation of DABSO 
by aryl diazonium salts 430 to generate the ammonium cation of DABCO•(SO2), sulfur dioxide 
and aryl radical (Scheme 5-12).247 The aryl radical is then trapped by sulfur dioxide to give aryl 
sulfonyl radical, which attacks the alkyne 432 to produce a phenyl-stabilised C-centred radical. 
The intermediary phenyl-stabilised C-centred radical engages in cyclisation with a distal 
alkene to yield a nucleophilic tertiary C-centred radical, which attacks diazonium salt 430 
forming a N-centred radical cation that oxidises another DABSO to generate the desired 
product 433. The newly oxidised DABSO decomposes to ammonium cation of DABCO•(SO2) 
and sulfur dioxide, which with the previously formed ammonium cation of DABCO•(SO2) 
eventually forms two equivalents of DABCO•(SO2) and one equivalent sulfuryl fluoride. 
 










Due to the nature of aryl diazonium salts to act as radical acceptors, it is a natural progression 
for them to be used as substrates in PRC. Xiao and co-workers demonstrated the ruthenium 
complex 80 catalysed azo-trifluoromethylation of alkenes (434) with aryl diazonium salts 
(435) and Langlois reagent (134) to give trifluoromethyl-containing azo compounds (436) 
(Scheme 5-13).248 Reductive cleavage of the azo bond of the azo-trifluoromethylation product 
436 to the primary amine 437 was demonstrated by use of acid and elemental zinc. 
Additionally, azo-trifluoromethylation product 436 was shown to participate in an acid 
facilitated isomerization/cyclization cascade to yield indole 438. 
 











The mechanism of Scheme 5-13 was proposed to proceed by photoexcitation of ruthenium 
complex 80 (439) (Scheme 5-14). It was noted that photoexcited ruthenium complex 439 is 
not a strong enough oxidant (E1/2 (PC*/PC−) = 0.77 V vs SCE) for the oxidation of Langlois 
reagent (134) (E1/2ox = 1.05 V vs SCE).86 Instead photoexcited 439 first reduces aryl diazonium 
salt (435) to generate ruthenium complex (405), aryl radical (440) and molecular nitrogen. 
Ruthenium complex 405 serves as a powerful oxidant (E1/2 (PC+/PC) = 1.29 V vs SCE), which 
oxidises Langlois reagent (134) and decomposes to trifluoromethyl radical (331) and sulfur 
dioxide. Trifluoromethyl radical attacks the terminal end of olefin 434 to give C-centred 
radical 441, which attacks an aryl diazonium salt (435) to yield N-centred radical cation 442. 
Radical cation 442 is reduced by photoexcited ruthenium complex 80 (439) to yield desired 
product 436 and regenerate ruthenium complex 405, which continues the catalytic cycle. This 
work highlights the dual nature of aryl diazonium salts to act as radical acceptors and 
sacrificial oxidants to promote an oxidative quenching PRC manifold.248 
 
Scheme 5-14. Proposed mechanism for the azo-trifluoromethylation of olefins by photoredox 












6. Results and Discussion 
6.1 Project Aims 
This project aims to develop methodology for the construction of 1,2,3-triamine and           
1,2,3-diamino alcohol fragments, from azo compound derivatives of imidazolidinone and 2-
oxazolidone (443) (Scheme 6-1). It is reported that imidazolidinones and 2-oxazolidones can 
be hydrolysed, implying the conversion of common intermediate 443 to azo compound 444 
to be possible.249  As previously discussed, azo compounds can be reductively cleaved to 
primary amines, giving confidence that transformation of common intermediate 443 to 
primary amine 445 is feasible. Finally, the removal of an appropriate protecting group of the 
central nitrogen of common intermediate 443 to give azo compound 446 was planned. 
Therefore, azo compound derivatives of imidazolidinone and 2-oxazolidone (443) may 
practically offer an approach to individually reveal each heteroatom of 1,2,3-triamine and        
1,2,3-diamino alcohol fragments for further functionalisation. 
 
Scheme 6-1. Deprotection strategy of each heteroatom of a generalised azo compound 











It was envisaged that the generalised azo compound 443 could be formed from a reaction 
between allyl carbamates or ureas (447) and aryl diazonium salts (424) (Scheme 6-2). As 
demonstrated by Knowles and co-workers, oxidative-PCET offers a simple method of forming 
amidyl radicals of allyl ureas and carbamates, through combinatorial use of reductive-
quenching PRC with a hydrogen-bond acceptor.231 Instead, it was hypothesised that the N-
centred radical of 447 generated by oxidative-PCET could instead be achieved by an oxidative-
quenching photoredox cycle, where a photoexcited PC (97) first reduces aryl diazonium salt 
(424) to molecular nitrogen and aryl radical (440) forming PC radical cation (449), a more 
potent oxidant than photoexcited PC (97). The cooperative action of a hydrogen-bond 
acceptor and the PC radical cation (449) forms N-centred radical by oxidative-PCET, which 
undergoes 5-membered cycloamination yielding C-centred radical (448). As previously 
discussed, alkyl radicals perform terminal addition into aryl diazonium salts, giving confidence 
that reaction between C-centred radical 448 and aryl diazonium salts (424) to yield radical 
cation 450 is possible. Lastly, reduction of radical cation 450, by oxidation of photoexcited PC 
(97), yields the desired azo compound and regenerates PC radical cation (449). The joint use 
of an oxidative quenching redox cycle and oxidative-PCET could mean that only weakly 
oxidising and reducing PCs (104) are required to facilitate this azo-cycloamination.  
 
Scheme 6-2. Hypothesised photoredox cycle to achieve the azo-cycloamination of allyl 








6.2 Discovery and Optimisation of Azo-Cycloamination Conditions 
Phosphate 415 is a common hydrogen bond acceptor to facilitate the proton transfer in 
oxidative PCET activation of ureas and carbamates.218 Phosphate 415 was synthesised 
quantitatively by deprotonation of dibutyl hydrogen phosphate (419) with hydroxide 451 
(Scheme 6-3).250 
 
Scheme 6-3. Synthesis of phosphate 415. 
Initial work focused on assessing the ability for PCs 4CzIPN (91) and 3DPAFIPN (106) to 
facilitate N-centred radical formation of allyl carbamates by oxidative-PCET. Allyl carbamate 
453 was synthesised from allyl alcohol 452 and phenyl isocyanate (204) (Scheme 6-4).  
 
Scheme 6-4. Synthesis of allyl carbamate 453. 
Allyl carbamate 453 was submitted to conditions for 4CzIPN (91) and 3DPAFIPN (106) 
catalysed carboamination with tert-butyl acrylate (454) (Scheme 6-5).231 Gratifyingly, by using 
4CzIPN (91) allyl carbamate 453 was successfully converted to the carboamination product 
455 in reasonable yield and anti-diastereoselectivity. Contrarily, use of 3DPAFIPN (106) only 
yielded starting allyl carbamate (453), presumably due to being insufficiently oxidising from 
the photoexcited state to facilitate oxidative-PCET. The observed anti-diastereoselectivity is 
presumably derived from the oxazolidinone ring blocking the required trajectory of the 
acrylate (454) to the C-centred radical post-cycloamination for syn-diastereoselectivity.  
 
Scheme 6-5. 4CzIPN (91) catalysed carboamination of allyl carbamate 453. Yield is of isolated 





Encouraged by scheme 6-5, focus was directed towards identifying conditions for the azo-
cycloamination of allyl carbamates with aryl diazonium salts by PRC. Carbamate 457 was 
selected as a model substrate to test initial azo-cycloamination activity and was synthesised 
by coupling prenol (456) with phenyl isocyanate (204) (Scheme 6-6).  
 
Scheme 6-6. Synthesis of allyl carbamate 457. 
Aryl diazonium salt 430 was synthesised by the diazotisation of aniline 458 in moderate yield 
(Scheme 6-7).241c 
 



















The azo-cycloamination of allyl carbamate 457 with aryl diazonium salt 430 to form azo 
compound 489 was investigated (Table 6-1). Gratifyingly, use of photocatalyst 4CzIPN (91) 
and an excess of hydrogen bond acceptor (415) resulted in azo compound (459) formation 
(Table 6-1, Entry 1).231 Switching the reaction solvent to DMSO gave lower azo compound 
(459) generation compared to using DCM (Table 6-1, entry 2). Photocatalyst 3DPAFIPN (106) 
in place of 4CzIPN (91) incurred an increase in azo compound (459) productivity (Table 6-1, 
entry 3), despite showing no activity in the carboamination of allyl carbamate 453           
(Scheme 6-5). The activity observed in using 3DPAFIPN (106) was rationalised to be due to an 
oxidative quenching photoredox cycle being promoted by reduction of aryl diazonium salt 
(430) (Scheme 6-2). Meaning the oxidative  species involved in oxidative-PCET of allyl 
carbamate 457 could be 3DPAFIPN (106) radical cation (E1/2 (P+/P) = 1.34 V vs SCE), a similar 
strength oxidant to photoexcited 4CzIPN (91) (E1/2 (P*/P‒) = 1.35 V vs SCE).94 
Increasing the 3DPAFIPN (106) loading from 3 mol% to 7 mol% gave a small increase in azo 
compound (459) yield (Table 6-1, entry 4), but no more benefit was observed when the 
loading  was increased to 12 mol% (Table 6-1, entry 5). Increasing the stoichiometry of aryl 
diazonium salt (430) was detrimental to azo compound (459) productivity (Table 6-1, entry 
6), while using 1.5 equivalents gave a small reduction in yield (Table 6-1, entry 7). Remarkably, 
in the absence of 3DPAFIPN (106) and light, significant levels of azo compound (459) 
formation were observed (Table 6-1, entry 8), with blue LED irradiation appearing to have a 
negligible effect on this catalyst-free reactivity (Table 5-1, entry 9).  
 
Entry PC (mol%) 430 eq. Solvent Yield/ %[a] 
1 4CzIPN (91) (3) 2.0 DCM 34 
2 4CzIPN (91) (3) 2.0 DMSO 8 
3 3DPAFIPN (106) (3) 2.0 DCM 42 
4 3DPAFIPN (106) (7) 2.0 DCM 54 
5 3DPAFIPN (106) (12) 2.0 DCM 52 
6 3DPAFIPN (106) (7) 3.0 DCM 8 
7 3DPAFIPN (106) (12) 1.5 DCM 43 
8[b] - 2.0 DCM 24 
9 - 2.0 DCM 26 
Table 6-1. Optimisation of the azo-cycloamination of allyl carbamate 457 with aryl diazonium 
salt 430. [a] Yields obtained by 19F NMR and compared to a benzotrifluoride internal standard. 






As it is intended to reductively cleave the azo group of azo-cycloamination products, the 
precise structure of the aryl diazonium salt used is inconsequential, as such an optimal aryl 
diazonium salt to promote this reaction was sought. Allyl carbamate 457 was exposed to 
optimised azo-cycloamination conditions for azo compound 459 formation, but instead with 
aryl diazonium salt 460 (Table 6-2), which pleasingly gave a good yield for azo compound 461 
(Table 6-2, entry 1). Interestingly, significant quantities of azo compound 461 were obtained 
in the absence of 3DPAFIPN (106) while still under blue LED irradiation (Table 6-2, entry 2), 
while near trace amounts of product were returned in the absence of 3DPAFIPN (106) and 
light (Table 2-6, entry 3). These observations imply that a photochemical reaction between 
allyl carbamate 457 and aryl diazonium salt 460 occurs, which is promoted by 3DPAFIPN (106).  
 
Entry 3DPAFIPN (106)/ mol% Yield / %[a] 
1 7 74 
2 0 47 
3 0[b] <10 
Table 6-2. Azo-cycloamination between allyl carbamate 457 and aryl diazonium salt 460.        
[a] Isolated yields. [b] In the absence of light.* 
Aryl diazonium salt 463 was synthesised by the diazotisation of aniline 462 in moderate yield 
(Scheme 6-8).241c 
 













Unlike Table 6-2, when aryl diazonium salt 463 is used in the azo-cycloamination of allyl 
carbamate 457 to form azo compound 464, optimal conditions identified were under blue 
LED irradiation (Table 6-3, entry 2). Addition of 3DPAFIPN (106) partially hinders azo 
compound 464 formation (Table 6-3, entry 1), while in the absence of 3DPAFIPN (106) and 
light product output persists but at an attenuated level (Table 6-3, entry 3). 
 
Entry 3DPAFIPN (106)/ mol% Yield / %[a] 
1 7 62 
2 0 69 
3 0[b] 38 
Table 6-3. Azo-cycloamination between allyl carbamate 457 and aryl diazonium salt 463. [a] 
Isolated yields. [b] In the absence of light. 
As the 3DPAFIPN (106) mediated conversion of allyl carbamate 457 to azo compound 461 
(Table 6-2, entry 1) gave the most productive azo-cycloamination, it was hoped that these 
conditions would also be applicable to allyl ureas, for access to 1,2,3-triamines. In-house 
prepared allyl ureas 465, 466 and 467 were submitted to optimised conditions for azo-
cycloamination with 3DPAFIPN (106) and aryl diazonium salt 460 (Scheme 6-9). Yet 
disappointingly, no azo-cycloamination product (468, 469, 470) could be discerned despite 
full starting material consumption being observed in all cases.  
 
Scheme 6-9. Attempts at the 3DPAFIPN (106) mediated azo-cycloamination of allyl ureas with 









Undeterred by Scheme 6-9, allyl ureas 465 and 466 were both subjected to optimised 
3DPAFIPN (106) mediated azo-cycloamination conditions with aryl diazonium salt 430 
(Scheme 6-10). Unfortunately, this again resulted in no production of the desired azo 
compounds 471 and 472 despite achieving reaction completion.  
 
Scheme 6-10. Attempts at the 3DPAFIPN (106) mediated azo-cycloamination of allyl ureas 
with aryl diazonium salt 430.* 
The results of Scheme 6-9 and Scheme 6-10 present a significant flaw in this methodology for 
achieving the aims of this project (Scheme 6-1), as 1,2,3-triamines would not be accessible by 
this azo-cycloamination approach. To identify conditions compatible with allyl ureas, an 
investigation into the electronics of the N-aryl of allyl carbamates was performed. Carbamate 
474 was synthesised from prenol (456) and aryl isocyanate 473 in good yield (Scheme 6-11). 
It was hypothesised changing the N-phenyl of allyl carbamate 457 for a more electron rich 
aryl may promote oxidative-PCET for N-centred radical formation over decomposition 
pathways, by enhancing the propensity of the N-aryl to be oxidised. Adversely, introducing an 
electron donating-substituent to the N-aryl also weakens any hydrogen bond with phosphate 
base 415 while increasing the N-H bond pKa, which according to Scheme 5-4 increases the 
effective BDE of the N-H bond. However, without formal examination of the pKa and oxidation 
potential of carbamate 474, it is not clear to what extent the para-methoxy group aids 
electron transfer and hinders proton transfer for PCET. 
 










With allyl carbamate 474 in hand, conditions for PCET of allyl carbamates were used with aryl 
diazonium salt 430, which pleasantly gave azo-compound 475 (Table 6-4, entry 1).231 
Increasing the equivalents of phosphate base (415) from 1.0 to 1.25 to 2.0 each gave a small 
increase in yield for azo compound 475 (Table 6-4, entries 1-3). Changing the reaction solvent 
from DCM to DMSO resulted in a significant rise in azo-compound 475 output (Table 6-4, 
entries 4 and 5), a contradiction to the azo-cycloamination of allyl carbamate 457 (Table 6-1, 
entries 2 and 3). Finally, using photocatalyst 3DPAFIPN (106) in place of 4CzIPN (91) gave an 
increase in yield for azo compound 475 (Table 6-4, entries 6 and 7) and optimised conditions 
that show good agreement between spectroscopic and isolated yields (Table 6-4, entry 7). 
Control experiments implied that photocatalyst 3DPAFIPN (106) was necessary for good azo-
compound 475 formation when under blue LED irradiation (Table 6-4, entry 8). However 
surprisingly, in the absence of 3DPAFIPN (106) and light the yield for azo compound (475) was 
practically identical to if these components were present (Table 6-4, entry 9). This implies that 
blue LED irradiation attenuates azo-compound 475 formation, which is overcome by the 
addition of blue light absorbing 3DPAFIPN (106). As such, a serendipitous discovery of 
conditions for the azo-cycloamination of allyl carbamate 474 with aryl diazonium salt 430 that 
do not require PRC had occurred, seemingly enabled by the para-methoxyphenyl of allyl 
carbamate 474. 
 
Entry PC 415 eq. Solvent Yield/ %[a] 
1 4CzIPN (91) 1.0 DCM 30 
2 4CzIPN (91) 1.25 DCM 34 
3 4CzIPN (91) 2.0 DCM 47 
4 4CzIPN (91) 1.25 DMSO 60 
5 4CzIPN (91) 2.0 DMSO 65 
6 3DPAFIPN (106) 2.0 DCM 57 
7 3DPAFIPN (106) 2.0 DMSO 81 (70)[b] 
8 - 2.0 DMSO 44 
9 -[c] 2.0 DMSO 79 
Table 6-4. Optimisation of the azo-cycloamination of allyl carbamate 474 with aryl diazonium 
salt 430. [a] Yields obtained by 19F NMR and compared with benzotrifluoride internal 







It was questioned whether these new non-catalysed azo-cycloamination conditions would be 
applicable to allyl ureas. Allyl urea 479 was synthesised by reductive amination of prenal (476) 
with para-methoxy aniline (477), followed by coupling of the crude allyl amine 478 with para-
methoxyphenyl isocyanate (473) in good yield (Scheme 6-12). 
 
Scheme 6-12. Synthesis of allyl urea 479. 
Allyl urea 479 was subjected to catalyst-free azo-cycloamination conditions with aryl 
diazonium salt 430 (Scheme 6-13). Remarkably, unlike previous unsuccessful attempts at the 
3DPAFIPN (106) mediated azo-cycloamination of allyl ureas (Scheme 6-9 and Scheme 6-10), 
catalyst-free azo-cycloamination conditions gave azo compound 480 in good yield. 
 















This new catalyst-free azo-cycloamination method was proposed to proceed by a radical chain 
mechanism, on the basis that the cycloamination is likely a radical process (Scheme 6-14). As 
Heinrich and co-workers have previously shown, decomposition of aryl diazonium salt (424) 
to aryl radical (440) can occur in the presence of carbonate base, and so the same may be 
able to occur with phosphate base 415. The bond dissociation energy of the C-H bonds of 
aromatics (482) (~113 kcal/mol)251 is much greater than the N-H bond of N-PMP ureas (481) 
(~90.5 kcal/mol),252 suggesting N-H homolytic activation of allyl carbamates and allyl ureas 
(481) can occur by hydrogen atom abstraction from aryl radical 440. Amidyl radical (483) 
performs cycloamination forming C-centred radical 484, which attacks aryl diazonium salt 
(424) giving radical cation 485. It is suspected that radical cation 485 is the key propagating 
species of the radical chain as observed in other reactions.248 It was postulated that radical 
cation 485 could oxidise allyl carbamate or allyl urea (481) with assistance from a hydrogen-
bonding base, resulting in amidyl radical (483), azo compound (486) and turnover of the 
radical chain.  
 
Scheme 6-14. Azo-cycloamination of allyl carbamates and allyl ureas by a radical chain 





Aryl diazonium salt optimisation studies for the azo-cycloamination of allyl urea 479 were 
performed (Table 6-5). Firstly, carrying out the reaction at 30 °C, the temperature of the blue 
LED photoreactor, incurred a diminishment in azo compound 480 yield compared to using 
room temperature (Table 6-5, entries 1 and 2). Next, it was found that aryl diazonium salt 460 
performed poorly in forming azo compound 487 (Table 6-5, entry 3). While the 
trifluoromethyl containing aryl diazonium salt 463 gave comparable yields for azo compound 
488 to aryl diazonium salt 430 for azo compound 480, but in a shorter reaction time (Table 6-






Table 6-5. Aryl diazonium salt optimisation studies for the catalyst-free azo-cycloamination 
of allyl urea 479. [a] Isolated yields. [b] Yields obtained by 19F NMR and compared with 
benzotrifluoride internal standard. [c] Reaction performed at 30 °C. [d] Reaction performed 
for 2 hours.  
Use of tetrabutylammonium hydroxide (451) in the synthesis of phosphate 415 is costly and 
atom inefficient (Scheme 6-3), furthermore phosphate 415 is hygroscopic making its handling 
difficult. To address this shortcoming, alkali hydroxide derived phosphate bases 489, 490 and 
491 were all synthesised quantitatively (Scheme 6-15).250 
 
Scheme 6-15. Synthesis of phosphate bases 489, 490 and 491. 
 
* Experiment performed and analysed by Dr Quentin Lefebvre. 
Entry R Yield/ %[a] 
1 F (480) 77[b] 
2[c] F (480) 69[b] 
3* MeO (487) <30 




For the azo-cycloamination of allyl urea 479 with aryl diazonium salt 463, it was found that 
lithium phosphate 489 and sodium phosphate 490 performed similarly to 
tetrabutylammonium phosphate 415 (Table 6-5, entry 4 and Table 6-6, entry 1 and 2). A small 
decrease in azo compound 488 yield occurred when using potassium phosphate 491 (Table 
6-6, entry 3). Commercially available bases were also tested, with lithium tribasic phosphate 
performing similarly to potassium phosphate 491 and sodium tribasic phosphate giving only 
a moderate yield for azo compound 488 (Table 6-6, entry 4 and 5). Direct use of 
tetrabutylammonium hydroxide (451) yielded only trace amounts of azo compound 480 
(Table 6-6, entry 6). 
 
 
Table 6-6. Base screen for the azo-cycloamination of allyl urea 479. [a] Isolated yields. [b] 











Entry R Base Yield/ %[a] 
1 CF3 (488) Li[O2P(OBu)2] (489) 84 
2 CF3 (488) Na[O2P(OBu)2] (490) 84 
3 CF3 (488) K[O2P(OBu)2] (491) 72 
4 CF3 (488) Li3PO4 72 
5 CF3 (488) Na3PO4 56 




Additional optimisation of Table 6-6 entry 2 was performed (Table 6-7). It was found that the 
azo-cycloamination of allyl urea 479 with aryl diazonium salt 463 reached completion in half 
an hour (Table 6-7, entry 1). Reducing the equivalents of phosphate base 490 and aryl 
diazonium salt 463 gave reduced yield for azo compound 488 (Table 6-7, entry 2). Finally, 
performing the azo-cycloamination of allyl urea 479 at a higher concentration did not alter 
the yield for azo compound 488, but did reduce the reaction duration to 15 minutes           
(Table 6-7, entry 3). 
 
Entry 463/490 eq. Conc./ M Time/ min. Yield/ %[a] 
1 2.0/2.0 0.1 30 84 
2 1.5/1.5 0.1 30 67 
3 2.0/2.0 0.2 15 84 
Table 6-7. Further optimisation of azo-cycloamination conditions for the synthesis of azo 

















6.3 Scope of Catalyst-Free Azo-Cycloamination Conditions 
With optimised conditions identified for the azo-cycloamination of allyl urea 479 by use of 
aryl diazonium salt 463 and phosphate base 490 (Table 6-7, entry 3), attention was next 
directed to applying these results to other substrates. Allyl ureas 496 and 497 were 
synthesised by reductive amination of prenal (476) with anilines 492 and 493, followed by 
coupling of the crude allyl amines 494 and 495 with p-methoxyphenyl isocyanate (473) 
(Scheme 6-16).  
 
Scheme 6-16. Synthesis of allyl ureas 496 and 497. Yields are over two steps. 
With access to allyl ureas 496 and 497, and a variety of other in-house prepared prenal (476) 
derived N’, N’’ diaryl ureas, an investigation into the functional group tolerance of this new 
azo-cycloamination method was carried out (Scheme 6-17). Pleasingly, azo compounds 498 
to 509 were all successfully synthesised in good to excellent yield. Compatible para-aryl 
substituents included halogens fluoro (499), chloro (500) and bromo (501), thioether (502), 
trifluoromethoxy (503) and cyano (504). Furthermore, tolerated meta- substituents consisted 
of tolyl (505), tert-butyl carboxylate (507) and di-methoxy (506). Unfortunately, ortho-
functionalised N-aryl ureas did not participate in this azo-cycloamination reaction as azo 
compounds 508 and 509 were not observed, which may be due to promotion of an 





Scheme 6-17. Azo-cycloamination of a variety of N’, N’’ diaryl ureas. * 
 
 




Next, azo-cycloamination conditions were applied to allyl carbamates, using aryl diazonium 
salt 463 (Scheme 6-18). As previously shown, N-PMP allyl carbamate 474 afforded azo 
compound 511 in good yield. The N-phenyl allyl carbamate 457 gave a diminished yield of azo 
compound 464. Finally, allyl carbamate 510 containing an electron-deficient N-aryl failed to 
give any azo compound 512, even with an extended reaction time. Scheme 6-18 implies that 
the electron density of the N-aryl undergoing cycloamination is important for azo compound 
formation. This may be rationalised in two ways when considering Scheme 6-14: 1) An 
electron-rich N-aryl is more easily oxidised, so may be required to maintain propagation of 
the radical chain by oxidative-PCET from the radical cation 485; 2) para-trifluoromethylphenyl 
radical may be weakly electrophilic, so an electron-rich N-aryl carbamate may assist N-H 
hydrogen atom abstraction by the aryl radical  through enhanced polarity matching.160 
 














As N-PMP allyl ureas and allyl carbamates are compatible substrates in azo-cycloamination 
with aryl diazonium salt 463 (Scheme 6-17 and Scheme 6-18), it was thought N-aryl amides 
would work as well. Amide 516 was synthesised by Wittig olefination of aldehyde 513 with 
phosphonium 514; the resulting styrene 515 was then coupled with aniline 477                 
(Scheme 6-19). 
 
Scheme 6-19. Synthesis of N-PMP amide 516. Yield over two steps. 
The azo-cycloamination of amide 516 gave azo compound 517 in good yield, by running the 
reaction at a concentration of 0.1 M instead of 0.2 M to aid solubility of the starting material 
(Scheme 6-20).  
 
Scheme 6-20. Azo-cycloamination of amide 516. 
So far, this new azo-cycloamination method has only been demonstrated on prenyl derived 
allyl ureas and allyl carbamates. It was queried whether other allylic carbamates containing 
more complex carbon skeletons would be applicable substrates in this azo-cycloamination. 
The cyclic allyl carbamate 518 was synthesised by coupling allylic alcohol 453 with aryl 
isocyanate 473 (Scheme 6-21). 
 






The azo-cycloamination of cyclic allyl carbamate 518 with aryl diazonium salt 463 pleasingly 
yielded azo compound 519, albeit in moderate yield and syn-diastereoselectivity (Scheme 6-
22). 
 
Scheme 6-22. Azo-cycloamination of cyclic allyl carbamate 518. Yield is of mixture of 
inseparable diastereomers. 
The syn-diastereoselectivity observed in the azo-cycloamination of cyclic allyl carbamate 518 
can be rationalised by inspecting the computed 3-D structure of the intermediary C-centred 
radical 520 (Scheme 6-23). The anti-diastereoselective outcome requires the trajectory of the 
aryl diazonium salt 463 to pass through the interior of the cyclohexyl skeleton, near an axial 
methyl and C-H bond. While for syn-diastereoselectivity the aryl diazonium salt 463 must 
approach from the exterior of the cyclohexyl skeleton near the adjacent oxazolidinone. 
Scheme 6-5 implies the trajectory for syn-diastereoselectivity is likely to be more sterically 
encumbered than for anti-diastereoselectivity, meaning steric shielding does not explain the 
observed diastereoselective outcome. Instead three propositions may explain the observed 
selectivity: 1) a -stacking interaction between the electron-rich N-PMP ring and the electron 
deficient aryl diazonium salt 463 stabilises the approach for syn-diastereoselectivity. 2) 
Radical 520 addition to aryl diazonium salt 463 is reversible and faster than subsequent 
reduction of radical cation (485), so an equilibrium forms favouring the more 
thermodynamically stable syn-epimer of azo compound 519. 3) Related to proposition 2, a 
Curtin–Hammett principle scenario could be in play, where a syn relationship between the 
intermediary azo bond radical cation and the N-PMP group accelerates the proceeding 
reduction of radical cation (485), potentially by electron transfer between the two aryl rings 




Scheme 6-23. 3-D depictions of the intermediary C-centred radical 520, with carbon radical 
highlighted in yellow in 3-D depictions. Geometry optimised using MM2 energy 




Encouraged by the results of Scheme 6-24, geraniol (521) was coupled with PMP isocyanate 
473, affording allyl carbamate 522 in moderate yield (Scheme 6-24). 
 
Scheme 6-24. Synthesis of allyl carbamate 522. 
However, when the azo-cycloamination of geraniol derived allyl carbamate 522 with aryl 
diazonium salt 463 was attempted, only starting material was returned (Scheme 6-25). 
Scheme 6-25 implies that substrates containing alkenes that are not a part of the allyl 
carbamate inhibit azo-cycloamination. It may be that the second olefin is subject to addition 
from aryl radical (440) lowering the number of initiation events.244,253 
 














Next, it was queried whether an allyl carbamate that would form a resonance stabilised C-
centred radical (484) after cycloamination would partake in subsequent addition to aryl 
diazonium salt 463. Dienyl containing allyl carbamate 527 was selected for synthesis in three 
steps (Scheme 6-26), as radical cycloamination would generate a vinyl-stabilised C-centred 
radical. First the Horner-Wadsworth-Emmons reaction was applied by coupling prenal (476) 
with phosphonate 524 to form diene 525 in moderate yield. The ester of diene 525 was 
selectively reduced giving the allyl alcohol 526, which was coupled with PMP isocyanate 473 
giving the desired dienyl carbamate 527. 
 
Scheme 6-26. Synthesis of diene containing carbamate 527. 
The attempted azo-cycloamination of dienyl allyl carbamate 527 with aryl diazonium salt 463 
only returned starting material and no azo compound 528 (Scheme 6-27). 
 






Undeterred by Scheme 6-27, styrene containing cyclic allyl carbamate 532 was targeted for 
synthesis (Scheme 6-28), the C-centred radical of which after radical cycloamination would 
be phenyl stabilised. First, Michael addition on to enone 529 with phenylmagnesium bromide 
followed by E1cB elimination of ethoxide formed styrene 530 in good yield. Reduction of 
enone 530 gives allyl alcohol 531, which was coupled with aryl isocyanate 473 to give styrene 
containing allyl carbamate 532. 
 
Scheme 6-28. Synthesis of styrene containing allyl carbamate 532. 
Again, like Scheme 6-27 the azo-cycloamination of styrene containing allyl carbamate 532 
failed to yield the intended azo compound 533 with only starting material being returned 
(Scheme 6-29). The negative results of Scheme 6-27 and Scheme 6-29 may indicate that the 
intermediary C-centred radical (484) after cycloamination of carbamates 527 and 532 are too 
stabilised, potentially resulting in reversible radical addition into aryl diazonium salt 463. 
 







Finally, it was queried whether allyl ureas that would generate primary or secondary C-
centred radicals after cycloamination would engage in azo-cycloamination. Disappointingly, 
both allyl ureas 534 and 535 failed to give their respective azo compound products (536 and 
537) and only returned starting material, even with extended reaction times (Scheme 6-30). 
This outcome is presumably due to the radical cycloaminations being reversible, as the 
stability of the intermediary primary and secondary C-centred radicals would be lesser than 
the tertiary C-centred radicals that have proved successful. 
 



















6.4 Synthetic Modifications of Azo-Cycloamination Products 
With conditions established for the azo-cycloamination of allyl ureas and allyl carbamates, 
effort was next directed at the derivatisation of the azo products. First, an investigation was 
conducted into methods for the reductive cleavage of the azo bond of 488 to access the 
primary amine 538. Initial attempts used zinc in an acidic solution (Scheme 6-31), but when 
azo compound 488 was exposed to acid, its rapid consumption was observed along with no 
indication of primary amine 538 formation.248 
 
Scheme 6-31. Initial attempt at the reductive cleavage of azo compound 488. 
Now aware azo compound 488 decomposes in acidic media (Scheme 6-31), strong acid-free 
conditions for its conversion to amine 538 were explored. Disappointingly, when mildly acidic 
conditions were used only starting material was returned (Scheme 6-32).254 
 










Literature precedent shows the reductive cleavage of azo bonds can be achieved by transition 
metal-catalysed hydrogenation (Scheme 6-33).244 A palladium-catalysed hydrogenation of azo 
compound 488 afforded only the partial reduction product hydrazine 539 (Scheme 6-33). 
 
Scheme 6-33. Palladium catalysed hydrogenation of azo compound 488. 
More forcing hydrogenation conditions were tested in the reductive cleavage of azo 
compound 488, by using a stoichiometric amount of Raney nickel and a high pressure of 
hydrogen (Scheme 6-34).244 However, again only the hydrazine product 539 was afforded. 
 
Scheme 6-34. Attempted hydrogenation of azo compound 488 by using Raney nickel.  
Reports indicate that palladium-catalysed hydrogenations of azo compounds to amines can 
be assisted by acid. 255  However, when the hydrogenation of azo compound 488 was 
performed with acid-assistance, complete consumption of starting material was observed 
without indication of amine 538 formation (Scheme 6-35). 
 








As acid mediated approaches to the reductive cleavage of azo compound 488 resulted in 
decomposition, it was wondered whether hydrazine 539 would demonstrate greater stability. 
First, azo compound 488 was hydrogenated in the absence of acid quantitatively yielding 
hydrazine 539; acid was then added to the reaction mixture and re-exposed to an atmosphere 
of hydrogen (Scheme 6-36). TLC analysis indicated full consumption of intermediary hydrazine 
539, so in order to aid product isolation the crude mixture was subjected to amine protection 
separately yielding the N-Boc product 540 and N-tosyl product 541 in good yields. 
 
Scheme 6-36. One-pot reductive cleavage of azo compound 488 followed by subsequent N-
protections.  
With a method established for the conversion of azo compound 488 to sulfonamide 571 
(Scheme 6-36), next the opening of its imidazolidin-2-one was explored (Scheme 6-37). First, 
the reduction of sulfonamide 541 to aminal 542 was attempted, with TLC analysis indicating 
full conversion of starting material (541) to a new species, which was presumed to be the 
desired aminal 542. Attempts to isolate products from the reduction of sulfonamide 541 
curiously only yielded starting material, implying that if aminal 542 had formed it is prone to 
atmospheric oxidation. Next, the crude product of the reduction of sulfonamide 541 to aminal 
542 was immediately exposed to hydrolysis conditions, but instead only sulfonamide 541 was 
again returned. 
 





With the ring-opening/hydrolysis of sulfonamide 541 proving problematic (Scheme 6-37), 
attention was turned to the removal of its para-methoxyphenyl rings. Ceric ammonium 
nitrate is commonly used in the oxidative hydrolysis of N-electron-rich aryls from amides, 
carbamates and ureas.256  Exposure of sulfonamide 541 to ceric ammonium nitrate in an 
aqueous reaction medium yielded imidazolidin-2-one 544 in good yield (Scheme 6-38). 
 
Scheme 6-38. Removal of the para-methoxyphenyl rings of sulfonamide 541. 
With access to imidazolidin-2-one 544 its hydrolytic ring opening was attempted; however, 
the desired triamine (545) could not be identified from the reaction crude despite full 
consumption of starting material (Scheme 6-39). Furthermore, TLC and 1H NMR analysis 
indicated that the tosyl protecting group had been removed.  
 
Scheme 6-39. Attempted hydrolysis of imidazolidin-2-one 544. 
Conditions for the reductive cleavage followed by tosyl protection of azo compound 488 
were tested on carbamate 511, yielding the sulfonamide 547 in moderate yield. 
 








Finally, the oxazolidin-2-one of sulfonamide 547 was opened by basic hydrolysis affording the 
1,2,3-diamino alcohol 548 in excellent yield (Scheme 6-41).   
 


























6.5 Mechanistic Investigation 
With the synthetic utility established for this newly developed aryl diazonium salt 463 
promoted azo-cycloamination of allyl ureas and allyl carbamates, attention was directed 
towards mechanistic understanding. As previously stated (Scheme 6-14), a preliminary 
mechanism based on a radical chain process was proposed (Scheme 6-42), which begins with 
sodium dibutyl phosphate (490) facilitated decomposition of aryl diazonium salt 463 forming 
aryl radical 549. The aryl radical 549 hydrogen atom-abstracts the N-H of an allyl carbamate 
or allyl urea (481) generating amidyl radical (483), which rapidly undergoes cycloamination 
forming C-centred radical 484 that adds to aryl diazonium salt 463 yielding radical cation 485. 
Propagation of the radical-chain by electron transfer from an allyl carbamate or allyl urea 
(481) to radical cation 485 may be feasible by assistance from sodium dibutyl phosphate (490) 
through oxidative-PCET, reforming amidyl radical (483) and producing azo compound 486. 
 
Scheme 6-42. Azo-cycloamination of allyl carbamates and allyl ureas by a radical chain 





A TEMPO radical trapping experiment was performed to test for the presence of aryl radical 
549 in the azo-cycloamination of allyl urea 479 with aryl diazonium salt 463 (Scheme 6-43). 
For Scheme 6-43, no azo compound 488, TEMPO-aryl radical adduct 551, or any other obvious 
TEMPO adducts were observed; instead, only the starting allyl urea (479), which may imply 
either an electron transfer mode of TEMPO reaction inhibition or very small quantities of 
initiator are generated.  
 
Scheme 6-43. Attempted azo-cycloamination of allyl urea 479 in the presence of TEMPO. 
A second radical trapping experiment was performed using 1,1-diphenylethylene (338),167 as 
it is resistant to electron transfer. The azo-cycloamination of allyl carbamate 474 with aryl 
diazonium salt 463 in the presence of styrene 338 gave diminished levels of azo compound 
511 formation, while forming the triaryl olefin 552 (Scheme 6-44).   
 
Scheme 6-44. Azo-cycloamination of allyl carbamate 474 in the presence of styrene 338. 














The formation of triaryl olefin 552 from styrene 338 under azo-cycloamination conditions is 
intriguing and presumably proceeds by aryl diazonium salt 463 decomposition to aryl radical 
549 (Scheme 6-45). Aryl diazonium salt 463 decomposition could potentially occur in two 
ways: 1) A Gomberg−Bachmann-type sequence occurs, where adventitious traces of water 
present in sodium phosphate 490 and aryl diazonium salt 463 lead to the formation of 
oxybis(diazene) 553, which decomposes to molecular nitrogen, aryl radical 549 and azoxy 
radical 554.244,257 2) Sodium phosphate 490 directly attacks aryl diazonium salt 463 forming 
compound 555, which decomposes to molecular nitrogen, aryl radical 549 and O-centred 
radical 556. Aryl radical 549 adds to styrene 338 forming benzhydryl radical 557 (E1/2ox = 0.27 
V vs SCE, for Ph2C•Me),258 which may be directly oxidised to carbocation 558 by electron 
transfer to aryl diazonium salt 463 reforming aryl radical 549 and so propagate a radical chain. 
Carbocation 558 then undergoes elimination to form triaryl olefin 552. Alternatively, azoxy 
radical 554 or O-centred radical 556 could oxidise benzhydryl radical 557 to form carbocation 
558, or hydrogen atom abstract a C-H adjacent to the benzhydryl radical of 557 to directly 
form triaryl olefin 552. Regardless of the precise mechanism for triaryl olefin 552 formation 
in Scheme 6-44, it does confirm that aryl radical 549 is formed under azo-cycloamination 
conditions and is implicated in azo compound product generation as formation of azo 
compound 511 was attenuated.  
 




An investigation into how the reduction of proposed radical cationic intermediate 485 may 
occur was carried out using cyclic voltammetry. Initial cyclic voltammetry studies used a set-
up consisting of a glassy carbon working electrode, a platinum mesh counter electrode, and 
a silver wire reference electrode. Firstly, the redox window of DMSO was established to be 
between –1.0 V and 1.0 V versus the ferrocenium couple (Figure 6-1). 
 
Figure 6-1. Cyclic voltammogram of DMSO. 
Next, sodium dibutyl phosphate (490) was found to be redox inactive within the redox 
window of DMSO (Figure 6-2). 
 





Aryl diazonium salts exhibit low reduction potentials (PhN2BF4: E1/2red = ‒0.06 V vs SCE),242 this 
being true as well for aryl diazonium salt 463, which demonstrates an irreversible half-wave 
reduction at –0.72 V versus the ferrocenium couple (Figure 6-3). Little change was found upon 
the addition of sodium dibutyl phosphate (490). 
 
Figure 6-3. Cyclic voltammograms of aryl diazonium salt 463 (Blue) and in the presence of 


















Cyclic voltammetry analysis of allyl urea 479 gives an irreversible half-wave oxidation at 0.57 
V vs (Fc/Fc+), addition of sodium dibutyl phosphate (490) moves the oxidation half-wave to 
0.43 V vs (Fc/Fc+) (Figure 6-4). This decrease in allyl urea 479 oxidation potential by the 
introduction of a hydrogen-bonding base (490) is indicative of PCET. It is feasible that the 
oxidation wave of allyl urea 479 originates from the oxidation of the para-methoxyphenyl of 
the tertiary amidyl, however the effect exhibited by the sodium dibutyl phosphate (490) 
implies that it is the para-methoxy phenyl of the secondary amidyl that is undergoing 
oxidation. Also, alkyl olefins demonstrate large oxidation potentials (E1/2ox = 1.98 V vs SCE, for 
amylene),230 so the prenyl of allyl urea 479 is unlikely to result in this oxidation wave of Figure 
6-4. As the oxidation wave of allyl urea 479 and the reduction wave of aryl diazonium salt 463 
do not intersect in the absence or presence of sodium dibutyl phosphate (490), electron 
transfer between the two is unlikely (Figure 6-3 and Figure 6-4). 
 
Figure 6-4. Cyclic voltammograms of allyl urea 479 (Blue) and in the presence of sodium 
















Finally for initial cyclic voltammetry studies, analysis of azo compound 488 was performed, 
giving an irreversible oxidation half-wave at 0.67 V, which decreased by 0.1 V upon addition 
of sodium dibutyl phosphate (490) (Figure 6-5). The observed oxidation wave presumably 
originates from oxidation of the para-methoxyphenyl rings rather than the azo bond. 
However, all observable oxidation waves of azo compound 488 are at higher potential than 
the oxidation wave of the secondary amidyl of allyl urea 479 in the presence of sodium dibutyl 
phosphate (490) (Figure 6-4 and Figure 6-5). This may show a thermodynamic driver for the 
proposed oxidative-PCET of allyl urea (481) by radical cation 485. 
 
Figure 6-5. Cyclic voltammograms of allyl urea 488 (Blue), and in the presence of sodium 

















Follow up cyclic voltammetry studies were performed to further clarify the structural motifs 
of the analytes undergoing electron transfer, by using a glassy carbon working electrode, a 
platinum wire counter electrode, and a Ag/AgNO3 reference electrode. Firstly, allyl 
carbamates 457, 474 and 510 were analysed by cyclic voltammetry. Allyl carbamate 474 
demonstrates an irreversible oxidation half-wave at 0.71 V vs (Fc/Fc+), which is shifted to 0.53 
V vs (Fc/Fc+) upon addition of sodium dibutyl phosphate (490) (Figure 6-6). 
 
Figure 6-6. Cyclic voltammograms of allyl carbamate 474 (Blue) and in the presence of sodium 
dibutyl phosphate (490, 4 eq.) (Orange). 
Next, no oxidation wave was founded within the redox window of DMSO for allyl carbamate 
457 (Figure 6-7). However, in the presence of sodium dibutyl phosphate (490) an irreversible 
oxidation half-wave at 0.75 V vs (Fc/Fc+) was observed. 
 
Figure 6-7. Cyclic voltammograms of allyl carbamate 457 (Blue) and in the presence of sodium 










Lastly, allyl carbamate 510 showed no oxidation wave within the redox window of DMSO, but 
part of an oxidation half-wave was founded at 0.96 V vs (Fc/Fc+) upon addition of sodium 
dibutyl phosphate (490) (Figure 6-8). Figure 6-6, Figure 6-7 and Figure 6-8 indicate an increase 
in oxidation potential from allyl carbamates 474 to 457 to 510, confirming the observed 
oxidation waves stem from oxidation of the N-aryl. 
 
Figure 6-8. Cyclic voltammograms of allyl carbamate 510 (Blue) and in the presence of sodium 
dibutyl phosphate (490, 4 eq.) (Orange). 
Following on, azo-cycloamination products 464, 511 and 513 were analysed by cyclic 
voltammetry. A partial oxidation wave at 1.04 V vs (Fc/Fc+) was observed for azo compound 
511, which did not move upon addition of sodium dibutyl phosphate (Figure 6-9). 
 
Figure 6-9. Cyclic voltammograms of azo compound 511 (Blue) and in the presence of sodium 








Next, no oxidation wave was founded within the redox window of DMSO for azo compound 
464, even in the presence of sodium dibutyl phosphate (490) (Figure 6-10). 
 
Figure 6-10. Cyclic voltammograms of azo compound 464 (Blue) and in the presence of 
sodium dibutyl phosphate (490, 4 eq.) (Orange). 
Finally, like azo compound 464, azo compound 513 also did not show an oxidation wave 
within the redox window of DMSO, even upon addition of sodium dibutyl phosphate (490) 
(Figure 6-11).  
 
Figure 6-11. Cyclic voltammograms of azo compound 513 (Blue) and in the presence of 






Figure 6-9, Figure 6-10 and Figure 6-11 show that the oxidation waves observed in Figure 6-5 
and Figure 6-9 for azo compounds 488 and 511 are derived from oxidation of the para-
methoxyphenyl rings and not the azo bond. Unfortunately, due to the limited redox window 
of DMSO, the oxidation potential for the azo bond of the azo-cycloamination products could 
not be determined, but by consulting literature they are likely to be large (ca. >1.5 V vs SCE).230 
As such, only speculative evidence for the electron transfer of an allyl urea or allyl carbamate 
(481) to radical cation intermediate (485) can be given, other than it appears possible that 
intermediate 485 could perform an intramolecular oxidation of its para-methoxyphenyl ring 
or oxidise the para-methoxyphenyl rings of the starting allyl urea or allyl carbamate (481). 
This allows three possible routes for the reduction of radical cation intermediate 485 to azo-
cycloamination product (486): 
1) Scheme 6-42 is correct and direct electron transfer between allyl urea or allyl carbamate 
(481) in a hydrogen bond complex and radical cation 485 occurs (Scheme 6-46). However, this 
would not explain why allyl carbamates 457 and 510 gave low yields in their respective azo-
cycloaminations (Scheme 6-18) when examining Figure 6-7 and Figure 6-8. Unless the para-
methoxyphenyl ring enhances polarity-matching of the hydrogen-atom abstraction from aryl 
radical 549. 
 
Scheme 6-46. Reduction of radical cation 485 by direct oxidation of allyl urea or allyl 













2) Intramolecular electron transfer from the para-methoxyphenyl ring to the azo radical 
cation of intermediate 485 occurs forming the new radical cation 559 (Scheme 6-47), which 
then through outer-sphere electron transfer oxidises allyl urea or allyl carbamate in a 
hydrogen bond complex (481). This may explain why allyl carbamates 457 and 510 performed 
poorly in their respective azo-cycloaminations (Scheme 6-18), as it is not clear whether the 
respective N-phenyl or N-para-trifluoromethylphenyl rings are oxidisable by radical cation 
intermediate 485 (Figure 6-10 and Figure 6-11). 
 
Scheme 6-47. Reduction of radical cation 485 by intramolecular electron transfer, then 
oxidation of hydrogen-bond complex 481. 
3) Lastly, radical cation intermediate 485 could be reduced by DMSO solvent forming DMSO 
radical cation, which facilitates the oxidation of allyl urea or allyl carbamate in a hydrogen 
bond complex (481) (Scheme 6-48). However like case 1, without invoking enhanced polarity-
matching in the initiating N-H hydrogen-atom abstraction from aryl radical 549, this 
mechanism does not explain why allyl carbamates 457 and 510 should perform so poorly in 
their respective azo-cycloaminations (Scheme 6-18). 
 







A new method has been discovered for the synthesis of 2-oxazolidone and imidazolidone 
containing azo compounds, by azo-cycloamination of allyl ureas and carbamates. This has 
been achieved by use of the dual reactivity of aryl diazonium salts to act as a source of aryl 
radicals for oxidative HAT of amidyl N-H and as an electrophilic radical acceptor. It has been 
found that the electronics of the N-aryl undergoing cyclisation and aryl diazonium salt are 
important in governing whether the reaction is promoted or hindered by light or PRC. 
The photocatalyst-free variant of this azo-cycloamination has been applied to a variety of allyl 
carbamates and allyl ureas (Scheme 6-49). Limitations of this protocol have been identified, 
in that only tertiary C-centred alkyl radicals have been found to be efficient in aryl diazonium 
addition.231 A protocol has been developed for the reductive cleavage of the azo-
cycloamination products to their protected primary amine analogues plus other 
deprotections. 
 
Scheme 6-49. Azo-cycloamination of ureas and carbamates. 
Finally, radical trapping experiments were used to give evidence for the existence of a radical 
chain mechanism that is initiated by the decomposition of the aryl diazonium salt to an aryl 
radical, that then hydrogen atom abstracts the amidyl N-H to form amidyl radical. Propagation 
of the radical chain was investigated by CV and is proposed to occur by oxidative PCET from 
the urea or carbamate starting material, facilitated by the phosphate hydrogen bonding-













7. Future Work 
 
The contents of this thesis has demonstrated that N-aryl vinyl ureas are competent 
electrophilic radical acceptors that when used in a reductive quenching photoredox cycle 
result in Truce-Smiles rearrangement, and that aryl diazonium salts initiate and propagate the 
homolytic activation of amidyl N-H bonds. In principle, this work could be further developed 
in a variety of manners to establish new synthetic tools. Firstly like the Truce-Smiles 
rearrangement of -metalated ureas, Clayden and co-workers have also shown that -
metalated carbamates and thiocarbamates undergo N to C aryl migration in the context of 
direct C-H lithiation259 and carbolithiation of a vinyl group.260 It is conceivable that conditions 
for the 4CzIPN (91)-catalysed alkyl-arylation of vinyl ureas could be applied to vinyl 
carbamates and vinyl thiocarbamates (559), for the respective preparation of -tertiary 
carbamates and -tertiary thiocarbamates (560) (Scheme 7-1). Subsequently allowing access 
to -tertiary alcohols and -tertiary thiols (561) by hydrolysis. 
 
Scheme 7-1. Photoredox-catalysed alkylation-arylation of vinyl carbamates and vinyl 
thiocarbamates (559). 
Despite the negative result of Scheme 3-24, implying that 4CzIPN (91)-catalysed 
trifluoromethyl-arylation is incompatible with amino acid-derived vinyl ureas, Scheme 2-35 
and other reports by Clayden and co-workers show that such substrates are amenable to 
Truce-Smiles rearrangement under base-conditions.147,149 By applying Seebach’s concept of 
Self-Regeneration of Stereocentres to the preparation of vinyl ureas, imidazolidine-4-one 563 
can be formed from serine (562) (Scheme 7-2). 261  Performing the 4CzIPN (91)-catalysed 
radical addition followed by Truce-Smiles rearrangement of vinyl urea 563  to form -tertiary 
urea 564 may be possible, as the resulting anion is amide-stabilised and so more nucleophilic 
than the intermediary ester-stabilised anion formed in Scheme 3-24. -Tertiary urea 564 
could then be converted into enantiopure quaternary amino acids (565). 
 
Scheme 7-2. 4CzIPN (91)-catalysed radical addition-arylation of vinyl urea 563 for enantiopure 




The concept of photoredox-mediated radical addition to vinyl urea, followed by subsequent 
reduction of the resulting intermediary ureido benzyl radical (198) to an -metalated urea 
(200) for Truce-Smiles arylation, could be extended to electrochemical-mediation. Use of 
electrochemistry for radical generation then subsequent -metalated urea (200) formation 
by cathodic reduction would allow for reducible radical precursors to be used, potentially 
opening the scope of compatible radicals-partners (Scheme 7-3). This electrochemical 
approach would require the reduction potential of the radical precursor and the subsequently 
formed radical to be more negative than the reduction potential of the intermediary ureido 
benzyl radical (198). 
 
Scheme 7-3. Electrochemically-mediated radical addition followed by Truce-Smiles 
rearrangement of vinyl urea 205 forming -tertiary urea (565). 
For the azo-cycloamination of allyl ureas a method still needs to be identified for the 
hydrolytic ring-opening of the imidazolidin-2-one of the resulting products after 
hydrogenation and PMP removal (566), to allow this method to access vicinal triamines. So 
far, attempts at the opening of the imidazolidin-2-one ring have been unsuccessful (Scheme 
6-37 and Scheme 6-39). However, another potential method could be tosylation of the 
imidazolidin-2-one ring of 566 forming 567, which would be more prone to basic hydrolysis 
to yield vicinal triamine 568 (Scheme 7-4). 
 












It would be noteworthy if this aryl diazonium salt 463 promoted azo-cycloamination of allyl 
carbamates could be developed into an intermolecular three-component reaction                        
(Scheme 7-5). This approach could be achieved by homolytic activation of N-PMP carbamate 
(569), with the resulting amidyl radical then adding to a 1,1-disubstituted alkene (570) 
forming tertiary C-centered radical that would add to aryl diazonium salt 463, giving a simple 
method for the diamination of 1,1-disubstituted alkenes (571). 
 






















Finally, methods for the homolytic activation of amidyl N-H bonds in the presence of C-H 
bonds are contiually sought. In the proposed radical-chain for the azo-cycloamination of allyl 
ureas and carbamates, aryl diazonium salt 463 plays a key role in initiation and propagation. 
It may be possible to decouple the dual function of aryl diazonium salt 463 and render it as 
only an initiator by introducing a distinct radical acceptor (Scheme 7-6). For example, based-
mediated decomposition of aryl diazonium salt 463 yields aryl radical 549, which hydrogen 
atom abstracts the N-H of an allyl urea or carbamate (481) forming amidyl radical 483. 
Cycloamination of amidyl radical 483 forms C-centred radical 484, which could add to a 
different radical acceptor to aryl diazonium salt 463, such as iminium 572 forming radical 
cation 573. Radical cation 573 may be able to oxidise an allyl urea or carbamate (481) with 
assistance from a hydrogen-bonding base by PCET, forming 1,2,4-triamine 574 and amidyl 
radical 483. 
 
Scheme 7-6. Aryl diazonium salt 463 initiated and iminium 572 propagated alkyl-





































8.1 General Information 
8.1.1 Solvents, Reagents and Starting Materials 
 
Reactions requiring anhydrous conditions (where specified) were performed under dry 
nitrogen atmosphere in glassware that was dried using a combination of vacuum and heat-
gun. Air- and moisture-sensitive liquids and solutions were transferred by syringe or cannula 
into the reaction vessels through rubber septa. Reactions run in a microwave oven were 
completed on a Biotage Initiator+. Reaction mixtures were stirred magnetically. Room 
temperature denotes a temperature range of 19-21 °C. 
All reagents were purchased (unless specified) at highest commercial quality and used as 
received. Non-anhydrous solvents were purchased (unless specified) at the highest 
commercial quality and used as received. Anhydrous THF, DCM, Et2O and MeCN were purified 
by filtration over a column of activated alumina (A-2). Anhydrous DMF was purchased from 
Sigma-Aldrich and anhydrous acetone was purchased from Acros Organics. DMSO was 
distilled from CaH2 and stored under nitrogen in a Young’s tube. Langlois reagent (134) was 
purchased from Apollo Scientific and Sigma-Aldrich. Sodium difluoromethanesulfinate was 
purchased from J&K Scientific. Sodium 1,1-difluoroethane-1-sulfinate, sodium 2-(4-
bromophenyl)-1,1-difluoroethane-1-sulfinate, sodium 2-(3-bromophenyl)-1,1-
difluoroethane-1-sulfinate, sodium 2-(2-bromophenyl)-1,1-difluoroethane-1-sulfinate, 
sodium 7-chloro-1,1-difluoroheptane-1-sulfinate, sodium 7-azido-1,1-difluoroheptane-1-
sulfinate and sodium 1,1-difluoro-4-(2-methyl-1,3-dioxolan-2-yl)butane-1-sulfinate were all 
purchased from Sigma-Aldrich as a part of their DiversinatesTM catalogue. Diphenylphosphine 
oxide, di(naphthalen-2-yl)phosphine oxide and bis(3,5-dimethylphenyl)phosphine oxide were 
all purchased from FluoroChem. For quantum yield experiments, commercially available 
potassium ferrioxalate trihydrate (Alfa Aesar) was used for actinometry. Caesium carbonate 














8.1.2 Analytical Directions 
 
Chromatography: Flash chromatography was performed on an automated Biotage IsoleraTM 
Spektra Four using gradient elution on pre-packed silica gel Biotage® SNAP Ultra or Biotage® 
Sfär columns. THF used in chromatography was distilled before use to remove BHT inhibitor. 
M.p.: Melting points were measured on a Scientific SMP10 melting point apparatus and are 
uncorrected. 
IR: IR spectra were recorded on either neat or films of neat compounds deposited as a 
solution in DCM, using a Perkin Elmer (Spectrum One) FT-IR spectrometer. Only strong and 
selected absorbance’s (νmax expressed in cm−1) are reported. 
1H NMR: Spectra were recorded on Bruker Avance (400 MHz or 500 MHz). Chemical shifts (δΗ) 
are quoted in parts per million (ppm) downfield to trimethylsilane and are referenced to the 
appropriate NMR solvent peak(s). Assignment follow the denotation of ArCH, CH, CHAHB 
(diastereotopic protons), CH2, CH3, OH and NH. Coupling constants (J) are reported to the 
nearest 0.1 Hz. The splitting patterns for spectra assignments are abbreviated to singlet (s), 
doublet (d), triplet (t), quartet (q), quintet (qn), hextet (h), septet (sep.), multiplet (m), broad 
(br.) and combination of these.  2-D NMR experiments COSY, HSQC and HMBC were used 
where necessary in assigning NMR spectra. 
13C NMR: Spectra were recorded on Bruker Avance (101 MHz or 126 MHz). Chemical shifts 
(δC) are quoted in parts per million (ppm) and referenced to the appropriate solvent peak(s) 
and are assigned Cquat, CH, CH2, CH3, CF3, CF2 and ArCX as determined using 2-D NMR 
experiments HSQC and HMBC where necessary. Coupling constants (J) are reported to the 
nearest 0.1 Hz. The splitting patterns for spectra assignments are abbreviated to singlet (s), 
doublet (d), triplet (t), quartet (q), quintet (qn), hextet (h), septet (sep.), multiplet (m), broad 
(br.) and combination of these. 
19F NMR: Spectra were recorded on Bruker Avance (376 MHz) instruments. Chemical shifts 
(δF) are quoted in parts per million (ppm) and referenced to α, α, α-trifluorotoluene internal 
standard. Coupling constants (J) are reported to the nearest 0.1 Hz. The splitting patterns for 
spectra assignments are abbreviated to singlet (s), doublet (d), triplet (t), quartet (q), quintet 
(qn), hextet (h), septet (sep.), multiplet (m), broad (br.) and combination of these. 
31P NMR: Spectra were recorded on Bruker Avance (162 MHz) instruments. Chemical shifts 
(δP) are quoted in parts per million (ppm). 
HRMS: High resolution mass spectra were recorded on a Bruker Daltronics MicrOTOF 2 mass 
spectrometer (ESI). 
Cyclic Voltammetry (CV): CV measurements were performed at room temperature using a 
PalmSens4 or a CH Instruments 600E potentiostat.  All working electrodes were polished 
before each experiment. Before each CV, the solution was stirred for approximately 2 




UV/Vis Spectrometry: Absorption spectra were measured using an Agilent Technologies Cary 
Series UV-Vis Spectrophotometer. Quartz cuvettes of a path length of 1 cm were used. 
Fluorescence Spectrometry: Fluorometry was performed on a PerkinElmer LS-45 




8.1.3 Photochemical Equipment and Setup 
 
Blue LEDs used were LED Strip Light MINGER 16.4ft(5m) RGB SMD 5050 LED Rope Lighting 
Colour Changing Full Kit with 44-Keys IR Remote Controller LED Lighting Strips for Kitchen 
Christmas Decoration (controller was used to set lights to highest blue light intensity). The 
LEDs required 12 V direct current and were powered by a 2 A power supply resulting in a 
power output of 24 watts. The LEDs were wrapped around the interior of a glass beaker 
(diameter: 9 cm, height: 16 cm), with the exterior of the glass beaker wrapped in aluminium 
foil. During photochemical reactions, the heat generated from the LED strips resulted in a 
reaction temperature of 30 °C. 
Photo reaction set-up:   
Photoreaction mixtures were contained in a 10 mL Biotage® Initiator+ microwave vials sealed 
with a rubber septum that was wrapped with Parafilm, and placed upon the interior wall of 
the photoreactor (Figure 8-1). The photoreactor could accommodate a maximum of four 
microwave vials. 
 









8.2 Chapter 1 Experimental 
8.2.1 General Procedures 
 
General Procedure 1 (GP1): Synthesis of vinyl ureas by imine formation.  
 
A 20 mL microwave vial was charged with methylamine (5 mL, 40.0 mmol, 8 M in EtOH, 4.0 
eq.) and acetophenone derivative (10.0 mmol, 1.0 eq.). The microwave vial was sealed and 
the contents were heated to 125 °C by microwave irradiation and stirred for 1.25 hours. After 
which, the reaction mixture was concentrated under reduced pressure to give crude imine 
that was used without further purification.  
A flame-dried Schlenk tube was sequentially charged with nitrogen, crude imine, anhydrous 
THF (33 mL, 0.3 M) and aryl isocyanate (10.0 mmol, 1 eq.). The resulting reaction mixture was 
stirred for a defined amount of time at room temperature. After which, the reaction mixture 
was cooled to 0 °C and 60% sodium hydride dispersed in mineral oil (800 mg, 20.0 mmol,            
2.0 eq.) was added portion-wise. The reaction mixture was stirred at 0 °C for 30 minutes, then 
methyl iodide (1.25 mL, 20.0 mmol, 2.0 eq.) was added. The reaction mixture was warmed to 
room temperature and allowed to stir for a defined amount of time, after which the reaction 
was quenched with water (80 mL) and extracted with ethyl acetate (3 x 50 mL). The combined 
organic extracts were dried (Na2SO4), concentrated under reduced pressure and purified by 
flash column chromatography to give the desired vinyl urea.  
Note: Yield of vinyl urea synthesis is sensitive to quality of aryl isocyanate, therefore it is 












General Procedure 2 (GP2): 4CzIPN catalysed alkylation-arylation of vinyl ureas. 
 
A flame-dried 10 mL microwave vial was charged with starting vinyl urea (0.2 mmol, 1.0 eq.), 
caesium carbonate (98 mg, 0.3 mmol, 1.5 eq.), 4CzIPN (91) (8 mg, 0.01 mmol, 0.05 eq.) and 
sodium sulfinate radical precursor, then flushed with nitrogen. Anhydrous solvent (0.1 M 
either DMF, MeCN or acetone) was added, the reaction mixture was stirred and degassed for 
10 minutes by sparging with nitrogen. The reaction vessel was exposed to 24 W blue LED 
irradiation and allowed to stir (600 rpm) for a defined amount of time at 30 °C. The reaction 
was quenched with water (5 mL) and extracted with ethyl acetate (3 x 4 mL). The combined 
organic extracts were concentrated under reduced pressure, then purified by flash column 
chromatography (SiO2, 0% to 80% Et2O in n-pentane) to obtain the desired product. 
Note: Langlois reagent (134) is hygroscopic, if significant amounts of 
hydrotrifluoromethylation over trifluoromethyl-arylation is observed a new sample of 
Langlois reagent with a water content below 1% by Karl Fischer titration should be used. 
General Procedure 3 (GP3): 4CzIPN mediated arylphosphonylation of vinyl ureas. 
 
A flame-dried 10 mL microwave vial was charged with 1-(4-chlorophenyl)-3-(1-(4-
iodophenyl)vinyl)-1,3-dimethylurea (249) (43 mg, 0.1 mmol, 1.0 eq.), caesium carbonate (59 
mg, 0.18 mmol, 1.8 eq.), 4CzIPN (91) (0.8 mg, 1 mol, 0.01 eq.) and diarylphosphine oxide 
derivative, then flushed with nitrogen. Anhydrous acetonitrile (1 mL) was added, the reaction 
mixture was stirred and degassed for 10 minutes by sparging with nitrogen. The reaction 
vessel was exposed to 24 W blue LED irradiation and allowed to stir (600 rpm) for a defined 
amount of time at 30 °C. The reaction was quenched with water (5 mL) and extracted with 
ethyl acetate (3 x 4 mL). The combined organic extracts were concentrated under reduced 









General Procedure 4 (GP4): Solvolysis of -tertiary ureas. 
 
A flame-dried 10 mL microwave vial was charged with -tertiary urea starting material and   
n-butanol (1 mL per 10 mg of starting material used). The reaction mixture was briefly 
exposed to reduced pressure then nitrogen three times. The reaction vessel was sealed and 
stirred for 16 hours at 122 °C. The reaction mixture was cooled to room temperature and 
concentrated under reduced pressure to give crude material, which was purified by flash 























8.2.2 Synthetic Procedures 
 
4CzIPN - 2,4,5,6-Tetra(9H-carbazol-9-yl)isophthalonitrile (91) 
 
To a flame-dried Schlenk tube, carbazole (202) (1.67 g, 10.0 mmol) was added under a 
nitrogen atmosphere followed by anhydrous THF (40 mL), the solution was cooled to 0 °C. 
60% Sodium hydride dispersed in mineral oil (600 mg, 15.0 mmol) was added portion-wise to 
the Schlenk tube. The reaction mixture was warmed to room temperature and allowed to stir 
for 30 minutes. 2,4,5,6-Tetrafluoroisophthalonitrile (105) (400 mg, 2.0 mmol) was added to 
the Schlenk tube and the contents were stirred for 24 hours at room temperature. The 
reaction mixture was quenched with water (5 mL) then concentrated under reduced pressure 
to yield an orange solid as crude product, which was purified by sequentially washing with 
water (2 x 50 mL), ethanol (2 x 50 mL) and diethyl ether (2 x 50 mL), yielding the title 
compound (861 mg, 55%) a yellow solid. 
1H NMR (400MHz, DMSO-d6) δ 8.35 (2 H, d, J 7.8, 2 x ArCH), 8.19 (2 H, d, J 8.3, 2 x ArCH), 7.86 
(4 H, d, J 7.5, 4 x ArCH), 7.77-7.72 (6 H, m, 6 x ArCH), 7.54 (2 H, d, J 8.3, 2 x ArCH), 7.51-7.44 
(4 H, m, 4 x ArCH), 7.17-7.07 (8 H, m, 8 x ArCH), 6.81 (2 H, t, J 7.7, 2 x ArCH), 6.70 (2 H, t, J 7.7, 















3DPAFIPN - 2,4,6-Tris(diphenylamino)-5-fluoroisophthalonitrile (106) 
 
To a flame-dried Schlenk tube diphenyl amine (1.69 g, 10.0 mmol) was added under a nitrogen 
atmosphere followed by anhydrous THF (40 mL), the mixture was cooled to 0 °C. A solution 
of n-butyllithium in THF (6.24 mL, 1.6 M, 10.0 mmol) was slowly added to the Schlenk tube. 
The reaction mixture was warmed to room temperature and allowed to stir for 40 minutes. A 
solution of 2,4,5,6-tetrafluoroisophthalonitrile (105) (400 mg, 2.0 mmol) dissolved in 
anhydrous THF (8 mL) was added slowly to the Schlenk tube, the contents were heated to     
60 °C and stirred for 48 hours. The reaction mixture was quenched with water (5 mL) then 
concentrated under reduced pressure to yield an orange solid as crude product, which was 
purified by sequentially washing with water (2 x 50 mL), ethanol (2 x 50 mL) and diethyl ether 
(2 x 50 mL), yielding the title compound (1.16 g, 90%) a yellow solid. 
1H NMR (400MHz, CDCl3) δ 7.28-7.22 (12 H, m, 12 x ArCH), 7.08-7.02 (6 H, m, 6 x ArCH), 7.02-
6.96 (12 H, m, 12 x ArCH). 19F NMR (377 MHz, CDCl3) δ –121.2 (1 F, s, ArCF). Data in good 
agreement with literature.97a 
1,3-Dimethyl-3-phenyl-1-(1-phenylvinyl)urea (205) 
 
Formation of the title compound was carried out by following GP1 with acetophenone (81) 
(1.16 mL, 1.20 g, 10.0 mmol) and phenyl isocyanate (204) (1.09 mL, 1.19 g, 10.0 mmol) used 
as starting materials. The imine intermediate was stirred with the requisite aryl isocyanate for 
28 hours, subsequent methylation with methyl iodide was stirred for 24 hours. The resulting 
crude material was purified by flash column chromatography (SiO2, 0 to 15% THF in 40-60 
petroleum ether) yielding the title compound (0.595 g, 22%) as a pale-yellow oil. 
IR (film, cm-1) νmax = 2936, 1655, 1354, 693. 1H NMR (400 MHz, CDCl3) δ 7.27-7.24 (3 H, m,      
3 x ArCH), 7.21-7.16 (2 H, m, 2 x ArCH), 7.13-7.08 (2 H, m, 2 x ArCH), 7.07-7.02 (1 H, m, ArCH), 
6.82-6.76 (2 H, m, 2 x ArCH), 4.84 (1 H, d, J 0.6, CHaHb), 4.58 (1 H, d, J 0.6, CHaHb), 3.23 (3 H, s, 
CH3), 2.98 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 160.9 (CO), 150.3 (Cquat), 145.0 (Cquat), 
138.3 (Cquat), 128.7 (2 x ArCH), 128.4 (ArCH), 128.1 (2 x ArCH), 125.9 (2 x ArCH), 125.3 (2 x 
ArCH), 124.8 (ArCH), 107.0 (CH2), 39.5 (CH3), 38.6 (CH3). HRMS m/z (ESI+) m/z calcd for 







Formation of the title compound was carried out by following GP2 with 1,3-dimethyl-3-
phenyl-1-(1-phenylvinyl)urea (205) (53 mg, 0.2 mmol) and sodium trifluoromethanesulfinate 
(134) (92 mg, 3.0 eq., 0.6 mmol) used as starting materials and DMF used as solvent, but with 
the omission of caesium carbonate. The reaction mixture was stirred for 17 hours. The 
resulting crude material was purified by flash column chromatography (SiO2, 0% to 15% 
acetone in n-pentane) yielding the title compound (39 mg, 58%) as a colourless film. 
IR (film, cm-1) νmax = 2953, 1657, 1379, 1116. 1H NMR (400 MHz, CDCl3) δ 7.42-7.34 (4 H, m, 2 
x ArCH + 2 x ArCH), 7.33-7.28 (1 H, m, ArCH), 7.20 (1 H, ddd, J 8.3, 7.3, 1.5, ArCH), 6.86 (1 H, 
dd, J 8.3, 1.1, ArCH), 6.80 (1 H, ddd, J 7.3, 6.5, 1.1, ArCH), 6.54 (1 H, dd, J 7.3, 1.5, ArCH), 3.44 
(3 H, s, NCH3), 3.28-3.16 (1 H, m, CHaHb), 3.08-2.96 (1 H, m, CHaHb), 2.68 (3 H, s, NCH3). 13C 
NMR (101 MHz, CDCl3) δ 153.2 (CO), 145.6 (Cquat), 138.0 (Cquat), 129.0 (2 x ArCH), 128.8 (ArCH), 
128.3 (ArCH), 128.1 (ArCH), 126.7 (2 x ArCH), 125.9 (CF3, q, JCF 278.9), 124.2 (Cquat), 121.7 
(ArCH), 112.9 (ArCH), 64.4 (Cquat, q, JCF 2.0), 40.7 (CH2, q, JCF 25.9), 31.7 (NCH3), 30.3 (NCH3). 
19F NMR (377 MHz, CDCl3) δ –61.7 (3 F, t, J 10.0, CF3). HRMS m/z (ESI+) m/z calcd for 
C18H18F3N2O+ [M+H]+ 335.1366; found 335.1359. 
1,3-Dimethyl-1-(3,3,3-trifluoro-1,1-diphenylpropyl)urea (207) 
 
Formation of the title compound was carried out by following GP2 with 1,3-dimethyl-3-
phenyl-1-(1-phenylvinyl)urea (205) (53 mg, 0.2 mmol) and sodium trifluoromethanesulfinate 
(134) (92 mg, 3.0 eq., 0.6 mmol) used as starting materials and DMF used as solvent. The 
reaction mixture was stirred for 17 hours to give the title compound (48 mg, 71%) as a white 
solid. 
M.p. 158-161 °C (Et2O).  IR (film, cm-1) νmax 3364, 2945, 1639, 1259, 1117. 1H NMR (400 MHz, 
CDCl3) δ 7.30 (4 H, dd, J 8.1, 1.6, 4 x ArCH), 7.26 (4 H, dd, J 8.1, 7.1, 4 x ArCH), 7.14 (2 H, tt,         
J 7.1, 1.6, 2 x ArCH), 4.58 (1 H, br. q, J 4.7, NH), 3.96 (2 H, q, J 11.0, CH2), 2.79 (3 H, s, CH3), 
2.77 (3 H, d, J 4.7, CH3). 13C NMR (101 MHz, CDCl3) δ 159.7 (CO), 144.4 (2 x Cquat), 128.3                
(4 x ArCH), 126.8 (2 x ArCH), 126.6 (4 x ArCH), 126.5 (CF3, q, JCF 278.0), 68.4 (Cquat, q, JCF 2.4), 
38.8 (CH2, q, JCF 26.9), 36.6 (CH3), 27.7 (CH3). 19F NMR (377 MHz, CDCl3) δ –58.3 (3 F, t, J 11.0, 







Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and 1-chloro-4-
isocyanatobenzene (210) (1.54 g, 10.0 mmol) used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 21 hours, subsequent 
methylation with methyl iodide was stirred for 18 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 1% to 20% acetone + 3% triethylamine in 40-
60 petroleum ether) yielding the title compound (750 mg, 22%) as a white solid. 
M.p. 69-72 °C (Et2O). IR (film, cm-1) νmax = 2939, 1662, 1491, 1351, 1093, 834. 1H NMR (400 
MHz, CDCl3) δ 7.24 (2 H, d, J 8.7, 2 x ArCH), 7.16 (2 H, d, J 8.8, 2 x ArCH), 7.02 (2 H, d, J 8.7,        
2 x ArCH), 6.70 (2 H, d, J 8.8, 2 x ArCH), 4.86 (1 H, d, J 0.9, CHaHb), 4.61 (1 H, d, J 0.9, CHaHb), 
3.24 (3 H, s, CH3), 2.95 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 160.3 (CO), 149.2 (Cquat), 
143.4 (Cquat), 136.7 (Cquat), 134.4 (ArCCl), 130.3 (ArCCl), 128.9 (2 x ArCH), 128.5 (2 x ArCH), 
127.1 (2 x ArCH), 126.4 (2 x ArCH), 107.9 (CH2), 39.6 (CH3), 38.6 (CH3). HRMS m/z (ESI+) m/z 
calcd for C17H17N2OCl2+ [M+H]+ 335.0712; found 335.0727. 
1-(4-Chlorophenyl)-1,3-dimethylurea (212) 
 
Formation of the title compound was carried out by following GP2 with 1-(4-chlorophenyl)-3-
(1-(4- chlorophenyl) vinyl)-1,3-dimethylurea (211) (65 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (92 mg, 3.0 eq., 0.6 mmol) used as starting materials and 
acetonitrile used as solvent, but with the omission of caesium carbonate. The reaction 
mixture was stirred for 15 hours to give the title compound (24 mg, 61%) as a white solid. 
M.p. 94-97 °C (Et2O). IR (film, cm-1) νmax = 3355, 2949, 1652, 1525, 1492. 1H NMR (400 MHz, 
CDCl3) δ 7.38 (2 H, d, J 8.7, 2 x ArCH), 7.18 (2 H, d, J 8.7, 2 x ArCH), 4.22 (1 H, br. s, NH), 3.24 
(3 H, s, NCH3), 2.74 (3 H, d, J 4.7, NCH3). 13C NMR (101 MHz, CDCl3) δ 157.8 (CO), 142.2 (Cquat), 
133.0 (ArCCl), 130.3 (2 x ArCH), 128.9 (2 x ArCH), 37.4 (NCH3), 27.7 (NCH3). HRMS m/z (ESI+) 










Formation of the title compound was carried out by following GP2 with 1-(4-chlorophenyl)-3-
(1-(4-chlorophenyl)vinyl)-1,3-dimethylurea (211) (65 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (46 mg, 1.5 eq., 0.3 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 17 hours to give the title 
compound (71 mg, 88%) as a pale-yellow solid. 
M.p. 176-179 °C (Et2O). IR (film, cm-1) νmax = 3365, 2958, 1642, 1258, 1105. 1H NMR (400 MHz, 
CDCl3) δ 7.24 (4 H, d, J 8.9, 4 x ArCH), 7.20 (4 H, d, J 8.9, 4 x ArCH), 4.63 (1 H, br. q, J 4.2, NH), 
3.90 (2 H, q, J 10.9, CH2), 2.84-2.70 (6 H, m, 2 x CH3). 13C NMR (101 MHz, CDCl3) δ 159.5 (CO), 
142.7 (2 x Cquat), 132.9 (2 x ArCCl), 128.7 (4 x ArCH), 127.8 (4 x ArCH), 126.2 (CF3, q, JCF 278.1), 
67.8 (Cquat, q, JCF 2.0), 38.4 (CH2, q, JCF 27.4), 36.5 (NCH3), 27.7 (NCH3). 19F NMR (377 MHz, 
CDCl3) δ –58.5 (3 F, t, J 10.9, CF3). HRMS m/z (ESI+) m/z calcd for C18H17N2OCl2F3Na+ [M+Na]+ 
427.0562; found 427.0561. 
1-(4-Fluorophenyl)-1,3-dimethyl-3-(1-phenylvinyl)urea (218) 
 
Formation of the title compound was carried out by following GP1 with acetophenone (81)        
(1.16 mL, 1.20 g, 10.0 mmol) and 1-fluoro-4-isocyanatobenzene (1.14 mL, 1.37 g, 10.0 mmol) 
used as starting materials. The imine intermediate was stirred with the requisite aryl 
isocyanate for 69 hours, subsequent methylation with methyl iodide was stirred for 25 hours. 
The resulting crude material was purified by flash column chromatography (SiO2, 1% to 20% 
acetone + 3% trimethylamine in 40-60 petroleum ether) yielding the title compound (1.49 g, 
52%) as a pale-yellow oil. 
IR (film, cm-1) νmax = 3060, 1657, 1508, 1354, 1218, 777. 1H NMR (400 MHz, CDCl3) δ 7.30-7.26 
(3 H, m, 3 x ArCH), 7.16-7.10 (2 H, m, 2 x ArCH), 6.89 (2 H, dd, J 9.1, 8.3, 2 x ArCH), 6.76 (2 H, 
dd, J 9.1, 4.9, 2 x ArCH), 4.92 (1 H, d, J 0.7, CHaHb), 4.62 (1 H, d, J 0.7, CHaHb), 3.23 (3 H, s, CH3), 
2.98 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 160.8 (CO), 160.1 (ArCF, d, JCF 244.7), 150.3 
(Cquat), 141.1 (Cquat, d, JCF 2.9), 138.0 (Cquat), 128.6 (ArCH), 128.2 (2 x ArCH), 127.2 (2 x ArCH, d, 
JCF 8.5), 125.8 (2 x ArCH), 115.5 (2 x ArCH, d, JCF 22.7), 107.3 (CH2), 39.6 (CH3), 39.0 (CH3). 19F 
NMR (377 MHz, CDCl3) δ –117.2-–117.4 (1 F, m, ArCF). HRMS m/z (ESI+) m/z calcd for 







Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol)  and 1-fluoro-3-
isocyanatobenzene (1.14 mL, 1.37 g, 10.0 mmol) used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 18 hours, subsequent 
methylation with methyl iodide was stirred for 27 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 1% to 20% acetone + 3% trimethylamine in 
40-60 petroleum ether) yielding the title compound (1.23 g, 39%) as a pale-yellow oil, which 
solidified over time to give a white solid. 
M.p. 43-45 °C (Et2O). IR (film, cm-1) νmax = 3069, 1662, 1610, 1490, 1354, 1327, 837. 1H NMR 
(400 MHz, CDCl3) δ 7.23 (2 H, d, J 8.9, 2 x ArCH), 7.13 (1 H, dt, J 8.2, 6.5, ArCH), 7.03 (2 H, d, J 
8.9, 2 x ArCH), 6.74 (1 H, tdd, J 8.2, 2.3, 0.9, ArCH), 6.56 (1 H, ddd, J 8.2, 2.3, 0.9, ArCH), 6.48 
(1 H, dt, J 10.4, 2.3, ArCH), 4.84 (1 H, d, J 1.0, CHaHb), 4.63 (1 H, d, J 1.0, CHaHb), 3.24 (3 H, s, 
CH3), 2.95 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 162.8 (ArCF, d, JCF 256.6), 160.2 (CO), 
149.1 (Cquat), 146.3 (Cquat, d, JCF 10.0), 136.7 (Cquat), 134.3 (ArCCl), 129.7 (ArCH, d, JCF 9.2), 128.4 
(2 x ArCH), 127.0 (2 x ArCH), 120.4 (ArCH, d, JCF 2.9), 112.1 (ArCH, d, JCF 23.3), 111.5 (ArCH, d, 
JCF 21.1), 107.8 (CH2), 39.5 (CH3), 38.3 (CH3). 19F NMR (377 MHz, CDCl3) δ –112.3-–112.5 (1 F, 



















Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and 1-fluoro-2-
isocyanatobenzene (1.12 mL, 1.37 g, 10.0 mmol)  used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 20 hours, subsequent 
methylation with methyl iodide was stirred for 25 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 1% to 20% acetone + 3% trimethylamine in 
40-60 petroleum ether), followed by additional purification by flash column chromatography 
(SiO2, 0% to 10% Et2O in DCM), yielding the title compound (339 mg, 11%) as a colourless oil. 
IR (film, cm-1) νmax = 1659, 1503, 1353, 1327, 1094, 758. 1H NMR (400 MHz, CDCl3) δ 7.20         
(2 H, d, J 8.4, 2 x ArCH), 7.09-7.02 (3 H, m, ArCH + 2 x ArCH), 6.98-6.91 (2 H, m, ArCH + ArCH), 
6.83 (1 H, t, J 7.7, ArCH), 4.94 (1 H, s, CHaHb), 4.75 (1 H, s, CHaHb), 3.12 (3 H, s, CH3), 3.06 (3 H, 
s, CH3). 13C NMR (101 MHz, CDCl3) δ 160.8 (CO), 157.7 (ArCF, d, JCF 249.9), 148.8 (Cquat), 135.5 
(Cquat), 134.3 (ArCCl), 132.4 (Cquat, d, JCF 11.6), 129.0 (ArCH, d, JCF 1.4), 128.4 (2 x ArCH), 127.6 
(ArCH, d, JCF 7.9), 127.2 (2 x ArCH), 124.3 (ArCH, d, JCF 3.6), 116.4 (ArCH, d, JCF 20.3), 107.5 
(CH2), 39.0 (NCH3), 38.6 (NCH3). 19F NMR (377 MHz, CDCl3) δ –120.8-–121.0 (1 F, m, ArCF). 



















Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and 1-bromo-4-
isocyanatobenzene (245) (1.98 g, 10.0 mmol) used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 24 hours, subsequent 
methylation with methyl iodide was stirred for 20 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 5% to 30% Et2O in 40-60 petroleum ether) 
yielding the title compound (980 mg, 26%) as a pale-yellow solid. 
M.p. 86-89 °C (Et2O). IR (film, cm-1) νmax = 2938, 1659, 1488, 1349, 1327. 1H NMR (400 MHz, 
CDCl3) δ 7.31 (2 H, d, J 8.6, 2 x ArCH), 7.24 (2 H, d, J 8.5, 2 x ArCH), 7.02 (2 H, d, J 8.5, 2 x ArCH), 
6.64 (2 H, d, J 8.6, 2 x ArCH), 4.86 (1 H, s, CHaHb), 4.61 (1 H, s, CHaHb), 3.25 (3 H, s, CH3), 2.94 
(3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 160.2 (CO), 149.2 (Cquat), 143.9 (Cquat), 136.8 (Cquat), 
134.4 (ArCCl), 131.8 (2 x ArCH), 128.5 (2 x ArCH), 127.0 (2 x ArCH), 126.7 (2 x ArCH), 118.0 
(ArCBr), 108.0 (CH2), 39.6 (NCH3), 38.5 (NCH3). HRMS m/z (ESI+) m/z calcd for C17H17N2OBrCl+ 





















Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and 1-isocyanato-3-
methoxybenzene (1.31 mL, 1.49 g, 10.0 mmol) used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 17 hours, subsequent 
methylation with methyl iodide was stirred for 26 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 1% to 20% acetone + 3% trimethylamine in 
40-60 petroleum ether) yielding the title compound (1.29 g, 39%) as a yellow oil. 
IR (film, cm-1) νmax = 2943, 1659, 1596, 1489, 1353, 836. 1H NMR (400 MHz, CDCl3) δ 7.21        
(2 H, d, J 8.7, 2 x ArCH), 7.08 (1 H, t, J 8.2, ArCH), 7.04 (2 H, d, J 8.7, 2 x ArCH), 6.59 (1 H, ddd, 
J 8.2, 2.4, 0.8, ArCH), 6.39 (1 H, ddd, J 8.2, 2.4, 0.8, ArCH), 6.30 (1 H, t, J 2.4, ArCH), 4.84 (1 H, 
d, J 0.7, CHaHb), 4.61 (1 H, d, J 0.7, CHaHb), 3.72 (3 H, s, OCH3), 3.20 (3 H, s, CH3), 2.98 (3 H, s, 
CH3). 13C NMR (101 MHz, CDCl3) δ 160.6 (CO), 159.9 (ArCO), 149.3 (Cquat), 146.0 (Cquat), 136.8 
(Cquat), 134.1 (ArCCl), 129.4 (ArCH), 128.3 (2 x ArCH), 127.2 (2 x ArCH), 117.9 (ArCH), 111.6 
(ArCH), 110.4 (ArCH), 107.5 (CH2), 55.4 (OCH3), 39.4 (CH3), 38.8 (CH3). HRMS m/z (ESI+) m/z 




















Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and 1-isocyanato-3-
methylbenzene (1.29 mL, 1.33 g, 10.0 mmol) used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 24 hours, subsequent 
methylation with methyl iodide was stirred for 20 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 5% to 40% Et2O in 40-60 petroleum ether), 
followed by additional purification by flash column chromatography (SiO2, 0% to 10% Et2O in 
DCM), yielding the title compound (1.04 g, 33%) as a pale-yellow oil. 
IR (film, cm-1) νmax = 2918, 1657, 1605, 1353, 1327. 1H NMR (400 MHz, CDCl3) δ 7.22 (2 H, d, J 
8.5, 2 x ArCH), 7.07 (1 H, t, J 7.7, ArCH), 7.02 (2 H, d, J 8.5, 2 x ArCH), 6.86 (1 H, d, J 7.7, ArCH), 
6.61 (1 H, d, J 7.7, ArCH), 6.56 (1 H, br. s, ArCH), 4.81 (1 H, s, CHaHb), 4.59 (1 H, s, CHaHb), 3.19 
(3 H, s, CH3), 3.01 (3 H, s, CH3), 2.25 (3 H, s, ArCCH3). 13C NMR (101 MHz, CDCl3) δ 160.7 (CO), 
149.3 (Cquat), 144.7 (Cquat), 138.4 (Cquat), 136.8 (Cquat), 134.1 (ArCCl), 128.6 (ArCH), 128.2               
(2 x ArCH), 127.2 (2 x ArCH), 126.3 (ArCH), 125.8 (ArCH), 122.6 (ArCH), 107.2 (CH2), 39.3 
(NCH3), 38.9 (NCH3), 21.4 (ArCCH3). HRMS m/z (ESI+) m/z calcd for C18H20N2OCl+ [M+H]+ 



















Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and 1-isocyanato-4-
(trifluoromethyl)benzene (1.34 mL, 1.87 g, 10.0 mmol) used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 72 hours, subsequent 
methylation with methyl iodide was stirred for 24 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 1% to 20% acetone + 3% trimethylamine in 
40-60 petroleum ether) yielding the title compound (1.24 g, 34%) as a white solid. 
M.p. 54-56 °C (Et2O). IR (film, cm-1) νmax = 1666, 1612, 1321, 1109, 834. 1H NMR (400 MHz, 
CDCl3) δ 7.44 (2 H, br. d, J 8.5, 2 x ArCH), 7.24 (2 H, d, J 8.6, 2 x ArCH), 6.99 (2 H, d, J 8.6, 2 x 
ArCH), 6.84 (2 H, br. d, J 8.5, 2 x ArCH), 4.85 (1 H, d, J 1.0, CHaHb), 4.61 (1 H, d, J 1.0, CHaHb), 
3.29 (3 H, s, CH3), 2.95 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 160.1 (CO), 149.1 (Cquat), 
147.7 (Cquat, q, JCF 1.2), 136.8 (Cquat), 134.5 (ArCCl), 128.5 (2 x ArCH), 126.9 (2 x ArCH), 126.2 
(Cquat, q, JCF 32.8), 125.9 (2 x ArCH, q, JCF 3.8), 124.2 (CF3, q, JCF 271.9), 124.1 (2 x ArCH), 108.2 
(CH2), 39.6 (CH3), 37.9 (CH3). 19F NMR (377 MHz, CDCl3) δ –62.0 (3 F, s, CF3). HRMS m/z (ESI+) 




















Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and 1-isocyanato-3,5-
bis(trifluoromethyl)benzene (1.73 mL, 2.55 g, 10.0 mmol) used as starting materials. The 
imine intermediate was stirred with the requisite aryl isocyanate for 72 hours, subsequent 
methylation with methyl iodide was stirred for 24 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 1% to 20% acetone + 3% trimethylamine in 
40-60 petroleum ether) yielding the title compound (423 mg, 10%) as a white solid. 
M.p. 95-97 °C (Et2O). IR (film, cm-1) νmax = 1669, 1381, 1278, 1126. 1H NMR (400 MHz, CDCl3) 
δ 7.53 (1 H, br. s, ArCH), 7.24 (2 H, d, J 8.7, 2 x ArCH), 7.13 (2 H, br. s, 2 x ArCH), 6.91 (2 H, d, J 
8.7, 2 x ArCH), 4.85 (1 H, s, CHaHb), 4.64 (1 H, s, CHaHb), 3.35 (3 H, s, CH3), 2.99 (3 H, s, CH3). 
13C NMR (101 MHz, CDCl3) δ 159.3 (CO), 149.1 (Cquat), 145.7 (Cquat), 136.5 (Cquat), 135.0 (ArCCl), 
132.1 (2 x Cquat, q, JCF 33.4), 128.8 (2 x ArCH), 126.7 (2 x ArCH), 124.2 (2 x ArCH, q, JCF 3.4), 
132.1 (2 x CF3, q, JCF 273.0), 117.4 (ArCH, sep., JCF 3.9), 108.4 (CH2), 40.0 (CH3), 37.8 (CH3). 19F 
NMR (377 MHz, CDCl3) δ –63.1 (6 F, s, 2 x CF3). HRMS m/z (ESI+) m/z calcd for 

















Ethyl 4-(3-(1-(4-chlorophenyl)vinyl)-1,3-dimethylureido)benzoate (226) 
 
Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and ethyl 4-isocyanatobenzoate 
(1.91 g, 10.0 mmol) used as starting materials. The imine intermediate was stirred with the 
requisite aryl isocyanate for 72 hours, subsequent methylation with methyl iodide was stirred 
for 24 hours. The resulting crude material was purified by flash column chromatography (SiO2, 
0% to 30% THF in 40-60 petroleum ether), yielding the title compound (443 mg, 12%) as a 
white solid. 
M.p. 49-52 °C (Et2O). IR (film, cm-1) νmax = 2981, 1712, 1665, 1604, 1274. 1H NMR (400 MHz, 
CDCl3) δ 7.88 (2 H, d, J 8.7, 2 x ArCH), 7.24 (2 H, d, J 8.7, 2 x ArCH), 6.98 (2 H, d, J 8.6, 2 x ArCH), 
6.76 (2 H, d, J 8.7, 2 x ArCH), 4.78 (1 H, d, J 0.7, CHaCHb), 4.61 (1 H, d, J 0.7, CHaCHb), 4.36 (2 H, 
q, J 7.1, OCH2), 3.33 (3 H, s, CH3), 2.92 (3 H, s, CH3), 1.40 (3 H, t, J 7.1, CH3). 13C NMR (101 MHz, 
CDCl3) δ 166.3 (CO), 160.0 (CO), 149.0 (Cquat), 148.6 (Cquat), 137.1 (Cquat), 134.4 (ArCCl), 130.3 
(2 x ArCH), 128.5 (2 x ArCH), 126.9 (2 x ArCH), 125.8 (Cquat), 123.2 (2 x ArCH), 108.1 (CH2), 61.0 
(OCH2), 39.6 (NCH3), 37.6 (NCH3), 14.5 (CH3). HRMS m/z (ESI+) m/z calcd for C20H22N2O3Cl+ 




















Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and 1-naphthyl isocyanate (1.44 
mL, 1.69 g, 10.0 mmol) used as starting materials. The imine intermediate was stirred with 
the requisite aryl isocyanate for 25 hours, after which additional 1-naphthyl isocyanate (0.72 
mL, 0.85 g, 5.0 mmol) was added followed by 21 hours of stirring, then the reaction mixture 
was concentrated under reduced pressure and the received crude material was purified by 
flash column chromatography (SiO2, 0% to 25% MTBE in 40-60 petroleum ether) yielding 
crude material (505 mg) as a yellow oil. Subsequent methylation with methyl iodide was 
carried out on a 1.5 mmol scale (by making as if the received crude material was pure) and 
was stirred for 16 hours. The resulting crude material was purified by flash column 
chromatography (SiO2, 0% to 25% MTBE in 40-60 petroleum ether) yielding the title 
compound (347 mg, 10% over three steps) as an orange oil. 
IR (film, cm-1) νmax = 2971, 1652, 1354, 1093, 775. 1H NMR (400 MHz, CDCl3) δ 7.80-7.76 (1 H, 
m, ArCH), 7.60-7.56 (2 H, m, 2 x ArCH), 7.49-7.40 (2 H, m, 2 x ArCH), 7.21 (1 H, dd, J 7.4, 0.6, 
ArCH), 7.03 (2 H, d, J 8.7, 2 x ArCH), 6.98 (1 H, dd, J 7.2, 1.0, ArCH), 6.68 (2 H, d, J 8.7, 2 x ArCH), 
4.77 (1 H, s, CHaHb), 4.47 (1 H, s, CHaHb), 3.28 (3 H, s, NCH3), 3.02 (3 H, s, NCH3). 13C NMR (101 
MHz, CDCl3) δ 161.9 (CO), 148.8 (Cquat), 141.2 (Cquat), 135.0 (Cquat), 134.5 (Cquat), 133.9 (Cquat), 
130.3 (ArCCl), 128.5 (ArCH), 128.2 (2 x ArCH), 127.2 (ArCH), 126.9 (2 x ArCH), 126.5 (ArCH), 
126.1 (ArCH), 125.9 (ArCH), 125.5 (ArCH), 122.8 (ArCH), 108.9 (CH2), 40.1 (NCH3), 39.3 (NCH3). 

















Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and 4-methoxyphenyl 
isocyanate (473) (1.29 mL, 1.49 g, 10.0 mmol) used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 21 hours, then concentrated 
under reduced pressure and the received crude material was purified by flash column 
chromatography (SiO2, 0% to 60% Et2O in 40-60 petroleum ether) yielding crude material 
(1.24 g) as a yellow oil. Subsequent methylation with methyl iodide was carried out on a 3.9 
mmol scale (by making as if the received crude material was pure) and was stirred for 16 
hours. The resulting crude material was purified by flash column chromatography (SiO2, 0% 
to 30% acetone in 40-60 petroleum ether) yielding the title compound (944 mg, 29% over 
three steps) as a pale-yellow oil. 
IR (film, cm-1) νmax = 2948, 1655, 1510, 1356, 1246. 1H NMR (400 MHz, CDCl3) δ 7.22 (2 H, d, J 
8.9, 2 x ArCH), 7.05 (2 H, d, J 8.9, 2 x ArCH), 6.75-6.70 (4 H, m, 4 x ArCH), 4.86 (1 H, d, J 0.8, 
CHaHb), 4.61 (1 H, d, J 0.8, CHaHb), 3.76 (3 H, s, OCH3), 3.17 (3 H, s, NCH3), 3.00 (3 H, s, NCH3). 
13C NMR (101 MHz, CDCl3) δ 161.0 (CO), 157.2 (ArCO), 149.4 (Cquat), 138.0 (Cquat), 136.6 (Cquat), 
134.1 (ArCCl), 128.3 (2 x ArCH), 127.3 (2 x ArCH), 127.2 (2 x ArCH), 114.0 (2 x ArCH), 107.4 
(CH2), 55.6 (OCH3), 39.4 (NCH3), 39.4 (NCH3). HRMS m/z (ESI+) m/z calcd for C18H19N2O2ClNa+ 


















Formation of the title compound was carried out by following GP2 with 1-(4-fluorophenyl)-
1,3-dimethyl-3-(1-phenylvinyl)urea (218) (57 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (61 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetone used as solvent. The reaction mixture was stirred for 23 hours to give the title 
compound (53 mg, 74%) as a pale-yellow solid. 
M.p. 191-194 °C (Et2O). IR (film, cm-1) νmax = 3362, 1640, 1509, 1259, 1122. 1H NMR (400 MHz, 
CDCl3) δ 7.32-7.25 (6 H, m, 6 x ArCH), 7.23-7.15 (1 H, m, ArCH), 6.96 (2 H, t, J 8.6, 2 x ArCH), 
4.60 (1 H, br. q, J 4.1, NH), 3.96 (2 H, q, J 10.9, CH2), 2.86-2.75 (6 H, m, 2 x CH3). 13C NMR (101 
MHz, CDCl3) δ 161.3 (ArCF, d, JCF 246.6), 159.7 (CO), 143.9 (Cquat), 140.5 (Cquat, d, JCF 3.2), 128.4 
(2 x ArCH), 128.2 (2 x ArCH, d, JCF 7.9), 127.0 (ArCH), 126.8 (2 x ArCH), 126.4 (CF3, q, JCF 279.1), 
115.1 (2 x ArCH, d, JCF 21.5), 68.1 (Cquat, q, JCF 2.3), 39.1 (CH2, q, JCF 27.0), 36.5 (CH3, q, JCF 1.8), 
27.7 (CH3). 19F NMR (377 MHz, CDCl3) δ –58.4 (3 F, t, J 10.9, CF3), –116.0-–116.2 (1 F, m, ArCF). 
HRMS m/z (ESI+) m/z calcd for C18H19N2OF4+ [M+H]+ 355.1428; found 355.1425. 
1-(1-(4-Chlorophenyl)-3,3,3-trifluoro-1-(3-fluorophenyl)propyl)-1,3-dimethylurea (232) 
 
Formation of the title compound was carried out by following GP2 with 1-(1-(4-
chlorophenyl)vinyl)-3-(3-fluorophenyl)-1,3-dimethylurea (219) (64 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (46 mg, 1.5 eq., 0.3 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 24 hours to give the title 
compound (65 mg, 84%) as a pale-yellow solid. 
M.p. 145-147 °C (Et2O). IR (film, cm-1) νmax = 3371, 2926, 1645, 1530, 1488, 1258, 1105. 1H 
NMR (400 MHz, CDCl3) δ 7.26-7.23 (4 H, m, 2 x ArCH + 2 x ArCH), 7.23-7.19 (1 H, m, ArCH), 
7.04 (1 H, d, J 8.2, ArCH), 6.98 (1 H, dt, J 10.8, 2.0, ArCH), 6.86 (1 H, td, J 8.2, 2.0, ArCH), 4.62 
(1 H, br. q, J 4.2, NH), 3.98-3.83 (2 H, m, CH2), 2.85-2.75 (6 H, m, 2 x CH3). 13C NMR (101 MHz, 
CDCl3) δ 162.8 (ArCF, d, JCF 244.2), 159.5 (CO), 147.1 (Cquat), 142.5 (Cquat), 132.9 (ArCCl), 130.0 
(ArCH, d, JCF 8.2), 128. 7 (2 x ArCH), 127.9 (2 x ArCH), 126.1 (CF3, q, JCF 276.1), 121.9 (ArCH, d, 
JCF 2.9), 114.1 (ArCH), 113.7 (ArCH, d, JCF 24.3), 67.9 (Cquat), 38.3 (CH2, q, JCF 27.0), 36.5 (NCH3, 
q, JCF 2.3), 27.8 (NCH3). 19F NMR (377 MHz, CDCl3) δ –58.5 (3 F, t, J 10.9, CF3), –111.9-–112.1 







Formation of the title compound was carried out by following GP2 with 1-(1-(4-
chlorophenyl)vinyl)-3-(2-fluorophenyl)-1,3-dimethylurea (220) (64 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetone used as solvent. The reaction mixture was stirred for 18 hours to give the title 
compound (64 mg, 82%) as a white solid. 
M.p. 166-169 °C (Et2O). IR (film, cm-1) νmax = 3363, 2958, 1642, 1484, 1258, 1105. 1H NMR 
(400 MHz, CDCl3) δ 7.34-7.20 (6 H, m, 2 x ArCH + 2 x ArCH + ArCH + ArCH), 7.12 (1 H, t, J 7.5, 
ArCH), 6.95 (1 H, dd, J 12.7, 7.5, ArCH), 4.63 (1 H, br. s, NH), 4.16-3.96 (2 H, m, CH2), 2.84 (3 H, 
s, CH3), 2.81 (3 H, d, J 4.4, CH3). 13C NMR (101 MHz, CDCl3) δ 159.7 (ArCF, d, JCF 248.3), 159.2 
(CO), 140.8 (Cquat), 133.0 (ArCCl), 130.9 (Cquat, d, JCF 10.1), 129.7 (ArCH, d, JCF 9.3), 128.7 (2 x 
ArCH), 128.2 (2 x ArCH), 128.2 (ArCH), 126.2 (CF3, q, JCF 278.4), 124.1 (ArCH, d, JCF 3.1), 116.9 
(ArCH, d, JCF 24.4), 67.1 (Cquat, q, JCF 2.6), 38.6 (CH2, q, JCF 27.3), 35.4 (NCH3), 27.7 (NCH3). 19F 
NMR (377 MHz, CDCl3) δ –58.5 (3 F, t, J 10.8, CF3), –107.7 (1 F, s, ArCF). HRMS m/z (ESI+) m/z 
calcd for C18H18N2OClF4+ [M+H]+ 389.1038; found 389.1032. 
1-(1-(4-Bromophenyl)-1-(4-chlorophenyl)-3,3,3-trifluoropropyl)-1,3-dimethylurea (234) 
 
Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(4-chlorophenyl)vinyl)-1,3-dimethylurea (221) (76 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (47 mg, 1.5 eq., 0.3 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 18 hours to give the title 
compound (76 mg, 84%) as a white solid. 
M.p. 184-187 °C (Et2O). IR (film, cm-1) νmax = 3369, 2971, 1646, 1258, 1105. 1H NMR (400 MHz, 
CDCl3) δ 7.39 (2 H, d, J 8.6, 2 x ArCH), 7.24 (2 H, d, J 9.0, 2 x ArCH), 7.20 (2 H, d, J 9.0, 2 x ArCH), 
7.14 (2 H, d, J 8.6, 2 x ArCH), 4.61 (1 H, br. s, NH), 3.90 (2 H, q, J 10.8, CH2), 2.82-2.77 (6 H, m, 
2 x CH3). 13C NMR (101 MHz, CDCl3) δ 159.5 (CO), 143.4 (Cquat), 142.6 (Cquat), 132.9 (ArCCl), 
131.6 (2 x ArCH), 128.7 (2 x ArCH), 128.1 (2 x ArCH), 127.9 (2 x ArCH), 126.2 (CF3, q, JCF 279.7), 
121.0 (ArCBr), 67.8 (Cquat, d, JCF 2.0), 38.3 (CH2, q, JCF 27.4), 36.4 (NCH3, q, JCF 2.0), 27.7 (NCH3). 
19F NMR (377 MHz, CDCl3) δ –58.5 (3 F, t, J 10.8, CF3). HRMS m/z (ESI+) m/z calcd for 








Formation of the title compound was carried out by following GP2 with 1-(1-(4-
chlorophenyl)vinyl)-3-(3-methoxyphenyl)-1,3-dimethylurea (222) (66 mg, 0.2 mmol) and 
sodium trifluoromethanesulfinate (134) (46 mg, 1.5 eq., 0.3 mmol) used as starting materials 
and acetonitrile used as solvent. The reaction mixture was stirred for 23 hours to give the title 
compound (57 mg, 71%) as a pale-yellow solid. 
M.p. 70-73 °C (Et2O). IR (film, cm-1) νmax = 3363, 2945, 1642, 1490, 1256, 1105. 1H NMR (400 
MHz, CDCl3) δ 7.24-7.20 (4 H, m, 4 x ArCH), 7.18 (1 H, t, J 8.1, ArCH), 6.87 (1 H, br. d, J 8.1, 
ArCH), 6.83 (1 H, t, J 1.9, ArCH), 6.70 (1 H, dd, J 8.1, 1.9, ArCH), 4.59 (1 H, br. q, J 4.7, NH), 3.91 
(2 H, q, J 11.0, CH2), 3.75 (3 H, s, OCH3), 2.80 (3 H, s, CH3), 2.79 (3 H, d, J 4.7, CH3). 13C NMR 
(101 MHz, CDCl3) δ 159.6 (CO) 159.5 (ArCO), 145.3 (Cquat), 143.7 (Cquat), 132.5 (ArCCl), 129.4 
(ArCH), 128.5 (2 x ArCH), 127.5 (2 x ArCH), 126.4 (CF3, q, JCF 278.1), 119.2 (ArCH), 114.0 (ArCH), 
111.4 (ArCH), 60.0 (Cquat), 55.4 (OCH3), 38.4 (CH2, q, JCF 27.6), 36.5 (CH3, q, JCF 1.9), 27.8 (CH3). 
19F NMR (377 MHz, CDCl3) δ –58.4 (3 F, t, J 11.0, CF3). HRMS m/z (ESI+) m/z calcd for 





















Formation of the title compound was carried out by following GP2 with 1-(1-(4-
chlorophenyl)vinyl)-1,3-dimethyl-3-(m-tolyl)urea (223) (63 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 19 hours to give the title 
compound (56 mg, 73%) as a white solid. 
M.p. 129-131 °C (Et2O). IR (film, cm-1) νmax = 3360, 2959, 1642, 1258, 1122, 1106. 1H NMR 
(400 MHz, CDCl3) δ 7.23-7.19 (4 H, m, 4 x ArCH), 7.16 (1 H, t, J 7.7, ArCH), 7.09 (1 H, d, J 7.7 
ArCH), 7.06 (1 H, br. s, ArCH), 6.98 (1 H, d, J 7.7 ArCH), 4.58 (1 H, br. s, NH), 3.92 (2 H, dq, J 
11.0, 3.0, CH2), 2.83-2.76 (6 H, m, 2 x CH3), 2.30 (3 H, s, ArCCH3). 13C NMR (101 MHz, CDCl3) δ 
159.6 (CO), 144.0 (Cquat), 143.3 (Cquat), 138.0 (Cquat), 132.3 (ArCCl), 128.4 (2 x ArCH), 128.3 
(ArCH), 127.9 (ArCH), 127.5 (ArCH), 127.5 (2 x ArCH), 126.4 (CF3, q, JCF 279.4), 124.0 (ArCH), 
68.1 (Cquat, q, JCF 2.5), 38.4 (CH2, q, JCF 27.1), 36.5 (NCH3), 27.7 (NCH3), 21.9 (CH3). 19F NMR (377 
MHz, CDCl3) δ –58.4 (3 F, t, J 11.0, CF3). HRMS m/z (ESI+) m/z calcd for C19H21N2OClF3+ [M+H]+ 




Formation of the title compound was carried out by following GP2 with 1-(1-(4-
chlorophenyl)vinyl)-1,3-dimethyl-3-(4-(trifluoromethyl)phenyl)urea (224) (74 mg, 0.2 mmol) 
and sodium trifluoromethanesulfinate (134) (46 mg, 1.5 eq., 0.3 mmol) used as starting 
materials and acetonitrile used as solvent. The reaction mixture was stirred for 19 hours to 
give the title compound (65 mg, 74%) as a white solid. 
M.p. 139-141 °C (Et2O). IR (film, cm-1) νmax = 3361, 1641, 1530, 1326, 1104. 1H NMR (400 MHz, 
CDCl3) δ 7.50 (2 H, d, J 8.4, 2 x ArCH), 7.36 (2 H, d, J 8.4, 2 x ArCH), 7.26-7.21 (4 H, m, 4 x ArCH), 
4.64 (1 H, br. q, J 4.2, NH), 4.03-3.85 (2 H, m, CH2), 2.88-2.76 (6 H, m, 2 x CH3). 13C NMR (101 
MHz, CDCl3) δ 159.5 (CO), 149.0 (Cquat), 141.8 (Cquat), 132.2 (ArCCl), 128.9 (Cquat, q, JCF 32.7) 
128.8 (2 x ArCH), 128.2 (2 x ArCH), 126.2 (CF3, q, JCF 278.5) 126.2 (2 x ArCH), 125.5 (2 x ArCH, 
q, JCF 3.8), 124.0 (ArCCF3, q, JCF 271.8), 68.0 (Cquat, q, JCF 2.1), 38.0 (CH2, q, JCF 27.4), 36.4 (NCH3, 
q, JCF 2.0), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) δ –58.6 (3 F, t, J 10.7, CF3), –62.5 (3 F, s, 







Formation of the title compound was carried out by following GP2 with 1-(3,5-
bis(trifluoromethyl)phenyl)-3-(1-(4-chlorophenyl)vinyl)-1,3-dimethylurea (225) (87 mg, 0.2 
mmol) and sodium trifluoromethanesulfinate (134) (46 mg, 1.5 eq., 0.3 mmol) used as starting 
materials and acetonitrile used as solvent. The reaction mixture was stirred for 19 hours to 
give the title compound (85 mg, 84%) as a white solid. 
M.p. 140-143 °C (Et2O). IR (film, cm-1) νmax = 3365, 1642, 1534, 1360, 1278, 1135. 1H NMR 
(400 MHz, CDCl3) δ 7.66 (1 H, br. s, ArCH), 7.64 (2 H, br. s, 2 x ArCH), 7.30 (2 H, d, J 9.0, 2 x 
ArCH), 7.25 (2 H, d, J 9.0, 2 x ArCH), 4.72 (1 H, br. q, J 4.7, NH), 4.08-3.94 (1 H, m, CHaHb), 3.92-
3.79 (1 H, m, CHaHb), 2.83 (3 H, s, CH3), 2.79 (3 H, d, J 4.7, CH3). 13C NMR (101 MHz, CDCl3) δ 
159.3 (CO), 149.0 (Cquat), 140.0 (Cquat), 133.9 (ArCCl), 131.7 (2 x Cquat, q, JCF 33.4), 129.2 (2 x 
ArCH), 128.6 (2 x ArCH), 126.0 (CF3, q, JCF 278.3), 125.3 (2 x ArCH, q, JCF 3.1), 123.3 (2 x ArCF3, 
q, JCF 272.8), 120.6 (ArCH, sep., JCF 3.7), 67.7 (Cquat), 37.6 (CH2, q, JCF 27.6), 36.3 (NCH3, q, JCF 
2.5), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) δ –58.4 (3 F, t, J 10.5, CF3), –62.7 (6 F, s, 2 x CF3). 


















Ethyl 4-(1-(4-chlorophenyl)-1-(1,3-dimethylureido)-3,3,3-trifluoropropyl)benzoate (239) 
 
Formation of the title compound was carried out by following GP2 with ethyl 4-(3-(1-(4-
chlorophenyl)vinyl)-1,3-dimethylureido)benzoate (226) (77 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (47 mg, 1.5 eq., 0.3 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 15 hours to give the title 
compound (71 mg, 80%) as a white solid. 
M.p. 191-194 °C (Et2O). IR (film, cm-1) νmax = 3369, 2978, 1711, 1643, 1279, 1104. 1H NMR 
(400 MHz, CDCl3) δ 7.93 (2 H, d, J 8.6, 2 x ArCH), 7.34 (2 H, d, J 8.6, 2 x ArCH), 7.25-7.21 (4 H, 
m, 4 x ArCH), 4.64 (1 H, br. q, J 4.7, NH), 4.33 (2 H, q, J 7.1, OCH2), 4.05-3.84 (2 H, m, CH2), 2.82 
(3 H, s, NCH3), 2.80 (3 H, d, J 4.7, NHCH3), 1.35 (3 H, t, J 7.1, CH3). 13C NMR (101 MHz, CDCl3) 
δ 166.1 (CO), 159.5 (CO), 149.6 (Cquat), 142.1 (Cquat), 133.0 (ArCCl), 129.8 (2 x ArCH), 129.0 
(Cquat), 128.7 (2 x ArCH), 128.1 (2 x ArCH), 125.9 (2 x ArCH), 126.2 (CF3, q, JCF 279.4), 68.1 (Cquat, 
q, JCF 2.4), 61.1 (OCH2), 37.8 (CH2, q, JCF 27.1), 36.5 (NCH3, q, JCF 2.7), 27.7 (NCH3), 14.4 (CH3). 
19F NMR (377 MHz, CDCl3) δ –58.6 (3 F, t, J 10.9, CF3). HRMS m/z (ESI+) m/z calcd for 
C21H23N2O3ClF3+ [M+H]+ 443.1344; found 443.1339. 
1-(4-Chlorophenyl)-1,3-dimethyl-3-(1-(p-tolyl)vinyl)urea (243) 
 
Formation of the title compound was carried out by following GP1 with 1-(p-tolyl)ethan-1-
one (1.33 mL, 1.34 g, 10.0 mmol) and 1-chloro-4-isocyanatobenzene (210) (1.54 g, 10.0 mmol) 
used as starting materials. The imine intermediate was stirred with the requisite aryl 
isocyanate for 69 hours, subsequent methylation with methyl iodide was stirred for 26 hours. 
The resulting crude material was purified by flash column chromatography (SiO2, 1% to 20% 
acetone + 3% trimethylamine in 40-60 petroleum ether) yielding the title compound (547 mg, 
17%) as a pale-yellow oil that solidified over time to give a white solid. 
M.p. 46-48 °C (Et2O). IR (film, cm-1) νmax = 2928, 1660, 1491, 1351, 1324, 824. 1H NMR (400 
MHz, CDCl3) δ 7.14 (2 H, d, J 8.8, 2 x ArCH), 7.07 (2 H, br. d, J 8.2, 2 x ArCH), 7.00 (2 H, d, J 8.2, 
2 x ArCH), 6.72 (2 H, d, J 8.8, 2 x ArCH), 4.86 (1 H, s, CHaHb), 4.56 (1 H, s, CHaHb), 3.23 (3 H, s, 
CH3), 2.94 (3 H, s, CH3), 2.34 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 160.6 (CO), 150.1 (Cquat), 
143.6 (Cquat), 138.5 (Cquat), 135.2 (Cquat), 130.0 (ArCCl), 128.9 (2 x ArCH), 128.7 (2 x ArCH), 126.4 
(2 x ArCH), 125.7 (2 x ArCH), 106.8 (CH2), 39.6 (CH3), 38.5 (CH3), 21.3 (CH3). HRMS m/z (ESI+) 






Formation of the title compound was carried out by following GP1 with 1-(4-
(trifluoromethoxy)phenyl)ethan-1-one (1.60 mL, 2.04 g, 10.0 mmol) and 1-chloro-4-
isocyanatobenzene (210) (1.54 g, 10.0 mmol)  used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 21 hours, subsequent 
methylation with methyl iodide was stirred for 24 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 0% to 30% THF in 40-60 petroleum ether), 
yielding the title compound (1.45 g, 38%) as a pale-yellow oil. 
IR (film, cm-1) νmax = 2943, 1660, 1491, 1252, 1215, 1160. 1H NMR (400 MHz, CDCl3) δ 7.16     
(2 H, d, J 8.8, 2 x ArCH), 7.13-7.10 (4 H, m, 2 x ArCH + 2 x ArCH), 6.69 (2 H, d, J 8.8, 2 x ArCH), 
4.89 (1 H, s, CHaHb), 4.65 (1 H, s, CHaHb), 3.24 (3 H, s, NCH3), 2.95 (3 H, s, NCH3). 13C NMR (101 
MHz, CDCl3) δ 160.3 (CO), 149.3 (ArCO, q, JCF 2.0), 149.0 (Cquat), 143.3 (Cquat), 136.8 (Cquat), 
130.4 (ArCCl), 128.9 (2 x ArCH), 127.2 (2 x ArCH), 126.4 (2 x ArCH), 120.7 (2 x ArCH), 120.6 
(CF3, q, JCF 257.2), 108.1 (CH2), 39.5 (NCH3), 38.6 (NCH3). 19F NMR (377 MHz, CDCl3) δ –57.7   





















Formation of the title compound was carried out by following GP1 with 1-(3,4-
dichlorophenyl)ethan-1-one (1.89 g, 10.0 mmol) and 1-bromo-4-isocyanatobenzene (242) 
(1.98 g, 10.0 mmol) used as starting materials. The imine intermediate was stirred with the 
requisite aryl isocyanate for 71 hours, subsequent methylation with methyl iodide was stirred 
for 20 hours. The resulting crude material was purified by flash column chromatography (SiO2, 
0% to 30% THF in 40-60 petroleum ether), yielding the title compound (1.94 g, 47%) as pale-
yellow solid. 
M.p. 139-141 °C (Et2O). IR (film, cm-1) νmax = 2940, 1660, 1488, 1352, 1324. 1H NMR (400 MHz, 
CDCl3) δ 7.37-7.29 (3 H, m, 2 x ArCH + ArCH), 7.10 (1 H, d, J 1.9, ArCH), 6.94 (1 H, dd, J 8.3, 1.9, 
ArCH), 6.67 (2 H, d, J 8.7, 2 x ArCH), 4.90 (1 H, s, CHaHb), 4.68 (1 H, s, CHaHb), 3.20 (3 H, s, 
NCH3), 2.98 (3 H, s, NCH3). 13C NMR (101 MHz, CDCl3) δ 160.2 (CO), 148.3 (Cquat), 143.8 (Cquat), 
138.2 (Cquat), 132.5 (ArCCl), 132.4 (ArCCl), 131.9 (2 x ArCH), 130.2 (ArCH), 127.7 (ArCH), 126.8 
(2 x ArCH), 124.9 (ArCH), 118.4 (ArCBr), 108.7 (CH2), 39.3 (NCH3), 38.6 (NCH3). HRMS m/z (ESI+) 





















Formation of the title compound was carried out by following GP1 with 1-(3-
chlorophenyl)ethan-1-one (1.30 mL, 1.55 g, 10.0 mmol) and 1-bromo-4-isocyanatobenzene 
(242) (1.98 g, 10.0 mmol) used as starting materials. The imine intermediate was stirred with 
the requisite aryl isocyanate for 25 hours, subsequent methylation with methyl iodide was 
stirred for 18 hours. The resulting crude material was purified by flash column 
chromatography (SiO2, 0% to 20% THF in 40-60 petroleum ether), followed by additional 
purification by flash column chromatography (neutral Al2O3, 100% CHCl3), yielding the title 
compound (122 mg, 3%) as a colourless oil. 
IR (film, cm-1) νmax = 2941, 1659, 1487, 1351, 1324. 1H NMR (400 MHz, CDCl3) δ 7.32 (2  H, d, 
J 8.8, 2 x ArCH), 7.26-7.23 (1 H, m, ArCH), 7.20 (1 H, t, J 7.6, ArCH), 7.02 (1 H, t, J 1.4, ArCH), 
7.00 (1 H, dt, J 7.6, 1.4, ArCH), 6.66 (2 H, d, J 8.8, 2 x ArCH), 4.91 (1 H, d, J 0.7, CHaHb), 4.68 (1 
H, d, J 0.7, CHaHb), 3.22 (3 H, s, CH3), 2.96 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 160.3 
(CO), 149.1 (Cquat), 143.9 (Cquat), 140.0 (Cquat), 134.3 (ArCCl), 131.9 (2 x ArCH), 129.5 (ArCH), 
128.6 (ArCH), 126.7 (2 x ArCH), 126.1 (ArCH), 123.8 (ArCH), 118.1 (ArCBr), 108.4 (CH2), 39.4 




















Formation of the title compound was carried out by following GP1 with 1-(4-
methoxyphenyl)ethan-1-one (1.50 g, 10.0 mmol) and 1-bromo-4-isocyanatobenzene (242) 
(1.98 g, 10.0 mmol) used as starting materials. The imine intermediate was stirred with the 
requisite aryl isocyanate for 25 hours, subsequent methylation with methyl iodide was stirred 
for 17 hours. The resulting crude material was purified by flash column chromatography (SiO2, 
0% to 15% THF in 40-60 petroleum ether), yielding the title compound (213 mg, 6%) as a 
colourless oil. 
IR (film, cm-1) νmax = 2954, 1659, 1488, 1250. 1H NMR (400 MHz, CDCl3) δ 7.29 (2 H, d, J 8.7,   
2 x ArCH), 7.03 (2 H, d, J 8.9, 2 x ArCH), 6.79 (2 H, d, J 8.7, 2 x ArCH), 6.67 (2 H, d, J 8.9, 2 x 
ArCH), 4.80 (1 H, s, CHaHb), 4.52 (1 H, s, CHaHb), 3.82 (3 H, s, OCH3), 3.24 (3 H, s, NCH3), 2.95 
(3 H, s, NCH3). 13C NMR (101 MHz, CDCl3) δ 160.5 (CO), 160.0 (ArCO), 149.8 (Cquat), 144.0 
(Cquat), 131.7 (2 x ArCH), 130.6 (Cquat), 127.1 (2 x ArCH), 126.8 (2 x ArCH), 117.8 (ArCBr), 113.6 
(2 x ArCH), 106.1 (CH2), 55.5 (OCH3), 39.7 (NCH3), 38.5 (NCH3). HRMS m/z (ESI+) m/z calcd for 





















Formation of the title compound was carried out by following GP1 with 1-(3-
(trifluoromethyl)phenyl)ethan-1-one (1.52 mL, 1.88 g, 10.0 mmol) and 1-chloro-4-
isocyanatobenzene (210) (1.54 g, 10.0 mmol) used as starting materials. The imine 
intermediate was stirred with the requisite aryl isocyanate for 22 hours, subsequent 
methylation with methyl iodide was stirred for 19 hours. The resulting crude material was 
purified by flash column chromatography (SiO2, 0% to 30% THF in 40-60 petroleum ether), 
yielding the title compound (751 mg, 20%) as a white solid. 
M.p. 64-67 °C (Et2O). IR (film, cm-1) νmax = 2937, 1663, 1493, 1340, 1307, 1126. 1H NMR (400 
MHz, CDCl3) δ 7.54 (1 H, d, J 7.9, ArCH), 7.39 (1 H, t, J 7.9, ArCH), 7.30 (1 H, d, J 7.9, ArCH), 
7.26-7.25 (1 H, m, ArCH), 7.16 (2 H, d, J 8.9, 2 x ArCH), 6.67 (2 H, d, J 8.9, 2 x ArCH), 4.94 (1 H, 
d, J 1.1, CHaHb), 4.73 (1 H, d, J 1.1, CHaHb), 3.24 (3 H, s, NCH3), 2.94 (3 H, s, NCH3). 13C NMR 
(101 MHz, CDCl3) δ 160.2 (CO), 149.1 (Cquat), 143.2 (Cquat), 139.0 (Cquat), 130.7 (Cquat, q, JCF 32.4), 
130.6 (ArCCl), 129.0 (2 x ArCH), 128.9 (ArCH, q, JCF 1.2), 128.7 (ArCH), 126.5 (2 x ArCH), 125.2 
(ArCH, q, JCF 3.8), 124.1 (CF3, q, JCF 272.4), 122.9 (ArCH, q, JCF 3.8), 108.4 (CH2), 39.4 (NCH3), 
38.6 (NCH3). 19F NMR (377 MHz, CDCl3) δ –62.7 (3 F, s, CF3). HRMS m/z (ESI+) m/z calcd for 



















Formation of the title compound was carried out by following GP1 with 1-(4-
iodophenyl)ethan-1-one (2.46 g, 10.0 mmol) and 1-chloro-4-isocyanatobenzene (210) (1.54 
g, 10.0 mmol) used as starting materials. The imine intermediate was stirred with the requisite 
aryl isocyanate for 50 hours, subsequent methylation with methyl iodide was stirred for 24 
hours. The resulting crude material was purified by flash column chromatography (SiO2, 0% 
to 30% THF in 40-60 petroleum ether), yielding the title compound (1.44 g, 34%) as a yellow 
solid. 
M.p. 82-84 °C (Et2O). IR (film, cm-1) νmax = 2936, 1653, 1615, 1489, 1350, 1324, 826. 1H NMR 
(400 MHz, CDCl3) δ 7.58 (2 H, d, J 8.6, 2 x ArCH), 7.14 (2 H, d, J 8.9, 2 x ArCH), 6.82 (2 H, d,         
J 8.6, 2 x ArCH), 6.68 (2 H, d, J 8.9, 2 x ArCH), 4.85 (1 H, s, CHaHb), 4.59 (1 H, s, CHaHb), 3.22      
(3 H, s, NCH3), 2.93 (3 H, s, NCH3). 13C NMR (101 MHz, CDCl3) δ 160.2 (CO), 149.3 (Cquat), 143.3 
(Cquat), 137.8 (Cquat), 137.3 (2 x ArCH), 130.3 (ArCCl), 128.8 (2 x ArCH), 127.5 (2 x ArCH), 126.3 
(2 x ArCH), 108.0 (CH2), 94.1 (ArCI), 39.6 (NCH3), 38.6 (NCH3). HRMS m/z (ESI+) m/z calcd for 
C17H17N2OICl+ [M+H]+ 427.0069; found 427.0062. 
1-(4-Chlorophenyl)-1,3-dimethyl-3-(1-(thiophen-2-yl)vinyl)urea (250) 
 
Formation of the title compound was carried out by following GP1 with 2-acetylthiophene 
(1.08 mL, 1.26 g, 10.0 mmol) and 1-chloro-4-isocyanatobenzene (210) (1.54 g, 10.0 mmol) 
used as starting materials. The imine intermediate was stirred with the requisite aryl 
isocyanate for 48 hours, subsequent methylation with methyl iodide was stirred for 22 hours. 
The resulting crude material was purified by flash column chromatography (SiO2, 0% to 30% 
THF in 40-60 petroleum ether), yielding the title compound (581 mg, 19%) as a yellow oil that 
slowly turned to a brown oil over time. 
IR (film, cm-1) νmax = 2929, 1653, 1491, 1345. 1H NMR (400 MHz, CDCl3) δ 7.18-7.13 (3 H, m, 2 
x ArCH + ArCH), 6.91 (1 H, dd, J 5.1, 3.7, ArCH), 6.87 (2 H, d, J 8.7, 2 x ArCH), 6.85 (1 H, dd, J 
3.7, 1.2, ArCH), 5.00 (1 H, d, J 0.9, CHaHb), 4.57 (1 H, d, J 0.9, CHaHb), 3.16 (3 H, s, NCH3), 3.10 
(3 H, s, NCH3). 13C NMR (101 MHz, CDCl3) δ 160.5 (CO), 144.3 (Cquat), 143.8 (Cquat), 141.7 (Cquat), 
130.8 (ArCCl), 129.0 (2 x ArCH), 127.2 (2 x ArCH), 127.2 (ArCH), 125.3 (ArCH), 124.9 (ArCH), 
108.2 (CH2), 39.2 (NCH3), 39.2 (NCH3). HRMS m/z (ESI+) m/z calcd for C15H16N2OClS+ [M+H]+ 






Formation of the title compound was carried out by following GP1 with 1-(thiophen-3-
yl)ethan-1-one (1.26 g, 10.0 mmol) and 1-chloro-4-isocyanatobenzene (210) (1.54 g, 10.0 
mmol)  used as starting materials. The imine intermediate was stirred with the requisite aryl 
isocyanate for 17 hours, subsequent methylation with methyl iodide was stirred for 24 hours. 
The resulting crude material was purified by flash column chromatography (SiO2, 0% to 30% 
THF in 40-60 petroleum ether), yielding the title compound (359 mg, 12%) as a pale-yellow 
oil. 
IR (film, cm-1) νmax = 3105, 2937, 1657, 1492, 1350. 1H NMR (400 MHz, CDCl3) δ 7.19 (1 H, dd, 
J 5.1, 3.0, ArCH), 7.13 (2 H, d, J 8.9, 2 x ArCH), 7.04-6.99 (1 H, m, ArCH), 6.85 (1 H, d, J 5.1, 
ArCH), 6.76 (2 H, d, J 8.9, 2 x ArCH), 4.90 (1 H, s, CHaHb), 4.57 (1 H, s, CHaHb), 3.19 (3 H, s, 
NCH3), 3.04 (3 H, s, NCH3). 13C NMR (101 MHz, CDCl3) δ 160.4 (CO), 145.5 (Cquat), 143.7 (Cquat), 
139.8 (Cquat), 130.4 (ArCCl), 128.8 (2 x ArCH), 126.9 (2 x ArCH), 125.8 (ArCH), 125.6 (ArCH), 
121.8 (ArCH), 107.3 (CH2), 39.2 (NCH3), 38.9 (NCH3). HRMS m/z (ESI+) m/z calcd for 
C15H16N2OSCl+ [M+H]+ 307.0666; found 307.0662. 
1-(1-(4-Chlorophenyl)-3,3,3-trifluoro-1-(p-tolyl)propyl)-1,3-dimethylurea (260) 
 
Formation of the title compound was carried out by following GP2 with 1-(4-chlorophenyl)-
1,3-dimethyl-3-(1-(p-tolyl)vinyl)urea (243) (63 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (46 mg, 1.5 eq., 0.3 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 18 hours to give the title 
compound (59 mg, 77%) as a pale-yellow solid. 
M.p. 148-151 °C (Et2O). IR (film, cm-1) νmax = 3371, 2962, 1642, 1530, 1258, 1104. 1H NMR 
(400 MHz, CDCl3) δ 7.23-7.19 (4 H, m, 4 x ArCH), 7.17 (2 H, d, J 8.2, 2 x ArCH), 7.07 (2 H, d,         
J 8.2, 2 x ArCH), 4.58 (1 H, br. q, J 4.4, NH), 3.99-3.83 (2 H, m, CH2), 2.81-2.77 (6 H, m, 2 x CH3), 
2.27 (3 H, s, ArCCH3). 13C NMR (101 MHz, CDCl3) δ 159.6 (CO), 144.3 (Cquat), 140.3 (Cquat), 136.9 
(Cquat), 132.3 (ArCCl), 129.2 (2 x ArCH), 128.5 (2 x ArCH), 127.3 (2 x ArCH), 126.9 (2 x ArCH), 
126.4 (CF3, q, JCF 277.7), 67.9 (Cquat, q, JCF 2.2), 38.5 (CH2, q, JCF 27.1), 36.4 (CH3, q, JCF 2.1), 27.7 
(CH3), 21.0 (CH3). 19F NMR (377 MHz, CDCl3) δ –58.4 (3 F, t, J 10.9, CF3). HRMS m/z (ESI+) m/z 








Formation of the title compound was carried out by following GP2 with 1-(4-chlorophenyl)-
1,3-dimethyl-3-(1-(4-(trifluoromethoxy)phenyl)vinyl)urea (244) (77 mg, 0.2 mmol) and 
sodium trifluoromethanesulfinate (134) (46 mg, 1.5 eq., 0.3 mmol) used as starting materials 
and acetonitrile used as solvent. The reaction mixture was stirred for 22 hours to give the title 
compound (77 mg, 85%) as a white solid. 
M.p. 64-67 °C (Et2O). IR (film, cm-1) νmax = 3361, 2930, 1639, 1255, 1220, 1104. 1H NMR (400 
MHz, CDCl3) δ 7.29 (2 H, d, J 9.0, 2 x ArCH), 7.26-7.21 (4 H, m, 4 x ArCH), 7.10 (2 H, d, J 8.4,       
2 x ArCH), 4.62 (1 H, br. q, J 4.6, NH), 3.92 (2 H, q, J 10.8, CH2), 2.82-2.77 (6 H, m, 2 x NCH3). 
13C NMR (126 MHz, CDCl3) δ 159.5 (CO), 147.9 (ArCO, q, JCF 1.7), 142.6 (Cquat + Cquat), 132.9 
(ArCCl), 128.7 (2 x ArCH), 128.0 (2 x ArCH), 127.9 (2 x ArCH), 126.2 (CF3, q, JCF 278.5), 120.6       
(2 x ArCH), 120.5 (OCF3, q, JCF 257.1), 67.8 (Cquat, q, JCF 2.2), 38.7 (CH2, q, JCF 27.1), 36.5 (NCH3), 
27.7 (NCH3). 19F NMR (377 MHz, CDCl3) δ –57.6 (3 F, s, OCF3), –58.5 (3 F, t, J 10.8, CF3). HRMS 


















1-(1-(4-Bromophenyl)-1-(3,4-dichlorophenyl)-3,3,3-trifluoropropyl)-1,3-dimethylurea         
(262) 
 
Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(3,4-dichlorophenyl)vinyl)-1,3-dimethylurea (245) (83 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (46 mg, 1.5 eq., 0.3 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 20 hours to give the title 
compound (88 mg, 91%) as a white solid. 
M.p. 92-95 °C (Et2O). IR (film, cm-1) νmax = 3360, 2967, 1642, 1532, 1255, 1105. 1H NMR (400 
MHz, CDCl3) δ 7.41 (2 H, d, J 8.7, 2 x ArCH), 7.32 (1 H, d, J 8.6, ArCH), 7.31 (1 H, d, J 2.4, ArCH), 
7.22 (2 H, d, J 8.7, 2 x ArCH), 7.11 (1 H, dd, J 8.6, 2.4, ArCH), 4.80 (1 H, br. q, J 4.6, NH), 4.00-
3.75 (2 H, m, CH2), 2.85-2.74 (6 H, m, CH3 + CH3). 13C NMR (101 MHz, CDCl3) δ 159.4 (CO), 
145.4 (Cquat), 142.1 (Cquat), 132.7 (ArCCl), 131.8 (2 x ArCH), 131.0 (ArCCl), 130.4 (ArCH), 128.5 
(2 x ArCH), 127.9 (ArCH), 126.1 (CF3, q, JCF 277.8), 125.3 (ArCH), 121.5 (ArCBr), 67.6 (Cquat, q, 
JCF 2.2), 37.9 (CH2, q, JCF 27.2), 36.4 (NCH3, q, JCF 1.9), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) 





















Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(3-chlorophenyl)vinyl)-1,3-dimethylurea (246) (76 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 22 hours to give the title 
compound (68 mg, 76%) as a white solid. 
M.p. 81-83 °C (Et2O). IR (film, cm-1) νmax = 3357, 2971, 1642, 1532, 1257, 1129. 1H NMR (400 
MHz, CDCl3) δ 7.40 (2 H, d, J 8.7, 2 x ArCH), 7.23 (1 H, br. s, ArCH), 7.21-7.12 (5 H, m, 5 x ArCH), 
4.63 (1 H, br. s, NH), 3.98-3.82 (2 H, m, CH2), 2.84-2.77 (6 H, m, 2 x CH3). 13C NMR (126 MHz, 
CDCl3) δ 159.4 (CO), 146.5 (Cquat), 143.0 (Cquat), 134.5 (ArCCl), 131.7 (2 x ArCH), 129.8 (ArCH), 
128.3 (2 x ArCH), 127.2 (ArCH), 126.5 (ArCH), 126.2 (CF3, q, JCF 278.3), 124.4 (ArCH), 121.1 
(ArCBr), 67.9 (Cquat, q, JCF 2.2), 38.0 (CH2, q, JCF 27.3), 36.5 (NCH3, q, JCF 1.8), 27.7 (NCH3). 19F 
NMR (377 MHz, CDCl3) δ –58.8 (3 F, t, J 10.8, CF3). HRMS m/z (ESI+) m/z calcd for 
C18H18N2OBrClF3+ [M+H]+ 449.0238; found 449.0239. 
1-(1-(4-Bromophenyl)-3,3,3-trifluoro-1-(4-methoxyphenyl)propyl)-1,3-dimethylurea (264) 
 
Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(4-methoxyphenyl)vinyl)-1,3-dimethylurea (247) (75 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 17 hours to give the title 
compound (51 mg, 57%) as a white solid. 
M.p. 79-82 °C (Et2O). IR (film, cm-1) νmax = 3369, 2958, 1644, 1513, 1257, 1103. 1H NMR (400 
MHz, CDCl3) δ 7.36 (2 H, d, J 8.7, 2 x ArCH), 7.19 (2 H, d, J 9.0, 2 x ArCH), 7.13 (2 H, d, J 8.7,      
2 x ArCH), 6.80 (2 H, d, J 9.0, 2 x ArCH), 4.58 (1 H, br. s, NH), 3.99-3.79 (2 H, m, CH2), 3.76 (3 
H, s, OCH3), 2.81-2.76 (6 H, m, 2 x NCH3). 13C NMR (126 MHz, CDCl3) δ 159.6 (CO), 158.4 
(ArCO), 145.2 (Cquat), 134.8 (Cquat), 131.4 (2 x ArCH), 128.5 (2 x ArCH), 127.5 (2 x ArCH), 126.4 
(CF3, q, JCF 278.4), 120.4 (ArCBr), 113.8 (2 x ArCH), 67.7 (Cquat, q, JCF 2.2), 55.3 (OCH3), 38.7 
(CH2, q, JCF 26.8), 36.3 (NCH3), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) δ –58.4 (3 F, t, J 10.8, 








Formation of the title compound was carried out by following GP2 with 1-(4-chlorophenyl)-
1,3-dimethyl-3-(1-(3-(trifluoromethyl)phenyl)vinyl)urea (248) (74 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetone used as solvent. The reaction mixture was stirred for 17 hours to give the title 
compound (62 mg, 71%) as a white solid. 
M.p. 71-74 °C (Et2O). IR (film, cm-1) νmax = 3360, 2921, 1640, 1327, 1124, 1104. 1H NMR (400 
MHz, CDCl3) δ 7.49-7.45 (2 H, m, 2 x ArCH), 7.44-7.37 (2 H, m, 2 x ArCH), 7.28-7.25 (2 H, m,     
2 x ArCH), 7.25-7.22 (2 H, m, 2 x ArCH), 4.65 (1 H, br. q, J 4.5, NH), 3.95 (1 H, q, J 10.8, CHaHb), 
3.93 (1 H, q, J 10.8, CHaHb), 2.80 (3 H, s, NCH3), 2.79 (3 H, d, J 4.8 NCH3). 13C NMR (126 MHz, 
CDCl3) δ 159.5 (CO), 145.9 (Cquat), 141.9 (Cquat), 133.2 (ArCCl), 130.8 (ArCCF3, q, JCF 32.2), 129.3 
(ArCH), 129.0 (ArCH), 128.8 (2 x ArCH), 128.1 (2 x ArCH), 126.2 (ArCCF3, q, JCF 278.4), 124.1 
(CF3, q, JCF 272.9), 123.8 (ArCH, q, JCF 3.7), 122.8 (ArCH, q, JCF 3.8), 67.9 (Cquat, q, JCF 1.9), 38.2 
(CH2, q, JCF 27.3), 36.5 (NCH3, q, JCF 2.0), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) δ –58.6 (3 F, 
t, J 10.8, CF3), –62.5 (3 F, s, ArCCF3). HRMS m/z (ESI+) m/z calcd for C19H18N2OClF6+ [M+H]+ 



















Formation of the title compound was carried out by following GP2 with 1-(4-chlorophenyl)-3-
(1-(4-iodophenyl)vinyl)-1,3-dimethylurea (249) (85 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetone used as solvent. The reaction mixture was stirred for 16 hours to give the title 
compound (83 mg, 84%) as a yellow solid. 
M.p. 84-87 °C (Et2O). IR (film, cm-1) νmax = 3368, 2968, 1641, 1256, 1103, 730. 1H NMR (400 
MHz, CDCl3) 7.58 (2 H, d, J 8.5, 2 x ArCH), 7.26-7.17 (4 H, m, 4 x ArCH), 7.01 (2 H, d, J 8.5, 2 x 
ArCH), 4.63 (1 H, br. s, NH), 3.96-3.82 (2 H, m, CH2), 2.83-2.76 (6 H, m, 2 x NCH3). 13C NMR 
(101 MHz, CDCl3) δ 159.5 (CO), 144.2 (Cquat), 142.6 (Cquat), 137.6 (2 x ArCH), 132.9 (ArCCl), 
128.7 (2 x ArCH), 128.3 (2 x ArCH), 127.9 (2 x ArCH), 126.2 (CF3, q, JCF 278.6), 92.6 (ArCI), 67.9 
(Cquat, q, JCF 2.2), 38.2 (CH2, q, JCF 27.2), 36.5 (NCH3, q, JCF 2.3), 27.7 (NCH3). 19F NMR (377 MHz, 
CDCl3) δ –58.5 (3 F, t, J 10.5, CF3). HRMS m/z (ESI+) m/z calcd for C18H18N2OIF3Cl+ [M+H]+ 
497.0097; found 497.0091. 
1-(1-(4-Chlorophenyl)-3,3,3-trifluoro-1-(thiophen-2-yl)propyl)-1,3-dimethylurea (267) 
 
Formation of the title compound was carried out by following GP2 with 1-(4-chlorophenyl)-
1,3-dimethyl-3-(1-(thiophen-2-yl)vinyl)urea (250) (61 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetone used as solvent. The reaction mixture was stirred for 16 hours to give the title 
compound (34 mg, 45%) as a white solid, which decomposes slowly in solution. 
M.p. 132-134 °C (Et2O). IR (film, cm-1) νmax = 3353, 2957, 1639, 1258, 1117, 1099. 1H NMR 
(400 MHz, CDCl3) δ 7.26-7.20 (5 H, m, 5 x ArCH), 7.02 (1 H, br. s, ArCH), 6.90-6.84 (1 H, m, 
ArCH), 4.59 (1 H, br. s, NH), 3.99 (1 H, dq, J 15.0, 11.1 CHaHb), 3.75 (1 H, dq, J 15.0, 11.1 CHaHb), 
2.81 (3 H, s, NCH3), 2.75 (3 H, d, J 4.4, NCH3). 13C NMR (101 MHz, CDCl3) δ 159.2 (CO), 148.4 
(Cquat), 145.2 (Cquat), 132.8 (ArCCl), 128.6 (2 x ArCH), 126.9 (ArCH), 126.6 (2 x ArCH), 126.3 
(ArCH, q, JCF 2.0), 126.2 (ArCH), 126.1 (CF3, q, JCF 277.8), 65.7 (Cquat, q, JCF 2.4), 41.6 (CH2, q, JCF 
27.4), 35.8 (NCH3, q, JCF 1.7), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) δ –58.5 (3 F, t, J 11.1, 








Formation of the title compound was carried out by following GP2 with 1-(4-chlorophenyl)-
1,3-dimethyl-3-(1-(thiophen-3-yl)vinyl)urea (251) (61 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetone used as solvent. The reaction mixture was stirred for 15 hours to give the title 
compound (54 mg, 71%) as a white solid. 
M.p. 143-145 °C (Et2O). IR (film, cm-1) νmax = 3358, 2963, 1640, 1258, 1108. 1H NMR (400 MHz, 
CDCl3) δ 7.26-7.17 (5 H, m, 5 x ArCH), 7.14 (1 H, br. s, ArCH), 6.88 (1 H, dd, J 5.1, 1.5, ArCH), 
4.57 (1 H, br. s, NH), 4.00 (1 H, dq, J 15.1, 10.9, CHaHb), 3.69 (1 H, dq, J 15.1, 10.9, CHaHb), 2.80 
(3 H, s, NCH3), 2.78 (3 H, d, J 4.7, NCH3). 13C NMR (101 MHz, CDCl3) δ 159.2 (CO), 144.8 (Cquat), 
143.6 (Cquat), 132.4 (ArCCl), 128.6 (2 x ArCH), 128.4 (ArCH) 126.5 (2 x ArCH), 126.3 (CF3, q, JCF 
278.0), 126.0 (ArCH), 122.4 (ArCH, q, JCF 2.1), 65.5 (Cquat, q, JCF 2.2), 40.0 (CH2, q, JCF 27.4), 35.6 
(NCH3, d, JCF 1.7), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) δ –58.6 (3 F, t, J 10.9, CF3). HRMS 
m/z (ESI+) m/z calcd for C16H17N2OSClF3+ [M+H]+ 377.0697; found 377.0690. 
1-(4-Chlorophenyl)-3-(3,4-dihydronaphthalen-1-yl)-1,3-dimethylurea (271) 
 
Formation of the title compound was carried out by following GP1 with α-tetralone (269) 
(1.33 mL, 1.46 g, 10.0 mmol) and 1-chloro-4-isocyanatobenzene (210) (1.54 g, 10.0 mmol) 
used as starting materials. The imine intermediate was stirred with the requisite aryl 
isocyanate for 24 hours, subsequent methylation with methyl iodide was stirred for 18 hours. 
The resulting crude material was purified by flash column chromatography (SiO2, 0% to 30% 
THF in 40-60 petroleum ether), yielding the title compound (362 mg, 11%) as a colourless oil. 
IR (film, cm-1) νmax = 2937, 1654, 1626, 1491, 1348. 1H NMR (400 MHz, CDCl3) δ 7.15-7.10         
(2 H, m, ArCH + ArCH), 7.07 (2 H, d, J 8.8, 2 x ArCH), 7.03-6.99 (1 H, m, ArCH), 6.96-6.92 (1 H, 
m, ArCH), 6.72 (2 H, d, J 8.8, 2 x ArCH), 5.46 (1 H, t, J 4.7, CH), 3.17 (3 H, s, NCH3), 3.08 (3 H, s, 
NCH3), 2.53-2.23 (2 H, br. m, CH2), 2.14-1.96 (2 H, br. m, CH2). 13C NMR (101 MHz, CDCl3) δ 
160.6 (CO), 144.1 (Cquat), 141.2 (Cquat), 136.6 (Cquat), 131.9 (Cquat), 130.3 (ArCCl), 128.8 (2 x 
ArCH), 127.7 (ArCH), 127.6 (ArCH), 127.2 (2 x ArCH), 126.2 (ArCH), 123.5 (CH), 122.2 (ArCH), 
39.5 (CH3), 39.1 (CH3), 26.8 (CH2), 22.4 (CH2). HRMS m/z (ESI+) m/z calcd for C19H20N2OCl+ 







Formation of the title compound was carried out by following GP1 with 1-benzosuberone 
(270) (1.50 mL, 1.60 g, 10.0 mmol) and 1-fluoro-3-isocyanatobenzene (1.14 mL, 1.37 g, 10.0 
mmol) used as starting materials. The imine intermediate was stirred with the requisite aryl 
isocyanate for 72 hours, subsequent methylation with methyl iodide was stirred for 20 hours. 
The resulting crude material was purified by flash column chromatography (SiO2, 0% to 30% 
THF in 40-60 petroleum ether), yielding the title compound (1.02 g, 32%) as a pale-yellow 
solid. 
M.p. 59-61 °C (Et2O). IR (film, cm-1) νmax = 2932, 1656, 1606, 1333, 771. 1H NMR (400 MHz, 
CDCl3) δ 7.18-7.09 (3 H, m, 3 x ArCH), 7.09 (2 H, m, 2 x ArCH), 6.72-6.63 (2 H, m, 2 x ArCH), 
6.57 (1 H, dt, J 10.7, 2.2, ArCH), 5.71 (1 H, t, J 6.5, CH), 3.12 (3 H, s, NCH3), 2.96 (3 H, s, NCH3), 
2.12 (2 H, t, J 6.5, CH2), 1.86 (2 H, qn, J 6.5, CH2), 1.78 (2 H, q, J 6.5, CH2). 13C NMR (101 MHz, 
CDCl3) δ 162.8 (ArCF, q, JCF 245.4), 160.5 (CO), 146.6 (Cquat, q, JCF 9.6), 142.3 (Cquat), 142.3 (Cquat), 
136.6 (Cquat), 129.6 (ArCH, q, JCF 9.6), 129.3 (ArCH), 127.6 (ArCH), 125.9 (ArCH), 125.8 (ArCH), 
123.6 (CH), 119.4 (ArCH, q, JCF 2.9), 111.1 (ArCH, q, JCF 23.4), 110.7 (ArCH, q, JCF 21.2), 39.3 
(NCH3), 38.2 (NCH3), 33.6 (CH2), 32.6 (CH2), 25.2 (CH2). 19F NMR (377 MHz, CDCl3) δ –112.5     
(1 F, ddd, J 10.9, 8.4, 6.6 ArCF). HRMS m/z (ESI+) m/z calcd for C20H21N2OFNa+ [M+Na]+ 

















Ethyl 4-(3-(6,7-dihydro-5H-benzo[7]annulen-9-yl)-1,3-dimethylureido)benzoate (273) 
 
Formation of the title compound was carried out by following GP1 with 1-benzosuberone 
(270) (1.50 mL, 1.60 g, 10.0 mmol) and ethyl 4-isocyanatobenzoate (1.91 g, 10.0 mmol) used 
as starting materials. The imine intermediate was stirred with the requisite aryl isocyanate for 
22 hours, subsequent methylation with methyl iodide was stirred for 18 hours. The resulting 
crude material was purified by flash column chromatography (SiO2, 0% to 30% THF in 40-60 
petroleum ether), yielding the title compound (975 mg, 26%) as a white solid. 
M.p. 113-116 °C (Et2O). IR (film, cm-1) νmax = 2932, 1710, 1659, 1603, 1275, 1106. 1H NMR 
(400 MHz, CDCl3) δ 7.87 (2 H, d, J 8.9, 2 x ArCH), 7.17 (1 H, td, J 7.3, 1.6, ArCH), 7.12 (1 H, td, 
J 7.3, 1.6, ArCH), 7.09-7.04 (2 H, m, ArCH + ArCH), 6.82 (2 H, d, J 8.9, 2 x ArCH), 5.72 (1 H, t,       
J 6.5, CH), 4.32 (2 H, q, J 7.1, OCH2), 3.24 (3 H, s, NCH3), 2.88 (3 H, s, NCH3), 1.94 (2 H, t, J 6.3, 
CH2), 1.85-1.72 (4 H, m, CH2 + CH2), 1.35 (3 H, t, J 7.1, CH3). 13C NMR (101 MHz, CDCl3) δ 166.2 
(CO), 160.3 (CO), 148.9 (Cquat), 142.3 (Cquat), 142.2 (Cquat), 137.1 (Cquat), 130.3 (2 x ArCH), 129.5 
(ArCH), 127.6 (ArCH), 126.0 (ArCH), 125.5 (ArCH), 124.6 (Cquat), 123.9 (CH), 121.4 (2 x ArCH), 
60.8 (OCH2), 39.7 (NCH3), 37.3 (NCH3), 33.7 (CH2), 32.4 (CH2), 25.1 (CH2), 14.4 (CH3). HRMS 




















Formation of the title compound was carried out by following GP2 with 1-(4-chlorophenyl)-3-
(3,4-dihydronaphthalen-1-yl)-1,3-dimethylurea (271) (65 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (78 mg, 2.5 eq., 0.5 mmol) used as starting materials and 
acetone used as solvent. The reaction mixture was stirred for 17 hours to give the title 
compound (54 mg, 68%, >20:1 d.r.) as a white solid. 
M.p. 80-83 °C (Et2O). IR (film, cm-1) νmax = 3352, 2962, 1644, 1530, 1492, 1317, 1123. 1H NMR 
(400 MHz, CDCl3) δ 7.44 (2 H, d, J 8.8, 2 x ArCH), 7.37-7.33 (1 H, m, ArCH), 7.22 (2 H, d, J 8.8, 
2 x ArCH), 7.16-7.12 (2 H, m, 2 x ArCH), 7.10-7.06 (1 H, m, ArCH), 4.44 (1 H, br. q, J 4.6, NH), 
4.20-4.07 (1 H, m, CH), 3.01 (1 H, dt, J 17.4, 7.5, CHaHb), 2.81 (3 H, s, NCH3), 2.75 (1 H, dt, J 
17.4, 7.5, CHaHb), 2.68 (3 H, d, J 4.6, NCH3), 2.47-2.37 (2 H, m, CH2). 13C NMR (126 MHz, CDCl3) 
δ 159.5 (CO), 145.0 (Cquat), 136.9 (Cquat), 136.9 (Cquat), 132.3 (ArCCl), 130.1 (ArCH), 129.8 
(ArCH), 128.2 (2 x ArCH), 128.2 (2 x ArCH), 127.8 (CF3, q, JCF 281.9), 127.4 (ArCH), 126.0 (ArCH), 
67.3 (Cquat), 45.5 (CH, q, JCF 24.3), 37.2 (NCH3, q, JCF 3.2), 27.8 (NCH3), 27.0 (CHaHb), 21.8 (CH2, 
q, JCF 2.8). 19F NMR (377 MHz, CDCl3) δ –62.4 (3 F, d, J 10.4, CF3). HRMS m/z (ESI+) m/z calcd 










Methyl 2-(1,3-dimethyl-3-phenylureido)acrylate (285) 
 
A solution of L-serine methyl ester hydrochloride (282) (1.0 g, 6.5 mmol) in anhydrous 
acetonitrile (14.0 mL) was prepared in a flame-dried RBF under a nitrogen atmosphere. 
Triethylamine (2.30 mL, 1.65 g, 16.3 mmol) was added to the mixture at room temperature 
then stirred for 30 minutes. Methyl(phenyl)carbamic chloride (276) (1.22 g, 7.2 mmol) was 
added to the reaction mixture then stirred for 18 hours at room temperature. The reaction 
was quenched with water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined 
organic extracts were sequentially washed with 1 M HCl(aq) (50 mL) and saturated NaHCO3(aq) 
(50 mL), then dried (Na2SO4) and concentrated under reduced pressure yielding methyl 
(methyl(phenyl)carbamoyl)serinate (283) (1.34 g, 82 %) as colourless oil, which was used 
without further purification. 
 
1H NMR (400 MHz, CDCl3) δ 7.48-7.43 (2 H, m, 2 x ArCH), 7.36-7.29 (3 H, m, 2 x ArCH + ArCH), 
5.31 (1 H, d, J 6.9, NH), 4.56 (1 H, dt, J 6.9, 3.7, CH), 3.94-3.82 (2 H, m, CH2), 3.74 (3 H, s, OCH3), 
3.29 (3 H, s, NCH3). OH not observed. Data in good agreement with literature.262 
A solution of methyl (methyl(phenyl)carbamoyl)serinate (283) (1.34 g, 5.3 mmol) in 
anhydrous acetonitrile (10.6 mL) was prepared in a flame-dried RBF under a nitrogen 
atmosphere. Triethylamine (1.48 mL, 1.07 g, 10.6 mmol) was added to the mixture at room 
temperature then stirred for 30 minutes at room temperature. p-Toluenesulfonyl chloride 
(2.02 g, 10.6 mmol) was added to the reaction mixture, then stirred for 20 hours at room 
temperature. The reaction was quenched with water (50 mL) and extracted with ethyl acetate 
(2 x 50 mL). The combined organic extracts were dried (Na2SO4) and concentrated under 
reduced pressure to yield crude material that was purified by flash column chromatography 
(SiO2, 0% to 60% Et2O in 40-60 petroleum ether), yielding methyl 2-(3-methyl-3-





1H NMR (400 MHz, CDCl3) δ 7.51-7.45 (2 H, m, 2 x ArCH), 7.37 (1 H, tt, J 7.3, 1.2, ArCH), 7.31-
7.27 (2 H, m, 2 x ArCH), 7.00 (1 H, br. s, NH), 6.34 (1 H, s, CHaHb), 5.66 (1 H, d, J 1.26, CHaHb), 
3.71 (3 H, s, OCH3), 3.31 (3 H, s, NCH3). Data in good agreement with literature.262 
A flame-dried Schlenk tube was charged with 2-(3-methyl-3-phenylureido)acrylate (284) (795 
mg, 3.4 mmol) and anhydrous DMF (11.3 mL) then cooled to 0 °C. 60% Sodium hydride 
dispersed in mineral oil (271 mg, 6.8 mmol) was added to the Schlenk tube and the contents 
stirred for 30 minutes at 0 °C. Methyl iodide (0.84 mL, 13.6 mmol) was added to the Schlenk 
tube at 0 °C, the mixture was warmed to room temperature and stirred for 23 hours. The 
reaction was quenched with water (80 mL) and extracted with ethyl acetate (3 x 50 mL). The 
combined organic extracts were dried (Na2SO4), concentrated under reduced pressure and 
purified by flash column chromatography (SiO2, 0% to 60% Et2O in 40-60 petroleum ether), 
yielding the title compound (446 mg, 53%) as a colourless oil. 
 
1H NMR (400 MHz, CDCl3) δ 7.31 (2 H, dd, J 8.4, 7.3, 2 x ArCH), 7.25-7.21 (2 H, m, 2 x ArCH), 
7.13 (1 H, tt, J 7.3, 1.2, ArCH), 5.52 (1 H, d, J 0.9, CHaHb), 4.98 (1 H, d, J 0.9, CHaHb), 3.77 (3 H, 
s, OCH3), 3.25 (3 H, s, NCH3), 2.85 (3 H, s, NCH3). Data in good agreement with literature.262 
Methyl 2-(1,3-dimethyl-3-phenylureido)-4,4,4-trifluorobutanoate (287) 
 
Formation of the title compound was carried out by following GP2 with methyl 2-(1,3-
dimethyl-3-phenylureido)acrylate (285) (50 mg, 0.2 mmol) and sodium 
trifluoromethanesulfinate (134) (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and 
acetone used as solvent. The reaction mixture was stirred for 17 hours to give the title 
compound (43 mg, 68%) as a white solid.  
IR (film, cm-1) νmax = 2958, 1746, 1644, 1256, 1104. 1H NMR (400 MHz, CDCl3) δ 7.36-7.30               
(2 H, m, 2 x ArCH), 7.17-7.12 (3 H, m, 2 x ArCH + ArCH), 4.39 (1 H, dd, J 9.8, 3.4, CH), 3.76 (3 H, 
s, OCH3), 3.21 (3 H, s, NCH3), 2.99-2.85 (1 H, m, CHaHb), 2.80-2.65 (1 H, m, CHaHb), 2.50 (3 H, 
s, NCH3). 13C NMR (126 MHz, CDCl3) δ 170.5 (CO), 161.1 (CO), 145.9 (Cquat), 129.6 (2 x ArCH), 
126.2 (CF3, q, JCF 276.8), 125.5 (ArCH), 125.0 (2 x ArCH), 57.0 (CH, q, JCF 3.2), 52.9 (OCH3), 40.4 
(NCH3), 36.9 (NCH3), 33.6 (CH2, q, JCF 28.9). 19F NMR (377 MHz, CDCl3) δ -64.5 (3 F, t, J 10.7, 




Sodium 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfinate (288) 
 
While open, to air a solution of 1,1,1,2,2,3,3,4,4-nonafluoro-4-iodobutane (1.72 mL, 3.46 g, 
10.0 mmol) in acetonitrile (6.0 mL) was prepared and cooled to 0 °C. Sequentially sodium 
bicarbonate (1.68 g, 20.0 mmol), sodium dithionite (2.05 g, 85 % wt., 10.0 mmol) and water 
(5.0 mL) were added to the 1,1,1,2,2,3,3,4,4-nonafluoro-4-iodobutane solution. The reaction 
mixture was warmed to room temperature and stirred for 23 hours. The reaction was 
quenched by addition of water (5 mL), then extracted with ethyl acetate (3 x 10 mL). The 
combined organic extracts were dried (Na2SO4) and concentrated under reduced pressure 
yielding white solid as crude product, which was purified by washing with diethyl ether               
(3 x 10 mL) affording the title compound (1.72 g, 56%) as a white solid. 
19F NMR (377 MHz, DMSO-d6) δ –80.5 (3 F, t, J 9.3, CF3), –122.4 (2 F, br. q, J 9.3, CF2), –126.0 
(2 F, t, J 11.2, CF2), –130.5-–130.6 (2 F, m, CF2). Data in good agreement with literature.263 
Sodium 1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfinate (289) 
 
While open, to air a solution of 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-6-iodohexane (2.20 mL, 
4.46 g, 10.0 mmol) in acetonitrile (6.0 mL) was prepared and cooled to 0 °C. Sequentially 
sodium bicarbonate (1.68 g, 20 mmol), sodium dithionite (2.05 g, 85 % wt., 10.0 mmol) and 
water (5 mL) were added to the 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-6-iodohexane solution. 
The reaction mixture was warmed to room temperature and stirred for 23 hours. The reaction 
was quenched by addition of water (5 mL), then extracted with ethyl acetate (3 x 10 mL). The 
combined organic extracts were dried (Na2SO4) and concentrated under reduced pressure 
yielding white solid as crude product, which was purified by washing with diethyl ether               
(3 x 10 mL) affording the title compound (2.48 g, 61%) as a white solid. 
19F NMR (377 MHz, DMSO-d6) δ –80.5 (3 F, t, J 9.6, CF3), –122.1 (2 F, br. s, CF2), –122.4 (2 F, 
br. s, CF2), –122.9 (2 F, br. s, CF2), –125.9-–126.1 (2 F, m, CF2), –130.5 (2 F, tt, J 12.6, 3.5, CF2). 












Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(3,4-dichlorophenyl)vinyl)-1,3-dimethylurea (245) (83 mg, 0.2 mmol) and sodium 
difluoromethanesulfinate (55 mg, 2.0 eq., 0.4 mmol) used as starting materials and acetone 
used as solvent. The reaction mixture was stirred for 17 hours to give the title compound       
(60 mg, 64%) as a white solid. 
M.p. 72-75 °C (Et2O). IR (film, cm-1) νmax = 3365, 2955, 1640, 1531, 1078. 1H NMR (400 MHz, 
CDCl3) δ 7.44 (2 H, d, J 8.8, 2 x ArCH), 7.35 (1 H, d, J 8.6, ArCH), 7.35 (1 H, d, J 2.4, ArCH), 7.17 
(2 H, d, J 8.8, 2 x ArCH), 7.14 (1 H, dd, J 8.6, 2.4, ArCH), 5.90 (1 H, tt, J 55.9, 4.4, CHF2), 4.64     
(1 H, q, J 4.4, NH), 3.34 (2 H, tdd, J 15.6, 7.3, 4.4, CH2), 2.77 (3 H, d, J 4.4, NCH3), 2.70 (3 H, s, 
NCH3). 13C NMR (126 MHz, CDCl3) δ 159.5 (CO), 144.6 (Cquat), 142.1 (Cquat), 132.7 (ArCCl), 131.9 
(2 x ArCH), 131.3 (ArCCl), 130.4 (ArCH), 128.8 (2 x ArCH), 128.6 (ArCH), 126.1 (ArCH), 121.7 
(ArCBr), 116.3 (CF2H, t, JCF 239.1), 67.7 (Cquat, t, JCF 6.1), 42.4 (CH2, t, JCF 22.5), 36.1 (NCH3), 27.8 
(NCH3). 19F NMR (377 MHz, CDCl3) δ –112.2 (2 F, dt, J 55.8, 15.9, CHF2). HRMS m/z (ESI+) m/z 





















Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(3,4-dichlorophenyl)vinyl)-1,3-dimethylurea (245)  (83 mg, 0.2 mmol) and sodium 1,1-
difluoroethane-1-sulfinate  (61 mg, 2.0 eq., 0.4 mmol) used as starting materials and acetone 
used as solvent. The reaction mixture was stirred for 17 hours to give the title compound       
(76 mg, 79%) as a colourless film. 
IR (film, cm-1) νmax = 3365, 2960, 1640, 1529, 1479. 1H NMR (400 MHz, CDCl3) 7.37 (2 H, d,       
J 8.9, 2 x ArCH), 7.31 (1 H, d, J 2.2, ArCH), 7.28 (1 H, d, J 8.6, ArCH), 7.15 (2 H, d, J 8.9, 2 x ArCH), 
7.12 (1 H, dd, J 8.6, 2.2, ArCH), 4.64 (1 H, br. s, NH), 3.69-3.45 (2 H, m, CH2), 2.80 (3 H, s, NCH3), 
2.78 (3 H, d, J 4.8, NCH3), 1.72 (3 H, t, J 18.6, CH3). 13C NMR (101 MHz, CDCl3) δ 159.6 (CO), 
146.8 (Cquat), 143.5 (Cquat), 132.3 (ArCCl), 131.5 (2 x ArCH), 130.4 (ArCCl), 130.1 (ArCH), 128.7 
(2 x ArCH), 128.1 (ArCH), 125.5 (ArCH), 123.8 (CF2, t, JCF 241.1), 120.9 (ArCBr), 68.4 (Cquat), 40.5 
(CH2, t, JCF 23.1), 36.6 (NCH3, t, JCF 4.0), 27.7 (NCH3), 26.5 (CH3, t, JCF 28.2). 19F NMR (377 MHz, 
CDCl3) δ –87.0-–89.7 (2 F, m, CF2). HRMS m/z (ESI+) m/z calcd for C19H20N2OCl2F2Br+ [M+H]+ 




















Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(3,4-dichlorophenyl)vinyl)-1,3-dimethylurea (245) (83 mg, 0.2 mmol) and sodium 7-
chloro-1,1-difluoroheptane-1-sulfinate (103 mg, 2.0 eq., 0.4 mmol) used as starting materials 
and acetone used as solvent. The reaction mixture was stirred for 18 hours to give the title 
compound (64 mg, 55%) as a white solid. 
M.p. 64-67 °C (Et2O). IR (film, cm-1) νmax = 3368, 2932, 1641, 1527, 1315. 1H NMR (400 MHz, 
CDCl3) δ 7.37 (2 H, d, J 8.6, 2 x ArCH), 7.30 (1 H, d, J 2.3, ArCH), 7.28 (1 H, d, J 8.9, ArCH), 7.14 
(2 H, d, J 8.6, 2 x ArCH), 7.11 (1 H, dd, J 8.9, 2.3, ArCH), 4.65 (1 H, q, J 4.5, NH), 3.63-3.42 (4 H, 
m, CH2 + CH2Cl), 2.80 (3 H, s, NCH3), 2.78 (3 H, d, J 4.5, NCH3), 1.94 (2 H, dq, J 22.5, 8.6, CH2), 
1.78 (2 H, qn, J 6.9, CH2), 1.57 (2 H, qn, J 7.8, CH2), 1.51-1.43 (2 H, m, CH2), 1.41-1.35 (2 H, m, 
CH2). 13C NMR (126 MHz, CDCl3) δ 159.6 (CO), 146.9 (Cquat), 143.6 (Cquat), 132.2 (ArCCl), 131.5 
(2 x ArCH), 130.3 (ArCCl), 130.1 (ArCH), 128.6 (2 x ArCH), 128.0 (ArCH), 125.5  (ArCH), 124.6 
(CF2, t, JCF 244.8), 120.8 (ArCBr), 68.4 (Cquat), 45.1 (CH2Cl), 39.3 (CH2, t, JCF 25.5), 39.0 (CH2, t, 
JCF 23.0), 36.6 (NCH3, t, JCF 4.0), 32.5 (CH2), 28.6 (CH2), 27.7 (NCH3), 26.7 (CH2), 22.1 (CH2, t, JCF 
4.2). 19F NMR (377 MHz, CDCl3) δ –95.9-–96.1 (2 F, m, CF2). HRMS m/z (ESI+) m/z calcd for 

















Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(3,4-dichlorophenyl)vinyl)-1,3-dimethylurea (245) (83 mg, 0.2 mmol) and sodium 
difluoroheptylazidosulfinate  (100 mg, 1.9 eq., 0.38 mmol) used as starting materials and 
acetone used as solvent. The reaction mixture was stirred for 18 hours to give the title 
compound (95 mg, 80%) as a white solid. 
M.p. 53-57°C (Et2O). IR (film, cm-1) νmax = 3363, 2934, 2094, 1640, 1313. 1H NMR (400 MHz, 
CDCl3) δ 7.36 (2 H, d, J 8.8, 2 x ArCH), 7.30 (1 H, d, J 2.3, ArCH), 7.28 (1 H, d, J 8.6, ArCH), 7.14 
(2 H, d, J 8.8, 2 x ArCH), 7.11 (1 H, dd, J 8.6, 2.3, ArCH), 4.67 (1 H, q, J 4.6, NH), 3.65-3.41 (2 H, 
m, CH2), 3.27 (2 H, t, J 6.9, CH2N3), 2.79 (3 H, s, NCH3), 2.77 (3 H, d, J 4.6, NCH3), 2.01-1.85         
(2 H, m, CH2), 1.65-1.52 (4 H, m, CH2 + CH2), 1.44-1.33 (4 H, m, CH2 + CH2). 13C NMR (101 MHz, 
CDCl3) δ 159.6 (CO), 146.9 (Cquat), 143.6 (Cquat), 132.2 (ArCCl), 131.4 (2 x ArCH), 130.3 (ArCCl), 
130.0 (ArCH), 128.6 (2 x ArCH), 128.0 (ArCH), 125.5 (ArCH), 124.6 (CF2, t, JCF 244.2), 120.8 
(ArCBr), 68.3 (Cquat), 51.5 (CH2N3), 39.2 (CH2, t, JCF 25.5), 39.0 (CH2, t, JCF 22.9), 36.6 (NCH3, t, 
JCF 3.8), 28.9 (CH2), 28.8 (CH2), 27.7 (CH3), 26.6 (CH2), 22.1 (CH2, t, JCF 4.3). 19F NMR (377 MHz, 
CDCl3) δ –96.2-–96.4 (2 F, m, CF2). HRMS m/z (ESI+) m/z calcd for C24H29N5OF2Cl2Br+ [M+H]+ 














1-(1,4-Bis(4-bromophenyl)-1-(3,4-dichlorophenyl)-3,3-difluorobutyl)-1,3-dimethylurea       
(296) 
 
Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(3,4-dichlorophenyl)vinyl)-1,3-dimethylurea (245) (83 mg, 0.2 mmol) and sodium 2-(4-
bromophenyl)-1,1-difluoroethanesulfinate (123 mg, 2.0 eq., 0.4 mmol) used as starting 
materials and acetone used as solvent. The reaction mixture was stirred for 20 hours to give 
the title compound (90 mg, 71%) as a white solid. 
M.p. 196-200 °C (Et2O). IR (film, cm-1) νmax = 3367, 2962, 1640, 1489, 1008. 1H NMR (400 MHz, 
CDCl3) δ 7.53 (2 H, d, J 8.2, 2 x ArCH), 7.31 (2 H, d, J 8.7, 2 x ArCH), 7.25-7.20 (3 H, m, 2 x ArCH 
+ ArCH), 7.12 (1 H, d, J 1.4, ArCH), 6.99-6.93 (3 H, m, 2 x ArCH + ArCH), 4.65 (1 H, q, J 4.5, NH), 
3.62-3.42 (2 H, m, CH2), 3.19 (2 H, t, J 16.0, CH2), 2.80-2.76 (6 H, m, 2 x CH3). 13C NMR (126 
MHz, CDCl3) δ 159.6 (CO), 146.4 (Cquat), 143.7 (Cquat), 132.5 (2 x ArCH), 132.3 (ArCCl), 132.0 (2 
x ArCH), 131.9 (Cquat),  131.5 (2 x ArCH), 130.4 (ArCCl), 130.1 (ArCH), 128.3 (2 x ArCH), 127.9 
(ArCH), 125.6 (ArCH), 123.3 (CF2, t, JCF 246.5), 122.1 (ArCBr), 120.8 (ArCBr), 68.3 (Cquat), 44.7 
(CH2, t, JCF 26.5), 38.3 (CH2, t, JCF 22.4), 36.5 (NCH3, t, JCF 3.9), 27.7 (NCH3). 19F NMR (377 MHz, 
CDCl3) δ –94.2-–94.4 (2 F, m, CF2). HRMS m/z (ESI+) m/z calcd for C25H23N2OF2Cl2Br2+ [M+H]+ 


















Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(3,4-dichlorophenyl)vinyl)-1,3-dimethylurea (245)  (83 mg, 0.2 mmol) and sodium 2-(3-
bromophenyl)-1,1-difluoroethanesulfinate  (123 mg, 2.0 eq., 0.4 mmol) used as starting 
materials and DMF used as solvent. The reaction mixture was stirred for 23 hours to give the 
title compound (61 mg, 48%) as a pale-yellow solid. 
M.p. 179-182 °C (CDCl3). IR (film, cm-1) νmax = 3366, 2929, 1643, 1476. 1H NMR (400 MHz, 
CDCl3) δ 7.60-7.50 (2 H, m, ArCH + ArCH), 7.35 (2 H, d, J 8.5, 2 x ArCH), 7.33-7.26 (3 H, m, ArCH 
+ ArCH + ArCH), 7.18 (1 H, d, J 1.2, ArCH), 7.05 (3 H, m, 2 x ArCH + ArCH), 4.68 (1 H, q, J 4.5, 
NH), 3.56-3.44 (2 H, m, CH2), 3.24 (2 H, t, J 16.1, CH2), 2.90-2.77 (6 H, m, NCH3 + NCH3). 13C 
NMR (126 MHz, CDCl3) δ 156.9 (CO), 146.5 (Cquat), 143.6 (Cquat), 135.2 (Cquat, t, JCF 3.9), 133.7 
(ArCH), 132.3 (ArCCl), 131.5 (2 x ArCH), 131.1 (ArCH), 130.4 (ArCCl), 130.3 (ArCH), 130.1 
(ArCH), 129.4 (ArCH), 128.3 (2 x ArCH), 127.9 (ArCH), 125.5 (ArCH), 123.3 (CF2, t, JCF 244.7), 
122.8 (ArCBr), 120.8 (ArCBr), 68.3 (Cquat), 44.9 (CH2, t, JCF 26.2), 38.4 (CH2, t, JCF 22.4), 36.5 
(NCH3, t, JCF 3.9), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) δ –94.1-–94.3 (2 F, m, CF2). HRMS 


















Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(3,4-dichlorophenyl)vinyl)-1,3-dimethylurea (245)  (83 mg, 0.2 mmol) and sodium 2-(2-
bromophenyl)-1,1-difluoroethanesulfinate (123 mg, 2.0 eq., 0.4 mmol) used as starting 
materials and acetone used as solvent. The reaction mixture was stirred for 23 hours to give 
the title compound (120 mg, 94%) as a beige solid. 
M.p.  92-94 °C (CHCl3). IR (film, cm-1) νmax = 3367, 2936, 1642, 1476.  1H NMR (400 MHz, CDCl3) 
δ 7.69 (1 H, dd, J 7.6, 1.3, ArCH), 7.44 (1 H, d, J 7.6, ArCH), 7.36 (1 H, td, J 7.6, 1.3, ArCH), 7.27 
(2 H, d, J 8.8, 2 x ArCH), 7.23 (1 H, td, J 7.6, 1.3, ArCH), 7.21 (1 H, d, J 8.6, ArCH), 7.16 (1 H, d,  
J 2.3, ArCH), 7.00 (1 H, dd, J 8.6, 2.3, ArCH), 6.90 (2 H, d, J 8.8, 2 x ArCH),  4.62 (1 H, q, J 4.6, 
NH), 3.67-3.48 (4 H, m, CH2 + CH2), 2.80 (3 H, s, NCH3), 2.79 (3 H, d, J 4.6, NCH3). 13C NMR (126 
MHz, CDCl3) δ 159.5 (CO), 146.8 (Cquat), 144.0 (Cquat), 135.5 (ArCH), 133.0 (ArCH), 133.0 (Cquat), 
132.3 (ArCCl), 131.5 (2 x ArCH), 130.2 (ArCCl), 130.1 (ArCH), 129.7 (ArCH), 128.2 (2 x ArCH), 
127.8 (ArCH), 127.8 (ArCH), 126.0 (ArCBr), 125.4 (ArCH), 123.8 (CF2, t, JCF 246.8), 120.7 (ArCBr), 
68.1 (Cquat), 44.4 (CH2, t, JCF 26.6), 38.0 (CH2, t, JCF 22.2), 36.4 (CH3, t, JCF 4.0), 27.7 (CH3). 19F 
NMR (377 MHz, CDCl3) δ –93.5-–93.7 (2 F, m, CF2). HRMS m/z (ESI+) m/z calcd for 


















Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(4-chlorophenyl)vinyl)-1,3-dimethylurea (221) (76 mg, 0.2 mmol) and sodium 
1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfinate (288)  (122 mg, 2.0 eq., 0.4 mmol) used as 
starting materials and acetonitrile used as solvent. The reaction mixture was stirred for 16 
hours to give the title compound (84 mg, 70%) as a white solid. 
M.p. 172-174 °C (Et2O). IR (film, cm-1) νmax = 3366, 2971, 1639, 1221, 1132. 1H NMR (400 MHz, 
CDCl3) δ 7.38 (2 H, d, J  8.6, 2 x ArCH), 7.23 (2 H, d, J  8.7, 2 x ArCH), 7.18 (2 H, d, J  8.7, 2 x 
ArCH), 7.12 (2 H, d, J  8.6, 2 x ArCH), 4.64 (1 H, br. q, J 4.4, NH), 3.88 (2 H, t, J 19.5, CH2), 2.82 
(3 H, s, CH3), 2.79 (3 H, d, J 4.4, CH3). 19F decoupled 13C NMR (101 MHz, CDCl3) δ 159.4 (CO), 
143.8 (Cquat), 143.1 (Cquat), 132.8 (ArCCl), 131.6 (2 x ArCH), 128.7 (2 x ArCH), 127.9 (2 x ArCH), 
127.6 (2 x ArCH), 120.9 (ArCBr), 118.7 (CH2CF2), 117.5 (CF3), 110.6 (CF2), 108.9 (CF2), 68.2 
(Cquat), 36.4 (NCH3), 33.4 (CH2CF2), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) δ –80.8 (3 F, t, J 9.5, 
CF3), –110.7 (2 F, br. qn, J 15.0, CF2), –123.8 (2 F, br. s, CF2), –125.4-–125.6 (2 F, m, CF2). HRMS 



















Formation of the title compound was carried out by following GP2 with 1-(4-bromophenyl)-
3-(1-(4-chlorophenyl)vinyl)-1,3-dimethylurea (221) (76 mg, 0.2 mmol) and sodium 
1,1,2,2,3,3,4,4,5,5,6,6,6-tridecafluorohexane-1-sulfinate (289) (162 mg, 2.0 eq., 0.4 mmol) 
used as starting materials and acetone used as solvent. The reaction mixture was stirred for 
19 hours to give the title compound (93 mg, 66%) as a white solid. 
M.p. 87-90 °C (Et2O). IR (film, cm-1) νmax = 3360, 2969, 1642, 1235, 1195, 1143. 1H NMR (400 
MHz, CDCl3) δ 7.38 (2 H, d, J  8.4, 2 x ArCH), 7.23 (2 H, d, J  8.8, 2 x ArCH), 7.18 (2 H, d, J  8.8, 
2 x ArCH), 7.12 (2 H, d, J  8.4, 2 x ArCH), 4.64 (1 H, br. s, NH), 3.88 (2 H, t, J 19.2, CH2), 2.82       
(3 H, s, CH3), 2.79 (3 H, d, J 4.1, CH3). 19F decoupled 13C NMR (101 MHz, CDCl3) δ 159.4 (CO), 
143.9 (Cquat), 143.1 (Cquat), 132.8 (ArCCl), 131.6 (2 x ArCH), 128.7 (2 x ArCH), 127.9 (2 x ArCH), 
127.6 (2 x ArCH), 120.9 (ArCBr), 118.8 (CH2CF2), 117.3 (CF3), 111.2 (CF2), 111.1 (CF2), 110.4 
(CF2), 108.6 (CF2), 68.2 (Cquat), 36.3 (NCH3), 33.4 (CH2), 27.7 (NCH3). 19F NMR (377 MHz, CDCl3) 
δ –80.6 (3 F, t, J 9.4, CF3), –110.4 (2 F, br. qn, J 16.3, CF2), –121.3 (2 F, br. s, CF2), –122.6 (2 F, 
br. s, CF2), –122.9 (2 F, br. s, CF2), –126.0 (2 F, br. s, CF2). HRMS m/z (ESI+) m/z calcd for 















1-(1-(4-Chlorophenyl)-2-(diphenylphosphoryl)-1-(4-iodophenyl)ethyl)-1,3-dimethylurea   
(306) 
 
Formation of the title compound was carried out by following GP3, with diphenylphosphine 
oxide (304) (28 mg, 1.4 eq., 0.14 mmol) used as starting material. The reaction mixture was 
stirred for 16 hours, then purified by flash column chromatography (SiO2, 0% to 55% THF + 
3% NEt3 in n-pentane) to give the title compound (40 mg, 64%) as a colourless film. 
IR (film, cm-1) νmax = 3343, 2924, 1635, 1534, 1485, 1183. 1H NMR (500 MHz, CDCl3) δ 7.75     
(4 H, br. t, J 9.0, 4 x ArCH), 7.48 (2 H, d, J 8.6, 2 x ArCH), 7.47 (2 H, br. t, J 7.3, 2 x ArCH), 7.44-
7.38 (4 H, m, 4 x ArCH), 7.29 (2 H, d, J 8.6, 2 x ArCH), 7.14 (2 H, d, J 8.6, 2 x ArCH), 7.08 (2 H, d,             
J 8.6, 2 x ArCH), 4.37 (1 H, q, J 4.5, NH), 4.09 (2 H, d, J 11.4, CH2), 2.63 (3 H, s, CH3), 2.43 (3 H, 
d, J 4.5, CH3). 13C NMR (126 MHz, CDCl3) δ 159.1 (CO), 144.7 (Cquat, d, JCP 5.7), 143.0 (Cquat, d, 
JCP 5.7), 137.1 (2 x ArCH), 134.4 (Cquat, d, JCP 99.8), 134.2 (Cquat, d, JCP 99.8), 132.7 (ArCCl), 131.4 
(2 x ArCH, t, JCP 2.5), 130.8 (4 x ArCH, dd, JCP 9.1, 6.4), 129.4 (2 x ArCH), 128.9 (2 x ArCH), 128.5 
(4 x ArCH, dd, JCP 11.8, 4.6), 128.2 (2 x ArCH), 92.7 (ArCI), 69.6 (Cquat, d, JCP 5.6), 38.4 (CH2, d, 
JCP 71.4), 36.9 (CH3), 27.3 (CH3). 31P NMR (162 MHz, CDCl3) δ 24.8 (1 P, br. t, J 11.4, PO). HRMS 

















Bis(3-methoxyphenyl)phosphine oxide (312) 
 
A solution of 1-bromo-3-methoxybenzene (307) (1.89 g, 2.80 g, 15.0 mmol) in anhydrous THF              
(20.0 mL) was prepared under a nitrogen atmosphere in a flame-dried Schlenk tube. To a 
separate flame-dried Schlenk tube magnesium turnings (510 mg, 21 mmol) and a single crystal 
of iodine were added under a nitrogen atmosphere. The solution of 1-bromo-4-
chlorobenzene was added to the magnesium turnings at a rate to achieve a gently refluxing 
solution from the exotherm while stirring. The reaction mixture was stirred for 1.5 hours at 
room temperature. A solution of diethyl phosphonate (311) (0.64 mL, 691 mg, 5 mmol) in 
anhydrous THF (10 mL) was prepared under a nitrogen atmosphere in a flame-dried Schlenk 
tube and cooled to 0 °C. The solution of Grignard reagent was added slowly to the solution of 
diethyl phosphonate. The reaction mixture was warmed to room temperature and stirred 18 
hours, then quenched with water (40 mL) and extracted with ethyl acetate (3 x 40 mL). The 
combined organic extracts were dried (Na2SO4) and concentrated under reduced pressure to 
yield a white solid as crude product. Crude product was purified by flash column 
chromatography (SiO2, 20% to 100% EtOAc in 40-60 petroleum ether) yielding the title 
compound (229 mg, 17%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 8.03 (1 H, d, J 482.0, PH), 7.41 (2 H, td, J 7.9, 3.9, 2 x ArCH), 7.29-

















Bis(4-chlorophenyl)phosphine oxide (313) 
 
A solution of 1-bromo-4-chlorobenzene (308) (2.87 g, 15 mmol) in anhydrous THF (20 mL) was 
prepared under a nitrogen atmosphere in a flame-dried Schlenk tube. To a separate flame-
dried Schlenk tube magnesium turnings (510 mg, 21 mmol) and a single crystal of iodine were 
added under a nitrogen atmosphere. The solution of 1-bromo-4-chlorobenzene was added to 
the magnesium turnings at a rate to achieve a gently refluxing solution from the exotherm 
while stirring. The reaction mixture was stirred for 1.5 hours at room temperature. A solution 
of diethyl phosphonate (0.64 mL, 691 mg, 5 mmol) (311) in anhydrous THF (10 mL) was 
prepared under a nitrogen atmosphere in a flame-dried Schlenk tube and cooled to 0 °C. The 
solution of Grignard reagent was added slowly to the solution of diethyl phosphonate. The 
reaction mixture was warmed to room temperature and stirred 18 hours, then quenched with 
water (40 mL) and extracted with ethyl acetate (3 x 40 mL). The combined organic extracts 
were dried (Na2SO4) and concentrated under reduced pressure to yield a white solid as crude 
product. The crude product was purified by flash column chromatography (SiO2, 20% to 100% 
Et2O in 40-60 petroleum ether) yielding the title compound (507 mg, 38%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 8.06 (1 H, d, J 486.0, PH), 7.62 (4 H, dd, J 13.2 ,8.5, 4 x ArCH), 7.50 




















Formation of the title compound was carried out by following GP3, with bis(3,5-
dimethylphenyl)phosphine oxide (36 mg, 1.4 eq., 0.14 mmol) used as starting material. The 
reaction mixture was stirred for 20 hours, then purified by flash column chromatography 
(SiO2, 0% to 3% MeOH in DCM) then again (SiO2, 0% to 60% Et2O in n-pentane) to give the title 
compound (41 mg, 60%) as a colourless film. 
IR (film, cm-1) νmax = 3335, 2924, 1650, 1487, 1179. 1H NMR (500 MHz, CDCl3) δ 7.47 (2 H, d, J 
8.7, 2 x ArCH), 7.31 (4 H, dd, J  9.0, 3.0, 4 x ArCH), 7.3 (2 H, d, J  8.7, 2 x ArCH), 7.13 (2 H, d, J  
8.7, 2 x ArCH), 7.08 (2 H, d, J 8.7, 2 x ArCH), 7.06 (2 H, s, 2 x ArCH), 4.48 (1 H, q, J 4.7, NH), 3.98 
(2 H, d, J  11.4, CH2), 2.64 (3 H, s, CH3), 2.47 (3 H, d, J 4.7, CH3), 2.31 (12 H, s, 4 x CH3). 13C NMR 
(126 MHz, CDCl3) δ 159.2 (CO), 144.7 (Cquat, d, JCP 6.1), 143.0 (Cquat, d, JCP 5.9), 138.1 (4 x Cquat, 
dd, JCP 12.3, 6.8), 137.0 (2 x ArCH), 134.3 (Cquat, d, JCP 99.0), 134.1 (Cquat, d, JCP 99.0), 133.1 (2 x 
ArCH, dd, JCP 2.9, 1.5), 132.6 (ArCCl), 129.3 (2 x ArCH), 128.9 (2 x ArCH), 128.2 (4 x ArCH, dd, 
JCP 9.0, 6.6), 128.1 (2 x ArCH), 92.7 (ArCI), 69.6 (Cquat, d, JCP 5.4), 37.9 (CH2, d, JCP 70.6), 36.9 
(CH3), 27.3 (CH3), 21.5 (4 x CH3). 31P NMR (162 MHz, CDCl3) δ 25.2 (1 P, br. t, J 11.4, PO). HRMS 


















Formation of the title compound was carried out by following GP3, with di(naphthalen-2-
yl)phosphine oxide (42 mg, 1.4 eq., 0.14 mmol) used as starting material. The reaction mixture 
was stirred for 18 hours, then purified by flash column chromatography (SiO2, 0% to 55% THF 
+ 3% NEt3 in n-pentane) then again (SiO2, 0% to 40% acetone in n-pentane) to give the title 
compound (53 mg, 73%) as a colourless film. 
IR (film, cm-1) νmax = 3349, 2925, 1639, 1485, 1085. 1H NMR (500 MHz, CDCl3) δ 8.41 (2 H, d, J 
13.3, 2 x ArCH), 7.90 (2 H, d, J 8.0, 2 x ArCH), 7.89-7.80 (6 H, m, 6 x ArCH), 7.55 (4 H, pd, J 7.2, 
2.0, 4 x ArCH), 7.49 (2 H, d, J 8.7, 2 x ArCH), 7.33 (2 H, d, J 8.8, 2 x ArCH), 7.15 (2 H, d, J 8.8,      
2 x ArCH), 7.12 (2 H, d, J 8.7, 2 x ArCH), 4.31 (2 H, d, J 11.1, CH2), 4.13 (1 H, q, J 4.6, NH), 2.65 
(3 H, s, CH3), 2.08 (3 H, d, J 4.7, CH3). 13C NMR (126 MHz, CDCl3) δ 158.7 (CO), 145.0 (Cquat, d, 
JCP 6.0), 143.3 (Cquat, d, JCP 5.7), 137.0 (2 x ArCH), 134.5 (2 x Cquat, d, JCP 2.3), 132.7 (ArCCl), 
132.5 (2 x ArCH), 132.4 (2 x Cquat, d, JCP 5.5), 131.4 (Cquat, d, JCP 100.2), 131.3 (Cquat, d, JCP 100.2), 
129.2 (2 x ArCH), 129.1 (2 x ArCH), 128.8 (2 x ArCH), 128.3 (2 x ArCH, dd, JCP 11.5, 7.4), 128.2 
(2 x ArCH), 128.2 (2 x ArCH), 127.9 (2 x ArCH), 126.9 (2 x ArCH), 126.0 (2 x ArCH, dd, JCP 9.9, 
7.0), 92.6 (ArCI), 69.7 (Cquat, d, JCP 5.5), 37.9 (CH2, d, JCP 71.6), 37.0 (CH3), 26.8 (CH3). 31P NMR 
(162 MHz, CDCl3) δ 25.0 (1 P, br. t, J 11.1, PO). HRMS m/z (ESI+) m/z calcd for C37H32ClIN2O2P+ 
















Formation of the title compound was carried out by following GP3, with bis(4-
chlorophenyl)phosphine oxide (313) (38 mg, 1.4 eq., 0.14 mmol) used as starting material. 
The reaction mixture was stirred for 18 hours, then purified by flash column chromatography 
(SiO2, 0% to 50% Et2O in DCM) to give the title compound (33 mg, 48%) as a colourless film. 
Note - Product was observed to decompose in CDCl3 over the course of a night. 
IR (film, cm-1) νmax = 3351, 2919, 1644, 1481, 1088. 1H NMR (400 MHz, CDCl3) δ 7.66 (4 H, dd, 
J 10.9, 8.5, 4 x ArCH), 7.50 (2 H, d, J 8.8, 2 x ArCH), 7.39 (4 H, dd, J 8.5, 7.4, 4 x ArCH), 7.27 (2 
H, d, J 8.9, 2 x ArCH), 7.16 (2 H, d, J 8.9, 2 x ArCH), 7.06 (2 H, d, J 8.8, 2 x ArCH), 4.28 (1 H, q, J 
4.9, NH), 4.10 (2 H, d, J 11.2, CH2), 2.63 (3 H, s, CH3), 2.47 (3 H, d, J 4.9, CH2). 13C NMR (101 
MHz, CDCl3) δ 159.0 (CO), 144.4 (Cquat, d, JCP 6.0), 142.7 (Cquat, d, JCP 5.8), 138.3 (2 x ArCCl, d, 
JCP 3.1), 137.2 (2 x ArCH), 133.0 (ArCCl), 132.5 (Cquat, d, JCP 101.2), 132.3 (Cquat, d, JCP 101.2),  
132.2 (4 x ArCH, dd, JCP 9.9, 4.7), 129.3 (2 x ArCH), 128.9 (4 x ArCH, dd, JCP 12.4, 4.1), 128.9     
(2 x ArCH), 128.3 (2 x ArCH), 92.9 (ArCI), 69.6 (Cquat, d, JCP 5.5), 38.7 (CH2, d, JCP 72.7), 36.9 
(CH3), 27.3 (CH3). 31P NMR (162 MHz, CDCl3) δ 25.0 (1 P, br. t, J 11.2, PO). HRMS m/z (ESI+) 

















Formation of the title compound was carried out by following GP4 with 1-(1-(4-
bromophenyl)-1-(3,4-dichlorophenyl)-3,3,3-trifluoropropyl)-1,3-dimethylurea (262) (75 mg, 
0.16 mmol) used as starting material. The reaction gave the title compound (51 mg, 77%) as 
a colourless oil. 
IR (film, cm-1) νmax = 2925, 1257, 1115. 1H NMR (400 MHz, CDCl3) δ 7.46 (1 H, d, J 2.2, ArCH), 
7.44 (2 H, d, J 8.6, 2 x ArCH), 7.36 (1 H, d, J 8.5, ArCH), 7.18 (2 H, d, J 8.6, 2 x ArCH), 7.11 (1 H, 
dd, J 8.5, 2.2, ArCH), 3.14 (2 H, qd, J 10.7, 1.8, CH2), 2.16 (3 H, s, CH3), 1.82 (1 H, br. s, NH).     
13C NMR (101 MHz, CDCl3) δ 145.2 (Cquat), 143.2 (Cquat), 132.6 (ArCCl), 131.6 (2 x ArCH), 131.3 
(ArCCl), 130.3 (ArCH), 128.7 (ArCH), 128.4 (2 x ArCH), 126.3 (ArCH), 125.8 (CF3, q, JCF 279.0), 
121.4 (ArCBr), 62.3 (Cquat, q, JCF 1.8), 38.4 (CH2, q, JCF 25.5), 26.3 (NCH3). 19F NMR (377 MHz, 
CDCl3) δ –59.0 (3 F, t, J 10.7, CF3). HRMS m/z (ESI+) m/z calcd for C16H14NCl2BrF3+ [M+H]+ 
425.9633; found 425.9626. 
1-(4-Chlorophenyl)-3,3,3-trifluoro-1-(4-iodophenyl)-N-methylpropan-1-amine (327) 
 
Formation of the title compound was carried out by following GP4 with 1-(1-(4-chlorophenyl)-
3,3,3-trifluoro-1-(4-iodophenyl)propyl)-1,3-dimethylurea (266) (49 mg, 0.1 mmol) used as 
starting material. The reaction gave the title compound (32 mg, 74%) as a colourless oil. 
IR (film, cm-1) νmax = 2955, 1259, 1004, 807. 1H NMR (400 MHz, CDCl3) δ 7.62 (2 H, d, J 8.7,      
2 x ArCH), 7.27 (2 H, d, J 9.0, 2 x ArCH), 7.23 (2 H, d, J 9.0, 2 x ArCH), 7.05 (2 H, d, J 8.7,                       
2 x ArCH), 3.15 (2 H, q, J 10.3, CH2), 2.15 (3 H, s, NCH3), 1.83 (1 H, br. s, NH). 13C NMR (101 
MHz, CDCl3) δ 144.8 (Cquat), 143.3 (Cquat), 137.6 (2 x ArCH), 133.1 (ArCCl), 128.9 (2 x ArCH), 
128.6 (2 x ArCH), 128.3 (2 x ArCH), 126.1 (CF3, q, JCF 278.6), 92.9 (ArCI), 62.6 (Cquat, q, JCF 1.7), 
38.7 (CH2, q, JCF 25.3), 29.4 (NCH3). 19F NMR (377 MHz, CDCl3) δ –59.0 (3 F, t, J 10.3, CF3). 











Formation of the title compound was carried out by following GP4 with 1-(1-(4-chlorophenyl)-
3,3,3-trifluoro-1-(4-(trifluoromethoxy)phenyl)propyl)-1,3-dimethylurea (261) (34 mg, 0.08 
mmol) used as starting material. The reaction gave the title compound (17 mg, 57%) as a 
colourless oil. 
IR (film, cm-1) νmax = 3049, 1255, 1211, 1109. 1H NMR (400 MHz, CDCl3) δ 7.33 (2 H, d, J 8.9,   
2 x ArCH), 7.28 (2 H, d, J 9.0, 2 x ArCH), 7.25 (2 H, d, J 9.0, 2 x ArCH), 7.14 (2 H, dq, J 8.9, 1.0,  
2 x ArCH), 3.17 (2 H, q, J 10.2, CH2), 2.16 (3 H, s, NCH3), 1.88 (1 H, br. s, NH). 13C NMR (126 
MHz, CDCl3) δ 148.2 (Cquat), 143.5 (Cquat), 143.4 (Cquat), 133.2 (ArCCl), 128.7 (2 x ArCH), 128.4 
(2 x ArCH), 128.3 (2 x ArCH), 126.0 (CF3, q, JCF 278.3), 120.7 (2 x ArCH), 120.6 (OCF3, q, JCF 
257.8), 62.5 (Cquat), 38.9 (CH2, q, JCF 25.5), 29.4 (NCH3). 19F NMR (377 MHz, CDCl3) δ –57.9          
(3 F, s, OCF3), –59.1 (3 F, t, J 10.2, CF3). HRMS m/z (ESI+) m/z calcd for C17H15NOClF6+ [M+H]+ 
398.0741; found 398.0727; m/z calcd for C16H10OClF6+ [M-NHMe]+ 367.0319; found 367.0312. 




Formation of the title compound was carried out by following GP4 with 1-(1-(4-chlorophenyl)-
3,3,3-trifluoro-1-(3-(trifluoromethyl)phenyl)propyl)-1,3-dimethylurea (265) (31 mg, 0.07 
mmol) used as starting material. The reaction gave the title compound (21 mg, 79%) as a 
colourless oil. 
IR (film, cm-1) νmax = 2955, 1328, 1121, 1075. 1H NMR (400 MHz, CDCl3) δ 7.65 (1 H, br. s, 
ArCH), 7.50 (1 H, br. d, J 7.3, ArCH), 7.46 (1 H, td, J 8.1, 1.6, ArCH), 7.41 (1 H, dd, J 8.1, 7.3, 
ArCH), 7.29 (2 H, d, J 9.0, 2 x ArCH), 7.25 (2 H, d, J 9.0, 2 x ArCH), 3.21 (2 H, qd, J 10.9, 1.6, 
CH2), 2.17 (3 H, s, NCH3), 1.90 (1 H, br. s, NH). 13C NMR (101 MHz, CDCl3) δ 146.1 (Cquat), 143.0 
(Cquat), 133.3 (ArCCl), 130.9 (Cquat, q, JCF 32.3), 130.5 (ArCH), 129.0 (ArCH), 128.8 (2 x ArCH), 
128.3 (2 x ArCH), 126.0 (CF3, q, JCF 278.9), 124.2 (ArCCF3, q, JCF 272.2), 124.2 (ArCH, q, JCF 3.8), 
123.3 (ArCH, q, JCF 3.8), 62.8 (Cquat, q, JCF 1.7), 38.8 (CH2, q, JCF 25.4), 29.4 (NCH3). 19F NMR (377 
MHz, CDCl3) δ –59.1 (3 F, t, J 10.9, CF3), –62.5 (3 F, s, ArCF3). HRMS m/z (ESI+) m/z calcd for 






Following GP2 with 1-(4-bromophenyl)-3-(1-(4-chlorophenyl)vinyl)-1,3-dimethylurea (221) 
(76 mg, 0.2 mmol), sodium trifluoromethanesulfinate (134)  (47 mg, 1.5 eq., 0.3 mmol) and  
ethene-1,1-diyldibenzene (135) (53 L, 1.5 eq., 0.3 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 15 hours. The obtained crude 
material was analysed by 19F NMR and yields were calculated by use of α,α,α-trifluorotoluene 
as an internal standard (0.2 mmol), indicating the presence of 1-(1-(4-bromophenyl)-1-(4-
chlorophenyl)-3,3,3-trifluoropropyl)-1,3-dimethylurea (234) (6%) and (3,3,3-
trifluoropropane-1,1-diyl)dibenzene (338) (17%). Isolation of the title compounds was 
attempted by flash column chromatography (SiO2, 0% to 1% Et2O in n-pentane), but could not 
be separated from ethene-1,1-diyldibenzene (135). 
1H NMR (400 MHz, CDCl3) δ 7.29-7.19 (10 H, m, 10 x ArCH), 4.32 (1 H, t, J 7.4, CH), 2.89 (2 H, 
qd, J, 10.4, 7.4, CH2). 19F NMR (377 MHz, CDCl3) δ –63.5 (3 F, t, J 10.4, CF3). Data in good 





















Formation of the title compound was carried out by following GP1 with 1-(4-
chlorophenyl)ethan-1-one (208) (1.30 mL, 1.54 g, 10.0 mmol) and ethyl isocyanate (12.0 mL, 
10.7 g, 151 mmol) used as starting materials. The imine intermediate was stirred with the 
requisite alkyl isocyanate for 28 hours. The excess ethyl isocyanate was removed under 
reduced pressure and the received crude material was purified by flash column 
chromatography (SiO2, 0% to 30% acetone in 40-60 petroleum ether) yielding crude material 
(1.43 g) as a yellow oil. Subsequent methylation with methyl iodide was carried out on a 6.0 
mmol scale (by making as if the received crude material was pure) and was stirred for 20 
hours. The resulting crude material was purified by flash column chromatography (SiO2, 0% 
to 30% acetone in 40-60 petroleum ether) yielding the title compound (638 mg, 27% over 
three steps) as a colourless oil. 
IR (film, cm-1) νmax = 2970, 1650, 1487, 1307. 1H NMR (400 MHz, CDCl3) δ 7.43-7.39 (2 H, m,   
2 x ArCH), 7.33-7.30 (2 H, m, 2 x ArCH), 5.10 (1 H, d, J 0.8, CHaHb), 4.79 (1 H, d, J 0.8, CHaHb), 
3.20 (2 H, q, J  7.1, CH2), 2.97 (3 H, s, NCH3), 2.72 (3 H, s, NCH3), 0.97 (3 H, t, J  7.1, CH3). 13C 
NMR (101 MHz, CDCl3) δ 161.6 (CO), 150.1 (Cquat), 136.2 (Cquat), 134.5 (ArCCl), 128.8 (2 x ArCH), 
127.6 (2 x ArCH), 104.0 (CH2), 44.3 (NCH2), 38.0 (NCH3), 35.0 (NCH3), 12.3 (CH3). HRMS m/z 



















Formation of the title compound was carried out by following GP2 with 1-(1-(4-
chlorophenyl)vinyl)-3-ethyl-1,3-dimethylurea (339) (25 mg, 0.1 mmol) and sodium 
trifluoromethanesulfinate (134) (31 mg, 2.0 eq., 0.2 mmol) used as starting materials and 
acetonitrile used as solvent. The reaction mixture was stirred for 16 hours to give the title 
compound (25 mg, 76%) as a yellow oil. 
IR (film, cm-1) νmax = 2974, 1634, 1493, 1386, 1122. 1H NMR (400 MHz, CDCl3) δ 7.30-7.36        
(2 H, m, 2 x ArCH), 7.34-7.30 (2 H, m, 2 x ArCH), 5.43 (1 H, dd, J 9.9, 5.0, CH), 3.28-3.10 (2 H, 
m, NCH2), 2.99-2.83 (1 H, m, CHaHb), 2.77 (3 H, s, CH3), 2.71-2.64 (1 H, m, CHaHb), 2.63 (3 H, s, 
CH3), 1.14 (3 H, t, J 7.1, CH3). 13C NMR (101 MHz, CDCl3) δ 164.7 (CO), 137.2 (Cquat), 133.9 
(Cquat), 129.5 (2 x ArCH), 128.8 (2 x ArCH), 126.3 (CF3, q, JCF 272.9), 53.7 (CH, q, JCF 3.3), 45.1 
(NCH2), 35.5 (NCH3), 34.9 (CH2, q, JCF 27.6), 32.9 (NCH3), 12.8 (CH3). 19F NMR (377 MHz, CDCl3) 




Formation of the title compound was carried out by following GP2 with 1-(1-(4-
chlorophenyl)vinyl)-1,3-dimethyl-3-(m-tolyl)urea (223) (32 mg, 0.1 mmol), sodium 
trifluoromethanesulfinate (134) (31 mg, 2.0 eq., 0.2 mmol) and water (18 mg, 10 eq., 1.0 
mmol) used as starting materials and acetone used as solvent. The reaction mixture was 
stirred for 16 hours to give the title compound (23 mg, 61%) as a yellow oil. 
IR (film, cm-1) νmax = 2931, 1639, 1493, 1333, 1122. 1H NMR (400 MHz, CDCl3) δ 7.33-7.29        
(2 H, m, 2 x ArCH), 7.28-7.24 (2 H, m, 2 x ArCH), 7.18 (1 H, t, J 7.8, ArCH), 6.93 (1 H, br. d, J 7.8, 
ArCH), 6.84 (1 H, br. d, J 7.8, ArCH), 6.80 (1 H, br. s, ArCH), 5.68 (1 H, dd, J 8.8, 3.3, CH), 3.19 
(3 H, s, CH3), 2.83-2.93 (2 H, m, CH2), 2.29 (3 H, s, CH3), 2.26 (3 H, s, ArCCH3). 13C NMR (101 
MHz, CDCl3) δ 161.8 (CO), 146.3 (Cquat), 139.6 (ArCCH3), 136.8 (Cquat), 134.0 (ArCCl), 129.5 
(ArCH), 129.3 (2 x ArCH), 128.8 (2 x ArCH), 126.1 (CF3, q, JCF 278.9) 126.0 (ArCH), 125.6 (ArCH), 
122.0 (ArCH), 53.5 (CH, q, JCF 3.9), 40.7 (NCH3), 34.8 (CH2, q, JCF 28.2) 32.3 (NCH3), 21.3 
(ArCCH3). 19F NMR (377 MHz, CDCl3) δ –63.7 (3 F, t, J 10.4, CF3). HRMS m/z (ESI+) m/z calcd 






Formation of the title compound was carried out by following GP1 with acetophenone (81)        
(1.16 mL, 1.20 g, 10.0 mmol) and 1-isocyanato-4-methylbenzene (343) (1.26 mL, 1.33 g, 10.0 
mmol) used as starting materials. The imine intermediate was stirred with the requisite aryl 
isocyanate for 69 hours, subsequent methylation with methyl iodide was stirred for 23 hours. 
The resulting crude material was purified by flash column chromatography (SiO2, 1% to 20% 
acetone + 3% trimethylamine in 40-60 petroleum ether) yielding the title compound (587 mg, 
21%) as a pale-yellow solid. 
M.p. 61-63 °C (Et2O). IR (film, cm-1) νmax = 2924, 1656, 1613, 1513, 1353. 1H NMR (400 MHz, 
CDCl3) δ 7.28-7.23 (3 H, m, ArCH + 2 x ArCH), 7.15-7.10 (2 H, m, 2 x ArCH), 6.99 (2 H, d, J 8.7, 
2 x ArCH), 6.69 (2 H, d, J 8.7, 2 x ArCH), 4.86 (1 H, d, J 0.5, CHaCHb), 4.60 (1 H, d, J 0.5, CHaHb), 
3.20 (3 H, s, NCH3), 2.97 (3 H, s, NCH3), 2.27 (3 H, s, ArCCH3). 13C NMR (101 MHz, CDCl3) δ 
161.0 (CO), 150.4 (Cquat), 142.5 (Cquat), 138.3 (Cquat), 134.6 (Cquat), 129.3 (2 x ArCH), 128.3 
(ArCH), 128.1 (2 x ArCH), 126.0 (2 x ArCH), 125.4 (2 x ArCH), 106.9 (CH2), 39.4 (NCH3), 38.8 





















Formation of the title compound was carried out by following GP2 with 1,3-dimethyl-1-(1-
phenylvinyl)-3-(p-tolyl)urea (344) (56 mg, 0.2 mmol) and sodium trifluoromethanesulfinate 
(134)  (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and DMF used as solvent. The 
reaction mixture was stirred for 14 hours and purified by flash column chromatography (SiO2, 
0% to 20% acetone in n-pentane) to give the title compound (46 mg, 66%) as a pale-yellow 
solid. 
M.p. 116-120 °C (Et2O). IR (film, cm-1) νmax = 3369, 2951, 1640, 1529, 1259, 1107. 1H NMR 
(400 MHz, CDCl3) δ 7.29 (2 H, d, J 7.7, 2 x ArCH), 7.26-7.22 (2 H, m, 2 x ArCH), 7.19 (2 H, d,          
J 8.2, 2 x ArCH), 7.14 (1 H, br. t, J 7.1, ArCH), 7.06 (2 H, d, J 8.2, 2 x ArCH), 4.54 (1 H, br. q,            
J 4.6, NH), 3.94 (1 H, q, J 10.9, CHaHb), 3.94 (1 H, q, J 10.9, CHaHb), 2.81 (3 H, s, NCH3), 2.78       
(3 H, d, J 4.6, CH3), 2.26 (3 H, s, ArCCH3). 13C NMR (101 MHz, CDCl3) δ 159.7 (CO), 144.8 (Cquat), 
141.3 (Cquat), 136.4 (Cquat), 129.0 (2 x ArCH), 128.3 (2 x ArCH), 126.7 (ArCH), 126.7 (2 x ArCH), 
126.5 (CF3, q, JCF 279.4), 126.4 (2 x ArCH), 68.2 (Cquat, q, JCF 1.8), 38.9 (CH2, q, JCF 26.9), 36.5 
(NCH3, q, JCF 1.9), 27.7 (NCH3), 21.0 (ArCCH3). 19F NMR (377 MHz, CDCl3) δ –58.3 (3 F, t, J 10.9, 
CF3). HRMS m/z (ESI+) m/z calcd for C19H22N2OF3+ [M+H]+ 351.1679; found 351.1675. 
1,3-Dimethyl-1-(p-tolyl)-3-(3,3,3-trifluoro-1-phenylpropyl)urea (346) 
 
Formation of the title compound was carried out by following GP2 with 1,3-dimethyl-1-(1-
phenylvinyl)-3-(p-tolyl)urea (344) (56 mg, 0.2 mmol) and sodium trifluoromethanesulfinate 
(134)  (62 mg, 2.0 eq., 0.4 mmol) used as starting materials and acetone used as solvent. The 
reaction mixture was stirred for 16 hours to give the title compound (43 mg, 62%) as a yellow 
oil. 
IR (film, cm-1) νmax = 2925, 1641, 1335, 1123, 1348. 1H NMR (400 MHz, CDCl3) δ 7.36-7.26        
(5 H, m, 2 x ArCH + 2 x ArCH + ArCH), 7.08 (2 H, dd, J 8.6, 0.7, 2 x ArCH), 6.92 (2 H, d, J 8.4,         
2 x ArCH), 5.75 (1 H, dd, J 8.5, 5.9, CH), 3.19 (3 H, s, NCH3), 2.85-2.64 (2 H, m, CH2), 2.30 (3 H, 
s, ArCCH3), 2.30 (3 H, s, NCH3). 13C NMR (101 MHz, CDCl3) δ 161.9 (CO), 144.0 (Cquat), 138.3 
(Cquat), 135.0 (Cquat), 130.2 (2 x ArCH), 128.6 (2 x ArCH), 128.0 (ArCH), 127.8 (2 x ArCH), 126.3 
(CF3, q, JCF 277.7), 124.9 (2 x ArCH), 54.0 (CH), 40.8 (NCH3), 34.7 (CH2, q, JCF 28.0), 32.3 (NCH3), 
21.0 (ArCCH3). 19F NMR (377 MHz, CDCl3) δ –63.6 (3 F, t, J 10.3, CF3).  HRMS m/z (ESI+) m/z 




8.2.3 Cyclic Voltammetry Data 
Analyte was added to a 0.1 M solution of tetra-n-butylammonium hexafluorophosphate in 
dry, degassed acetonitrile (5 mL). A glassy carbon working electrode, a silver wire counter 
electrode and a Ag/AgNO3 reference electrode were used. A scan rate of 100 or 500 mV.s-1 


































8.2.4 Stern-Volmer Fluorescence Quenching Studies 
Samples for quenching experiments were prepared in a rubber septum sealed 4 mL quartz 
cuvette (path length: 𝑙  = 1.0 cm) under an atmosphere of nitrogen. Using fluorometry 
solutions of 4CzIPN (91) in anhydrous and degassed acetonitrile were irradiated at 435 nm 
and the emission spectrum was recorded. The fluorescence intensities at 527 nm of the 
collected emission spectra were plotted against quencher concentration. 
8.2.4.1 Study at Low Quencher Concentration 
An 8.0 x 10-6 M solution of 4CzIPN (91) in anhydrous and degassed acetonitrile was prepared. 
A 4 mL quartz cuvette (path length: 𝑙 = 1.0 cm)  was charged with a known amount of Langlois 
reagent (134), sealed with a rubber septum, flushed with nitrogen three times and finally 













An 8.0 x 10-6 M solution of 4CzIPN (91) in anhydrous and degassed acetonitrile was prepared. 
A 4 mL quartz cuvette (path length: 𝑙 = 1.0 cm)  was charged with a known amount of 1-(1-(4-
chlorophenyl)vinyl)-3-(3-fluorophenyl)-1,3-dimethylurea (219), sealed with a rubber septum, 
flushed with nitrogen three times and finally charged with 3.0 mL of the 4CzIPN (91) solution. 








8.2.4.2 Study at High Quencher Concentration 
A 9.9 x 10-6 M solution of 4CzIPN (91) in anhydrous and degassed acetonitrile was prepared 
and 2.0 mL were transferred to a 4 mL quartz cuvette (path length: 𝑙 = 1.0 cm) under an 
atmosphere of nitrogen. A 0.85 M solution of Langlois reagent (134) in anhydrous and 
degassed acetonitrile was prepared under an atmosphere of nitrogen. Aliquots of the Langlois 
reagent (134) solution were added to the solution of 4CzIPN (91) contained in the quartz 
cuvette (path length: 𝑙 = 1.0 cm) under an atmosphere of nitrogen, emission spectra were 

















A 9.9 x 10-6 M solution of 4CzIPN (91) in anhydrous and degassed acetonitrile was prepared 
and 2.0 mL were transferred to a 4 mL quartz cuvette (path length: 𝑙 = 1.0 cm) under an 
atmosphere of nitrogen. A 0.83 M solution of 1-(1-(4-chlorophenyl)vinyl)-3-(3-fluorophenyl)-
1,3-dimethylurea (219) in anhydrous and degassed acetonitrile was prepared under an 
atmosphere of nitrogen. Aliquots of the vinyl urea 219 solution were added to the solution of 
4CzIPN (91) contained in the quartz cuvette (path length: 𝑙 = 1.0 cm) under an atmosphere of 







8.2.5 Quantum Yield Elucidation 
The quantum yield was measured for the reaction between 1-(1-(4-chlorophenyl)vinyl)-3-(3-
fluorophenyl)-1,3-dimethylurea (219) (64 mg, 0.2 mmol), sodium trifluoromethanesulfinate 
(134) (46 mg, 1.5 eq., 0.3 mmol), 4CzIPN (91) (8 mg, 5 mol%, 10 mol) and caesium carbonate 
(98 mg, 1.5 eq., 0.3 mmol) in DMF. The reaction was performed in a quartz cuvette (path 
length: 𝑙 = 1.0 cm) positioned 5 cm away from a single 0.1 W blue LED.  
Under optimal conditions acetonitrile would be used as solvent, however this provides a 
heterogeneous reaction mixture reaction soon after irradiation (ca. 30 mins). Heterogeneity 
will have an impact on light penetration and potentially affect the accuracy of the quantum 
yield measurements. Therefore, to obtain a more accurate measurement the reaction was 
performed in DMF, which greatly improved reaction homogeneity and still gave productive 
formation of -tertiary urea (232) (54 mg, 70%) by following GP2 over 18 hours. 
Determination of the Photon Flux: 
The photon flux of a 0.1 W blue LED setup was determined using standard ferrioxalate 
actinometry.180 A 0.15 M ferrioxalate solution was prepared by dissolving 2.21 g of potassium 
ferrioxalate trihydrate in 30 mL of 0.05 M H2SO4(aq). A buffered 5.5 mM phenanthroline 
solution was prepared by dissolving 50 mg of 1,10-phenanthroline, 11.25 g of NaOAc•3H2O in 
50 mL of 0.5 M aq. H2SO4. Both solutions were stored in the dark. Whilst working under low 
light, 2.0 mL of the 0.15 M ferrioxalate solution was added to a quartz cuvette (l = 1.0 cm). 
The cuvette was placed 5 cm from a single 0.1 W blue LED and irradiated for a specific time 
(between 15 and 75 seconds). After irradiation, 1.0 mL of the phenanthroline solution was 
added to the cuvette. The mixture was left to stand for approximately 30 minutes before the 
absorbance at λ = 510 nm was measured by UV/Vis. spectroscopy. The absorbance of a non-
irradiated sample was also measured. Spectra were zeroed with respect to the 0.15 M 







The moles of Fe2+ formed were calculated using: 
mol Fe2+ =  
V × ΔA
𝑙 ×  ε
 
Where V is the total volume of the solution after the addition of 1,10-phenanthroline (0.0030 
L), ΔA is the difference in absorbance at λ = 510 nm between the irradiated and non-irradiated 
ferrioxalate solutions, 𝑙 is the optical path length of the irradiation cell (1.0 cm), and ε is the 
molar absorptivity of the [Fe(phen)3]2+ complex at λ = 510 nm (11,100 L.mol–1.cm–1).267 
 
The photon flux was calculated using: 
Photon Flux =  
mol Fe2+
Φ ×  t ×  f
 
Where Φ is the quantum yield of the ferrioxalate actinometer (1.0 at λ = 450 nm),181 t is the 
irradiation time of the ferrioxalate actinometer solution in seconds and f is the fraction of 
absorbed light of the 0.15 M ferrioxalate actinometer solution at λ = 450 nm (f = 1 – 10–A - The 
absorbance (A) of the ferrioxalate solution at λ = 450 nm was measured by UV/Vis. 
spectroscopy (see below) to be 1.131, therefore f = 0.951,). The terms for mol Fe2+  and t 










Photon Flux =  
1.271 ×  10−9
1 × 0.951
= 1.34 × 10−9 einstein. s−1 
Determination of the Quantum Yield: 
A 4 mL quartz cuvette (path length: 𝑙 = 1.0 cm) was charged with 4CzIPN (91) (8 mg, 0.01 
mmol), 1-(1-(4-chlorophenyl)vinyl)-3-(3-fluorophenyl)-1,3-dimethylurea (219) (64 mg, 0.2 
mmol), sodium trifluoromethanesulfinate (134) (46 mg, 1.5 eq., 0.3 mmol) and caesium 
carbonate (98 mg, 1.5 eq., 0.3 mmol). The cuvette was sealed with a rubber septum and the 
contents were flushed with nitrogen. Under low light, DMF (2 mL) was added and the reaction 
mixture was degassed by sparging with nitrogen for 10 min. The nitrogen inlet was removed, 
and the vial further sealed with parafilm. The reaction mixture was positioned 5 cm away 
from a single 0.1 W blue LED, stirred and irradiated for 4 hours. The reaction was worked up 
according to GP2 and the yield for -tertiary urea 232 was determined, by 19F NMR using 
α,α,α-trifluorotoluene as an internal standard, to be 1.2% (2.4 × 10–6 mol). 
The quantum yield () was calculated using: 
Φ =  
mol product
photon flux × t × f
 
 
Where t is the irradiation duration (14400 s) and f is the fraction of light absorbed by 4CzIPN 
at λ = 450 nm (for a 5.0 × 10–3 M solution in DMF, this was determined by UV/Vis spectroscopy 
to be 0.999) (See below). 
Φ =   
2.40 × 10−6
1.34 ×  10−9  × 14400 × 0.999





The reaction with vinyl urea 219 was repeated with an irradiation time of 24 hours (86400 s) 
to give a 13.1% (2.62 × 10–5 mol) yield of -tertiary urea 232. 
Φ =   
2.62 × 10−5
1.34 ×  10−9  × 86400 × 0.999
 = 0.228 


















8.3 Chapter 2 Experimental 
8.3.1 General Procedures 
General Procedure 5 (GP5): Synthesis of dibutyl phosophate bases by deprotonation. 
 
A 50 mL RBF was charged with base (1.0 eq.) and methanol (25 mL), then dibutyl hydrogen 
phosphate (419) (0.94 mL, 1.0 g, 4.8 mmol) was added. The reaction mixture was stirred for 
1 hour at room temperature. The reaction mixture was concentrated under reduced pressure 
and transferred to a Schlenk tube. The contents of the Schlenk tube were placed under 
vacuum and heated at 80 °C for 4 hours to give the desired product, which was stored under 
nitrogen. 
General Procedure 6 (GP6): Synthesis of allyl carbamates. 
 
A flame-dried RBF was charged with anhydrous acetonitrile (0.25 M), allyl alcohol (5.0 mmol, 
1.0 eq.), triethylamine (2.09 mL, 15 mmol, 3.0 eq.) and aryl isocyanate (6.0 mmol, 1.2 eq.) 
under a nitrogen atmosphere. The reaction mixture was stirred at 70 °C for 23 hours. After 
which, the reaction mixture was concentrated under reduced pressure and the crude residue 
was purified by silica column chromatography (2% to 20% EtOAc in 40-60 petroleum ether) 














General Procedure 7 (GP7): Synthesis of allyl ureas by reductive amination. 
 
A RBF was charged with aniline derivative (5.0 mmol, 1.0 eq.), methanol (HPLC-grade, 10 mL) 
and triethylamine (0.70 mL, 5.0 mmol, 1.0 eq.), then 3-methyl-2-butenal (476) (0.48 mL, 5.0 
mmol, 1.0 eq.). The reaction mixture was stirred at room temperature for 4 hours then cooled 
to 0 °C and sodium borohydride (270 mg, 7.0 mmol, 1.4 eq.) was added portion wise. The 
reaction mixture was stirred at room temperature until completion was achieved (followed 
by TLC, 2-16 hours). Water (1 mL) was added dropwise and half of the solvent was removed 
under reduced pressure. The mixture was poured onto brine (20 mL) and extracted with ethyl 
acetate (2 x 20 mL). The combined organic extracts were evaporated under reduced pressure 
and the resulting residue was purified by flash column chromatography (SiO2, 5% to 10% 
EtOAc in n-pentane) to give crude intermediary allyl amine. 
Crude allyl amine was dissolved in DCM (20 mL) and aryl isocyanate (1.2 eq. based on the 
mass of the allyl amine) was added dropwise. The reaction mixture was stirred at room 
temperature until reaction completion (followed by TLC, 2-16 hours). The reaction mixture 
was evaporated under reduced pressure and the residue was purified by flash column 
chromatography (SiO2, 10% to 25% EtOAc in n-pentane) to give the desired product. 
General procedure 8 (GP8): Catalyst-free azo-cycloamination. 
 
A flame-dried 10 mL microwave vial was charged with starting material (0.2 mmol, 1.0 eq.), 
sodium dibutyl phosphate (490) (93 mg, 0.4 mmol, 2.0 eq.) and 4-
(trifluoromethyl)benzenediazonium tetrafluoroborate (463) (104 mg, 0.4 mmol, 2.0 eq.), then 
nitrogen. Degassed anhydrous DMSO (1 mL) was added and the reaction was stirred at room 
temperature for a defined amount of time. The reaction was quenched with water (5 mL) and 
extracted with ethyl acetate (3 x 3 mL). The combined organic extracts were concentrated 








8.3.2 Synthetic Procedures 
Tetrabutylammonium dibutyl phosphate (415) 
 
Using GP5 and tetrabutylammonium hydroxide 30-hydrate (451) (3.84 g, 4.8 mmol), 
tetrabutylammonium dibutyl phosphate was synthesised (2.15 g, quantitative) as a white 
solid. 
1H NMR (400 MHz, CDCl3) 3.85-3.80 (4 H, m, 2 x OCH2), 3.42-3.35 (8 H, m, 4 x NCH2), 1.72-
1.61 (8 H, m, 4 x CH2), 1.61-1.53 (4 H, m, 2 x CH2), 1.50-1.41 (8 H, m, 4 x CH2), 1.41-1.33 (4 H, 
m, 2 x CH2), 0.99 (12 H, t, J 7.4, 4 x CH3), 0.89 (6 H, t, J 7.4, 2 x CH3). Data in good agreement 
with literature.250 
3,5,5-Trimethylcyclohex-2-en-1-yl phenylcarbamate (453) 
 
Using GP6, and starting materials 3,5,5-trimethyl-2-cyclohexen-1-ol (452) (0.76 mL, 701 mg, 
5.0 mmol) and phenyl isocyanate (204) (0.65 mL, 714 mg, 6.0 mmol), the title compound was 
synthesised (765 mg, 59%) as a white solid. 
M.p. 82-84 °C (CDCl3). IR (neat, cm-1) νmax = 3313, 2954, 1692, 1538, 1227, 1051, 691. 1H NMR 
(400 MHz, CDCl3) δ 7.35 (2 H, d, J 8.2, 2 x ArCH), 7.29 (2 H, br. t, J 8.2 2 x ArCH), 7.04 (1 H, tt, 
J 8.2, 1.8, ArCH), 6.52 (1 H, s, NH), 5.49-5.45 (1 H, m, CH), 5.37-5.30 (1 H, m, OCH), 1.90 (1 H, 
d, J 16.4, CHaHb), 1.82 (1 H, dd, J 6.8, 6.4, CHaHb), 1.70 (3 H, s, CH3), 1.68 (1 H, d, J 16.4, CHaHb), 
1.42 (1 H, dd, J 8.0, 6.4 CHaHb), 1.01 (3 H, s, CH3), 0.95 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) 
δ 153. 6 (CO) 138.6 (Cquat), 138.2 (Cquat), 129.1 (2 x ArCH), 123.4 (ArCH), 119.5 (CH), 118.7 (2 x 
ArCH), 71.2 (OCH), 44.2 (CH2), 41.1 (CH2), 30.8 (Cquat), 30.6 (CH3), 27.1 (CH3), 23.8 (CH3). HRMS 














A flame dried 10 mL microwave vial was charged with 3,5,5-trimethylcyclohex-2-en-1-yl 
phenylcarbamate (453) (65 mg, 0.25 mmol), 4CzIPN (91) (6 mg, 0.008 mmol) and 
tetrabutylammonium dibutyl phosphate (415) (28 mg, 0.063 mmol). The vial was flushed with 
nitrogen then anhydrous DCM (2.5 mL) was added. The reaction mixture was degassed by 
sparging with nitrogen for 5 minutes. tert-Butyl acrylate (454) (0.11 mL, 96 mg, 0.75 mmol) 
was added to the reaction mixture then stirred at room temperature for 23 hours under 
irradiation from 24 W blue LEDs. The reaction was quenched with water (2 mL) and brine (1 
mL), then extracted with ethyl acetate (3 x 2 mL). The organic extracts were combined and 
concentrated under reduced pressure to give crude material, analysis of which by 1H NMR 
showed a 10.5:1 diastereomeric mixture of the title compound. The crude material was 
purified by flash column chromatography (SiO2, 10% to 25% EtOAc in n-pentane) to give the 
title compound (57 mg, 59%) as a white solid and single major diastereomer.  
M.p. 122-124 °C (CDCl3). IR (neat, cm-1) νmax = 2911, 1730, 1388, 1200, 1143, 763, 693. 1H 
NMR (400 MHz, CDCl3) δ 7.44 (2 H, d, J 8.3, 2 x ArCH), 7.36 (2 H, t, J 8.3, 2 x ArCH), 7.18 (1 H, 
tt, J 8.3, 1.4, ArCH), 4.87 (1 H, ddd, J 8.2, 7.1, 6.0, OCH), 4.24 (1 H, d, J 8.2, NCH), 2.03 (2 H, t, 
J 7.9, (OC)CH2), 2.01 (1 H, dd, J 14.0, 7.1, CHaHb), 1.85 (1 H, dd, J 14.0, 6.0, CHaHb), 1.41 (1 H, 
d, J 12.5, CHaHb), 1.41-1.26 (2, m, CH2), 1.34 (9 H, s, C(CH3)3), 1.20 (1 H, d, J 12.5, CHaHb), 1.09     
(3 H, s, CH3), 1.00 (3 H, s, CH3), 0.97 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 172.7 (CO), 
156.5 (CO), 138.9 (Cquat), 129.2 (2 x ArCH), 125.9 (ArCH), 124.0 (2 x ArCH), 80.5 (Cquat), 74.3 
(CH), 62.3 (CH), 45.8 (CH2), 38.8 (CH2), 38.7 (Cquat) 37.6 (CH2), 33.0 (CH3), 32.9 (CH3), 30.2 (CH2), 
28.5 (Cquat), 28.1 (3 x CH3), 23.4 (CH3). HRMS m/z (ESI+) m/z calcd for C23H34NO4+ [M+H]+ 














3-Methylbut-2-en-1-yl phenylcarbamate (457) 
 
Using GP6 and starting materials 3-methyl-2-buten-1-ol (456) (0.51 mL, 431 mg, 5.0 mmol) 
and  phenyl isocyanate (204) (0.65 mL, 714 mg, 6.0 mmol), the title compound was 
synthesised (606 mg, 59%) as a white solid. 
1H NMR (301 MHz, CDCl3) δ 7.40-7.34 (2 H, m, 2 x ArCH), 7.33-7.24 (2 H, m, 2 x ArCH), 7.09-
7.00 (1 H, m, ArCH), 6.61 (1 H, s, NH), 5.44-5.35 (1 H, m, CH), 4.66 (2 H, d, J 6.8, CH2), 1.78        














4-Fluorobenzenediazonium tetrafluoroborate (430) 
 
4-Fluoroaniline (458) (0.95 mL, 1.11 g, 10.0 mmol) was added to a 50% solution of 
tetrafluoroboric acid in water (3.5 mL) at 0 °C, resulting in a brown suspension that dissolves 
into solution after warming to room temperature. The reaction mixture was cooled to 5-10 
°C and sodium nitrate (0.74 g, 8.7 mmol) dissolved in water (1 mL) was added drop wise over 
5 mins. The resulting reaction mixture was stirred for 30 minutes at 5-10 °C, then filtered and 
the obtained solid was sequentially washed with water (20 mL) and Et2O (2 x 20 mL), to give 
the title compound (998 mg, 50%) as a brown solid. 
1H NMR (400 MHz, D2O) δ 8.73 (2 H, dd, J 9.0, 4.2, 2 x ArCH), 7.75 (2 H, t, J 9.0, 2 x ArCH). 19F 




A flame-dried 10 mL microwave vial was charged with 3-methylbut-2-en-1-yl (4-
methoxyphenyl)carbamate (457) (21 mg, 0.1 mmol), 3DPAFIPN (106) (4.8 mg, 8 mol), 
tetrabutylammonium dibutyl phosphate (415) (90 mg, 0.2 mmol) and                                                                    
4-fluorobenzenediazonium tetrafluoroborate (430) (84 mg, 0.4 mmol), then flushed with 
nitrogen. Anhydrous DCM (1 mL) was added and the reaction mixture was degassed by 
sparging with nitrogen for two minutes. The reaction mixture was irradiated with 24 W blue 
LEDs and stirred for 21 hours. The reaction was quenched with water (5 mL) and extracted 
with ethyl acetate (3 x 3 mL). The combined organic extracts were concentrated under 
reduced pressure and purified by flash column chromatography (SiO2, 45% EtOAc in 40-60 
petroleum ether) to give the title compound (18 mg, 54%) as a yellow solid. 
M.p. 98-102 °C (Et2O). IR (neat, cm-1) νmax = 2979, 1738, 1412, 1214, 1126, 759, 499. 1H NMR 
(400 MHz, CDCl3) δ 7.36 (2 H, d, J 9.2, 2 x ArCH) 7.34 (2 H, tt, J 9.2, 2 x ArCH), 7.26 (2 H, d, J 
7.5, 2 x ArCH), 7.07 (1 H, tt, J 7.5, 1.3 ArCH), 7.02 (2 H, t, J 7.5, 2 x ArCH), 5.00 (1 H, dd, J 8.9, 
3.7, CH), 4.60 (1 H, t, J 8.9, CHaHb), 4.46 (1 H, dd, J 9.4, 3.7, CHaHb), 1.21 (3 H, s, CH3), 1.20 (3 
H, s, CH3). 13C NMR (126 MHz, CDCl3) δ 164.3 (ArCF, d, JCF 251.8), 156.8 (CO), 148.1 (ArCNN, d, 
JCF 3.0), 138.1 (Cquat), 129.2 (2 x ArCH), 126.1 (ArCH), 124.8 (2 x ArCH), 124.4 (2 x ArCH, d, JCF 
9.0), 115.8 (2 x ArCH, d, JCF 22.8), 73.8 (Cquat), 64.3 (CH2), 63.7 (CH), 21.3 (CH3), 20.9 (CH3). 19F 
NMR (377 MHz, CDCl3) δ −109.0-−109.2 (1 F, m, CF). HRMS m/z (ESI+) m/z calcd for 





4-(Trifluoromethyl)benzenediazonium tetrafluoroborate (463) 
 
4-(Trifluoromethyl)aniline (462) (0.63 mL, 806 mg, 5.0 mmol) was added to a 50% solution of 
tetrafluoroboric acid in water (5 mL) at 0 °C, resulting in a white suspension in solution that 
dissolves after warming to room temperature. The reaction mixture was cooled to 5-10 °C, 
then sodium nitrate (0.793 g, 11.5 mmol) dissolved in water (1 mL) was added drop wise over 
5 mins. The resulting reaction mixture was stirred for 15 mins at 0 °C, after which the reaction 
mixture was filtered and the obtained solid was sequentially washed with water (10 mL) and 
Et2O (2 x 20 mL) to give the title compound (0.862 g, 67%) as a white solid. 
1H NMR (400 MHz, DMSO-d6) δ 8.90 (2 H, d, J 8.6, 2 x ArCH), 8.42 (2 H, d, J 8.6, 2 x ArCH). Data 
in good agreement with literature.268 
(E)-3-Phenyl-4-(2-((4-(trifluoromethyl)phenyl)diazenyl)propan-2-yl)oxazolidin-2-one (464)
 
Following GP8 with 3-methylbut-2-en-1-yl (4-methoxyphenyl)carbamate (457) (41 mg, 0.2 
mmol) used as staring material. Reaction was stirred for 60 minutes and purified by flash 
column chromatography (SiO2, 20% to 50% EtOAc in 40-60 petroleum ether) to give the title 
compound (18 mg, 24%) as a yellow solid. 
M.p. 133-135 °C. IR (film, cm-1) νmax = 2983, 2253, 1753, 1484, 1323, 1065. 1H NMR (400 MHz, 
CDCl3) δ 7.60 (2 H, d, J 8.0, 2 × ArCH), 7.38 (2 H, d, J 8.0, 2 × ArCH), 7.34 (2 H, d, J 8.7, 2 × ArCH), 
7.28-7.24 (2 H, m, 2 × ArCH), 7.09-7.05 (1 H, m, ArCH), 5.05 (1 H, dd, J 9.1, 3.6, CH), 4.63 (1 H, 
t, J 9.1, CHaHb), 4.47 (1 H, dd, J 9.1, 3.6, CHaHb), 1.26 (3 H, s, CH3), 1.24 (3 H, s, CH3). 13C NMR 
(100 MHz, CDCl3) δ 156.7 (CO), 153.4 (ArCNN), 138.0 (Cquat), 132.3 (Cquat, q, JCF 32.4), 129.2 (2 
x ArCH), 126.2 (ArCH), 126.1 (2 x ArCH, q, JCF 3.8), 124.8 (2 x ArCH), 123.9 (CF3, q, JCF 272.9), 
122.6 (2 x ArCH), 74.8 (Cquat), 64.2, (CH2), 63.6 (CH), 21.4 (CH3), 20.6 (CH3). 19F NMR (377 MHz, 











3-Methylbut-2-en-1-yl (4-methoxyphenyl)carbamate (474) 
 
Using GP6 and starting materials 3-methyl-2-buten-1-ol (456) (0.51 mL, 431 mg, 5.0 mmol) 
and 4-methoxyphenyl isocyanate (473) (0.78 mL, 894 mg, 6.0 mmol), 3-methylbut-2-en-1-yl 
(4-methoxyphenyl)carbamate was synthesised (0.918 g, 78%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.26 (2 H, d, J 9.1, 2 x ArCH), 6.83 (2 H, d, J 9.1, 2 x ArCH), 6.42 (1 
H, s, NH), 5.38 (1 H, thep, J 7.2, 1.4, CH), 4.63 (2 H, d, J 7.2, CH2), 3.77 (3 H, s, OCH3), 1.77 (3 




A flame-dried 10 mL microwave vial was charged with 3-methylbut-2-en-1-yl (4-
methoxyphenyl)carbamate (474) (47 mg, 0.2 mmol), 3DPAFIPN (106) (4.8 mg, 8 mol), 
tetrabutylammonium dibutyl phosphate (415) (180 mg, 0.4 mmol) and                                                     
4-fluorobenzenediazonium tetrafluoroborate (474) (84 mg, 2.0 eq., 0.4 mmol), then flushed 
with nitrogen. Anhydrous DMSO (2 mL) was added and the reaction mixture was degassed by 
sparging with nitrogen for 5 minutes. The reaction mixture was then stirred for 21 hours at 
room temperature. The reaction was quenched with water (5 mL) and extracted with ethyl 
acetate (3 x 3 mL). The combined organic extracts were concentrated under reduced pressure 
and purified by flash column chromatography (SiO2, 45% EtOAc in 40-60 petroleum ether) to 
give the title compound (55 mg, 70%) as a yellow solid. 
M.p. 120-124 °C (Et2O). IR (neat, cm-1) νmax = 2958, 1731, 1595, 1514, 1479, 1418, 1245, 1224, 
1132, 1034, 963, 824. 1H NMR (400 MHz, CD2Cl2) δ 7.39 (2 H, dd, J 9.0, 3.8, 2 × ArCH), 7.18 (2 
H, d, J 9.1, 2 × ArCH), 7.06 (2 H, t, J 9.0, 2 × ArCH), 6.77 (2 H, d, J 9.1, 2 × ArCH), 4.93 (1 H, dd, 
J 9.1, 4.3, CH), 4.60 (1 H, t, J 9.1, CHaHb), 4.44 (1 H, dd, J 9.1, 4.3, CHaHb), 3.69 (3 H, s, OCH3), 
1.23 (3 H, s, CH3), 1.19 (3 H, s, CH3). 13C NMR (101 MHz, CD2Cl2) δ 164.7 (CF, d, JCF 250.0), 158.3 
(ArCO), 157.5 (CO), 148.7 (ArCNN), 131.4 (Cquat), 127.2 (2 × ArCH), 124.8 (2 × ArCH, d, JCF 9.1), 
116.0 (2 × ArCH, d, JCF 22.8), 114.7 (2 × ArCH), 74.1 (Cquat), 64.7 (CH2), 64.6 (CH), 55.9 (OCH3), 
21.6 (CH3), 20.6 (CH3). 19F NMR (377 MHz, CDCl3) δ −109.0-−109.2 (1 F, m, CF). HRMS m/z 







Using GP7 and starting materials p-anisidine (477) (616 mg, 5.0 mmol) and 4-methoxyphenyl 
isocyanate (479) (0.63 mL, 727 mg, 4.9 mmol), the title compound was synthesised (1.20 g, 
71%) as a white solid.  
M.p. 125-127 °C (CDCl3). IR (film, cm-1) νmax = 3426, 3933, 1661, 1508, 1243, 1225, 728. 1H 
NMR (400 MHz, CDCl3) δ 7.21-7.16 (4 H, m, 2 × ArCH + 2 × ArCH), 6.95 (2 H, d, J 8.9, 2 × ArCH), 
6.76 (2 H, d, J 9.0, 2 × ArCH), 5.98 (1 H, br. s, NH), 5.33-5.29 (1 H, m, CH), 4.27 (2 H, d, J 7.1, 
CH2), 3.84 (3 H, s, OCH3), 3.74 (3 H, s, OCH3), 1.67 (3 H, s, CH3), 1.47 (3 H, s, CH3).  13C NMR 
(101 MHz, CDCl3) δ 159.2 (ArCO), 155.6 (ArCO), 155.0 (CO), 135.6 (Cquat), 134.1 (Cquat), 132.3 
(Cquat), 130.2 (2 × ArCH), 121.5 (2 × ArCH), 120.6 (CH), 115.3 (2 × ArCH), 114.1 (2 × ArCH), 55.6 
(2 × OCH3), 47.2 (CH2), 25.8 (CH3), 17.8 (CH3). HRMS m/z (ESI+) m/z calcd for C20H24N2O3Na+ 























A flame-dried 10 mL microwave vial was charged with 1,3-bis(4-methoxyphenyl)-1-(3-
methylbut-2-en-1-yl)urea (479) (34 mg, 0.1 mmol), tetrabutylammonium dibutyl phosphate 
(415) (90 mg, 0.2 mmol) and 4-(trifluoromethyl)benzenediazonium tetrafluoroborate (430) 
(42 mg, 0.2 mmol) then flushed with nitrogen. Anhydrous DMSO (1 mL) was added and the 
reaction mixture was degassed by sparging with nitrogen for 5 minutes. The reaction mixture 
was stirred at room temperature for 17 hours. The reaction was quenched with water (5 mL) 
and extracted with ethyl acetate (3 x 3 mL). The combined organic extracts were concentrated 
under reduced pressure and purified by flash column chromatography (SiO2, 20% to 100% 
Et2O in 40-60 petroleum ether) to give the title compound (35 mg, 75%) as a yellow solid. 
M.p. 125-128 °C (Et2O). IR (neat, cm-1) νmax = 2933, 1691, 1509, 1241, 1221, 1028, 827. 1H 
NMR (500 MHz, C6D6) 7.68 (2 H, d, J 8.7, 2 x ArCH), 7.36-7.30 (2 H, m, 2 x ArCH), 7.28 (2 H, d, 
J 8.1, 2 x ArCH), 6.68 (2 H, d, J 8.7, 2 x ArCH), 6.71 (2 H, t, J 8.1, 2 x ArCH), 6.66 (2 H, d, J 8.1,    
2 x ArCH), 4.53 (1 H, t, J 6.6, CH), 3.54-3.45 (2 H, m, CH2), 3.35 (3 H, s, OCH3), 3.23 (3 H, s, 
OCH3), 1.12 (3 H, s, CH3), 1.06 (3 H, s, CH3). 13C NMR (126 MHz, C6D6) δ 164.5 (CF, d, JCF 250.4), 
157.5 (ArCO), 156.2 (CO), 155.8 (ArCO), 148.6 (ArCNN, d, JCF 2.9), 134.4 (Cquat), 133.4 (Cquat), 
127.1 (2 x ArCH), 124.7 (2 x ArCH, d, JCF 8.9), 119.5 (2 x ArCH) 115.7 (2 x ArCH, d, JCF 22.9), 
114.5 (2 x ArCH), 114.3 (2 x ArCH), 74.6 (Cquat), 60.6 (CH), 55.1 (OCH3), 54.9 (OCH3), 45.1 (CH2), 
21.1 (CH3), 20.9 (CH3). 19F NMR (377 MHz, C6D6) −110.0-−110.2 (1 F, m, CF). δ HRMS m/z (ESI+) 

















Using GP8 and starting material 1,3-bis(p-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)urea      
(479) (68 mg, 0.2 mmol) the title compound was synthesised and purified by flash column 
chromatography (SiO2, 20% to 100% Et2O in 40-60 petroleum ether) to give a yellow solid      
(85 mg, 83%). 
M.p. 183-185 °C (Et2O). IR (film, cm-1) νmax = 3054, 1706, 1512, 1323, 1264, 732. 1H NMR (500 
MHz, CDCl3) δ 7.61 (2 H, d, J 8.3, 2 × ArCH), 7.50 (2 H, d, J 9.1, 2 × ArCH), 7.41 (2 H, d, J 8.2,      
2 × ArCH), 7.21 (2 H, d, J 8.9, 2 × ArCH), 6.90 (2 H, d, J 9.1, 2 × ArCH), 6.74 (2 H, d, J 8.9,                      
2 × ArCH), 4.98 (1 H, dd, J 9.8, 4.6, CH), 4.18 (1 H, t, J 9.7, CHaHb), 3.84 (1 H, dd, J 9.7, 4.6, 
CHaHb), 3.80 (3 H, s, OCH3), 3.66 (3 H, s, OCH3), 1.28 (6 H, s, 2 x CH3). 13C NMR (126 MHz, CDCl3) 
δ 157.4 (ArCO), 156.7 (CO), 155.6 (ArCO), 153.6 (ArCNN), 133.5 (Cquat), 132.4 (Cquat), 132.2 
(Cquat, q, JCF 32.4), 127.2 (2 x ArCH), 126.0 (2 x ArCH, q, JCF 3.7), 124.0 (CF3, q, JCF 272.3), 122.6                  
(2 × ArCH), 119.7 (2 x ArCH), 114.3 (2 x ArCH), 114.3 (2 x ArCH), 75.4 (Cquat), 60.9 (CH), 55.7 
(OCH3), 55.4 (OCH3), 45.5 (CH2), 21.5 (CH3), 20.4 (CH3). 19F NMR (470 MHz, CDCl3) δ −62.6 (3 
F, s, CF3). HRMS m/z (ESI+) m/z calcd for C27H27F3N4O3Na+ [M+Na]+ 535.1927; found 535.1923. 
Lithium dibutyl phosphate (489) 
 
Using GP5 and lithium hydroxide (115 mg, 4.8 mmol), lithium dibutyl phosphate was 
synthesised (1.03 g, quantitative) as a white solid.  
1H NMR (400 MHz, DMSO-d6) 3.63-3.55 (4 H, m, 2 x OCH2), 1.50-1.38 (4 H, m, 2 x CH2), 1.36-
1.23 (4 H, m, 2 x CH2), 0.86 (6 H, t, J 7.3, 2 x CH3). 13C NMR (101 MHz, DMSO-d6) δ 63.4                  
(2 x OCH2, d, JCP 5.7), 33.6 (2 x CH2, d, JCP 7.3), 18.7 (2 x CH2), 13.7 (2 x CH3). 31P NMR (162 MHz, 











Sodium dibutyl phosphate (490) 
 
Using GP5 and sodium hydroxide (192 mg, 4.8 mmol), sodium dibutyl phosphate was 
synthesised (1.11 g, quantitative) as a white solid. 
1H NMR (400 MHz, DMSO-d6) δ 3.63-3.56 (4 H, m, 2 x OCH2), 1.50-1.40 (4 H, m, 2 x CH2), 1.36-
1.24 (4 H, m, 2 x CH2), 0.86 (6 H, t, J 7.3, 2 x CH3). 13C NMR (101 MHz, DMSO-d6) δ 63.5                   
(2 x OCH2, d, JCP 5.7), 33.6 (2 x CH2, d, JCP 7.3), 18.7 (2 x CH2), 13.7 (2 x CH3). 31P NMR (162 MHz, 
DMSO-d6) δ 0.56 (1 P, br. s, P(O)3). 
Potassium dibutyl phosphate (491) 
 
Using GP5 and potassium hydroxide (269 mg, 4.8 mmol), potassium dibutyl phosphate was 
synthesised (1.18 g, quantitative) as a white solid. 
1H NMR (400 MHz, DMSO-d6) δ 3.62-3.55 (4 H, m, 2 x OCH2), 1.50-1.39 (4 H, m, 2 x CH2), 1.36-
1.23 (4 H, m, 2 x CH2), 0.86 (6 H, t, J 7.3, 2 x CH3). 13C NMR (101 MHz, DMSO-d6) δ 63.4                   
(2 x OCH2, d, JCP 5.7), 33.6 (2 x CH2, d, JCP 7.3), 18.7 (2 x CH2), 13.7 (2 x CH3). 31P NMR (162 MHz, 
DMSO-d6) δ 0.19 (1 P, br. s, P(O)O3). 
3-(p-Methoxyphenyl)- 1-(o,o’-dimethoxyphenyl)-1-(3-methylbut-2-en-1-yl)-urea (496) 
 
Using GP7 and starting materials 3,5-dimethoxyaniline (492) (0.766 g, 5.0 mmol) and 4-
methoxyphenyl isocyanate (473) (0.49 mL, 564 mg, 3.8 mmol), the title compound was 
synthesised (0.870 g, 47%) as a white solid. 
 M.p. 125-127 °C (CDCl3). IR (neat, cm-1) νmax = 3382, 2972, 2932, 1708, 1664, 1509, 1294, 
1220, 1154, 1035, 747. 1H NMR (400 MHz, CDCl3) 7.20 (2 H, d, J 9.0, 2 x ArCH), 6.78 (2 H, d,     
J 9.0, 2 x ArCH), 6.44 (3 H, s, 2 x ArCH + ArCH), 6.20 (1 H, s, NH), 5.37-5.30 (1 H, m, CH), 4.29 
(2 H, d, J 7.0, CH2), 3.79 (6 H, s, 2 x OCH3), 3.75 (3 H, s, OCH3), 1.69 (3 H, s, CH3), 1.54 (3 H, s, 
CH3). 13C NMR (101 MHz, CDCl3) δ 161.8 (2 x ArCO), 155.7 (ArCO), 154.4 (CO), 143.6 (Cquat), 
135.4 (Cquat), 132.2 (Cquat), 121.6 (2 x ArCH), 120.8 (CH), 114.1 (2 x ArCH), 106.7 (2 x ArCH), 
100.0 (ArCH), 55.7 (2 x OCH3), 55.6 (OCH3) 47.3 (CH2), 25.8 (CH3), 17.9 (CH3). HRMS m/z (ESI+) 





tert-Butyl 3-(3-(4-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)ureido)benzoate (497) 
 
Using GP7 and starting materials tert-butyl 3-aminobenzoate (493) (0.966 g, 5.0 mmol) and 
4-methoxyphenyl isocyanate (473) (0.36 mL, 418 mg, 2.8 mmol), the title compound was 
synthesised (0.869 g, 42%) as a yellow solid. 
M.p. 79-81 °C (CDCl3). IR (neat, cm-1) νmax = 3382, 2972, 2932, 1708, 1664, 1509, 1294, 1220, 
1154, 1035, 747. 1H NMR (400 MHz, CDCl3) δ 7.97 (1 H, dt, J 7.4, 1.3, ArCH), 7.90 (1 H, t, J 1.3, 
ArCH), 7.49 (1 H, t, J 7.4, ArCH), 7.45 (1 H, dt, J 7.4, 1.3, ArCH), 7.17 (2 H, d, J 8.9, 2 x ArCH), 
6.78 (2 H, d, J 8.9, 2 x ArCH), 5.94 (1 H, s, NH), 5.33 (1 H, t, J 6.9, CH), 4.32 (2 H, d, J 6.9, CH2), 
3.74 (3 H, s, OCH3), 1.68 (3 H, s, CH3), 1.60 (9 H, s, C(CH3)3), 1.48 (3 H, s, CH3). 13C NMR (101 
MHz, CDCl3) δ 164.8 (CO), 155.9 (Cquat), 154.5 (CO), 142.0 (Cquat), 136.0 (Cquat), 134.2 (Cquat), 
132.8 (ArCH), 131.9 (Cquat), 130.0 (ArCH), 129.5 (ArCH), 128.8 (ArCH), 121.8 (2 x ArCH), 120.4 
(CH), 114.1 (2 x ArCH), 81.9 (C(CH3)3), 55.6 (OCH3), 47.4 (CH2), 28.3 (C(CH3)3) 25.8 (CH3), 17.8 




Following GP8 with 3-(p-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)-1-(phenyl)urea (62 mg, 
0.2 mmol) used as staring material. Reaction was stirred for 40 minutes and purified by flash 
column chromatography (SiO2, 0% to 10 % MeOH in DCM) to give the title compound (73 mg, 
76%) as a yellow solid.  
M.p. 154-155 °C (Et2O). IR (neat, cm-1) νmax = 2934, 1696, 1599, 1502, 1412, 1321, 1243, 1163, 
1120, 1100, 1062, 835, 751, 689. 1H NMR (400 MHz, CDCl3) δ 7.63-7.58 (4 H, m, 2 × ArCH +      
2 × ArCH), 7.42 (2 H, d, J 8.3, 2 × ArCH), 7.35 (2 H, t, J 7.4, 2 × ArCH), 7.21 (2 H, d, J 8.9,                       
2 × ArCH), 7.07 (1 H, t, J 7.4, ArCH), 6.75 (2 H, d, J 8.9, 2 × ArCH), 4.99 (1 H, dd, J 9.9, 4.6, CH), 
4.21 (1 H, t, J 9.9, CHaHb), 3.88 (1 H, dd, J 9.9, 4.6, CHaHb), 3.66 (3 H, s, OCH3), 1.28 (6 H, s,           
2 x CH3). 13C NMR (126 MHz, CDCl3) δ 157.5 (ArCO), 156.4 (CO), 153.5 (ArCNN), 140.1 (Cquat), 
132.1 (Cquat), 132.1 (Cquat, q, JCF 32.4), 129.0 (2 x ArCH), 127.2 (2 x ArCH), 125.9 (2 x ArCH, q, JCF 
3.6), 123.9 (CF3, q, JCF 272.3), 122.8 (ArCH), 122.6 (2 x ArCH), 117.7 (2 x ArCH), 114.3 (2 x ArCH), 
75.3 (Cquat), 60.8 (CH), 55.4 (OCH3), 45.0 (CH2), 21.5 (CH3), 20.2 (CH3). 19F NMR (377 MHz, 








Following GP8 with 1-(p-fluorophenyl)-3-(p-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)-urea 
(66 mg, 0.2 mmol) used as staring material. Reaction was stirred for 30 minutes and purified 
by flash column chromatography (SiO2, DCM) to give the title compound (57 mg, 57%) as a 
yellow solid.  
M.p. 184-186 °C (Et2O). IR (neat, cm-1) νmax = 2927, 1697, 1509, 1411, 1324, 1250, 1222, 1128, 
1065, 833, 530. 1H NMR (400 MHz, CDCl3) δ 7.61 (2 H, d, J 8.3, 2 × ArCH), 7.55 (2 H, dd, J 8.7, 
4.6, 2 × ArCH), 7.42 (2 H, d, J 8.3, 2 × ArCH), 7.20 (2 H, d, J 9.0, 2 × ArCH), 7.04 (2 H, t, J 8.7,       
2 × ArCH), 6.75 (2 H, d, J 9.0, 2 × ArCH), 4.98 (1 H, dd, J 9.8, 4.6, CH), 4.18 (1 H, t, J 9.8, CHaHb), 
3.85 (1 H, dd, J 9.8, 4.6, CHaHb), 3.66 (3 H, s, OCH3), 1.28 (6 H, s, 2 x CH3). 13C NMR (126 MHz, 
CDCl3) δ 158.7 (ArCF, d, JCF 242.4), 157.6 (ArCO), 156.5 (CO), 153.5 (ArCNN), 136.2 (Cquat, d, JCF 
2.6), 132.2 (Cquat, q, JCF 32.6), 132.1 (Cquat), 127.2 (2 x ArCH), 126.0 (2 x ArCH, q, JCF 3.7), 123.9 
(CF3, q, JCF 272.3), 122.6 (2 x ArCH), 119.3 (2 x ArCH, d, JCF 7.6), 115.6 (2 x ArCH, d, JCF 22.4), 
114.3 (2 x ArCH), 75.3 (Cquat), 60.8 (CH), 55.4 (OCH3), 45.3 (CH2), 21.5 (CH3), 20.3 (CH3). 19F 
NMR (377 MHz, CDCl3) δ −62.6 (3 F, s, CF3), −120.3-−120.5 (1 F, m, ArCF). HRMS m/z (ESI+) 




















Following GP8 with 1-(p-chlorophenyl)-3-(p-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)urea 
(69 mg, 0.2 mmol) used as staring material. Reaction was stirred for 40 minutes and purified 
by flash column chromatography (SiO2, DCM) to give the title compound (82 mg, 80%) as a 
yellow solid.  
M.p. 179-181 °C (Et2O). IR (neat, cm-1) νmax = 2986, 1694, 1496, 1419, 1321, 1244, 1160, 1125, 
828. 1H NMR (400 MHz, CDCl3) δ 7.61 (2 H, d, J 8.3, 2 × ArCH), 7.56 (2 H, d, J 9.0, 2 × ArCH), 
7.42 (2 H, d, J 8.3, 2 × ArCH), 7.30 (2 H, d, J 9.0, 2 × ArCH), 7.20 (2 H, d, J 9.0, 2 × ArCH), 6.75 
(2 H, d, J 9.0, 2 × ArCH), 4.99 (1 H, dd, J 9.8, 4.6, CH), 4.17 (1 H, t, J 9.8, CHaHb), 3.84 (1 H, dd, 
J 9.8, 4.6,  CHaHb), 3.66 (3 H, s, OCH3), 1.27 (6 H, s, 2 x CH3). 13C NMR (126 MHz, CDCl3) δ 157.6 
(ArCO), 156.2 (CO), 153.5 (ArCNN), 138.7 (Cquat), 132.2 (Cquat, q, JCF 32.7), 131.9 (ArCCl), 128.9     
(2 x ArCH), 127.8 (Cquat), 127.2 (2 x ArCH), 125.9 (2 x ArCH, q, JCF 3.1), 123.9 (CF3, q, JCF 272.8), 
122.6 (2 x ArCH), 118.8 (2 x ArCH), 114.3 (2 x ArCH), 75.2 (Cquat), 60.8 (CH), 55.4 (OCH3), 45.0 
(CH2), 21.5 (CH3), 20.3 (CH3). 19F NMR (377 MHz, CDCl3) δ −62.6 (3 F, s, CF3). HRMS m/z (ESI+) 





















Following GP8 with 1-(p-bromophenyl)-3-(p-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)urea 
(78 mg, 0.2 mmol) used as staring material. Reaction was stirred for 30 minutes and purified 
by flash column chromatography (SiO2, 0% to 10% Et2O in DCM) to give the title compound 
(87 mg, 76%) as a yellow solid.  
M.p. 192-194 °C (Et2O). IR (neat, cm-1) νmax = 2983, 1692, 1492, 1417, 1321, 1286, 1243, 1160, 
1124, 1064, 827. 1H NMR (400 MHz, CDCl3) δ 7.61 (2 H, d, J 8.4, 2 × ArCH), 7.51 (2 H, d, J 9.2, 
2 × ArCH), 7.44 (2 H, d, J 9.2, 2 × ArCH), 7.42 (2 H, d, J 8.4, 2 × ArCH), 7.20 (2 H, d, J 9.0,                    
2 × ArCH), 6.75 (2 H, d, J 9.0, 2 × ArCH), 4.98 (1 H, dd, J 9.8, 4.6, CH), 4.16 (1 H, t, J 9.8, CHaHb), 
3.83 (1 H, dd, J 9.8, 4.7, CHaHb), 3.66 (3 H, s, OCH3), 1.27 (6 H, s, 2 x CH3). 13C NMR (126 MHz, 
CDCl3) δ 157.6 (ArCO), 156.2 (CO), 153.5 (ArCNN), 139.2 (Cquat), 132.2 (Cquat, q, JCF 32.5), 131.8   
(2 x ArCH), 131.8 (Cquat), 127.2 (2 x ArCH), 125.9 (2 x ArCH, q, JCF 3.8), 123.9 (CF3, q, JCF 272.6), 
122.6 (2 x ArCH), 119.1 (2 x ArCH), 115.4 (ArCBr) 114.3 (2 x ArCH), 75.2 (Cquat), 60.7 (CH), 55.4 
(OCH3), 44.9 (CH2), 21.5 (CH3), 20.3 (CH3). 19F NMR (377 MHz, CDCl3) δ −62.6 (3 F, s, CF3). 





















Following GP8 with 3-(p-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)-1-(p-
methylthiophenyl)urea (71 mg, 0.2 mmol) used as staring material. Reaction was stirred for 
20 minutes and purified by flash column chromatography (SiO2, 0% to 10% EtO2 in DCM) to 
give the title compound (69 mg, 65%) as a yellow solid. 
M.p. 150-152 °C (Et2O). IR (neat, cm-1) νmax = 2983, 1692, 1498, 1417, 1320, 1243, 1159, 1122, 
1063, 829. 1H NMR (400 MHz, CDCl3) δ 7.61 (2 H, d, J 8.3, 2 × ArCH), 7.55 (2 H, d, J 8.9,                    
2 × ArCH), 7.42 (2 H, d, J 8.3, 2 × ArCH), 7.28 (2 H, d, J 8.9, 2 × ArCH), 7.20 (2 H, d, J 8.9,                     
2 × ArCH), 6.74 (2 H, d, J 8.9, 2 × ArCH), 4.98 (1 H, dd, J 9.8, 4.6, CH), 4.18 (1 H, t, J 9.8, CHaHb), 
3.84 (1 H, dd, J 9.8, 4.6, CHaHb), 3.65 (3 H, s, OCH3), 2.47 (3 H, s, SCH3) 1.27 (6 H, s, 2 x CH3). 
13C NMR (126 MHz, CDCl3) δ 157.5 (ArCO), 156.3 (CO), 153.5 (ArCNN), 138.0 (Cquat), 132.1 
(Cquat, q, JCF 32.3), 132.1 (Cquat), 131.7 (Cquat), 128.5 (2 x ArCH), 127.2 (2 x ArCH), 125.9 (2 x 
ArCH, q, JCF 3.7), 124.0 (CF3, q, JCF 272.3), 122.6 (2 x ArCH), 118.3 (2 x ArCH), 114.3 (2 x ArCH), 
75.3 (Cquat), 60.8 (CH), 55.4 (OCH3), 45.0 (CH2), 21.5 (CH3), 20.3 (CH3), 17.2 (SCH3). 19F NMR 
(377 MHz, CDCl3) δ −62.6 (3 F, s, CF3). HRMS m/z (ESI+) m/z calcd for C27H27F3N4O2SNa+ 




















Following GP8 with 3-(p-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)-1-(p-
trifluoromethoxyphenyl)urea (79 mg, 0.2 mmol) used as staring material. Reaction was stirred 
for 30 minutes and purified by flash column chromatography (SiO2, 0% to 10% EtO2 in DCM) 
to give the title compound (70 mg, 62%) as a yellow solid.  
M.p. 172-174 °C (Et2O). IR (neat, cm-1) νmax = 2985, 1694, 1509, 1413, 1245, 1223, 1160, 1124, 
1064, 831. 1H NMR (400 MHz, CDCl3) δ 7.63 (2 H, d, J 9.1, 2 x ArCH), 7.61 (2 H, d, J 8.1,                      
2 × ArCH), 7.42 (2 H, d, J 8.1, 2 × ArCH), 7.24-7.17 (4 H, m, 4 x ArCH), 6.76 (2 H, d, J 8.9,                     
2 × ArCH), 4.99 (1 H, dd, J 9.9, 4.6, CH), 4.19 (1 H, t, J 9.9, CHaHb), 3.86 (1 H, dd, J 9.9, 4.6, 
CHaHb), 3.66 (3 H, s, OCH3), 1.27 (6 H, s, 2 x CH3). 13C NMR (126 MHz, CDCl3) δ 157.7 (ArCO), 
156.3 (CO), 153.5 (ArCNN, q, J 1.2), 144.3 (ArCO, q, J 1.8), 138.8 (Cquat), 132.2 (Cquat, q, JCF 32.2), 
131.9 (Cquat), 127.3 (2 x ArCH), 126.0 (2 x ArCH, q, JCF 3.8), 123.9 (CF3, q, JCF 272.3), 122.6                
(2 x ArCH), 121.8 (2 x ArCH), 120.7 (CF3, q, JCF 256.5), 118.5 (2 x ArCH), 114.4 (2 x ArCH), 75.2 
(Cquat), 60.8 (CH), 55.4 (OCH3), 45.1 (CH2), 21.5 (CH3), 20.3 (CH3). 19F NMR (377 MHz, CDCl3) δ 
−58.2 (3 F, s, OCF3), −62.6 (3 F, s, CF3). HRMS m/z (ESI+) m/z calcd for C27H25F6N4O3+ [M+H]+ 




















Following GP8 with 1-(4-cyanophenyl)-3-(4-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)urea 
(67 mg, 0.2 mmol) used as staring material. Reaction was stirred for 30 minutes and purified 
by flash column chromatography (SiO2, 0% to 10% EtO2 in DCM) to give the title compound 
(79 mg, 78%) as a yellow solid.  
M.p. 234-237 °C (Et2O). IR (neat, cm-1) νmax = 2970, 2936, 2843, 2220, 1700, 1606, 1510, 1410, 
1321, 1250, 1162, 1128, 835. 1H NMR (400 MHz, CDCl3) δ 7.73 (2 H, d, J 8.9, 2 x ArCH), 7.65-
7.59 (4 H, m, 2 x ArCH + 2 x ArCH), 7.43 (2 H, d, J 8.2, 2 × ArCH), 7.20 (2 H, d, J 8.9, 2 × ArCH), 
6.76 (2 H, d, J 8.9, 2 × ArCH), 5.01 (1 H, dd, J 9.9, 4.4, CH), 4.21 (1 H, t, J 9.9, CHaHb), 3.88 (1 H, 
dd, J 9.9, 4.4, CHaHb), 3.66 (3 H, s, OCH3), 1.28 (3 H, s, CH3), 1.26 (3 H, s, CH3). 13C NMR (126 
MHz, CDCl3) δ 157.9 (ArCO), 155.8 (CO), 153.4 (ArCNN), 143.9 (Cquat), 133.2 (2 x ArCH), 132.4 
(Cquat, q, JCF 32.2), 131.4 (Cquat), 127.3 (2 x ArCH), 126.0 (2 x ArCH, q, JCF 3.6), 123.9 (CF3, q,        
JCF 272.3), 122.6 (2 x ArCH), 119.3 (ArCCN), 117.2 (2 x ArCH), 114.5 (2 x ArCH), 105.4 (ArCCN), 
75.1 (Cquat), 60.8 (CH), 55.4 (OCH3), 44.7 (CH2), 21.5 (CH3), 20.4 (CH3). 19F NMR (377 MHz, 




















Following GP8 with 3-(p-methoxyphenyl)-1-(3-methylbut-2-en-1-yl)-1-(m-tolyl)urea (65 mg, 
0.2 mmol) used as staring material. Reaction was stirred for 1 hour and purified by flash 
column chromatography (SiO2, 0% to 15% DCM in Et2O) to give the title compound (86 mg, 
87%) as a yellow solid.  
M.p. 147-149 °C (Et2O). IR (neat, cm-1) νmax = 2952, 1696, 1586, 1514, 1412, 1323, 1244, 1160, 
1121, 1063, 835. 1H NMR (400 MHz, CDCl3) δ 7.61 (2 H, d, J 8.2, 2 × ArCH), 7.51 (1 H, s, ArCH), 
7.42 (2 H, d, J 8.2, 2 × ArCH), 7.35 (1 H, d, J 7.9, ArCH), 7.24 (1 H, t, J 7.9, ArCH), 7.21 (2 H, d,    
J 8.9, 2 × ArCH), 6.89 (1 H, d, J 7.9, ArCH), 6.74 (2 H, d, J 8.9, 2 × ArCH), 4.98 (1 H, dd, J 9.8, 4.6, 
CH), 4.20 (1 H, t, J 9.8, CHaHb), 3.87 (1 H, dd, J 9.8, 4.6, CHaHb), 3.66 (3 H, s, OCH3), 2.36 (3 H, 
s, CH3), 1.28 (6 H, s, 2 x CH3). 13C NMR (126 MHz, CDCl3) δ 157.4 (ArCO), 156.4 (CO), 153.5 
(ArCNN), 140.0 (Cquat), 138.8 (Cquat), 132.2 (Cquat), 132.1 (Cquat, q, JCF 32.2), 128.8 (ArCH), 127.2 
(2 x ArCH), 125.9 (2 x ArCH, q, JCF 3.6), 124.0 (CF3, q, JCF 272.2), 123.7 (ArCH), 122.6 (2 x ArCH), 
118.6 (ArCH), 114.8 (ArCH), 114.2 (2 x ArCH), 75.4 (Cquat), 60.8 (CH), 55.3 (OCH3), 45.1 (CH2), 
21.8 (CH3), 21.5 (CH3), 20.2 (CH3). 19F NMR (377 MHz, CDCl3) δ −62.6 (3 F, s, CF3). HRMS m/z 




















Following GP8 with 3-(p-methoxyphenyl)- 1-(o,o’-dimethoxyphenyl)-1-(3-methylbut-2-en-1-
yl)-urea (496) (74 mg, 0.2 mmol) used as staring material. Reaction was stirred for 30 minutes 
and purified using deactivated silica gel chromatography (Et2O) to give the title compound     
(61 mg, 67%) as an yellow solid.  
M.p. 142-144 °C (Et2O). IR (neat, cm-1) νmax = 2937, 1697, 1584, 1513, 1411, 1322, 1245, 1154, 
1062, 833, 813. 1H NMR (400 MHz, CDCl3) δ 7.61 (2 H, d, J 8.3, 2 × ArCH), 7.41 (2 H, d, J 8.3,      
2 × ArCH), 7.19 (2 H, d, J 9.0, 2 × ArCH), 6.90 (2 H, d, J 2.1, 2 × ArCH), 6.75 (2 H, d, J 9.0,                    
2 × ArCH), 6.20 (1 H, t, J 2.1, ArCH), 4.97 (1 H, dd, J 10.0, 4.9, CH), 4.14 (1 H, t, J 10.0, CHaHb), 
3.86 (1 H, dd, J 10.0, 4.9, CHaHb), 3.79 (6 H, s, 2 x OCH3), 3.65 (3 H, s, OCH3), 1.27 (6 H, s,                 
2 x CH3). 13C NMR (126 MHz, C6D6) δ 161.9 (2 x ArCO), 157.5 (ArCO), 155.8 (CO), 153.7 
(ArCNN), 142.9, (Cquat), 132.8 (Cquat), 132.0 (Cquat, q, JCF 32.1), 127.2 (2 x ArCH), 126.0 (2 x ArCH, 
q, JCF 3.6), 124.6 (CF3, q, JCF 272.1), 122.9 (2 x ArCH), 114.2 (2 x ArCH), 96.7 (2 x ArCH), 95.1 
(ArCH), 75.6 (Cquat), 60.4 (CH), 55.0 (2 x OCH3), 54.8 (OCH3), 44.9 (CH2), 21.5 (CH3), 19.8 (CH3). 
19F NMR (377 MHz, CDCl3) δ −62.6 (3 F, s, CF3). HRMS m/z (ESI+) m/z calcd for C28H29F3N4O4Na+ 




















Following GP8 with tert-butyl 3-(3-(4-methoxyphenyl)-1-(3-methylbut-2-en-1-
yl)ureido)benzoate (497) (82 mg, 0.2 mmol) used as staring material. Reaction was stirred for 
30 minutes and purified by flash column chromatography (SiO2, 0% to 10% EtO2 in DCM) to 
give the title compound (69 mg, 59%) as a yellow solid.  
M.p. 176-178 °C (Et2O). IR (neat, cm-1) νmax = 2979, 2935, 1712, 1691, 1514, 1416, 1322, 1248, 
1160, 1124, 1065, 848, 833, 759. 1H NMR (400 MHz, CDCl3) δ 8.19 (1 H, ddd, J 8.2, 2.5, 1.1, 
ArCH), 7.87 (1 H, dd, J 2.5, 1.6, ArCH), 7.67 (1 H, ddd, J 7.6, 1.6, 1.1, ArCH), 7.61 (2 H, d, J 8.2, 
2 × ArCH), 7.42 (2 H, d, J 8.8,  2 × ArCH), 7.37 (1 H, t, J 8.2, ArCH), 7.21 (2 H, d, J 9.0, 2 × ArCH), 
6.75 (2 H, d, J 9.0, 2 × ArCH), 5.01 (1 H, dd, J 9.8, 4.6, CH), 4.24 (1 H, t, J 9.8, CHaHb), 3.94 (1 H, 
dd, J 9.8, 4.6, CHaHb), 3.65 (3 H, s, OCH3), 1.60 (9 H, s, 3 x C(CH3)3), 1.28 (6 H, s, 2 x CH3). 13C 
NMR (126 MHz, CDCl3) δ 165.9 (CO), 157.6 (ArCO), 156.4 (CO), 153. 5 (ArCNN), 140. 2 (Cquat), 
132.6 (Cquat), 132.2 (Cquat, q, JCF 32.5), 132.0 (Cquat), 129.0 (ArCH), 127.3 (2 x ArCH), 125.9              
(2 x ArCH, q, JCF 3.5), 124.0 (CF3, q, JCF 272.3), 122.6 (ArCH), 122.4 (2 x ArCH), 122.5 (ArCH), 
117.3 (ArCH), 114.3 (2 x ArCH), 81.4 (C(CH3)3), 75.3 (Cquat), 60.9 (CH), 55.4 (OCH3), 45.0 (CH2), 
28.3 (C(CH3)3) 21.5 (CH3), 20.2 (CH3). 19F NMR (377 MHz, CDCl3) δ −62.6 (3 F, s, CF3). HRMS 



















Following GP8 with 3-methylbut-2-en-1-yl (4-methoxyphenyl)carbamate (474) (47 mg, 0.2 
mmol) used as staring material. Reaction was stirred for 30 minutes and purified by flash 
column chromatography (SiO2, 20% to 100% Et2O in 40-60 petroleum ether) to give the title 
compound (54 mg, 67%) as a yellow solid.  
M.p. 142-144 °C (Et2O). IR (neat, cm-1) νmax = 2986, 1733, 1513, 1324, 1243, 1166, 1128, 1062, 
823. 1H NMR (400 MHz, CDCl3) δ 7.62 (2 H, d, J 8.2, 2 × ArCH), 7.42 (2 H, d, J 8.2, 2 × ArCH), 
7.18 (2 H, d, J 8.8, 2 × ArCH), 6.74 (2 H, d, J 8.8, 2 × ArCH), 4.98 (1 H, dd, J 9.2, 4.0, CH), 4.63    
(1 H, t, J 9.2, CHaHb), 4.45 (1 H, dd, J 9.2, 4.0, CHaHb), 3.65 (3 H, s, OCH3), 1.28 (3 H, s, CH3), 
1.23 (3 H, s, CH3). 13C NMR (126 MHz, CDCl3) δ 157.9 (ArCO), 157.1 (CO), 153.4 (ArCNN), 132.3 
(Cquat, q, JCF 32.7), 130.6 (Cquat), 126.6 (2 x ArCH), 126.0 (2 x ArCH, q, JCF 3.8), 123.9 (CF3, q, JCF 
272.9), 122.6 (2 x ArCH), 114.5 (2 x ArCH), 74.7 (Cquat), 64.1 (CH2), 64.1 (CH), 55.4 (OCH3), 21.4 
(CH3), 20.1 (CH3). 19F NMR (377 MHz, CDCl3) δ −62.6 (3 F, s, CF3). HRMS m/z (ESI+) m/z calcd 





















A flame-dried 10 mL microwave vial was charged with 3-methylbut-2-en-1-yl (4-
(trifluoromethyl)phenyl)carbamate (510) (55 mg, 0.2 mmol), sodium dibutyl phosphate (490) 
(93 mg, 0.2 mmol) and 4-(trifluoromethyl)benzenediazonium tetrafluoroborate (463) (104 
mg, 0.4 mmol), then flushed with nitrogen and anhydrous DCM (2 mL) was added. The 
reaction mixture was stirred at room temperature for 18 hours under irradiation from 24 W 
blue LEDs. The reaction was quenched with water (5 mL) and extracted with ethyl acetate       
(3 x 3 mL). The combined organic extracts were concentrated under reduced pressure and 
purified by flash column chromatography (SiO2, 20% to 100% Et2O in 40-60 petroleum ether) 
to give the title compound (30 mg, 34%) as a yellow solid. 
M.p. 184-187 °C (CDCl3). IR (film, cm-1) νmax = 2982, 1732, 1330, 1120, 1069. 1H NMR (400 
MHz, CDCl3) δ 7.60 (2 H, d, J 8.4, 2 x ArCH), 7.47-7.44 (4 H, m, 4 x ArCH), 7.35 (2 H, d, J 8.4, 2 
x ArCH), 5.13 (1 H, dd, J 8.9, 3.2, CH), 4.69 (1 H, t, J 8.9, CHaHb), 4.54 (1 H, dd, J 8.9, 3.2, CHaHb), 
1.31 (3 H, s, CH3), 1.27 (3 H, s, CH3). 13C NMR (126 MHz, CDCl3) δ 156.0 (CO), 153.0 (ArCNN), 
141.1 (Cquat), 132.8 (Cquat, q, JCF 32.5), 127.6 (Cquat, q, JCF 33.0), 126.2 (2 x ArCH, q, JCF 3.7), 126.2 
(2 x ArCH, q, JCF 3.9), 124.2 (2 x ArCH), 123.8 (CF3, q, JCF 272.2), 123.7 (CF3, q, JCF 271.9), 122.4 
(2 x ArCH), 75.2 (Cquat), 64.2 (CH2), 63.0 (CH), 21.8 (CH3), 19.5 (CH3). 19F NMR (377 MHz, CDCl3) 
δ −62.5 (3 F, s, CF3), −62.7 (3 F, s, CF3). HRMS m/z (ESI+) m/z calcd for C20H17F6N3O2Na+ [M+Na]+ 
















 N-(4-Methoxyphenyl)-2-(2-methylprop-1-en-1-yl)benzamide (516) 
 
A solution of isopropyltriphenylphosphinium iodide (514) (4.31 g, 10.0 mmol) and potassium 
tert-butoxide (1.69 g, 15.0 mmol) in THF (20 mL) was stirred at room temperature for 1.5 
hours. 2-Carboxybenzaldehyde (513) (0.75 g, 5.0 mmol) was added and the solution was 
refluxed for 18 hours. The reaction was cooled to room temperature and quenched with a 
saturated NH4Cl(aq) (30 mL). The solution was diluted with ethyl acetate (20 mL) and the 
organic layer extracted with 2 M NaOH(aq) (6 x 25 mL). The combined aqueous layers were 
acidified with concentrated HCl and extracted with EtOAc (35 mL x 6). The combined organic 
layers were dried (Na2SO4) and concentrated under reduced pressure to yield crude material 
(460 mg) as a white solid that was used without further purification. 
The crude material (460 mg) was dissolved in DMF (5.2 mL); HTBU (1.20 g, 3.1 mmol) and 
DIPEA (2.3 mL, 5.0 eq., 13 mmol) were sequentially added to the reaction mixture, which was 
stirred at room temperature for 10 minutes at room temperature. 4-Methoxyaniline (477) 
(0.640 g, 2 eq., 5.2 mmol) was added to the reaction mixture, which was stirred for 23 hours 
at 60 °C. The reaction was quenched with water (50 mL) and extracted with ethyl acetate (2 
x 50 mL). The combined organic extracts were sequentially washed with NaHCO3(aq) (50 mL) 
and brine (50 mL), then dried (Na2SO4). The organic extracts were concentrated under 
reduced pressure to afford crude residue, which was purified by flash column 
chromatography (SiO2, 10% to 40% ethyl acetate in 40-60 petroleum ether) to give the title 
compound (425 mg, 30% over two steps) as a white solid. 
M.p. 99-101 °C (CDCl3). IR (neat, cm-1) νmax = 3336, 2956, 1692, 1527, 1415, 1246, 1230, 1175, 
1059, 1027, 825. 1H NMR (400 MHz, CDCl3) δ 8.01 (1 H, s, NH), 7.84 (1 H, d, J 7.5, ArCH), 7.49 
(2 H, d, J 8.9, 2 x ArCH), 7.41 (1 H, t, J 7.5, ArCH), 7.31 (1 H, t, J 7.5, ArCH), 7.22 (1 H, d, J 7.5, 
ArCH), 6.88 (2 H, d, J 8.9, 2 x ArCH), 6.50 (1 H, s, CH), 3.79 (3 H, s, OCH3), 1.97 (3 H, s, CH3), 
1.78 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 166.6 (CO), 156.5 (ArCO), 138.7 (Cquat), 136.0 
(Cquat), 134.8 (Cquat), 131.4 (Cquat), 130.6 (ArCH), 130.4 (ArCH), 129.1 (ArCH), 127.0 (ArCH), 
123.7 (CH), 121.5 (2 x ArCH), 114.3 (2 x ArCH), 55.6 (OCH3), 26.3 (CH3), 19.5 (CH3). HRMS m/z 












Following GP8 at a reaction concentration of 0.1 M, with N-(4-methoxyphenyl)-2-(2-
methylprop-1-en-1-yl)benzamide (516) (56 mg, 0.2 mmol) used as staring material. Reaction 
was stirred for 45 minutes and purified by flash column chromatography (SiO2, 0% to 10% 
Et2O in DCM) to give the title compound (70 mg, 77%) as a yellow solid.  
M.p. 184-187 °C (Et2O). IR (neat, cm-1) νmax = 2991, 2936, 1675, 1515, 1327, 1248, 1120, 1065, 
831, 739. 1H NMR (400 MHz, CDCl3) δ 7.99-7.94 (1 H, m, ArCH), 7.61 (2 H, d, J 8.4, 2 × ArCH), 
7.57-7.50 (3 H, m, ArCH + ArCH + ArCH), 7.46 (2 H, d, J 8.4, 2 × ArCH), 7.22 (2 H, d, J 8.9, 2 x 
ArCH), 6.74 (2 H, d, J 8.9, 2 × ArCH), 5.93 (1 H, s, CH), 3.62 (3 H, s, OCH3), 1.32 (3 H, s, CH3), 
1.01 (3 H, s, CH3). 13C NMR (126 MHz, CDCl3) δ 168.2 (CO), 157.7 (ArCO), 153.3 (ArCNN), 142.7 
(Cquat), 133.3 (Cquat), 132.2 (Cquat, q, JCF 32.2), 131.5 (ArCH), 131.3 (Cquat) 129.0 (ArCH), 127.5    
(2 x ArCH) 125.9 (2 x ArCH, q, JCF 3.8), 124.5 (ArCH), 124.2 (ArCH), 124.0 (CF3, q, JCF 272.3), 
122.7 (2 x ArCH), 114.3 (2 x ArCH), 75.8 (Cquat), 68.9 (CH), 55.3 (OCH3), 22.7 (CH3), 20.3 (CH3). 
19F NMR (377 MHz, CDCl3) δ −62.6 (3 F, s, CF3). HRMS m/z (ESI+) m/z calcd for C25H22F3N3O2Na+ 
[M+Na]+ 476.1556; found 476.1559. 
3,5,5-Trimethylcyclohex-2-en-1-yl (4-methoxyphenyl)carbamate (518) 
 
Using GP6 and starting materials 3,5,5-trimethyl-2-cyclohexen-1-ol (453) (0.76 mL, 701 mg, 
5.0 mmol) and 4-methoxyphenyl isocyanate (473) (0.78 mL, 895 mg, 6.0 mmol), the title 
compound was synthesised (0.654 g, 45%) as a white solid. 
M.p. 99-101 °C (CDCl3). IR (neat, cm-1) νmax = 3336, 2956, 1692, 1527, 1415, 1246, 1230, 1175, 
1059, 1027, 825. 1H NMR (400 MHz, CDCl3) δ 7.28 (2 H, br. d, J 9.0, 2 x ArCH), 6.82 (2 H, d, J 
9.0, 2 x ArCH), 6.68 (1 H, s, NH), 5.47 (1 H, s, CH), 5.33 (1 H, br. s, OCH), 3.76 (3 H, s, OCH3), 
1.86 (1 H, d, J 18.3, CHaHb), 1.81 (1 H, dd, J 13.1, 6.0, CHaHb), 1.69 (3 H, s, CH3), 1.67 (1 H, d, J 
18.3, CHaHb), 1.43 (1 H, dd, J 13.1, 8.1, CHaHb), 1.00 (3 H, s, CH3), 0.94 (3 H, s, CH3). 13C NMR 
(101 MHz, CDCl3) δ 155.9 (ArCO), 154.0 (CO), 138.2 (Cquat), 131.3 (Cquat), 120.6 (2 × ArCH), 
119.7 (CH), 114.2 (2 × ArCH), 70.9 (CH), 55.5 (OCH3), 44.1 (CH2), 41.0 (CH2), 30.7 (Cquat), 30.5 








Following GP8 with 3,5,5-trimethylcyclohex-2-en-1-yl (4-methoxyphenyl)carbamate (518) (58 
mg, 0.2 mmol) used as staring material. Reaction was stirred for 60 minutes and purified by 
flash column chromatography (SiO2, 10% to 50% EtOAc in 40-60 petroleum ether) to give the 
title compound (41 mg, 45%) as an orange solid in a 6.7:1 ratio of inseparable diastereomers.  
M.p. 159-161 °C (Et2O). IR (neat, cm-1 ) νmax = 2952, 1737, 1512, 1407, 1320, 1244, 1169, 1118, 
1061, 1038, 824. 1H NMR (400 MHz, CDCl3) δ 7.82 (0.3 H, d, J 8.5, 2 × min. ArCH), 7.76 (0.3 H, 
d, J 8.5, 2 × min. ArCH), 7.68 (2 H, d, J 8.5, 2 × maj. ArCH), 7.55 (2 H, d, J 8.5, 2 × maj. ArCH), 
7.29 (2 H, d, J 9.0, 2 × maj. ArCH), 7.17 (0.3 H, d, J 9.0, 2 × min. ArCH), 6.80-6.78 (0.3 H, m, 2 × 
min. ArCH), 6.76 (2 H, d, J 9.0, 2 × maj. ArCH), 5.23 (1 H, d, J 9.0, maj. NCH), 5.12-5.03 (1.3 H, 
m, maj. OCH + min. OCH), 4.55 (0.15 H, d, J 7.4, min. NCH), 3.73 (0.45 H, s, min. OCH3), 3.69 
(3 H, s, maj. OCH3), 2.11-2.07 (0.15 H, m, min. CHaHb), 2.04 (1 H, dd, J 14.7, 6.7, maj. CHaHb), 
1.93-1.87 (0.15 H, m, min. C’HaHb), 1.90 (1 H, d, J 14.7, maj. C’HaHb), 1.85-1.82 (0.15 H, m, min. 
CHaHb), 1.75 (1 H, dd, J 14.7, 5.3, maj. CHaHb), 1.62 (1 H, d, J 14.7, maj. C’HaHb), 1.51 (0.15 H, 
d, J 14.7, min. C’HaHb), 1.20 (3 H, s, maj. CH3), 1.19 (3 H, s, maj. CH3), 1.01 (3.45 H, s, maj CH3 
+ min. CH3), 0.89 (0.45 H, s, min. CH3), 0.84 (0.45 H, s, min. CH3). 13C NMR (101 MHz, CDCl3) δ 
157.7 (min. ArCO), 157.4 (maj. ArCO), 157.2 (min. CO), 156.7 (maj. CO), 153.4 (min. ArCNN), 
153.4 (maj. ArCNN), 132.6 (min. Cquat, q, JCF 32.2), 132.4 (maj. Cquat, q, JCF 32.2), 131.3              
(min. Cquat), 131.0 (maj. Cquat), 126.7 (min. 2 x ArCH, q, JCF 3.8), 126.7 (maj. 2 x ArCH, q, JCF 3.8), 
126.3 (min. 2 x ArCH), 125.3 (maj. 2 x ArCH), 123.9 (maj. CF3, q, JCF 272.3), 122.9 (min.                     
2 x ArCH), 122.5 (maj. 2 x ArCH), 114.4 (min. 2 x ArCH), 114.2 (maj. 2 x ArCH), 75.2 (maj. Cquat), 
74.4 (min. OCH), 73.6 (maj. OCH), 72.3 (min. Cquat), 65.1 (min. NCH), 61.0 (maj. NCH), 55.5 
(maj. OCH3), 55.5 (min. OCH3), 49.7 (min. CH2), 44.7 (maj. CH2), 39.3 (min. CH2), 38.3 (maj. 
CH2), 33.0 (maj. CH3), 33.0 (maj. CH3), 32.7 (min. CH3), 31.5 (min. CH3), 28.9 (min. Cquat), 28.7 
(maj. Cquat), 26.7 (min. CH3), 22.4 (maj. CH3). Minor CF3 signal not observed. 19F NMR (377 
MHz, CDCl3) δ –62.6 (3 F, s, maj. CF3 + min. CF3). HRMS m/z (ESI+) m/z calcd for 











(E)-3,7-Dimethylocta-2,6-dien-1-yl (4-methoxyphenyl)carbamate (522) 
 
Using GP6 and starting materials geraniol (521) (0.88 mL, 771 mg, 5.0 mmol) and 4-
methoxyphenyl isocyanate (473) (0.78 mL, 894 mg, 6.0 mmol), the title compound was 
synthesised (0.766 g, 50%) as an orange oil. 
IR (film, cm-1) νmax = 3323, 2913, 1698, 1512, 1030. 1H NMR (400 MHz, CDCl3) δ 7.28 (2 H,      
br. d, J 8.9, 2 x ArCH), 6.85 (2 H, d, J 8.9, 2 x ArCH), 6.46 (1 H, br. s, NH), 5.39 (1 H, tq, J 7.2, 
1.2, CH), 5.12-5.06 (1 H, m, CH), 4.67 (2 H, d, J 7.1, CH2), 3.78 (3 H, s, OCH3), 2.15-2.02 (4 H, m, 
CH2 + CH2), 1.73 (3 H, s, CH3), 1.68 (3 H, s, CH3), 1.61 (3 H, s, CH3). 13C NMR (126 MHz, CDCl3) 
δ 156.1 (ArCO), 154.1 (CO), 142.6 (Cquat), 132.0 (Cquat), 131.2 (Cquat), 123.9 (CH), 120.7                    
(2 x ArCH), 118.6 (CH), 114.4 (2 x ArCH), 62.1 (CH3), 55.7 (OCH3), 39.7 (CH2), 26.5 (CH2), 25.8 













(E)-5-Methylhexa-2,4-dien-1-yl (4-methoxyphenyl)carbamate (527) 
 
A solution of 60% sodium hydride in mineral oil (448 mg, 11.2 mmol) in anhydrous THF (15 
mL) was prepared in a flame-dried Schlenk tube. The sodium hydride solution was cooled to 
0 °C and charged with triethyl phosphonoacetate (524) (2.22 mL, 2.51 g, 11.2 mmol) in a 
dropwise fashion. The mixture was stirred at 0 °C for 20 minutes, then 3-methyl-2-butenal 
(476) (1.18 mL, 858 mg, 10.2 mmol) was added dropwise. The reaction mixture was warmed 
to room temperature and stirred for 18 hours. The reaction was quenched with saturated 
NH4Cl(aq) (20 mL) and extracted with ethyl acetate (3 x 10 mL). The combined organic extracts 
were dried (MgSO4), concentrated under reduced pressure and purified by flash column 
chromatography (SiO2, 0% to 10% Et2O in 40-60 petroleum ether) yielding ethyl (E)-5-
methylhexa-2,4-dienoate (525) (902 mg, 57%) as a yellow oil.  
1H NMR (400 MHz, CDCl3) δ 7.55 (1 H, dd, J 15.1, 11.6, CH), 5.98 (1 H, d, J 11.6, CH), 5.75 (1 H, 
d, J 15.1, CH), 4.16 (2 H, q, J 7.1, OCH2), 1.89 (3 H, s, CH3), 1.87 (3 H, s, CH3), 1.29 (3 H, t, J 7.1, 
CH3). Data in good agreement with literature.270 
Under a nitrogen atmosphere a flame dried RBF was charged with ethyl (E)-5-methylhexa-
2,4-dienoate (525) (902 mg, 5.8 mmol) and anhydrous DCM (32 mL), then cooled to -60 °C.     
1 M Diisobutylaluminium hydride in hexanes (17.4 mL, 17.4 mmol) was added to the reaction 
mixture slowly at −60 °C. The reaction mixture was warmed to 0 °C and allowed to stir for one 
hour. The reaction mixture was quenched with water (5 mL), followed by 15% NaOH(aq) (5 mL) 
forming a white precipitate. The mixture was vigorously stirred at room temperature for one 
hour. Magnesium sulfate was added, the mixture was filtered over a pad of celite and washed 
with DCM (20 mL). The organic filtrate was concentrated under reduced pressure yielding 





1H NMR (400 MHz, CDCl3) δ 6.45 (1 H, dd, J 15.1, 10.9, CH), 5.84 (1 H, d, J 10.9, CH), 5.71 (1 H, 
dt, J 15.1, 6.1, CH), 4.18 (2 H, d, J 6.1, CH2), 1.78 (3 H, s, CH3), 1.76 (3 H, s, CH3). OH not 
observed. Data in good agreement with literature.271 
Using GP6 on a 5.8 mmol scale and starting materials crude (E)-5-methylhexa-2,4-dien-1-ol 
(526) and 4-methoxyphenyl isocyanate (473) (0.90 mL, 1.04 g, 7.0 mmol), the title compound 
was synthesised (709 mg, 47% over two steps) as a white solid. 
M.p. 97-99 °C (Et2O). IR (film, cm-1) νmax = 3312, 2909, 1697, 1511, 1032, 827. 1H NMR (400 
MHz, CDCl3) δ 7.28 (2 H, br. d, J 8.9, 2 x ArCH), 6.84 (2 H, d, J 8.9, 2 x ArCH), 6.62 (1 H, br. s, 
NH), 6.53 (1 H, dd, J 15.2, 11.1, CH), 5.84 (1 H, d, J 11.1, CH), 5.66 (1 H, dt, J 15.2, 6.7, CH), 4.68 
(2 H, d, J 6.7, CH2), 3.77 (3 H, s, OCH3), 1.79 (3 H, s, CH3), 1.77 (3 H, s, CH3). 13C NMR (126 MHz, 
CDCl3) δ 156.1 (ArCO), 153.9 (CO), 137.6 (Cquat), 131.5 (CH), 131.1 (Cquat), 124.1 (CH), 123.8 
(CH), 120.8 (2 x ArCH), 114.3 (2 x ArCH), 66.1 (CH2), 55.6 (OCH3), 26.2 (CH3), 18.5 (CH3). HRMS 
























3,4,5,6-Tetrahydro-[1,1'-biphenyl]-3-yl (4-methoxyphenyl)carbamate (x-x-x) 
 
Under a nitrogen atmosphere a flame-dried Schlenk tube was charged with 3 M phenyl 
magnesium bromide (5 mL, 15.0 mmol) in diethyl ether and anhydrous THF (10 mL). The 
Schlenk tube was cooled to 0 °C and a solution of 3-ethoxycyclohex-2-enone (529) (1.92 mL, 
2.0 g, 14.3 mmol) in anhydrous THF (2 mL) was added slowly while stirring. The reaction 
mixture was warmed to room temperature and allowed to stir for 25 hours. The reaction was 
quenched with 1 M HCl (50 mL) and extracted with DCM (3 x 50 mL). The combined organic 
extracts were dried (MgSO4), concentrated under reduced pressure and purified by flash 
column chromatography (SiO2, 0% to 50% Et2O in 40-60 petroleum ether) to yield 5,6-dihydro-
[1,1'-biphenyl]-3(4H)-one (530) (2.15 g, 87%) as a white solid.  
1H NMR (400 MHz, CDCl3) δ 7.56-7.51 (2 H, m, 2 x ArCH), 7.44-7.39 (3 H, m, 3 x ArCH), 6.42    
(1 H, t, J 1.4, CH), 2.78 (2 H, td, J 6.2, 1.4, CH2), 2.49 (2 H, t, J 6.2, CH2), 2.16 (2 H, qn, J 6.2, 
CH2). Data in good agreement with literature.272 
A flame-dried 250 mL RBF was charged with 5,6-dihydro-[1,1'-biphenyl]-3(4H)-one (530) (2.15 
g, 12.5 mmol), flushed with nitrogen and charged with methanol (70 mL). The reaction 
mixture was cooled to -10 °C, then under stirring sodium borohydride (568 mg, 15.0 mmol) 
was added in portions. The reaction mixture was stirred for 1 hour at -10 °C, then quenched 
with saturated NH4Cl(aq) (100 mL) and extracted with diethyl ether (2 x 100 mL). The combined 
organic extracts were washed with brine (2 x 50 mL), dried (MgSO4) and concentrated under 
reduced pressure to yield crude 3,4,5,6-tetrahydro-[1,1'-biphenyl]-3-ol (531) as a brown solid, 
which was used without further purification.  
1H NMR (400 MHz, CDCl3) δ 7.43-7.39 (2 H, m, 2 x ArCH), 7.36-7.30 (2 H, m, 2 x ArCH), 7.26   
(1 H, tt, J 7.2, 1.4, ArCH), 6.13 (1 H, dt, J 3.6, 1.8, CH), 4.43-4.37 (1 H, m, CH), 2.52-2.43 (1 H, 
m, CHaHb), 2.41-2.32 (1 H, m, CHaHb), 2.00-1.85 (2 H, m, CH2), 1.80-1.63 (2 H, m, CH2). OH not 




Using GP6 on a 12.5 mmol scale and starting materials crude 3,4,5,6-tetrahydro-[1,1'-
biphenyl]-3-ol (531) and 4-methoxyphenyl isocyanate (473) (1.95 mL, 2.24 g, 15.0 mmol), the 
title compound was synthesised (1.42 g, 35% over two steps) as a brown solid. 
M.p. 108-110 °C (Et2O). IR (film, cm-1) νmax = 3316, 2936, 1693, 1512, 1215, 1030. 1H NMR 
(400 MHz, CDCl3) δ 7.39-7.37 (2 H, m, 2 x ArCH), 7.33-7.22 (5 H, m, ArCH + 2 x ArCH +                        
2 x ArCH), 6.81 (2 H, d, J 9.0, 2 x ArCH), 6.74 (1 H, br. s, NH), 6.15 (1 H, dt, J 3.9, 1.6, CH), 5.46 
(1 H, J, br. q, 4.0, CH), 3.74 (3 H, s, OCH3), 2.54-2.44 (1 H, m, CHaHb), 2.39-2.29 (1 H, m, CHaHb), 
1.99-1.74 (4 H, m, CH2 + CH2). 13C NMR (126 MHz, CDCl3) δ 155.9 (ArCO), 153.9 (CO), 142.1 
(Cquat), 141.0 (Cquat), 131.2 (Cquat), 128.4 (2 x ArCH), 127.7 (ArCH), 125.5 (2 x ArCH), 122.6 (CH), 
120.7 (2 x ArCH), 114.2 (2 x ArCH), 69.6 (CH), 55.5 (OCH3), 28.3 (CH2), 27.4 (CH2), 19.4 (CH2). 




A 10 mL RBF was charged with (E)-1,3-bis(4-methoxyphenyl)-4-(2-((4-
(trifluoromethyl)phenyl)diazenyl)propan-2-yl)imidazolidin-2-one (488) (102 mg, 0.2 mmol), 
methanol (5 mL) and 10 wt% palladium on carbon (42 mg, 0.4 mmol). The reaction mixture 
was exposed to an atmosphere of hydrogen and stirred at room temperature for 16 hours. 
The reaction mixture was filtered through celite, concentrated under reduced pressure and 
purified by flash column chromatography (0% to 100% Et2O in 40-60 petroleum ether) to give 
title compound (101 mg, 98%.) as a white solid. 
M.p. 157-159 °C (Et2O). IR (film, cm-1) νmax = 3302, 2974, 1693, 1617, 1321, 1245, 1105.             
1H NMR (400 MHz, CDCl3) δ 7.50 (2 H, d, J 9.2, 2 × ArCH), 7.39-7.35 (4 H, m, 4 x ArCH), 6.95      
(2 H, d, J 9.0, 2 × ArCH), 6.91 (2 H, d, J 9.2, 2 × ArCH), 6.79 (2 H, d, J 8.6, 2 x ArCH), 5.00 (1 H, 
br. s, NH), 4.40 (1 H, dd, J 9.5, 4.6, CH), 4.03 (1 H, t, J 9.5, CHaHb), 3.86 (1 H, dd, J 9.5, 4.6, 
CHaHb), 3.80 (6 H, s, OCH3 + OCH3), 3.26 (1 H, br. s, NH), 1.09 (3 H, s, CH3), 1.07 (3 H, s, CH3). 
13C NMR (126 MHz, CDCl3) δ 158.0 (ArCO), 156.9 (CO), 155.7 (ArCO), 152.9 (ArCNN, q, JCF 1.1), 
133.4 (Cquat), 133.0 (Cquat), 126.9 (2 x ArCH), 126.5 (2 x ArCH, q, JCF 3.8), 124.9 (CF3, q, JCF 271.1), 
120.7 (Cquat, q, JCF 32.6), 119.7 (2 x ArCH), 114.9 (2 x ArCH), 114.3 (2 x ArCH), 121.1 (2 x ArCH), 
60.3 (Cquat), 58.9 (CH), 55.7 (OCH3), 55.6 (OCH3), 45.9 (CH2), 21.7 (CH3), 21.6 (CH3). 19F NMR 
(377 MHz, CDCl3) δ −61.1 (3 F, s, CF3). HRMS m/z (ESI+) m/z calcd for C27H30F3N4O3+ [M+H]+ 







tert-Butyl (2-(1,3-bis(4-methoxyphenyl)-2-oxoimidazolidin-4-yl)propan-2-yl)carbamate      
(540) 
 
A 10 mL RBF was charged with (E)-1,3-bis(4-methoxyphenyl)-4-(2-((4-
(trifluoromethyl)phenyl)diazenyl)propan-2-yl)imidazolidin-2-one (488) (102 mg, 0.2 mmol), 
methanol (5 mL) and 10 wt% palladium on carbon (42 mg, 0.4 mmol). The reaction mixture 
was exposed to an atmosphere of hydrogen and stirred at room temperature for 4 hours. 
Concentrated HCl(aq) (1 mL) was added to the reaction mixture then re-exposed to an 
atmosphere of hydrogen for 1.5 hours at room temperature with stirring. The reaction 
mixture was filtered through celite and concentrated under reduced pressure to give a 
colourless residue, which was dissolved in DCM (4 mL) and water (0.5 mL). Potassium 
carbonate (138 mg, 1.0 mmol) and di-tert-butyl decarbonate (131 mg, 0.6 mmol) were added 
to the reaction mixture, which was stirred for 21 hours at room temperature. The reaction 
was quenched with water (20 mL) and extracted with DCM (3 x 20 mL). The combined organic 
extracts were dried (Na2SO4) and concentrated under reduced pressure to give a yellow 
residue, which was purified by flash column chromatography (0% to 50% EtOAc in 40-60 
petroleum ether) to give the title compound (56 mg, 62%) as a white solid. 
M.p. 151-154 °C (CDCl3). IR (neat, cm-1) νmax = 3292, 2977, 1699, 1678, 1508, 1410, 1243, 
1157, 1075, 829. 1H NMR (400 MHz, CDCl3) δ 7.49 (2 H, d, J 9.1, 2 x ArCH), 7.31 (2 H, d, J 8.8, 
2 x ArCH), 6.95-6.84 (4 H, m, 4 x ArCH), 5.06 (1 H, br. s, CH), 4.35 (1 H, s, NH), 4.01 (1 H, t,            
J 9.8, CHaHb), 3.80 (3 H, s, OCH3), 3.79 (3 H, s, OCH3), 3.68 (1 H, dd, J 9.8, 4.5, CHaHb), 1.35 (9 
H, s, C(CH3)3), 1.27 (3 H, s, CH3), 1.16 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 157.4 (ArCO), 
156.8 (CO), 155.4 (ArCO), 154.2 (CO), 133.4 (Cquat), 132.9 (Cquat), 126.5 (2 x ArCH), 119.5 (2 x 
ArCH), 114.4 (2 x ArCH), 114.1 (2 x ArCH), 79.3 (Cquat) 57.6 (CH), 56.1 (Cquat), 55.5 (OCH3) 55.4 
(OCH3), 45.4 (CH2), 28.4 (C(CH3)3), 24.0 (CH3), 23.1 (CH3). HRMS m/z (ESI+) m/z calcd for 













A 10 mL RBF was charged with (E)-1,3-bis(4-methoxyphenyl)-4-(2-((4- 
(trifluoromethyl)phenyl)diazenyl)propan-2-yl)imidazolidin-2-one (488) (102 mg, 0.2 mmol), 
methanol (5 mL) and 10 wt% palladium on carbon (42 mg, 0.04 mmol). The reaction mixture 
was exposed to an atmosphere of hydrogen and stirred at room temperature for 4 hours. 
Concentrated aqueous HCl (1 mL) was added to the reaction mixture, then re-exposed to an 
atmosphere of hydrogen for 1.5 hours at room temperature with stirring. The reaction 
mixture was filtered through Celite and concentrated under reduced pressure to give a 
colourless residue. The hydrogenated residue was dissolved in DCM (5 mL), then charged with 
triethylamine (0.14 mL, 1.0 mmol,) and p-toluenesulfonyl chloride (114 mg, 0.6 mmol). The 
reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was 
charged with additional triethylamine (1.0 mmol, 5.0 eq., 0.14 mL) and p-toluenesulfonyl 
chloride (114 mg, 0.6 mmol), then stirred at room temperature for an additional 18 hours. 
The reaction was quenched with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). 
The combined organic extracts were dried (Na2SO4) and concentrated under reduced 
pressure to give a yellow residue, which was purified by flash column chromatography (0% to 
50% EtOAc in 40-60 petroleum ether) to give the title compound (68 mg, 67%) as a white 
solid. 
M.p. 170-173 °C (CDCl3). IR (film, cm-1) νmax = 3281, 2921, 1687, 1510, 1433, 1246, 1161, 830. 
1H NMR (400 MHz, CDCl3) δ 7.67 (2 H, d, J 8.3, 2 x ArCH), 7.44 (2 H, d, J 9.0, 2 x ArCH), 7.28     
(2 H, d, J 9.0, 2 x ArCH), 7.22 (2 H, d, J 8.3, 2 x ArCH), 6.93-6.84 (4 H, m, 4 x ArCH), 5.03 (1 H, s, 
NH), 4.53 (1 H, dd, J 9.5, 4.5, CH), 3.95 (1 H, t, J 9.5, CHaHb), 3.82-3.76 (7 H, m, 2 x OCH3 + 
CHaHb), 2.39 (3 H, s, CH3), 1.08 (3 H, s, CH3), 0.99 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 
157.8 (ArCO), 156.8 (CO), 155.7 (ArCO), 143.4 (Cquat), 140.2 (Cquat), 133.1 (Cquat), 132.8 (Cquat), 
129.8 (2 × ArCH), 127.0 (2 × ArCH), 126.7 (2 × ArCH), 199.9 (2 × ArCH), 114.6 (2 × ArCH), 114.3 
(2 × ArCH), 61.2 (CH), 59.9 (Cquat), 55.7 (OCH3), 55.6 (OCH3), 45.5 (CH2), 25.0 (CH3), 23.7 (CH3), 









A 10 mL RBF was charged with N-(2-(1,3-bis(4-methoxyphenyl)-2-oxoimidazolidin-4-
yl)propan-2-yl)-4- methylbenzenesulfonamide (541) (68 mg, 0.13 mmol) and acetonitrile (3 
mL). The mixture was cooled to 0 °C and a solution of ceric ammonium nitrate (367 mg, 0.67 
mmol) dissolved in water (3 mL) was added drop wise over 3 minutes. The reaction mixture 
was stirred at 0 °C for 1 hour, then quenched with water (10 mL) and extracted with ethyl 
acetate (3 x 10 mL). The combined organic extracts were dried (Na2SO4) and concentrated 
under reduced pressure to give an orange residue, which was purified by flash column 
chromatography (0% to 10% MeOH in DCM) to give the title compound (25 mg, 63%) as a 
colourless film. 
IR (film, cm-1) νmax = 3266, 2923, 1689, 1318, 1147, 1093, 663, 556. 1H NMR (400 MHz, CDCl3) 
δ 7.84 (2 H, d, J 8.3, 2 x ArCH), 7.26 (2 H, d, J 8.3, 2 x ArCH), 7.12 (1 H, br. s, NH), 6.74 (1 H,      
br. s, NH), 6.01 (1 H, br. s, NH), 3.65-3.57 (1 H, m, CH), 3.50-3.38 (2 H, m, CH2), 2.41 (3 H, s, 
CH3), 1.16 (3 H, s, CH3), 1.13 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 165.0 (CO), 142.9 (Cquat), 
140.8 (Cquat), 129.6 (2 x ArCH), 127.1 (2 x ArCH), 62.7 (CH), 57.6 (Cquat), 42.2 (CH2), 26.5 (CH3), 





















A 10 mL RBF was charged (E)-3-(4-methoxyphenyl)-4-(2-((4-
(trifluoromethyl)phenyl)diazenyl)propan2-yl)oxazolidin-2-one (511) (82 mg, 0.2 mmol), 
methanol (5 mL) and 10 wt% palladium on carbon (42 mg, 0.04 mmol). The reaction mixture 
was exposed to an atmosphere of hydrogen and stirred at room temperature for 4 hours. 
Concentrated aqueous HCl (1 mL) was added to the reaction mixture then exposed again to 
an atmosphere of hydrogen for 1.5 hours at room temperature with stirring. The reaction 
mixture was filtered through Celite and concentrated under reduced pressure to give a 
colourless residue, which was dissolved in DCM (5 mL). Triethylamine (0.14 mL, 1.0 mmol) 
and p-toluenesulfonyl chloride (114 mg, 0.6 mmol) were added to the reaction mixture, which 
was stirred for 18 hours at room temperature. The reaction was quenched with water (10 mL) 
and extracted with ethyl acetate (3 x 10 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated under reduced pressure to give a colourless residue, which was 
purified by flash column chromatography (0% to 100% EtOAc in 40-60 petroleum ether) to 
give the title compound (43 mg, 53%) as a white solid. 
M.p. 111-113 °C (CDCl3). IR (film, cm-1) νmax = 3256, 2983, 1732, 1513, 1248, 1131, 727. 1H 
NMR (400 MHz, CDCl3) δ 7.65 (2 H, d, J 8.2, 2 x ArCH), 7.28-7.19 (4 H, m, 4 x ArCH), 6.85 (2 H, 
d, J 8.8, 2 x ArCH), 5.32 (1 H, s, NH), 4.66 (1 H, t, J 6.2, CH), 4.39 (2 H, d, J 6.3, CH2), 3.75 (3 H, 
s, OCH3), 2.37 (3 H, s, CH3), 1.07 (3 H, s, CH3), 0.85 (3 H, s, CH3). 13C NMR (101 MHz, CDCl3) δ 
158.0 (ArCO), 157.4 (CO), 143.6 (Cquat), 140.0 (Cquat), 130.8 (Cquat), 129.8 (2 x ArCH), 126.9 (2 x 
ArCH), 126.0 (2 x ArCH), 114.7 (2 x ArCH), 64.5 (CH2), 63.8 (CH), 59.4 (Cquat), 55.6 (OCH3), 25.4 
















A 5 mL RBF was charged with N-(2-(3-(4-methoxyphenyl)-2-oxooxazolidin-4-yl)propan-2-yl)-
4-methylbenzenesulfonamide (547) (40 mg, 0.1 mmol), ethanol (1 mL) and sodium hydroxide 
(40 mg 1.0 mmol). The reaction mixture was heated to 80 °C for 15 hours. The reaction 
mixture was concentrated under reduced pressure and the crude residue was dissolved in 
water (10 mL). The pH of the aqueous solution was adjusted to 7 by addition of aqueous 
hydrochloric acid (1 M), then extracted with ethyl acetate (3 x 10 mL). The combined organic 
extracts were dried (Na2SO4) and concentrated under reduced pressure to give the title 
compound (33 mg, 93%) as a red film. 
IR (film, cm-1) νmax = 3271, 2929, 1510, 1234, 1145, 1092, 815, 659, 548. 1H NMR (400 MHz, 
CDCl3) δ 7.78 (2 H, d, J 7.8, 2 x ArCH), 7.28 (2 H, d, J 7.8, 2 x ArCH), 6.74 (2 H, d, J 8.2, 2 x ArCH), 
6.59 (2 H, d, J 8.2, 2 x ArCH), 5.86 (1 H, s, NH), 3.85-3.79 (2 H, m, CH2), 3.73 (3 H, s, OCH3), 
3.37-2.92 (3 H, m, CH + OH + NH), 2.41 (3 H, s, CH3), 1.25 (3 H, s, CH3), 1.24 (3 H, s, CH3). 13C 
NMR (101 MHz, CDCl3) δ 152.7 (ArCO), 143.1 (Cquat), 142.2 (Cquat), 140.4 (Cquat), 129.8 (2 × 
ArCH), 127.1 (2 × ArCH), 115.4 (2 × ArCH), 115.1 (2 × ArCH), 64.0 (CH), 61.4 (CH2), 60.2 (Cquat), 
55.9 (OCH3), 26.4 (CH3), 25.0 (CH3), 21.6 (CH3). HRMS m/z (ESI+) m/z calcd for C19H26N2O4SNa+ 

















A flame-dried 10 mL microwave vial was charged with 3-methylbut-2-en-1-yl (4-
methoxyphenyl)carbamate (474) (47 mg, 0.2 mmol), sodium dibutyl phosphate  (490) (93 mg, 
0.2 mmol) and 4-(trifluoromethyl)benzenediazonium tetrafluoroborate (463) (104 mg, 0.4 
mmol), then flushed with nitrogen and charged with a solution of ethene-1,1-diyldibenzene 
(338) (0.11 mL, 0.6 mmol) in anhydrous DMSO (1 mL). The reaction mixture was stirred at 
room temperature for 2 hours. The reaction was quenched with water (5 mL) and extracted 
with ethyl acetate (3 x 3 mL). The combined organic extracts were concentrated under 
reduced pressure. The obtained crude material was analysed by 19F NMR and yields were 
calculated by use of α,α,α-trifluorotoluene as an internal standard (0.2 mmol), indicating the 
presence of (E)-3-(4-methoxyphenyl)-4-(2-((4-(trifluoromethyl)phenyl)diazenyl)propan-2-
yl)oxazolidin-2-one (511) (13%) and (2-(4-(trifluoromethyl)phenyl)ethene-1,1-diyl)dibenzene 
(552) (44%). Isolation of the title compounds was attempted by flash column chromatography 
(SiO2, 0% to 1% Et2O in n-pentane), but could not be separated from ethene-1,1-diyldibenzene 
(338) starting material. 
1H NMR (400 MHz, CDCl3) δ 7.38-7.30 (10 H, m, 10 x ArCH), 7.21-7.17 (2 H, m, 2 x ArCH), 7.11 
(2 H, d, J 8.3, 2 x ArCH), 6.98 (1 H, s, CH). 19F NMR (377 MHz, CDCl3) δ -62.5 (3 F, s, CF3). LRMS 
















8.3.3 Cyclic Voltammetry Data 
8.3.3.1 Initial Investigation 
Analyte was added to a 0.1 M solution of tetra-n-butylammonium hexafluorophosphate in 
dry, degassed DMSO (5 mL). Experiments were run using a glassy carbon working electrode, 







































8.3.3.2 Follow Up Studies 
Analyte was added to a 0.1 M solution of tetra-n-butylammonium hexafluorophosphate in 
dry, degassed DMSO (5 mL). Experiments were run using a glassy carbon working electrode, 
a platinum wire counter electrode, and a Ag/AgNO3 reference electrode. A scan rate of 100 
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